<?xml version="1.0" encoding="UTF-8"?>
<root>
    <row>
        <APP_ID>2014703</APP_ID>
        <Date_Announced>2022-01-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Jenkins</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 TCR - Participation in Cancer Screening Programs</Sub_Type>
        <Grant_Title>SMARTERscreen: A randomised controlled trial of patient SMS messaging in general practice to increase participation in the National Bowel Cancer Screening Program</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,595,838.95</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | preventive medicine | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | </Fields_of_Research>
        <Res_KW1>colorectal cancer p1-summary_of_results_2022_app_round_24022023revention</Res_KW1>
        <Res_KW2>bowel cancer screening</Res_KW2>
        <Res_KW3>patient participation</Res_KW3>
        <Res_KW4>primary care</Res_KW4>
        <Res_KW5>behaviour change</Res_KW5>
        <Plain_Description>Most people invited to take part in free screening for bowel cancer do not participate.  We will test whether a personalised SMS from the doctor, to their patients phone, will people completing and returning the home test kit sent.  The SMS will contain a message from the person's doctor recommending they do it, a video testimonial from someone affected by bowel cancer, a link to the website of the screening program for more information, and an animation of how to complete the home test kit.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014837</APP_ID>
        <Date_Announced>2022-01-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Elizabeth Buckley</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 TCR - Participation in Cancer Screening Programs</Sub_Type>
        <Grant_Title>A breakthrough approach to define screening gaps in priority groups to target screening</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$601,260.25</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cancer screening</Res_KW1>
        <Res_KW2>mammogram screening</Res_KW2>
        <Res_KW3>data linkage</Res_KW3>
        <Res_KW4>data analysis</Res_KW4>
        <Res_KW5>aboriginal health</Res_KW5>
        <Plain_Description>Improving breast screening participation requires accurate data of screening rates including within priority groups such as Aboriginal and Torres Strait Islander women, women from diverse cultural and language backgrounds and with different levels of educational attainment and income.  Linkage between Census and NSW screening records can provide best evidence of screening rates overall, within priority groups, and following the impact of COVID and previous attempts to improve screening.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014908</APP_ID>
        <Date_Announced>2022-01-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Lisa Whop</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 TCR - Participation in Cancer Screening Programs</Sub_Type>
        <Grant_Title>Embedding community driven models to increase cervical screening via HPV self-collection to improve cervical cancer outcomes for Aboriginal and Torres Strait Islander people</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,579,683.10</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | public health and health services | primary health care | public health and health services | preventive medicine | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>cervical screening</Res_KW2>
        <Res_KW3>community-based</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>equity</Res_KW5>
        <Plain_Description>Aboriginal and Torres Strait Islander people face an unfair burden of cervical cancer.  A new screening option lets people take their own sample; this may make screening easier. Working with communities and health services dedicated to Aboriginal and Torres Strait Islander health needs we will co-design ways services can use self-collection and other strategies that best suit them and their communities. This work will engage more people to participate in screening in a culturally safe environment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014964</APP_ID>
        <Date_Announced>2022-01-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Eleonora Feletto</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 TCR - Participation in Cancer Screening Programs</Sub_Type>
        <Grant_Title>MAIL, GP, and SCALE: Mobilising nAtIonaL bowel cancer screeninG Program participation through combining individual, health ServiCe, and populAtion Level intervEntions</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,749,059.70</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | primary health care | </Fields_of_Research>
        <Res_KW1>bowel cancer screening</Res_KW1>
        <Res_KW2>general practice</Res_KW2>
        <Res_KW3>intervention study</Res_KW3>
        <Res_KW4>disease modelling</Res_KW4>
        <Res_KW5>mass media</Res_KW5>
        <Plain_Description>We aim to better understand how Australians are screening for bowel cancer and design a new method for GPs to advocate for the National Bowel Cancer Screening Program, especially for people who screen outside the program but should not and those who have never or forgotten to screen. This project will take new and existing information on ways in which we can improve screening for bowel cancer and assess how they could be combined most effectively to prevent the greatest number of deaths.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015178</APP_ID>
        <Date_Announced>2022-01-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Claire Nightingale</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 TCR - Participation in Cancer Screening Programs</Sub_Type>
        <Grant_Title>It’s a gamechanger” – using HPV self-collection to improve equity and participation in Australia's National Cervical Screening Program</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,408,759.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | primary health care | public health and health services | preventive medicine | public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>human papillomavirus (hpv)</Res_KW1>
        <Res_KW2>cervical cancer</Res_KW2>
        <Res_KW3>equity</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>health care evaluation</Res_KW5>
        <Plain_Description>Integrating self-collection into Australia’s National Cervical Screening Program has game-changing potential to increase participation. We know that healthcare providers need more support to offer this option, and women need information to support decision-making. Our project will enable innovative solutions to support providers, women, and the scale-up of self-collection, and create an enabling environment for the consideration of models of care to increase access and equity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015215</APP_ID>
        <Date_Announced>2022-01-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Deborah Bateson</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 TCR - Participation in Cancer Screening Programs</Sub_Type>
        <Grant_Title>Overcoming Inequity: Increasing Cervical Screening Participation for People with Intellectual Disability (CIRCE)</Grant_Title>
        <Admin_Institution>Family Planning NSW</Admin_Institution>
        <State>NSW</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$1,433,806.71</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | care for disabled | public health and health services | health promotion | public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cervical cancer</Res_KW1>
        <Res_KW2>intellectual disability</Res_KW2>
        <Res_KW3>cancer screening</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>informed decision making</Res_KW5>
        <Plain_Description>People with intellectual disability (PWID) are under-screened for cervical cancer in Australia. Through a qualitative process, this project seeks to identify facilitators and barriers to screening. A cluster randomised controlled trial will be undertaken to test the effectiveness of a co-designed, co-produced suite of resources designed to support informed decision making and increase access and uptake of screening in the National Cervical Screening Program for PWID.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015286</APP_ID>
        <Date_Announced>2022-01-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jennifer Stone</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 TCR - Participation in Cancer Screening Programs</Sub_Type>
        <Grant_Title>BreastScreenPlus: A novel intervention targeting obesity-related barriers to mammographic screening</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$819,444.70</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | epidemiology | </Fields_of_Research>
        <Res_KW1>breast cancer</Res_KW1>
        <Res_KW2>mammogram screening</Res_KW2>
        <Res_KW3>obesity</Res_KW3>
        <Res_KW4>intervention study</Res_KW4>
        <Res_KW5>service delivery</Res_KW5>
        <Plain_Description>Eight breast cancer deaths are prevented for every 1,000 women aged 50-74 years who undergo biennial mammographic screening. However, despite the demonstrated benefits of (free) screening, many women fail to return for screening when next due. This project will evaluate a novel intervention nested within BreastScreen WA to improve the screening experience for both obese women and service delivery staff and thereby, increase rescreening participation in women with obesity. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015290</APP_ID>
        <Date_Announced>2022-01-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Gail Garvey</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 TCR - Participation in Cancer Screening Programs</Sub_Type>
        <Grant_Title>A preference-informed model to improve access and equity in bowel screening for Australia’s First Nations people through home care services</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$994,552.30</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>cancer screening</Res_KW2>
        <Res_KW3>bowel cancer screening</Res_KW3>
        <Res_KW4>health services research</Res_KW4>
        <Res_KW5>consumer preferences</Res_KW5>
        <Plain_Description>Bowel cancer is the third-most common cancer affecting Aboriginal and Torres Strait Islander Australians. Participation in the National Bowel Cancer Screening Program by Aboriginal and Torres Strait Islander people is lower than for non-Indigenous Australians. This project aims to increase participation among the Aboriginal and Torres Strait Islander Home Care Clients by co-developing and implementing a bowel cancer screening program that is informed by their preferences and values. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007402</APP_ID>
        <Date_Announced>2022-02-22T00:00:00</Date_Announced>
        <CIA_Name>Dr Skye McGregor</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Identifying the predictors and consequences of disparities in the uptake of HIV prevention and treatment programs in Australia: a national data linkage study</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,216,847.15</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | epidemiology | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv)</Res_KW1>
        <Res_KW2>disease prevention</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>sexual health</Res_KW4>
        <Res_KW5>infectious diseases</Res_KW5>
        <Plain_Description>We will create a national e-cohort of people with HIV, linking HIV diagnoses from 1997-2025 with nine other national datasets. This comprehensive dataset will enable us to achieve our aims of tracking and analysing: missed clinical opportunities for HIV testing, PrEP uptake and usage, HIV treatment uptake and adherence, and HIV-related morbidity and mortality. Outcomes will be used by Partner Organisations to develop tailored HIV programs, to achieve elimination of HIV transmission in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013921</APP_ID>
        <Date_Announced>2022-02-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Jason Grebely</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>A national program to scale-up point-of-care hepatitis C testing and treatment</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,498,085.85</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | infectious diseases | public health and health services | epidemiology | </Fields_of_Research>
        <Res_KW1>hepatitis c infection</Res_KW1>
        <Res_KW2>liver disease</Res_KW2>
        <Res_KW3>treatment strategies</Res_KW3>
        <Res_KW4>access</Res_KW4>
        <Res_KW5>treatment strategies</Res_KW5>
        <Plain_Description>Hepatitis C testing and treatment has declined in Australia, slowing elimination progress. Our team evaluated a new point-of-care test for detection of active hepatitis C infection in one hour, enabling same-visit diagnosis and treatment. This test is now approved in Australia and has changed how testing and treatment can be delivered. This Partnership Project will evaluate a national program funded by the Australian government to scale-up point-of-care hepatitis C testing in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014633</APP_ID>
        <Date_Announced>2022-02-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Andreas Obermair</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>A non-surgical alternative to hysterectomy for the treatment of endometrial cancer</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$739,425.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>endometrial cancer</Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>predictive</Res_KW3>
        <Res_KW4>molecular biology</Res_KW4>
        <Res_KW5>predictive</Res_KW5>
        <Plain_Description>This project aims to develop a personalised treatment decision tool used to counsel endometrial cancer patients about their surgical and non-surgical (hormonal) treatment options. It will take into account key attributes of importance such as fertility preservation, risk of surgical morbidity, risk of relapse, genetic factors, quality of life, patient values and treatment preferences. This work is of critical importance for patients with early onset endometrial cancer, and for frail patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014684</APP_ID>
        <Date_Announced>2022-02-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Helen Marshall</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Novel strategies to improve protection for pregnant women and medically at risk children from influenza and COVID-19 </Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$964,165.35</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | health promotion | </Fields_of_Research>
        <Res_KW1>pregnancy</Res_KW1>
        <Res_KW2>young children</Res_KW2>
        <Res_KW3>influenza</Res_KW3>
        <Res_KW4>covid-19</Res_KW4>
        <Res_KW5>influenza</Res_KW5>
        <Plain_Description>Pregnant women and children with chronic medical conditions are at increased risk of hospitalisation, intensive care admission and death from influenza and COVID-19 infections. However, there appears to be a high level of vaccine hesitancy among women of reproductive age.  We will develop “nudge” interventions to improve influenza and COVID vaccine uptake among pregnant women and medically at risk children and test the effectiveness of the interventions using randomised controlled trials. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014821</APP_ID>
        <Date_Announced>2022-02-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Yun-Hee Jeon</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Optimising functional and social independence and safety of older people living with dementia in care homes: Implementation research</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,206,733.71</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aged health care | </Fields_of_Research>
        <Res_KW1>dementia care</Res_KW1>
        <Res_KW2>rehabilitation</Res_KW2>
        <Res_KW3>aged care</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>aged care</Res_KW5>
        <Plain_Description>This program builds on true collaboration with the project partner organisations and decades of the research team's track records in promoting evidence informed best practice in dementia care, leveraging their extensive network of partners in research and the aged-care industry. The outcomes will inform researchers, service providers and policymakers working in the aged care sector about implementation of person centred, reablement approaches to dementia care, nationally and internationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015197</APP_ID>
        <Date_Announced>2022-02-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Gilles Guillemin</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 TCR - Biotoxin-related Illnesses</Sub_Type>
        <Grant_Title>An integrated platform for the early diagnosis and treatment of biotoxin-related illnesses in Australia like Chronic Inflammatory Response Syndrome</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,063,797.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | infectious diseases |</Fields_of_Research>
        <Res_KW1>fungal infection </Res_KW1>
        <Res_KW2>biomarkers </Res_KW2>
        <Res_KW3>chronic inflammatory disease </Res_KW3>
        <Res_KW4>fungal diagnosis </Res_KW4>
        <Res_KW5>immune response </Res_KW5>
        <Plain_Description>While many studies now suggest that living in dampness and mould can adversely affect the immune system in some people, few studies define tests that doctors could use to diagnose and treat affected individuals.  This research project will study both affected individuals and healthy controls, examining their blood, urine, and sweat along with other tests such as brain scans and environmental testing in their homes, in order to identify appropriate diagnostic tests that doctors can use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014696</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Ms Joanne Hedges</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>The Indigenous Australian HPV Cohort Study 2; continuation 5 to 10 years</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$3,107,613.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | </Fields_of_Research>
        <Res_KW1>indigenous australians</Res_KW1>
        <Res_KW2>human papillomavirus (hpv)</Res_KW2>
        <Res_KW3>cancer epidemiology</Res_KW3>
        <Res_KW4>cohort study</Res_KW4>
        <Res_KW5>cost-effectiveness</Res_KW5>
        <Plain_Description>Continuing a large, representative Indigenous adult cohort through which to track oral HPV infection, monitor early throat cancer and estimate cost-effectiveness of extensive HPV vaccination coverage in culturally safe ways is essential to yield critical information to include in the management armamentarium of health and wellbeing recommendations for Australia’s First Peoples. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014723</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ruth Peters</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>INTErGenerational intervention to Reduce fraIlTY trial (INTEGRITY). </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,711,897.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aged health care | </Fields_of_Research>
        <Res_KW1>frailty</Res_KW1>
        <Res_KW2>older people</Res_KW2>
        <Res_KW3>multiple risk factors</Res_KW3>
        <Res_KW4>community intervention</Res_KW4>
        <Res_KW5>community participation</Res_KW5>
        <Plain_Description>The recent ABC TV show ‘Old People’s Home For Four Year Olds’ shows on-screen benefits of bringing together older adults and pre-schoolers. This has enormous potential to benefit our ageing society and similar programs are becoming popular. but a TV show is not the same as everyday life. We now need to establish how these benefits work in a realistic everyday setting. We will test this using a community-based clinical trial: the INTErGenerational Intervention to Reduce fraIlTY trial (INTEGRITY).</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014729</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Lexine Stapinski</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Making Inroads: RCT of a web-based early intervention to interrupt the vicious cycle of co-occurring anxiety and hazardous alcohol use among young adults</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,295,748.84</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | mental health | </Fields_of_Research>
        <Res_KW1>anxiety</Res_KW1>
        <Res_KW2>alcohol abuse</Res_KW2>
        <Res_KW3>cognitive behaviour therapy</Res_KW3>
        <Res_KW4>young adults</Res_KW4>
        <Res_KW5>early intervention</Res_KW5>
        <Plain_Description>Anxiety and alcohol disorders often co-occur, fueling each other in a self-perpetuating cycle. Early intervention is crucial to engage people with effective management strategies when problematic symptoms first emerge, and before anxiety and alcohol use disorders become entrenched. This study will evaluate the Inroads program, an online early intervention to empower young adults, enhance coping skills, and interrupt the vicious cycle between anxiety and hazardous alcohol use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014740</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Trisha Peel</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (CALIPSO): multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$4,343,709.10</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | infectious diseases | clinical sciences | surgery | clinical sciences | anaesthesiology | </Fields_of_Research>
        <Res_KW1>prophylaxis</Res_KW1>
        <Res_KW2>cardiac surgery</Res_KW2>
        <Res_KW3>infection control</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>antimicrobial resistance</Res_KW5>
        <Plain_Description>Infections following surgery lead to significant patient suffering and healthcare costs. The administration of antibiotics at the time of surgery is an important strategy to prevent infections. In patients undergoing heart surgery we do not know whether there is an additional benefit to giving longer courses of antibiotics following surgery to help prevent infections or if this will lead to patient harm, such as drug-resistant infections. This project will answer these important questions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014750</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Joanne Said</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>PRECeDe: Prevention of neonatal Respiratory morbidity with antenatal corticosteroids prior to Elective Caesarean section in women with Diabetes: A Randomised trial</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,409,951.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>paediatrics and reproductive medicine | obstetrics and gynaecology | </Fields_of_Research>
        <Res_KW1>caesarean section</Res_KW1>
        <Res_KW2>neonatal respiratory distress syndrome</Res_KW2>
        <Res_KW3>gestational diabetes</Res_KW3>
        <Res_KW4>transient neonatal hyperglycaemia</Res_KW4>
        <Res_KW5>corticosteroids</Res_KW5>
        <Plain_Description>This research trial will determine whether giving corticosteroid injections to pregnant women with diabetes before elective Caesarean section between 35+0 and 39+6 weeks reduces the rate of breathing problems in their babies. We will study the short-term benefits and side effects in the mothers and babies, and also determine whether giving corticosteroid injections is good value for money.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014763</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Assam El-Osta</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Epigenetic Protection Predicts Risk Diabetic Nephropathy (EPICENTRE)</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$4,897,328.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>diabetes mellitus</Res_KW1>
        <Res_KW2>renal disease</Res_KW2>
        <Res_KW3>diabetic nephropathy</Res_KW3>
        <Res_KW4>dna methylation</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>Diabetes affects over 1 million Australians and disproportionately affects Indigenous Australians. We have established an international EPICENTRE consortium now seek to explore the potential role of epigenetic modifications to explain the development of diabetic renal disease. Over the last decade we have developed contemporary genomic technologies and new approaches that specifically characterise epigenetic modifications using overt renal disease as the primary outcome.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014800</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Patrick Kwan</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Personalised Selection of Medication for Newly Diagnosed Adult Epilepsy – the PERSONAL Trial</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,459,115.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>neurosciences | central nervous system | </Fields_of_Research>
        <Res_KW1>epilepsy</Res_KW1>
        <Res_KW2>decision support</Res_KW2>
        <Res_KW3>antiepileptic drugs</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>artificial neural networks</Res_KW5>
        <Plain_Description>We have trained a machine learning prediction model that can assist neurologists to select the most effective initial antiseizure medication for individual patients with newly diagnosed epilepsy. We propose a randomised controlled trial (PERSONAL) to evaluate whether incorporating the machine learning model in initial drug selection can render more patients seizure-free compared to usual care. A total of 234 patients will be recruited from 14 epilepsy centres across all six states of Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014833</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Daniel McAullay</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>A primary care provider intervention to improve early child neurodevelopment in Urban Aboriginal children</Grant_Title>
        <Admin_Institution>Edith Cowan University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,992,864.40</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | </Fields_of_Research>
        <Res_KW1>child development</Res_KW1>
        <Res_KW2>aboriginal child</Res_KW2>
        <Res_KW3>community child health</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>maternal mental health</Res_KW5>
        <Plain_Description>Despite a high level of developmental issues in Aboriginal babies, there has been no primary health care delivered early child development program starting in the first 4 weeks of life. We will address Aboriginal child’s development by improving primary health care’s ability to deliver child development services. We will do this by seeing if the CCD program commenced in the first 4-weeks of life will improves a child’s developmental needs in the first year of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014841</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Philip Batterham</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>The LifeTrack Project: Population-based longitudinal cohort study to understand suicidal transitions</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,062,723.20</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | mental health | </Fields_of_Research>
        <Res_KW1>suicide prevention</Res_KW1>
        <Res_KW2>suicide risk</Res_KW2>
        <Res_KW3>population-based</Res_KW3>
        <Res_KW4>longitudinal cohort study</Res_KW4>
        <Res_KW5>psychiatric epidemiology</Res_KW5>
        <Plain_Description>We don't understand why some people who think about suicide go on to make a suicide attempt, while others recover. There have been very few studies following individuals at risk of suicide over an extended time period. We will test a group of people with suicidal thoughts for three years to work out whether there are certain types of people who are more resistant to suicide attempt. We will use the information from the study to identify new ways to reduce suicide risk in the population. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014868</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Gregory Fox</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>The FLIRT-TB study: A fluoroquinolone-based regimen to treat the commonest form of drug-resistant tuberculosis </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$4,773,516.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>mycobacterium tuberculosis</Res_KW1>
        <Res_KW2>drug resistance</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>tuberculosis</Res_KW5>
        <Plain_Description>Tuberculosis (TB) is an infectious respiratory disease affecting 10 million people each year worldwide. Resistance to isoniazid, one of the most important first-line antibiotics used to treat TB, leads to increased mortality and more advanced drug resistance. We will undertake the first clinical trial to evaluate the effectiveness of new-generation fluoroquinolones antibiotics in treating isoniazid-resistant TB. This trial will be conducted in Australia, Vietnam and Canada.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014896</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Rachael Moorin</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Are calcium channel blockers associated with breast cancer? Assessing the impact of long-term use in large longitudinal cohorts</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,107,757.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>breast cancer</Res_KW1>
        <Res_KW2>pharmacoepidemiology</Res_KW2>
        <Res_KW3>high blood pressure</Res_KW3>
        <Res_KW4>data linkage</Res_KW4>
        <Res_KW5>longitudinal cohort study</Res_KW5>
        <Plain_Description>Breast cancer is the commonest cancer in women. Calcium channel blockers (CCBs) are frequently used worldwide to treat high blood pressure. A link between use of CCBs and breast cancer has been proposed with mixed findings in North American, European and Asian women. No data exist for Australian women or across populations. Since 1 in 8 Australian women will be diagnosed with breast cancer by age 85 years, it is important to determine whether this risk is increased by the use of CCBs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014899</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Megan Galbally</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Perinatal depression and antidepressants treatment: wave 7 follow up of the MPEWS longitudinal cohort study </Grant_Title>
        <Admin_Institution>The University of Notre Dame Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,585,413.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | psychiatry (incl. psychotherapy) | </Fields_of_Research>
        <Res_KW1>cohort study</Res_KW1>
        <Res_KW2>longitudinal study</Res_KW2>
        <Res_KW3>maternal depression</Res_KW3>
        <Res_KW4>antidepressants</Res_KW4>
        <Res_KW5>child development</Res_KW5>
        <Plain_Description>When examining the longer term outcomes from pregnancy treatment with antidepressants on maternal depression and on child developmental outcomes, randomized controlled trials for antidepressants are not ethically possible and as such cohort data are required. Currently there remains uncertainty about antidepressant treatment in pregnancy for clinicians and women. We will address this gap in cohort studies through undertaking a follow up wave of a prospective longitudinal pregnancy cohort study. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014900</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Asha Bowen</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>SNAP-PY: Staphylococcus aureus Network Adaptive Platform trial for Paediatrics and Youth</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,045,957.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>staphylococcus aureus</Res_KW1>
        <Res_KW2>antibiotic therapy</Res_KW2>
        <Res_KW3>randomised controlled trial (rct)</Res_KW3>
        <Res_KW4>bacteraemia</Res_KW4>
        <Res_KW5>paediatric</Res_KW5>
        <Plain_Description>Staphylococcus aureus is the most common cause of bloodstream infections resulting in hospital admission for children. The best antibiotic treatments for children are not known. The Staph aureus Network Adaptive Platform trial for Paediatrics and Youth (SNAP-PY) will find out the best antibiotic treatments for children and adolescents. This will optimise antibiotic treatment for children with Staph aureus bloodstream infections and reduce premature deaths.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014930</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Dr Danielle Wurzel</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Translatable Evidence To Improve Lung Health Outcomes In First Nations People – A Cohort Study From Birth to 6 Years </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,723,567.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>cardiorespiratory medicine and heamatology | respiratory diseases | public health and health services | aboriginal and torres strait islander health | paediatrics and reproductive medicine | paediatrics | </Fields_of_Research>
        <Res_KW1>lung function assessment</Res_KW1>
        <Res_KW2>disease prevention</Res_KW2>
        <Res_KW3>indigenous health</Res_KW3>
        <Res_KW4>aboriginal child</Res_KW4>
        <Res_KW5>cohort study</Res_KW5>
        <Plain_Description>Good lung health as an adult depends on how healthy we are as children. Good lung health predicts future heart health and how long we live.  First Nations children have unacceptably high rates of lung disease which means poorer adult health. There are certain exposures or events in childhood that can be protective or damaging to our lungs. This research will look at a range of these exposures and events and study them in detail to discover ways to help improve the health of FirstN People.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014932</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Dr Lucia Romani</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Can mass drug administration reduce the incidence of adverse perinatal outcomes and other health consequences of endemic sexually transmitted infections? A community effectiveness trial</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,148,887.90</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | pacific peoples health | public health and health services | preventive medicine | paediatrics and reproductive medicine | obstetrics and gynaecology | </Fields_of_Research>
        <Res_KW1>population health</Res_KW1>
        <Res_KW2>sexual health</Res_KW2>
        <Res_KW3>gonorrhoea</Res_KW3>
        <Res_KW4>chlamydia</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Sexual and reproductive health is an urgent global public health priority in Fiji and the Pacific region, where curable sexually transmitted infections (STIs) are endemic. This world first trial will use mass drug administration with azithromycin to reduce the prevalence of chlamydia and gonorrhoeae in a population of >180,000 people in Fiji and will be the first to measure the effect of MDA on serious complications of STIs in the general population.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014936</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Linda Mileshkin</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$494,131.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>oncology</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>ovarian cancer</Res_KW3>
        <Res_KW4>targeted therapy</Res_KW4>
        <Res_KW5>survival rate</Res_KW5>
        <Plain_Description>In Australia ovarian cancer is the most common cause of gynaecological cancer death. Despite surgery and chemotherapy 80% of affected women have cancer relapse which is ultimately fatal.  This international randomised clinical trial examines if combining 2 targeted therapies, cediranib and olaparib tablets taken after finishing chemotherapy, will help women live longer without cancer progression. The trial  will complete recruitment in 2022 and this funding will ensure patient follow-up continues</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014937</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kristen Gibbons</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Resuscitation in Paediatric Septic Shock using Mega-Dose Vitamin C and Hydrocortisone - A Randomised Controlled Multicentre Trial (RESPOND study)</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,305,172.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>paediatrics and reproductive medicine | paediatrics | </Fields_of_Research>
        <Res_KW1>clinical trial</Res_KW1>
        <Res_KW2>paediatric</Res_KW2>
        <Res_KW3>septic shock</Res_KW3>
        <Res_KW4>intensive care</Res_KW4>
        <Res_KW5>ascorbic acid</Res_KW5>
        <Plain_Description>Globally, a child dies from sepsis every 10 seconds; in Australia, a child dies every week. Many surviving children experience long term adverse outcomes. Australian states are implementing mandates for sepsis treatment. Yet, the evidence for sepsis treatment other than antibiotics is limited. We will perform an international study for children with sepsis which will test the use of mega-dose vitamin C and steroids - a promising treatment that has already shown some benefit in adults.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014952</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Henry Brodaty</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Understanding intergenerational change in the health and well-being of older adults and its effects: The Sydney Memory and Ageing Study 2.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,304,760.16</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aged health care | </Fields_of_Research>
        <Res_KW1>aged health</Res_KW1>
        <Res_KW2>cognition</Res_KW2>
        <Res_KW3>physical health</Res_KW3>
        <Res_KW4>mental health</Res_KW4>
        <Res_KW5>social health issues</Res_KW5>
        <Plain_Description>Has there been a generational change in health of older Australians? We aim to compare the cognitive, physical, psychological and social health of current older Australians and those from 17 years ago. Each generation undergoes different experiences compared to previous ones; these can effect health.  We will repeat and expand (using new technology) on our 2005+ survey of 1037 70-90 year olds to answer this question. Answers will shed light on protective factors and inform health planning. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014954</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Victoria Manning</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>AAT-APP Trial: A RCT of alcohol approach-avoidance training to reduce heavy drinking in people with alcohol use disorders</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$948,498.04</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>psychology | psychology not elsewhere classified | public health and health services | mental health | </Fields_of_Research>
        <Res_KW1>alcohol use disorders</Res_KW1>
        <Res_KW2>addiction treatment</Res_KW2>
        <Res_KW3>impulsivity</Res_KW3>
        <Res_KW4>health service utilisation</Res_KW4>
        <Res_KW5>randomised controlled trial (rct)</Res_KW5>
        <Plain_Description>When people undergoing alcohol treatment are given computerised training to avoid alcohol images, and approach positive images instead, it reduces their likelihood of relapsing. We have developed and tested the world’s first smartphone app that delivers a personalised version of this “approach/avoidance training” (“AAT-App”). We now aim to determine how effective AAT-App is at reducing alcohol use and craving in a large sample of people with alcohol dependence who are not receiving treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014960</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Dr Ary Serpa Neto</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>SODA-BIC: Sodium Bicarbonate For Decompensated Metabolic Acidosis in the Intensive Care Unit, A Multicentre, Randomised, Double-Blind Clinical Trial</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,920,486.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | intensive care | </Fields_of_Research>
        <Res_KW1>intensive care</Res_KW1>
        <Res_KW2>critical care medicine</Res_KW2>
        <Res_KW3>metabolic acidosis</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Metabolic acidosis is a term that means that the blood is acidic. Patients with this condition are typically very ill and may die. No specific therapy exists, but sodium bicarbonate (a cheap and widely available drug) may improve the condition of these patients. We will randomly (like tossing a coin) treat severe patients with either sodium bicarbonate or inactive fluid given into a vein by continuous drip. We will compare the mortality rate and the use of haemodialysis within the first 30 days.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014980</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Nicholas Lintzeris</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>A randomised controlled trial of cannabidiol (CBD) in the treatment of cannabis dependence</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,120,137.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | clinical sciences not elsewhere classified | clinical sciences | psychiatry (incl. psychotherapy) | public health and health services | aboriginal and torres strait islander health | </Fields_of_Research>
        <Res_KW1>cannabis</Res_KW1>
        <Res_KW2>substance use disorders</Res_KW2>
        <Res_KW3>randomised controlled trial (rct)</Res_KW3>
        <Res_KW4>addiction treatment</Res_KW4>
        <Res_KW5>aboriginal mental health</Res_KW5>
        <Plain_Description>Cannabis use is increasing in Australia, yet there are few effective treatments for cannabis dependence. This study will evaluate cannabidiol (CBD) combined with counselling to reduce illicit cannabis use and improve health and social outcomes, compared to placebo in a randomised trial with 250 participants across services in NSW and Victoria. Aboriginal people comprise 20% of people in treatment for cannabis, and we will purposively examine their outcomes and experiences in the study.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015020</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Parsons</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Magnetic Resonance imaging outcomes in the Colchicine After Stroke to Prevent Event Recurrence (MR-CASPER) trial</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,535,098.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>post-stroke dementia</Res_KW1>
        <Res_KW2>ischaemic stroke</Res_KW2>
        <Res_KW3>neuroinflammation</Res_KW3>
        <Res_KW4>magnetic resonance imaging (mri)</Res_KW4>
        <Res_KW5>cognition</Res_KW5>
        <Plain_Description>MR-CASPER is a multi-centre, prospective, randomised, double-blind trial of the anti-inflammatory agent colchicine to prevent recurrent stroke and rapid progression of atherosclerotic disease. The trial uses novel, serial Magnetic Resonance Imaging (MRI) of the brain and cerebral blood vessels to measure outcomes alongside cognitive, mood and quality of life assessments. MR-CASPER will give crucial mechanistic insights into the effects of colchicine on brain and blood vessel inflammation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015060</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Simon Craig</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Childhood febrile convulsions - do treatment patterns determine the risk of early recurrence? </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,490,416.30</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | emergency medicine | </Fields_of_Research>
        <Res_KW1>child health</Res_KW1>
        <Res_KW2>emergency medicine</Res_KW2>
        <Res_KW3>randomised controlled trial (rct)</Res_KW3>
        <Res_KW4>seizures</Res_KW4>
        <Res_KW5>caregivers</Res_KW5>
        <Plain_Description>A febrile convulsion in a young child is incredibly stressful. Parents often think their child is dying. Currently, no specific treatment is offered to parents when their child is discharged from hospital. Our research, to be conducted across 25 hospitals, will compare the current "wait and see" approach to treatment recommendations for regular doses of paracetamol or ibuprofen to control fevers. We hope to test if the new treatment reduces the risk of more seizures occurring in the same illness</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015100</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Bruce Campbell</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Accelerating clot lysis in ischemic stroke with dornase alfa in an Umbrella Bayesian Optimised Phase 2 trial</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,453,336.70</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>neurosciences | central nervous system | </Fields_of_Research>
        <Res_KW1>ischaemic stroke</Res_KW1>
        <Res_KW2>alternative thrombolytic agents</Res_KW2>
        <Res_KW3>haematology</Res_KW3>
        <Res_KW4>rural and remote health</Res_KW4>
        <Res_KW5>telemedicine</Res_KW5>
        <Plain_Description>Stroke remains a major cause of disability. Clot-dissolving medicines targeting fibrin can be rapidly delivered at most Australian hospitals. DNA extruded by white blood cells is another key structural component of clot. Dornase, an approved medicine for other diseases, dissolves DNA and we showed accelerated clot dissolving when combined with standard treatment. Our trial will test whether dornase can accelerate restoration of blood flow to improve outcomes in up to 300 patients with stroke.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015133</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Neil Thomas</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Avatar-mediated therapy for hallucinations: superiority trial (AMETHYST)</Grant_Title>
        <Admin_Institution>Swinburne University of Technology</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,746,774.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | health, clinical and counselling psychology | </Fields_of_Research>
        <Res_KW1>psychosis</Res_KW1>
        <Res_KW2>schizophrenia and related disorders</Res_KW2>
        <Res_KW3>cognitive behaviour therapy</Res_KW3>
        <Res_KW4>clinical psychology</Res_KW4>
        <Res_KW5>psychological treatment</Res_KW5>
        <Plain_Description>Hearing hostile and critical voices is a highly distressing experience that characterises psychosis. Current treatments have limited impact, and more potent therapies are urgently needed. A promising new approach uses virtual reality technology to recreate the voices the person hears as digital avatars, used in therapy sessions to help overcome this experience. This clinical trial will determine whether this therapy offers a more powerful therapeutic option than current recommended treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015140</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Dr Calum Roberts</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>A Surfactant Treatment Method for Modern Neonatal Care: SURFactant by SUPraglottic Airway (The SURFSUP RCT)</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,707,835.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>paediatrics and reproductive medicine | paediatrics | </Fields_of_Research>
        <Res_KW1>very preterm birth</Res_KW1>
        <Res_KW2>lung surfactant</Res_KW2>
        <Res_KW3>neonatal respiratory distress syndrome</Res_KW3>
        <Res_KW4>continuous positive airway pressure (cpap)</Res_KW4>
        <Res_KW5>neonatal intensive care (nicu)</Res_KW5>
        <Plain_Description>This trial will assess a new method of giving surfactant treatment into the lungs of premature babies with breathing difficulties. 'Supraglottic airway' are soft plastic devices that are easier to insert and more comfortable than current methods, which are challenging to learn and not possible for some neonatal units. We will test the effectiveness of supraglottic airway surfactant treatment, which will allow all babies who need surfactant to receive it in their birth hospital without delay.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015146</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Dr Ryan Courtney</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>EFFECT OF A VAPORISED NICOTINE PRODUCT vs VARENICLINE ON SMOKING CESSATION FOR LOW-SOCIOECONOMIC STATUS SMOKERS: A RANDOMISED TRIAL</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,659,251.03</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>smoking cessation</Res_KW1>
        <Res_KW2>smoking intervention</Res_KW2>
        <Res_KW3>randomised controlled trial (rct)</Res_KW3>
        <Res_KW4>intervention study</Res_KW4>
        <Res_KW5>social disadvantage</Res_KW5>
        <Plain_Description>Smoking cessation aids can support long-term smoking cessation, but quit rates from current approaches remain low. VNPs are one such approach that has shown some promise for cessation, but government and regulatory bodies have called for more trial evidence. Newer generation pod VNPs have not been evaluated in a clinical trial despite their popularity and wide use globally. Trial findings will have immediate practical applications and provide much needed evidence on a new alternative quit aid.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015147</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Thomas Snelling</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>ORVAC Stage 2 - Optimising Rotavirus Vaccine in Aboriginal Children: a double-blind, randomised, placebo-controlled, adaptive clinical trial of a third scheduled dose of oral rotavirus vaccine for Australian Aboriginal children.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,561,907.70</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | </Fields_of_Research>
        <Res_KW1>rotavirus</Res_KW1>
        <Res_KW2>diarrhoeal disease</Res_KW2>
        <Res_KW3>vaccine strategy</Res_KW3>
        <Res_KW4>aboriginal health</Res_KW4>
        <Res_KW5>randomised controlled trial (rct)</Res_KW5>
        <Plain_Description>Rotavirus can cause such bad diarrhoea in children that they need to be hospitalised. Aboriginal children in remote and rural parts of Australia are up to 20 times more likely to need hospitalisation with rotavirus than non-Indigenous children. There is a vaccine for rotavirus. Optimising Rotavirus Vaccination in Aboriginal Children (ORVAC) will test whether giving Aboriginal children aged 6-11 months an extra (booster) dose of rotavirus vaccine will give them better protection from rotavirus.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015173</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Dr Adrian Traeger</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>NUDG-ED: Trial of behavioural ‘nudging’ interventions to reduce unnecessary care for low back pain in the Emergency Department</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,119,327.80</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | health promotion | clinical sciences | emergency medicine | public health and health services | health information systems (incl. surveillance) | </Fields_of_Research>
        <Res_KW1>quality of care</Res_KW1>
        <Res_KW2>low back pain</Res_KW2>
        <Res_KW3>behavioural intervention</Res_KW3>
        <Res_KW4>communications/social research</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>In 2018 over 120 000 people went to an emergency department in Australia because of low back pain. Most had 'simple' low back pain, where medical care such as diagnostic imaging (x-Ray, CT, MRI) and strong opioid medicines offer little benefit. Yet 3 in every 4 patients still received this kind of care. Unnecessary care can harm patients and diverts substantial resources from where they are most needed. This project tests a new way to reduce unnecessary care in Australian hospitals.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015177</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Stuart Kinner</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Improving health outcomes in people with a dual diagnosis released from prison: a multi-jurisdictional, prospective cohort study</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,466,784.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | mental health | </Fields_of_Research>
        <Res_KW1>prison population</Res_KW1>
        <Res_KW2>health inequalities</Res_KW2>
        <Res_KW3>health service utilisation</Res_KW3>
        <Res_KW4>data linkage</Res_KW4>
        <Res_KW5>dual diagnosis</Res_KW5>
        <Plain_Description>People released from prison have poor health and die at a rate much higher than the general community. Among this already vulnerable group, people with co-occurring mental health and substance use problems (‘dual diagnosis’) are particularly at risk. This study will examine health and health service outcomes for 4,232 adults released from prisons in QLD, WA, NSW and VIC, and followed for more than 9 years through data linkage. The findings will inform improvements to throughcare nationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015203</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Gita Mishra</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Maternal and early life origins of adolescent menstrual disorders and pelvic pain </Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,475,456.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | public health and health services not elsewhere classified | public health and health services | epidemiology | </Fields_of_Research>
        <Res_KW1>menstruation</Res_KW1>
        <Res_KW2>adolescent</Res_KW2>
        <Res_KW3>dysmenorrhoea</Res_KW3>
        <Res_KW4>maternal health</Res_KW4>
        <Res_KW5>early childhood</Res_KW5>
        <Plain_Description>Menstrual disorders – irregular, heavy, or painful periods – and pelvic pain are common among adolescent girls and disrupt life activities. Not enough is known about the maternal and early life factors linked with these conditions. This study addresses evidence gaps with new data on menstruation in adolescence, combined with previous data available from these girls and their mothers. The new knowledge on the development of these conditions will inform and guide their prevention and management.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015208</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Sandra Eades</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>‘The Next Generation Aboriginal Youth Cohort Study’: Co-designing a strengths-based study to identify evidence-based, culturally strong, implementable strategies to improve youth health outcomes</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,619,818.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | public health and health services | epidemiology | public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>youth</Res_KW2>
        <Res_KW3>wellbeing</Res_KW3>
        <Res_KW4>aboriginal mental health</Res_KW4>
        <Res_KW5>resilience</Res_KW5>
        <Plain_Description>The project aims to undertake two waves of follow-up of young Aboriginal people from the 'Next Generation Youth Wellbeing study' in partnership with young people, their families and Aboriginal Community organisations. The study will examine changes in key health outcomes (social and emotional wellbeing, cardiovascular risk factors and avoidable injury) and factors that impact on those outcomes such as connection to culture, health behaviours and social challenges.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015248</APP_ID>
        <Date_Announced>2022-05-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Adrian Lowe</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2021 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Testing an implementable strategy to improve infant skin barrier to prevent asthma and preserve lung function: a 4-year follow-up of the existing PEBBLES RCT</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$756,239.42</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | preventive medicine | </Fields_of_Research>
        <Res_KW1>allergy prevention</Res_KW1>
        <Res_KW2>lung development</Res_KW2>
        <Res_KW3>asthma</Res_KW3>
        <Res_KW4>allergic airways disease</Res_KW4>
        <Res_KW5>neonatal</Res_KW5>
        <Plain_Description>We will test if improving the infant skin barrier by using daily regular skincare treatment can reduce early life asthma and lung function deficits. This trial may change infant skincare practices and reduce the amount of respiratory disease in our community. This is a follow-on study of our large NHMRC funded trial, testing if this intervention can improve skin barrier, and reduce the incidence of allergic sensitisation and food allergy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015584</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Fay Johnston</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Centre for Safe Air</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | epidemiology | public health and health services | environmental and occupational health and safety | applied economics | health economics | </Fields_of_Research>
        <Res_KW1>environmental epidemiology</Res_KW1>
        <Res_KW2>mathematical modelling</Res_KW2>
        <Res_KW3>risk assessment</Res_KW3>
        <Res_KW4>cost-effectiveness</Res_KW4>
        <Res_KW5>public health policy</Res_KW5>
        <Plain_Description>Outdoor air hazards like allergens, traffic emissions, and smoke cause a substantial health burden by contributing to diseases of the lungs, heart and brain. Some threats, like bushfire smoke, are increasing but research and policy responses remain fragmented across health and environmental fields.  We will bring together experts, policymakers, and consumers to create synergistic, innovative solutions for protecting community health in the face of existing and escalating airborne threats.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015587</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Tony Butler</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Violence Perpetration: Profiling, Prediction and Prevention</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>domestic violence</Res_KW1>
        <Res_KW2>aggression</Res_KW2>
        <Res_KW3>antisocial behaviour</Res_KW3>
        <Res_KW4>social and behavioural research</Res_KW4>
        <Res_KW5>childhood</Res_KW5>
        <Plain_Description>Violence is a major public health issue. It is a major cause of death, suffering and economic loss worldwide. The focus of this CRE is to better understand violence perpetration, and to facilitate improvements in its prediction and prevention. Eleven projects will observe individual factors such as early life experiences, cognition and medication use, and consider broader issues such as sentencing practices in court and how to optimize the collection and use of large violence-related data.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015611</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof John Wakerman</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>CRE for STrengthening Health Systems in Remote Australia (CRESTRA)</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | primary health care | </Fields_of_Research>
        <Res_KW1>health service accessibility</Res_KW1>
        <Res_KW2>health services research</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>remote communities</Res_KW4>
        <Res_KW5>rural and remote health services</Res_KW5>
        <Plain_Description>The Centre of Research Excellence for Strengthening Health Systems in Remote Australia brings together Australia’s leading remote health researchers and remote primary care services across four states to carry out a program of research that will ensure: (1) stable and competent staffing; (2) fair funding; and (3) well-coordinated health services, thereby improving access to high quality health services in remote areas, reducing hospitalisations and improving health outcomes at a lesser cost.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015613</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tamera Corte</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>CRE for Interstitial Lung Disease - towards Individualised Care</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>cardiorespiratory medicine and heamatology | respiratory diseases | </Fields_of_Research>
        <Res_KW1>pulmonary fibrosis</Res_KW1>
        <Res_KW2>individualising management</Res_KW2>
        <Res_KW3>disease aetiology</Res_KW3>
        <Res_KW4>phenotype</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>The Centre for Research Excellence in Interstitial Lung Disease (ILD) – towards Individualised Care (CRE-ILD) aims to transform and extend the lives of people with ILD, through effective, personalised approaches to identify and manage ILD. Building on our successful CRE for pulmonary fibrosis, exceptional national platforms and multidisciplinary expert team, CRE-ILD will broaden our focus to all ILD, in a personalised approach specifically addressing our patients’ identified research priorities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015615</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Rachelle Buchbinder</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>Australia and New Zealand Musculoskeletal (ANZMUSC)  Clinical Trials Network </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | rheumatology and arthritis | </Fields_of_Research>
        <Res_KW1>clinical effectiveness</Res_KW1>
        <Res_KW2>evidence-based health care</Res_KW2>
        <Res_KW3>capacity building</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>translation</Res_KW5>
        <Plain_Description>The Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trial Network was established in 2015 to address the immense burden of musculoskeletal conditions. With the aid of NHMRC-CRE investment (2018-22) we have already driven improvements in care. Our new CRE will significantly extend our reach, scope, depth and impact. Three new foci will be to bridge the bench to bedside gap, state-of-the-art trials of complex interventions, embedded in usual care, and 3) globalisation of our work.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015622</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Jeannette Milgrom</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>Science Translation for e-Psychological Perinatal Supports (STePPS CRE)</Grant_Title>
        <Admin_Institution>Institute for Breathing and Sleep</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | health, clinical and counselling psychology | psychology | developmental psychology and ageing | public health and health services | primary health care | </Fields_of_Research>
        <Res_KW1>maternal depression</Res_KW1>
        <Res_KW2>anxiety disorders</Res_KW2>
        <Res_KW3>psychological treatment</Res_KW3>
        <Res_KW4>mother-infant interaction</Res_KW4>
        <Res_KW5>internet service delivery</Res_KW5>
        <Plain_Description>Over 300,000 women give birth in Australia each year and 20% experience clinical depression, often with severe anxiety, either in pregnancy or the first postnatal year. By bringing together cutting edge Australian and international research in perinatal mental health, the goal is to reduce the burden of mental health difficulties on families and future generations. This CRE will produce better Knowledge, better Interventions and e-mental health treatments, Improved  access and treatment uptake.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015705</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Lindley</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>A Centre of Research Excellence to Accelerate Stroke Trial Innovation and Translation </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>randomised controlled trial (rct)</Res_KW1>
        <Res_KW2>stroke</Res_KW2>
        <Res_KW3>telemedicine</Res_KW3>
        <Res_KW4>public health impact</Res_KW4>
        <Res_KW5>public health policy</Res_KW5>
        <Plain_Description>Stroke remains a serious medical problem affecting tens of thousands of Australians each year. This CRE application will deliver better healthcare for those with stroke,  by co-designing new stroke trials with consumers, and using new technology to deliver stroke interventions in rural and remote Australia. Our 'whole of system" approach will speed up translation of new treatments and we will build a new generation of clinician researchers to increase future stroke research capacity. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015724</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kirsten Perrett</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Towards eradicating food allergy: from population to precision prevention, early intervention and management</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>paediatrics and reproductive medicine | paediatrics | </Fields_of_Research>
        <Res_KW1>food allergy</Res_KW1>
        <Res_KW2>paediatric</Res_KW2>
        <Res_KW3>population health</Res_KW3>
        <Res_KW4>allergy prevention</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Australia has the world’s highest rate of food allergy. We have made significant progress understanding strategies to prevent food allergy and are testing these in large clinical trials. We now aim to understand who will benefit from these strategies, to reduce the number of children developing allergies, how best to treat and manage allergy to improve the lives of those living with food allergy, and to rapidly transfer research findings into public health policy and clinical practice changes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015727</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Angela Morgan</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>Translational Centre for Speech Disorders</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>paediatrics and reproductive medicine | paediatrics and reproductive medicine not elsewhere classified | </Fields_of_Research>
        <Res_KW1>developmental disorders</Res_KW1>
        <Res_KW2>speech</Res_KW2>
        <Res_KW3>child development</Res_KW3>
        <Res_KW4>clinical genetics</Res_KW4>
        <Res_KW5>brain development</Res_KW5>
        <Plain_Description>One in 5 children have a speech or language disorder at school entry, with lifelong deficits in psychosocial, academic and employment outcomes. Current speech pathology management is severely limited because it focuses on symptoms and ignores critical growing evidence on underlying genetic and neural aetiologies. The vision of our CRE is to transform speech pathology, by identifying, understanding and targeting the underlying aetiology that results in the symptomatology. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015739</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Karen Canfell</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Centre for Research Excellence in Cervical Cancer Control (C4)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | preventive medicine | </Fields_of_Research>
        <Res_KW1>cervical screening</Res_KW1>
        <Res_KW2>vaccination</Res_KW2>
        <Res_KW3>cervical cancer</Res_KW3>
        <Res_KW4>human papillomavirus (hpv)</Res_KW4>
        <Res_KW5>screening</Res_KW5>
        <Plain_Description>This proposal will continue the work of our successful Centre of Research Excellence in Cervical Cancer Control - “C4”. To realise the elimination goal of cervical cancer, we will tackle the enormous inequities in access to cervical cancer control interventions, through implementation activities focused on achieving high and equitable participation in HPV vaccination, cervical screening, triage and treatment, including developing and evaluating new pathways for HPV self-collection for screening.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015747</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Susan Cotton</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>The Centre of Research Excellence in Bipolar Disorder (CORE-BD)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | mental health | </Fields_of_Research>
        <Res_KW1>bipolar affective disorder</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>early intervention</Res_KW3>
        <Res_KW4>quality of care</Res_KW4>
        <Res_KW5>quality of life</Res_KW5>
        <Plain_Description>Bipolar disorder (BD) is a pervasive and debilitating disorder. The Centre of Research Excellence in Bipolar Disorders (CORE-BD) presents a unique opportunity for Australia to position itself as an international leader in BD research, spanning early detection and intervention, through to helping those with chronic BD. By growing workforce capacity, we will ensure research findings are implemented into practice in order to help reduce the burden experienced by those impacted by BD. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015820</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof James Ward</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Urban Indigenous Health </Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | </Fields_of_Research>
        <Res_KW1>aboriginal health</Res_KW1>
        <Res_KW2>access to health care</Res_KW2>
        <Res_KW3>community health care</Res_KW3>
        <Res_KW4>health systems</Res_KW4>
        <Res_KW5>social determinants of health</Res_KW5>
        <Plain_Description>Unmet health needs for urban Indigenous Australians are well documented, alongside a persistent gap in health research conducted with this population. Australia’s first Centre of Research Excellence in Urban Indigenous Health will drive innovative research aimed at achieving excellence in health care delivery. Our CRE will harness existing partnerships and infrastructure to develop the next generation of health researchers to drive Australia's first urban Indigenous health research agenda. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015821</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Ruth Hubbard</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>Frailty ADD: Improving Hospital Outcomes for Frail Patients Across Different Disciplines</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | geriatrics and gerontology | public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>frailty</Res_KW1>
        <Res_KW2>hospitals</Res_KW2>
        <Res_KW3>multidisciplinary</Res_KW3>
        <Res_KW4>medical education</Res_KW4>
        <Res_KW5>clinical practice</Res_KW5>
        <Plain_Description>Frail patients are often harmed in hospitals. This CRE will improve hospital outcomes for frail patients by helping healthcare systems understand the impact of frailty on outcomes and costs, developing clinical practice guidelines for frailty informed care across multiple disciplines, developing a core outcome set for frail patients, and upskilling the next generation of researchers and clinicians to continue the legacy of this CRE.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015843</APP_ID>
        <Date_Announced>2022-09-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Iona Novak</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>DRIVE CP: Directing Research In Very Early Cerebral Palsy</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | health and community services | public health and health services | care for disabled | </Fields_of_Research>
        <Res_KW1>cerebral palsy</Res_KW1>
        <Res_KW2>cerebral palsy treatments</Res_KW2>
        <Res_KW3>allied health</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>translation</Res_KW5>
        <Plain_Description>Cerebral Palsy (CP) is common (1 in 700) and the cost is immense (0.14% GDP). The rate has fallen by 30% meaning more is possible. Our CRE is co-designed with consumers to directly address the priorities set by consumers in our National CP strategy. Together we will diagnose CP early through a national screening program, then develop and transmit new early interventions, that reduce severity and improve independence. We will use artificial intelligence to automate screening for diagnosis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015501</APP_ID>
        <Date_Announced>2022-09-05T00:00:00</Date_Announced>
        <CIA_Name>Dr Kheng-Seong Ng</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-NIHR Collaborative Research Grant Scheme Round 1</Sub_Type>
        <Grant_Title>Pathway Of Low Anterior Resection syndrome relief after Surgery (POLARiS) trial</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,106,974.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>cancer</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>rectum</Res_KW3>
        <Res_KW4>gastrointestinal surgery</Res_KW4>
        <Res_KW5>quality of life</Res_KW5>
        <Plain_Description>Disease-free survival is usually regarded as the most important consideration after rectal cancer surgery. As survival outcomes have improved, there is increasing focus on ‘survivorship’ and QoL. One important determinant of QoL is post-operative bowel function which can be deleteriously impacted by surgery. Optimal management of bowel dysfunction following surgery (LARS) remains unclear. This trial will compare 3 interventions for LARS, and assess their influence on QoL and cost-effectiveness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015726</APP_ID>
        <Date_Announced>2022-09-05T00:00:00</Date_Announced>
        <CIA_Name>Prof Nadine Foster</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-NIHR Collaborative Research Grant Scheme Round 1</Sub_Type>
        <Grant_Title>The clinical and cost-effectiveness of lumbar fusion surgery for patients with persistent, severe low back pain: FusiOn veRsus bEst coNServative Care (the FORENSIC trial)</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,373,198.49</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | orthopaedics | clinical sciences | physiotherapy | clinical sciences | surgery | </Fields_of_Research>
        <Res_KW1>orthopaedic surgery</Res_KW1>
        <Res_KW2>back pain</Res_KW2>
        <Res_KW3>physiotherapy</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>health economics</Res_KW5>
        <Plain_Description>Lumbar fusion is an operation in which bones in the spine (vertebrae) are fixed together to try to help patients who have persistent low back pain that is thought to be related to specific spine changes seen on scans. We do not know whether this type of surgery for these patients is better than offering further high quality non-surgical care. We will conduct a large trial to test whether lumbar fusion surgery is better for patients and the healthcare system than high quality non-surgical care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017548</APP_ID>
        <Date_Announced>2022-09-05T00:00:00</Date_Announced>
        <CIA_Name>Prof Christel Middeldorp</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-EU Collaborative Research Grant Scheme</Sub_Type>
        <Grant_Title>Youth-GEMs: Gene Environment interactions in Mental health trajectories of Youth</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$499,332.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | psychiatry (incl. psychotherapy) | </Fields_of_Research>
        <Res_KW1>prediction </Res_KW1>
        <Res_KW2>longitudinal cohort study </Res_KW2>
        <Res_KW3>adolescent health </Res_KW3>
        <Res_KW4>child health </Res_KW4>
        <Res_KW5>biomarkers </Res_KW5>
        <Plain_Description>Mental disorders in children and adolescents have a large impact on the individuals, their families and society. This project aims to improve prediction of mental health trajectories by including biological markers as that will facilitate targeted intervention. We will make use of already collected data in various cohorts in the general population, but will also collect longitudinal data in at risk clinical populations, presenting to emergency departments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017566</APP_ID>
        <Date_Announced>2022-09-05T00:00:00</Date_Announced>
        <CIA_Name>Prof Roslyn Boyd</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-EU Collaborative Research Grant Scheme</Sub_Type>
        <Grant_Title>Clinical validation of Artificial Intelligence for providing a personalized motor clinical profile assessment and rehabilitation of upper limb in children with unilateral Cerebral Palsy</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$499,778.84</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>paediatrics and reproductive medicine | paediatrics | neurosciences | central nervous system | clinical sciences | rehabilitation and therapy (excl. physiotherapy) | </Fields_of_Research>
        <Res_KW1>cerebral palsy </Res_KW1>
        <Res_KW2>hemiplegic cerebral palsy </Res_KW2>
        <Res_KW3>cerebral palsy treatments </Res_KW3>
        <Res_KW4>neuroscience </Res_KW4>
        <Res_KW5>stroke rehabilitation </Res_KW5>
        <Plain_Description>Cerebral Palsy is the most common physical disability in childhood (1 in 700) and Hemiplegia is the most common form (40%).  Children with hemiplegia have impairments to hand function and mobility that impact self care, participation in school and leisure and long term vocational aspirations.  Accurate diagnosis is important for accessing tailored interventions, individualised rehabilitation and prognosis for education, employment and independent living.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017666</APP_ID>
        <Date_Announced>2022-09-05T00:00:00</Date_Announced>
        <CIA_Name>Dr Eva Zopf</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-EU Collaborative Research Grant Scheme</Sub_Type>
        <Grant_Title>PREFERABLE-II - Personalised Exercise-Oncology for improvement of supportive care: a super umbrella trial to demonstrate the (cost)effectiveness of live-remote exercise in cancer survivors</Grant_Title>
        <Admin_Institution>Cabrini Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$457,547.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | human movement and sports science | exercise physiology | </Fields_of_Research>
        <Res_KW1>exercise </Res_KW1>
        <Res_KW2>supportive care </Res_KW2>
        <Res_KW3>quality of life </Res_KW3>
        <Res_KW4>side-effects </Res_KW4>
        <Res_KW5>cancer </Res_KW5>
        <Plain_Description>Cancer and its treatment can lead to sustained deleterious side effects. Exercise can improve long-term cancer side effects and quality of life; yet, access to high-quality exercise support is not routinely available. PREFERABLE-II evaluates the (cost)-effectiveness of a convenient, live-remote exercise intervention that targets common cancer-related side effects. The project aims to improve the accessibility of best-practice exercise to all cancer survivors and improve supportive cancer care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017786</APP_ID>
        <Date_Announced>2022-09-05T00:00:00</Date_Announced>
        <CIA_Name>Prof Yuming Guo</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-EU Collaborative Research Grant Scheme</Sub_Type>
        <Grant_Title>Improvement of school indoor air quality and children's health</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$499,557.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | environmental and occupational health and safety | public health and health services | epidemiology | public health and health services | preventive medicine | </Fields_of_Research>
        <Res_KW1>indoor air pollution </Res_KW1>
        <Res_KW2>environmental epidemiology </Res_KW2>
        <Res_KW3>child </Res_KW3>
        <Res_KW4>environmental intervention </Res_KW4>
        <Res_KW5>environmental health </Res_KW5>
        <Plain_Description>This Australian project will conduct short-term controlled trials to assess the effect of change in indoor air quality in primary schools on the health and cognitive outcomes of children in Melbourne. Together with InChildHealth supported by H2020, this project will fill information gaps for the indoor air quality legal framework, providing guidelines and recommendations that support health promotion and disease prevention for children in the schools.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017837</APP_ID>
        <Date_Announced>2022-09-05T00:00:00</Date_Announced>
        <CIA_Name>Prof Kevin Thomas</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-EU Collaborative Research Grant Scheme</Sub_Type>
        <Grant_Title>Identification of chemical and biological determinants, their sources, and strategies to promote healthier homes in Europe (INQUIRE)</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$499,818.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | environmental and occupational health and safety | </Fields_of_Research>
        <Res_KW1>indoor air pollution </Res_KW1>
        <Res_KW2>air pollution </Res_KW2>
        <Res_KW3>environmental health </Res_KW3>
        <Res_KW4>chemical exposure </Res_KW4>
        <Res_KW5>exposure assessment </Res_KW5>
        <Plain_Description>While Australians are estimated to spend roughly 90% of their time indoors, we understand little about the air pollutants that may be present in homes.  As part of a broader European study, this project aims to assess air and dust samples from Australian homes, along with urine samples from residents, to characterise indoor air pollutants, map their sources, and determine impacts on health. This knowledge can be used to guide policy and industry towards approaches to improve indoor air quality.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018124</APP_ID>
        <Date_Announced>2022-09-05T00:00:00</Date_Announced>
        <CIA_Name>Prof Angela Morgan</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-EU Collaborative Research Grant Scheme</Sub_Type>
        <Grant_Title>Risk and Resilience in Developmental Diversity and Mental Health</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$499,734.30</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>genetics | genomics | </Fields_of_Research>
        <Res_KW1>behaviour genetics </Res_KW1>
        <Res_KW2>molecular genetics </Res_KW2>
        <Res_KW3>speech and language development </Res_KW3>
        <Res_KW4>developmental disorders </Res_KW4>
        <Res_KW5>mental health </Res_KW5>
        <Plain_Description>Mental health problems affect a staggering 20% of the Australian population and cost our government $11 billion dollars in 2019-2020. Within any 12 month period, over half a million Australian children experience a mental disorder and prevalence is highest for those with pre-existing neurodevelopmental disorders. Current management is failing as it focuses entirely on mental health risk. Our pioneering work will move the field to understand and promote resilience in EU and Australian contexts.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018165</APP_ID>
        <Date_Announced>2022-09-05T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Klaus Oliver Schubert</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-EU Collaborative Research Grant Scheme</Sub_Type>
        <Grant_Title>PSYCH-STRATA  -  A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$498,335.30</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | psychiatry (incl. psychotherapy) | medicinal and biomolecular chemistry | molecular medicine | genetics | genetics not elsewhere classified | </Fields_of_Research>
        <Res_KW1>psychiatry </Res_KW1>
        <Res_KW2>drug treatment </Res_KW2>
        <Res_KW3>drug resistance </Res_KW3>
        <Res_KW4>schizophrenia </Res_KW4>
        <Res_KW5>mood disorders </Res_KW5>
        <Plain_Description>About 30% of people suffering from mental illnesses such as schizophrenia, bipolar disorder, and major depression don't benefit from treatment with standard medicines and have "treatment resistance" (TR). TR leads to great individual suffering and often to a sense of "failure". The vision of PsychSTRATA is to pave the way for a shift from the current step-wise trial-and-error paradigm of psychiatric therapies towards targeted early introduction of intensive treatments for people at risk of TR.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015018</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Iona Novak</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>TRANSMIT: A multifaceted knowledge TRANslation Strategy iMprovIng funcTion in children and youth with cerebral palsy </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,420,252.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>paediatrics and reproductive medicine | paediatrics | </Fields_of_Research>
        <Res_KW1>cerebral palsy</Res_KW1>
        <Res_KW2>evidence-based clinical practice</Res_KW2>
        <Res_KW3>translational research</Res_KW3>
        <Res_KW4>neurological disability</Res_KW4>
        <Res_KW5>allied health</Res_KW5>
        <Plain_Description>One third of children with cerebral palsy (CP) will never walk, and one quarter will never talk. These children receive ineffective treatments 43% of the time, lowering their chance of employment. We will build a mobile health aide that filters effective intervention options for children with CP, that overcomes the need to understand complex health information, and that supports consumers to choose, clinicians to provide, and policymakers to reimburse effective treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015440</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Dr Miranda Blake</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Promoting CHANGE (Community Health And Nutrition, and Government Engagement): a Randomised Controlled Trial to accelerate healthy food retail in local government settings</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,169,876.49</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>nutrition and dietics | public nutrition intervention | </Fields_of_Research>
        <Res_KW1>nutrition</Res_KW1>
        <Res_KW2>randomised controlled trial (rct)</Res_KW2>
        <Res_KW3>health policy</Res_KW3>
        <Res_KW4>capacity building</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>This grant will test if an intervention to support retail outlets in Local Government settings (e.g. community sports centres) to improve availability and promotion of healthy food and drink is effective and delivers good value for money. The study will provide evidence from a rigorous randomised controlled trial to support the creation of healthier food environments. Ultimately this will improve what people eat and help reduce the risk of diet-related diseases in an effective and sustained way.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015462</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Robyn Richmond</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>BUBs Quit study: Clinical Midwife Specialist to assist pregnant women to quit smoking using counselling and embedded technology</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,245,561.55</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>nursing | midwifery | public health and health services | preventive medicine | </Fields_of_Research>
        <Res_KW1>midwifery</Res_KW1>
        <Res_KW2>pregnancy</Res_KW2>
        <Res_KW3>smoking intervention</Res_KW3>
        <Res_KW4>translational research</Res_KW4>
        <Res_KW5>policy development</Res_KW5>
        <Plain_Description>This study will determine the effectiveness of the BUBs Quit smoking cessation intervention delivered by trained midwives compared to usual care in assisting pregnant women to quit during pregnancy and maintain abstinence at 6 months post-birth. We will explore factors affecting integration of the intervention into usual maternity care. We expect that the BUBs Quit intervention will reduce smoking rates among pregnant women compared to the comparison group by at least 8.5% and be cost effective.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015470</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Stevenson</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Delivering a population-based intervention to reduce young driver crashes</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$865,506.36</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>road safety</Res_KW1>
        <Res_KW2>injury epidemiology</Res_KW2>
        <Res_KW3>accident prevention</Res_KW3>
        <Res_KW4>evaluation</Res_KW4>
        <Res_KW5>population health</Res_KW5>
        <Plain_Description>Road crashes are a leading cause of injury mortality and morbidity. As a consequence of advances in telematics technology, there is an opportunity to deliver a unique prevention strategy that will influence a drivers’ risk taking and hence crash propensity. We propose a randomised controlled trial to assess the effects of personalised safety feedback and financial incentives, delivered using a smartphone application, on reducing motor vehicle crashes over the first 6-months of driving</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015514</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Susan Davis</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>MenoPROMPT: a co-designed, comprehensive, evidence-based program to improve the care of women at and after menopause.</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,096,144.35</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>women's health</Res_KW1>
        <Res_KW2>menopause</Res_KW2>
        <Res_KW3>disease prevention</Res_KW3>
        <Res_KW4>primary care</Res_KW4>
        <Res_KW5>clinical practice guidelines</Res_KW5>
        <Plain_Description>Menopausal symptoms are frequently debilitating. Despite readily available, safe therapy, most severely symptomatic women are not receiving evidenced-based therapy. We will develop a simple menopause assessment and decision-making tool, that will be integrated into general practitioner (GP) software, so that key information is immediately accessible to GPs, together with a pre-consultation women’s health self-assessment tool, delivered by SMS, to ensure menopausal symptoms are not overlooked. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015532</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Dr Judith Munday</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>The PeriWarm Trial: Transforming perioperative temperature management for better patient outcomes</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,145,483.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>nursing | clinical nursing: secondary (acute care) | clinical sciences | anaesthesiology | clinical sciences | surgery | </Fields_of_Research>
        <Res_KW1>implementation</Res_KW1>
        <Res_KW2>hypothermia</Res_KW2>
        <Res_KW3>anaesthesia</Res_KW3>
        <Res_KW4>surgery</Res_KW4>
        <Res_KW5>multidisciplinary</Res_KW5>
        <Plain_Description>Perioperative hypothermia occurs when patients undergoing surgery lose body heat. As well as discomfort, heat loss also causes other adverse health outcomes including wound infection, increased blood loss, longer hospital stays and increased costs. Although guidance to prevent perioperative hypothermia is available, this guidance is not widely used. This project seeks to reduce perioperative hypothermia through assisting health care providers to use guidance and improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015544</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Reema Harrison</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Smarter hospitals: Unlocking the promise of virtual models of care through infrastructure innovation in Australian healthcare facilities</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,276,987.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | health and community services | </Fields_of_Research>
        <Res_KW1>health systems</Res_KW1>
        <Res_KW2>quality of care</Res_KW2>
        <Res_KW3>access to health care</Res_KW3>
        <Res_KW4>hospitals</Res_KW4>
        <Res_KW5>electronic health information</Res_KW5>
        <Plain_Description>Virtual models of care can improve patient health outcomes and their healthcare experience, at a reduced cost in comparison to face-to-face care. Significant evidence gaps remain about how to design healthcare facilities to integrate virtual care, how to ensure equitable health outcomes when using virtual care, and how to support workforce change management. Our program of work provides the evidence and solutions required by our Partner Organisations and health services nationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015744</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Katharine Wallis</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>RELEASE: REdressing Long-tErm Antidepressant uSE in general practice</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$652,769.80</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | primary health care | </Fields_of_Research>
        <Res_KW1>general practice</Res_KW1>
        <Res_KW2>quality of care</Res_KW2>
        <Res_KW3>prescribing</Res_KW3>
        <Res_KW4>mental health services</Res_KW4>
        <Res_KW5>patient safety</Res_KW5>
        <Plain_Description>Our aim is to improve Australian health outcomes by decreasing unnecessary and potentially harmful long-term (&amp;gt;12 months) prescribing of antidepressants in general practice. The outcomes of our research will include a validated antidepressant discontinuation model and proven implementation strategies, including practical resources where currently there are none, to foster sustainable improvement in primary mental health care, including for urban and rural general practice. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015751</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Mario Alvarez-Jimenez</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Digitally Enhancing Youth Mental Health Services across Australia: cluster RCT of an Adaptive, TaiLored, and behAvioural Science-informed (ATLAS) Implementation Strategy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,306,238.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | psychiatry (incl. psychotherapy) | </Fields_of_Research>
        <Res_KW1>mental health services</Res_KW1>
        <Res_KW2>early intervention</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>health services research</Res_KW4>
        <Res_KW5>psychological treatment</Res_KW5>
        <Plain_Description>The mental health system is overwhelmed and has catastrophically failed to meet the needs of those with mental-ill health. Despite the potential for digital technology to be a pillar of a modern, sustainable, and adaptive mental health system, digital interventions have not been integrated into mental health services. This aim of this project is to address this global failure by integrating a fully-funded, evidenced-based digital platform (MOST) in a large network of mental health services.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015773</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Rachael Morton</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Strengthening Healthcare Systems with Patient Reported Outcome Measures (PROMs) </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,166,592.10</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>quality of care</Res_KW1>
        <Res_KW2>patient/doctor communication</Res_KW2>
        <Res_KW3>quality of life</Res_KW3>
        <Res_KW4>health systems</Res_KW4>
        <Res_KW5>health surveys</Res_KW5>
        <Plain_Description>The collection and use of Patient Reported Outcome Measures (PROMs) enhances two way communication between patients and clinicians, resulting in improved outcomes and quality of life for patients. This research aims to understand what makes PROMs acceptable to clinicians and consumers, when they should be collected, and how PRO data can best be displayed for quality assurance and care. This will facilitate use of PROMs in healthcare, driving change at an individual, service and system level. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015783</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Stoove</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Optimising public health notification systems to achieve hepatitis C elimination in Australia</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,383,550.42</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | health information systems (incl. surveillance) | </Fields_of_Research>
        <Res_KW1>hepatitis c infection</Res_KW1>
        <Res_KW2>health surveillance</Res_KW2>
        <Res_KW3>diagnostic test</Res_KW3>
        <Res_KW4>treatment strategies</Res_KW4>
        <Res_KW5>public health impact</Res_KW5>
        <Plain_Description>Australia can eliminate hepatitis C as a public health threat by sustaining high rates of hepatitis C treatment. But Australia’s rates of hepatitis C treatment have stalled over recent years. All hepatitis C diagnoses are notified to health departments and this partnership project will implement and evaluate a series of strategies across all states and territories and identify the most effective ways of following up notifications to enhance rates of hepatitis C treatment and cure in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015784</APP_ID>
        <Date_Announced>2022-09-16T00:00:00</Date_Announced>
        <CIA_Name>Dr Aswin Ratheesh</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects PRC3</Sub_Type>
        <Grant_Title>Bipolar Early intervention using New Digital technologies: a hybrid effectiveness-implementation trial of a multi-component model of evidence-based care</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,423,795.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | psychiatry (incl. psychotherapy) | </Fields_of_Research>
        <Res_KW1>bipolar affective disorder</Res_KW1>
        <Res_KW2>clinical effectiveness</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>early intervention</Res_KW4>
        <Res_KW5>relapse prevention</Res_KW5>
        <Plain_Description>Early intervention for young people with serious mood problems like Bipolar Disorder is largely unavailable in Australia. To address this, we have developed an innovative model of care that combines three effective interventions (BLEND). In this project, we will evaluate how effective the BLEND model is in improving young people’s quality of life, compared with standard mental health care. We will also aim to understand whether the strategies used to implement BLEND are acceptable and feasible.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016268</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Bernhard Lechtenberg</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>RBR E3 ubiquitin ligases in health and disease</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,476,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | biochemistry and cell biology | enzymes | biological sciences | biochemistry and cell biology | signal transduction</Fields_of_Research>
        <Res_KW1>ubiquitination </Res_KW1>
        <Res_KW2>protein biochemistry</Res_KW2>
        <Res_KW3>enzyme activity</Res_KW3>
        <Res_KW4>cell biology</Res_KW4>
        <Res_KW5>intracellular signal transduction</Res_KW5>
        <Plain_Description>Cells in the human body constantly process signals to react to changes in their environment. Errors in cellular signalling cause diseases like cancers and neurodegeneration. One key signalling molecule is the small protein ubiquitin.  My program will develop tools to uncover how the processes involved in ubiquitin signalling occur normally and how they can cause disease. This provides new opportunities to understand basic biology, discover and exploit new drug targets, and develop novel medicines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016274</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Ian Davis</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>More accurate disease assessment and improved clinical decision-making for patients with urothelial cancers</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,468,555.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies</Fields_of_Research>
        <Res_KW1>bladder cancer </Res_KW1>
        <Res_KW2>diagnostic marker</Res_KW2>
        <Res_KW3>clinical research</Res_KW3>
        <Res_KW4>minimal residual disease</Res_KW4>
        <Res_KW5>treatment evaluation</Res_KW5>
        <Plain_Description>Cancers of the bladder and similar tissues (“urothelial cancers”) can cause major health issues, including shortened survival and significant loss of quality of life. Some patients can benefit from more aggressive treatment while others will not, but we cannot yet tell who. We have developed a simple, quick, and easy method to look for urothelial cancer DNA in the blood. This project will test that method to see if it can help predict who might need more treatment and for whom it can be spared.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016277</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Janet Sluggett</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Leveraging big data to maximise the impact of pharmacists on medicines safety in aged care</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,261,112.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacy and pharmacy practice | health sciences | health services and systems | aged health care</Fields_of_Research>
        <Res_KW1>pharmacoepidemiology </Res_KW1>
        <Res_KW2>pharmacy</Res_KW2>
        <Res_KW3>aged care</Res_KW3>
        <Res_KW4>health services research</Res_KW4>
        <Res_KW5>medications</Res_KW5>
        <Plain_Description>The recent Aged Care Royal Commission recommended urgent action to improve medicines use in aged care services. This project will tell us more about the effects of medicines when they are used by people receiving aged care services, so that health professionals can make improvements. It will also establish a system to guide best practice for pharmacists who work in aged care settings and monitor for improvements in medicines use, health and wellbeing among people who receive aged care services.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016279</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Ye In (Jane) Hwang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>"No Place to Grow Old": Advancing health care and management of Australia's ageing prisoners</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$630,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>prison population </Res_KW1>
        <Res_KW2>health inequalities</Res_KW2>
        <Res_KW3>health literacy</Res_KW3>
        <Res_KW4>health outcomes</Res_KW4>
        <Res_KW5>ageing population</Res_KW5>
        <Plain_Description>This research was designed in response to the rapid ageing of Australia’s prisoner population, which is creating new, unique and expensive challenges to criminal justice and public health. The research aims to generate important data regarding the health and functioning status of older prisoners. It also aims to inform better health and service provision upon release from prison, where older prisoners are at particular risk of adverse outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016283</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Heather Lee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Detailing epigenetic mechanisms in cancer evolution for improved patient outcomes</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours</Fields_of_Research>
        <Res_KW1>dna methylation </Res_KW1>
        <Res_KW2>epigenetics</Res_KW2>
        <Res_KW3>acute myeloid leukaemia (aml)</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>sequencing</Res_KW5>
        <Plain_Description>  Cancers are very difficult to cure because they can adapt to therapy, become resistant and recur. The ability to evade treatment is linked to the diversity of cells in a cancer: the more keys a cancer has, the more likely it is to unlock resistance and escape therapy. This research project will explore cell diversity and cancer adaptation in a devastating blood cancer, revealing new treatments that can delay or prevent recurrence.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016286</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Narelle Cox</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving access to non-pharmacological treatment in chronic respiratory disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,526,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy</Fields_of_Research>
        <Res_KW1>telemedicine </Res_KW1>
        <Res_KW2>rehabilitation</Res_KW2>
        <Res_KW3>chronic obstructive pulmonary disease (copd)</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>For people with chronic lung disease, pulmonary rehabilitation improves symptoms and function, and helps reduce healthcare costs. Yet very few (less than 10%) people who would benefit from pulmonary rehabilitation have ever done a program. This work will explore new ways to deliver pulmonary rehabilitation, including directly to people’s homes, to make access to programs easier. If more people can access and thus benefit from pulmonary rehabilitation, health system costs could be reduced.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016301</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Louise Birrell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Stemming the rising tide of youth mental health problems: prevention through social connection</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$621,850.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care</Fields_of_Research>
        <Res_KW1>mental health </Res_KW1>
        <Res_KW2>mental health promotion</Res_KW2>
        <Res_KW3>adolescence</Res_KW3>
        <Res_KW4>substance misuse</Res_KW4>
        <Res_KW5>prevention</Res_KW5>
        <Plain_Description>Mental health problems, such as depression and anxiety, are rising in recent cohorts of adolescents. This research aims to generate new knowledge about effective prevention for these problems. It will utilise large-scale longitudinal data, include a world-first RCT and generate practical guidelines for the implementation of effective prevention within secondary school settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016308</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Alastair Stewart</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Structure-function relationships in drug transport and inhibition of membrane proteins</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling)</Fields_of_Research>
        <Res_KW1>structural biology </Res_KW1>
        <Res_KW2>membrane protein</Res_KW2>
        <Res_KW3>electron microscopy</Res_KW3>
        <Res_KW4>bioenergetics</Res_KW4>
        <Res_KW5>drug transport</Res_KW5>
        <Plain_Description>This project will study how drugs interact with bacterial targets and drug transporters. This work is instrumental in antimicrobial drug development and will also potentially increase current drug potency and effectiveness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016324</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof David J. (Jamie) Cooper</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Improving critically ill patient outcomes through randomised trials and registries in intensive care </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,487,110.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | intensive care</Fields_of_Research>
        <Res_KW1>intensive care medicine </Res_KW1>
        <Res_KW2>critical illness</Res_KW2>
        <Res_KW3>traumatic brain injury (tbi)</Res_KW3>
        <Res_KW4>blood transfusion</Res_KW4>
        <Res_KW5>respiratory failure</Res_KW5>
        <Plain_Description>Around 50% of Australians will be admitted to an intensive care unit in their lifetime, with more than 175,000 intensive care admissions each year. As a global leader in intensive care, including founding binational infrastructure, my research program using the gold standard of phase III multicentre, randomised, controlled trials and registries will continue to deliver improvements in clinical decision-making and outcomes for critically ill patients, as well as significant healthcare savings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016330</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Trevor Lithgow</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Investigations into phage biology directed at therapies for antimicrobial resistant (AMR) infections</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,937,110.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents</Fields_of_Research>
        <Res_KW1>bacteriophage </Res_KW1>
        <Res_KW2>klebsiella</Res_KW2>
        <Res_KW3>bacterial pathogen</Res_KW3>
        <Res_KW4>antimicrobial resistance</Res_KW4>
        <Res_KW5>antibiotic resistance</Res_KW5>
        <Plain_Description>The rise of drug-resistant superbugs is a global problem with a bleak outlook. A projected increase to 10 million human deaths per year here and around the world can only be addressed with new, sustainable solutions. My vision applies computational and structural biology as well as biochemistry and microbiology to evaluate and optimize the properties of viruses called "phages" to either resolve infections directly or re-sensitize bacteria in infection sites to existing drugs in clinical use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016334</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Benjamin Weger</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>The Microbiota-Growth Hormone Axis - From Metabolic Function to Liver Disease</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | systems biology</Fields_of_Research>
        <Res_KW1>circadian rhythms </Res_KW1>
        <Res_KW2>liver</Res_KW2>
        <Res_KW3>control of gene expression</Res_KW3>
        <Res_KW4>signalling pathways</Res_KW4>
        <Res_KW5>endocrine</Res_KW5>
        <Plain_Description>Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease. If left untreated, it can progress to advanced scarring, liver failure or cancer. Current therapies are limited and for many patients, ineffective. This project will investigate the involvement of gut microbes in the development of NAFLD and whether their targeted modulation could provide new treatment options.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016338</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Currie</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Genetic basis for skeletal muscle formation and regeneration in development and disease </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,537,110.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination)</Fields_of_Research>
        <Res_KW1>muscle </Res_KW1>
        <Res_KW2>muscular dystrophy</Res_KW2>
        <Res_KW3>zebrafish</Res_KW3>
        <Res_KW4>stem cells</Res_KW4>
        <Res_KW5>muscle regeneration</Res_KW5>
        <Plain_Description>I am a biomedical scientist who focuses on understanding how skeletal muscle is made and maintained, and how this process is perturbed in diseases of childhood such as muscular dystrophies. I study muscle formation and growth and the role of muscle stem cells during injury and disease, collaborating widely with an international and national  clinical networks and with industry. My main research tool is the zebrafish model, where the processes I study can be dissected in living muscle tissue.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016346</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Ian Hickie</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Right care, first time: delivering technology-enabled mental health care to young people at scale</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,437,110.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services</Fields_of_Research>
        <Res_KW1>mental health services </Res_KW1>
        <Res_KW2>youth</Res_KW2>
        <Res_KW3>health policy</Res_KW3>
        <Res_KW4>access to health care</Res_KW4>
        <Res_KW5>health outcomes</Res_KW5>
        <Plain_Description>Providing highly-personalised mental health care to young people, as early as possible in an illness, is a global priority. COVID-19 has been particularly harsh on the mental health of youth. This program (‘Right Care, First Time') uses digital technologies, new health planning tools, early intervention services and socio-economic policies to drive local delivery. These approaches require detailed studies to test whether they can deliver better health and economic outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016379</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Caroline Homer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Reducing maternal and newborn deaths: Transforming midwifery in the Asia-Pacific region through research and innovation</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,437,110.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | reproductive medicine not elsewhere classified</Fields_of_Research>
        <Res_KW1>midwifery </Res_KW1>
        <Res_KW2>maternal health</Res_KW2>
        <Res_KW3>newborn</Res_KW3>
        <Res_KW4>maternal and child health</Res_KW4>
        <Res_KW5>nursing</Res_KW5>
        <Plain_Description>A reduction in maternal and newborn deaths and stillbirths in the Asia-Pacific region is urgently needed. Midwives can save lives; there are, however, significant gaps in the knowledge-base about how best to strengthen midwifery. This Investigator Grant will support primary research across the region to improve maternal and newborn health post COVID-19. The outcomes will ensure that maternal and newborn health services can withstand future shocks such as pandemics and natural disasters.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016380</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Angela Chiew</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving Outcomes in Paracetamol Poisoning </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$327,575.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | toxicology (incl. clinical toxicology)</Fields_of_Research>
        <Res_KW1>poisoning </Res_KW1>
        <Res_KW2>paracetamol toxicity</Res_KW2>
        <Res_KW3>acute liver injury</Res_KW3>
        <Res_KW4>clinical practice guidelines</Res_KW4>
        <Res_KW5>toxicology</Res_KW5>
        <Plain_Description>Each year paracetamol leads to >10,000 hospital presentations following deliberate self-poisoning and accidental overdose in Australia. It is also the leading cause of acute liver failure. This study aims to improve the management of paracetamol poisoning through evaluating the use and outcomes from updated 2020 guidelines and clinical studies on new tests and treatments. Outcomes from this research will aim to improve management and decrease the rate of liver injury from paracetamol poisoning.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016381</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Lucy Furfaro</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Sewers to cures: Bacteriophages as a targeted treatment for Group B Streptococcal infections</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology</Fields_of_Research>
        <Res_KW1>bacteriophage </Res_KW1>
        <Res_KW2>streptococcus agalactiae</Res_KW2>
        <Res_KW3>perinatal</Res_KW3>
        <Res_KW4>therapeutic agents</Res_KW4>
        <Res_KW5>molecular biology</Res_KW5>
        <Plain_Description>Group B Streptococci are bacteria that can transfer from mother to baby during birth and cause severe disease. Mothers who carry these bacteria receive antibiotics, which kill the bacteria but also affects the baby’s natural beneficial bacteria. My research will investigate a century old treatment using phages, viruses that kill specific bacteria. I will use advanced genetic techniques to achieve a targeted, safe and effective treatment as a future alternative to antibiotic use in pregnancy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016390</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Jeanie Cheong</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Optimising lifelong health and development for our most immature newborns</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,505,432.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology</Fields_of_Research>
        <Res_KW1>prematurity </Res_KW1>
        <Res_KW2>follow-up</Res_KW2>
        <Res_KW3>developmental outcomes</Res_KW3>
        <Res_KW4>risk prediction</Res_KW4>
        <Res_KW5>extremely low birth weight</Res_KW5>
        <Plain_Description>Extremely preterm births, before 28 weeks of pregnancy, carry lifelong risks to health and development. Many unanswered questions posing barriers to optimising their health and development will be addressed in this proposal. These include outcomes in their mid -30s, and outcomes after change in care practices, and the COVID pandemic. I will advance ways to predict individuals at highest risk, and implement a surveillance program to ensure consistency and best care for this vulnerable group.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016391</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Geoffrey McFadden</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Tools to curb drug resistance in malaria parasites</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,437,110.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | microbial genetics | biological sciences | microbiology | infectious agents | biomedical and clinical sciences | medical microbiology | medical parasitology</Fields_of_Research>
        <Res_KW1>antimalarial </Res_KW1>
        <Res_KW2>malaria drug resistance</Res_KW2>
        <Res_KW3>malaria transmission</Res_KW3>
        <Res_KW4>malaria therapy</Res_KW4>
        <Res_KW5>resistance spread</Res_KW5>
        <Plain_Description>Drug resistance is a major challenge to controlling malaria. Resistant parasites emerge, spread geographically &amp; eventually render our drugs useless. We have been on a treadmill of using, then losing, malaria drugs for decades. I will identify antimalarial compounds to stem the spread of drug resistance. I exploit the fact that malaria must spread via mosquitoes.  I find drugs for which resistant parasites get trapped in the mosquito stopping them infecting new people &amp; spreading resistance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016394</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Amanda Ullman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Preventing harm from central venous catheters for children treated for cancer</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | nursing | acute care</Fields_of_Research>
        <Res_KW1>paediatric </Res_KW1>
        <Res_KW2>adverse incidents including complications</Res_KW2>
        <Res_KW3>nursing practice</Res_KW3>
        <Res_KW4>cancer care</Res_KW4>
        <Res_KW5>health service decision making</Res_KW5>
        <Plain_Description>Children with cancer often need a central line, which is a plastic tube that delivers medicine to directly to their bloodstream. Unfortunately, these tubes can also cause significant harm, like infections and blood clots. My research aims to change clinical practice by testing new technologies and educating healthcare workers to deliver best practice care. We expect outcomes will improve the experience and safety of care for children with cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016396</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof James McCarthy</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Translational studies in infectious diseases</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,968,555.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical microbiology | medical microbiology not elsewhere classified</Fields_of_Research>
        <Res_KW1>acute infective illnesses </Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>clinical malaria</Res_KW3>
        <Res_KW4>clinical microbiology</Res_KW4>
        <Res_KW5>antimicrobial therapy</Res_KW5>
        <Plain_Description>Testing new drugs and vaccines for infectious diseases has been impeded by difficulties in finding out how well these work in humans. I have developed a system where healthy human volunteers are experimentally infected with a microbe to test drugs or vaccines in controlled conditions. This  has accelerated the development of drugs and vaccines to treat these infectious diseases. In this Program I will extend this work and establish new challenge systems to deliver new vaccines and treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016399</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Claire Rickard</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>The IVCare adaptive platform trial: Towards zero bloodstream infections in IV catheters</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | nursing | acute care</Fields_of_Research>
        <Res_KW1>nursing practice </Res_KW1>
        <Res_KW2>infection control</Res_KW2>
        <Res_KW3>bacteraemia</Res_KW3>
        <Res_KW4>hospitals</Res_KW4>
        <Res_KW5>acute care</Res_KW5>
        <Plain_Description>Life-saving medical treatments are delivered into the bloodstream via intravenous (IV) catheters. This risks bacteria also entering the bloodstream through the catheter and causing a deadly whole-body infection. My research will use an advanced clinical trial design to test new medical equipment and decision support tools to block bacteria entering catheters and avoid infections during IV therapy. This will make patients safer and improve hospital care in developed and developing countries.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016406</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Arun Azad</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Optimising radiopharmaceutical therapy to improve clinical outcomes in advanced prostate cancer </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,802,716.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies</Fields_of_Research>
        <Res_KW1>prostate cancer </Res_KW1>
        <Res_KW2>radiopharmaceuticals</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>hormone-refractory prostate cancer</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>I will lead innovative clinical trials using radiopharmaceuticals to target a protein called PSMA (prostate-specific membrane antigen), which is found on most prostate cancer cells. Using scans from these trials and tiny fragments of DNA called circulating tumour DNA (ctDNA), I will try to understand why some patients respond better to PSMA radiopharmaceuticals than others. This study will lead to better and more effective treatments for advanced prostate cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016407</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Lisa McHugh</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Evaluation of antenatal vaccines and vaccination programs in pregnancy</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | disease surveillance</Fields_of_Research>
        <Res_KW1>influenza </Res_KW1>
        <Res_KW2>pertussis</Res_KW2>
        <Res_KW3>vaccination</Res_KW3>
        <Res_KW4>pregnancy</Res_KW4>
        <Res_KW5>indigenous australians</Res_KW5>
        <Plain_Description>Antenatal influenza, pertussis and now COVID vaccines reduce the severity of these illnesses and prevent deaths in pregnancy and young babies. We need to know the uptake, safety and effectiveness of these vaccines in pregnancy using large study numbers and gold standard methods. First we must ensure the way we currently collect vaccination information in pregnancy in Australia is valid. Results will be used to advocate including pregnancy status in the Australian Immunisation Register.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016410</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Brett Collins</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>From structural mechanisms of endosomal trafficking to therapies for neurodegenerative diseases</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,132,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology | biological sciences | biochemistry and cell biology | protein trafficking | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling)</Fields_of_Research>
        <Res_KW1>endosomes </Res_KW1>
        <Res_KW2>structural biology</Res_KW2>
        <Res_KW3>membrane trafficking</Res_KW3>
        <Res_KW4>alzheimer disease</Res_KW4>
        <Res_KW5>parkinson disease</Res_KW5>
        <Plain_Description>Disruption of the endolysosomal system is directly linked to neurological dysfunction leading to dementia and other neurodegenerative disorders for which no effective treatments are available. This proposal will build on my world-leading studies of Retromer to better understand its mechanism of action and its role in sporadic and inherited neurodegenerative disorders, and to ultimately deliver new molecular therapies that can promote Retromer’s neuroprotective functions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016415</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Tafireyi Marukutira</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Ensuring equitable access to care for migrants living with HIV in sub-Saharan Africa:  Lessons learnt from an evaluation of Botswana’s migrant inclusive program</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>migrant health </Res_KW1>
        <Res_KW2>human immunodeficiency virus (hiv)</Res_KW2>
        <Res_KW3>access to health care</Res_KW3>
        <Res_KW4>patient satisfaction</Res_KW4>
        <Res_KW5>surveillance</Res_KW5>
        <Plain_Description>Migration is a key consideration in controlling the spread of HIV. There is no formal evaluation of national HIV public health programs that are inclusive of migrants. Botswana a country in sub-Saharan Africa, the epicentre of the HIV epidemic has run a migrant inclusive public program since 2020. My research will evaluate Botswana's program to document lessons learnt and explore the practicality of implementing a linked HIV surveillance system to track progress to HIV elimination.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016420</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Kathryn Hayward</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Enhancing motor recovery after stroke using a discovery pipeline approach</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | health sciences | allied health and rehabilitation science | rehabilitation</Fields_of_Research>
        <Res_KW1>stroke rehabilitation </Res_KW1>
        <Res_KW2>clinical studies</Res_KW2>
        <Res_KW3>translational research</Res_KW3>
        <Res_KW4>rehabilitation</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Our emergency response to stroke has significantly improved. Nevertheless, many people are still left with disability, and current rehabilitation interventions have limited impact. This Investigator Grant will improve rehabilitation options by advancing the way these options are developed. My work will help establish a higher standard for trials, led by Australia, for global use. Taken together, this research will ultimately drive the most promising rehabilitation interventions into practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016432</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Nigel Lee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Water injections: Transforming childbirth pain management for any woman, anywhere.</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | midwifery | clinical midwifery</Fields_of_Research>
        <Res_KW1>labour </Res_KW1>
        <Res_KW2>birth</Res_KW2>
        <Res_KW3>pain management</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Medical options for relief of childbirth pain are unavailable to many women in rural Australia. My previous research has proven that small injections of water are effective in reducing labour back pain with minimal side effects. My research aim is to develop a water injection technique that reduces abdominal labour pain that can be used safely in childbirth . This will provide a safe, effective and low cost option for labour pain management for women in rural and other birthing settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016438</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Joanne Ryan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Personalised Dementia Prevention: Clinical Trials, Advanced Modelling &amp; Biomarker Discovery</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,256,790.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care</Fields_of_Research>
        <Res_KW1>dementia </Res_KW1>
        <Res_KW2>alzheimer disease</Res_KW2>
        <Res_KW3>primary prevention</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>There is no cure for dementia but understanding why some individuals are more likely to develop dementia, will enable the implementation of effective strategies and treatments to help reduce the risk. This research program will use clinical trials to test new drug treatments for dementia prevention, and large studies in communities of older Australians to better understand who is most at risk and why. Together this research program will deliver major advances in dementia prevention.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016461</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Guillaume Lessene</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Drug Discovery and Chemical Biology of cell Death processes: Novel Insights and First-in-Class Therapeutics</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | biological sciences | biochemistry and cell biology | cell development, proliferation and death | chemical sciences | medicinal and biomolecular chemistry | biomolecular modelling and design</Fields_of_Research>
        <Res_KW1>drug discovery </Res_KW1>
        <Res_KW2>drug development</Res_KW2>
        <Res_KW3>anti-inflammatory agents</Res_KW3>
        <Res_KW4>ocular disease</Res_KW4>
        <Res_KW5>anticancer drug</Res_KW5>
        <Plain_Description>Cell death processes are key for our development and our health. Most diseases are linked to cell death deregulation, either allowing rogue cells to survive (as in cancer) or inducing the death of healthy cells (inflammatory conditions). This program of work is focussed on developing new small molecules that modulate cell death to achieve two goals: the creation of new medicines for cancer and inflammatory diseases and the provision of new probes to better understand cell death biology.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016464</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Maria Kavallaris</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Childhood cancer precision diagnostics and therapeutics </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,437,110.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified</Fields_of_Research>
        <Res_KW1>tumour targeting </Res_KW1>
        <Res_KW2>cancer research</Res_KW2>
        <Res_KW3>drug delivery systems</Res_KW3>
        <Res_KW4>drug resistance</Res_KW4>
        <Res_KW5>nanotechnology</Res_KW5>
        <Plain_Description>Cancer is the lead cause of disease-related death in children in Australia and other developed countries. Resistance to therapy, toxic side effects of treatment, and delivery of effective doses of drugs to aggressive cancers are a major obstacle to cure. Our research will identify the right treatment for the right patient and target treatment delivery to cancer cells, reducing toxicity to healthy tissue. This will provide better treatment options for patients with aggressive cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016491</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephen Kent</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Immunity, Vaccines and Therapeutics for pandemic viruses</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,937,110.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care</Fields_of_Research>
        <Res_KW1>infectious diseases </Res_KW1>
        <Res_KW2>humoral immunity</Res_KW2>
        <Res_KW3>cellular immunology</Res_KW3>
        <Res_KW4>virus</Res_KW4>
        <Res_KW5>vaccination immunology</Res_KW5>
        <Plain_Description>Major ongoing global viral pandemics have swept the world in recent decades, including SARS-CoV-2, influenza and HIV. I present 3 inter-related research themes to address control of SARS-CoV-2, influenza and HIV. My overall vision is to bring our understanding of immunity to SARS-CoV-2, influenza and HIV to the point where we can improve vaccination strategies and treatment paradigms for these viruses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016501</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Gregory Armstrong</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Preventing suicide by improving mass media reporting of suicide in South Asia</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | human society | anthropology | medical anthropology | health sciences | public health | social determinants of health</Fields_of_Research>
        <Res_KW1>suicide prevention </Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>social determinants of health</Res_KW3>
        <Res_KW4>interdisciplinary</Res_KW4>
        <Res_KW5>social environment</Res_KW5>
        <Plain_Description>Responsible media reporting of suicide is a core suicide prevention intervention. Yet, there is a profound lack of robust evidence globally on the impacts of optimised media reporting. My proposed research in the South Asia region represents a rare opportunity to conduct trials to address global evidence gaps around the impact of media interventions, given the baseline context of extremely poor-quality reporting, high suicide rates and limited prior suicide prevention activity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016513</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Ehsan Kheradpezhouh</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Understanding the physiological and pathological roles for Transient Receptor Potential (TRP) channels in the mammalian cortex</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$630,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | biomedical and clinical sciences | neurosciences | central nervous system | biomedical and clinical sciences | neurosciences | sensory systems</Fields_of_Research>
        <Res_KW1>cerebral cortex </Res_KW1>
        <Res_KW2>calcium signalling</Res_KW2>
        <Res_KW3>intracellular calcium</Res_KW3>
        <Res_KW4>sensory systems</Res_KW4>
        <Res_KW5>neurodegenerative disorders</Res_KW5>
        <Plain_Description>My recent discovery that transient receptor potential Ankyrin 1 (TRPA1) is expressed in rodent cortical neurons has shed light on its role in the mammalian brain. Recent studies have proposed a role for cortical TRPA1 in Alzheimer’s disease and Multiple Sclerosis, and further suggested that its activation leads to neuronal death. I will investigate the physiological and pathological roles of cortical TRPA1, focusing on its activation mechanisms to develop targeted therapies for these diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016530</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Brian Drew</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Leveraging Polygenic Risk and Genetics for Pre-clinical Discovery in Cardiometabolic Disease</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,806,790.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical physiology | systems physiology</Fields_of_Research>
        <Res_KW1>lipotoxicity </Res_KW1>
        <Res_KW2>mitochondrial function</Res_KW2>
        <Res_KW3>complex genetic disease</Res_KW3>
        <Res_KW4>muscle physiology</Res_KW4>
        <Res_KW5>fatty liver disease</Res_KW5>
        <Plain_Description>Cardiometabolic diseases such as obesity, diabetes and cardiovascular disease, account for more deaths in the developed world than any other condition. Our genes play a major part in the development of these conditions, however the specific causal genes remain unknown. This proposal will engage new genetic technologies to identify these specific genes, whilst validation studies in lab based models and exclusive access to human datasets will ensure translational and commercial relevance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016545</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Emmanuelle Souzeau</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Integrated genetic approaches to improve glaucoma diagnosis and management</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | ophthalmology</Fields_of_Research>
        <Res_KW1>glaucoma </Res_KW1>
        <Res_KW2>genetic testing</Res_KW2>
        <Res_KW3>genetic counselling</Res_KW3>
        <Res_KW4>clinical patient management</Res_KW4>
        <Res_KW5>consumer participation</Res_KW5>
        <Plain_Description>Glaucoma robs individuals of their vision; however, genetic testing can identify at-risk individuals early and influence management. My research program will advance knowledge on genes and variants for glaucoma, develop novel genetic testing reporting strategies for glaucoma in clinical practice, and assess current genetic testing services. This work will improve glaucoma diagnosis and clinical management, access to genetic services and support for patients and their families.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016547</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Nadia Davidson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Pioneering data analysis methods to decrypt the cancer transcriptome </Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | sequence analysis | biological sciences | bioinformatics and computational biology | genomics and transcriptomics</Fields_of_Research>
        <Res_KW1>bioinformatics </Res_KW1>
        <Res_KW2>gene transcription</Res_KW2>
        <Res_KW3>data analysis</Res_KW3>
        <Res_KW4>sequence analysis</Res_KW4>
        <Res_KW5>alternative splicing</Res_KW5>
        <Plain_Description>Recent advances in technology mean that RNA, the functional read-out of DNA, can be sequenced to a new level of detail. However, this technology results in masses of information that we do not yet have the capacity to analyse. My program will develop computational methods that will analyse RNA in cancer. This will enable us to understand the cellular events that allow cancers to develop and spread and how these can be targeted to accelerate development of new cancer therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016566</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Kathryn Ramsey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving prognosis and quality of life in children with muco-obstructive lung disease</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases</Fields_of_Research>
        <Res_KW1>respiratory medicine </Res_KW1>
        <Res_KW2>child health</Res_KW2>
        <Res_KW3>cystic fibrosis</Res_KW3>
        <Res_KW4>bronchiectasis</Res_KW4>
        <Res_KW5>lung function</Res_KW5>
        <Plain_Description>Cystic fibrosis and bronchiectasis are life-shortening lung conditions that develop in childhood and progress throughout life. My research is focused on early detection, monitoring, and treatment of these conditions to improve outcomes. Through the analysis of biological samples, we can examine the early pathways associated with worse outcomes later in life. This work can identify new targets for therapies to prevent and slow disease progression, and ultimately improve health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016596</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Anthony Purcell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>An integrated approach to antigen discovery in autoimmunity and cancer</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,537,110.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - proteins and peptides (incl. medical proteomics) | biomedical and clinical sciences | immunology | tumour immunology | biomedical and clinical sciences | immunology | cellular immunology</Fields_of_Research>
        <Res_KW1>mass spectrometry </Res_KW1>
        <Res_KW2>peptides</Res_KW2>
        <Res_KW3>antigen processing</Res_KW3>
        <Res_KW4>antigen presentation</Res_KW4>
        <Res_KW5>vaccine candidate molecules</Res_KW5>
        <Plain_Description>Understanding the targets of immune recognition provides insight into the molecular basis of disease; including vaccine and immunotherapy targets for infections and cancer, as well as insights into aberrant immune recognition leading to autoimmune conditions. As a world leader in antigen discovery, I will apply and further develop technologies to address immune specificity in a variety of cancers and autoimmune diseases to improve vaccine design, immune monitoring and immunotherapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016598</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Rebecca Bennett</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving the psychosocial wellbeing of adults with hearing loss through a mHealth intervention</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$574,120.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | audiology | health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | mental health services</Fields_of_Research>
        <Res_KW1>psychosocial </Res_KW1>
        <Res_KW2>wellbeing</Res_KW2>
        <Res_KW3>hearing loss</Res_KW3>
        <Res_KW4>communications/social research</Res_KW4>
        <Res_KW5>psychosocial adjustment</Res_KW5>
        <Plain_Description>Hearing loss is common in Australia. People with hearing loss often avoid social situations for fear of mishearing. They can feel left out and disconnected. Hearing aids alone are not enough. Audiologists are well-placed to help people cope with these feelings. My research will develop an App to provide effective emotional support for people with hearing loss. Audiologists will be trained to support client’s using the App within routine audiological care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016627</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Susan Davis</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Role of testosterone in preventing major morbidity in women</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,937,110.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology</Fields_of_Research>
        <Res_KW1>women's health </Res_KW1>
        <Res_KW2>sex hormones</Res_KW2>
        <Res_KW3>testosterone</Res_KW3>
        <Res_KW4>postmenopausal</Res_KW4>
        <Res_KW5>androgen-response</Res_KW5>
        <Plain_Description>This research will determine if the hormone testosterone (often considered a male hormone) can serve as a new therapy to protect against the leading causes of ill health in older women, namely muscle wasting, heart failure and loss of brain function. We will establish whether this same intervention can prevent premature bone loss and sexual dysfunction in younger women with premature ovarian insufficiency. These are all conditions for which there are no proven preventive interventions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016629</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Gemma Sharp</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Super smart Smartphones: Sensing changes in mental health and delivering just-in-time adaptive interventions</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology</Fields_of_Research>
        <Res_KW1>mental health </Res_KW1>
        <Res_KW2>internet</Res_KW2>
        <Res_KW3>health promotion</Res_KW3>
        <Res_KW4>body image</Res_KW4>
        <Res_KW5>mass media</Res_KW5>
        <Plain_Description>Body image concerns impact more than a third of young people and are linked with eating disorders, anxiety, depression and suicidality. This program of research will harness the popularity of smartphones to predict when young people are struggling with their body image from the way they are using their phones, and provide the right level of personalised support via “just in time” online interventions. If effective, this work will translate into improved body image for at-risk young people.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016641</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Samuel Chan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reducing infectious complications in kidney transplant recipients</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$393,090.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology</Fields_of_Research>
        <Res_KW1>population health </Res_KW1>
        <Res_KW2>microbial infections</Res_KW2>
        <Res_KW3>kidney disease</Res_KW3>
        <Res_KW4>transplantation</Res_KW4>
        <Res_KW5>clinical epidemiology</Res_KW5>
        <Plain_Description>Infections commonly occur following kidney transplantation and are associated with significant morbidity and mortality. My research program addresses this public health burden by designing clinical trials that are of critical importance to patients, caregivers and healthcare professionals. My aim is to ensure views of patients and caregivers are addressed so that my research is relevant to our nephrology community. My research program will benefit patients both in Australia and also globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016647</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Leanne Teoh</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reducing antibiotic overprescribing in dentistry</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | dentistry | dental therapeutics, pharmacology and toxicology</Fields_of_Research>
        <Res_KW1>dentistry </Res_KW1>
        <Res_KW2>therapeutics</Res_KW2>
        <Res_KW3>medical informatics</Res_KW3>
        <Res_KW4>qualitative research</Res_KW4>
        <Res_KW5>antibiotic use</Res_KW5>
        <Plain_Description>Dentists prescribe over 800,000 antibiotic prescriptions yearly and 55% are overprescribed. The aim of this multimodal study is to improve dental prescribing by determining the patient factors that influence dental antibiotic prescribing and providing dentists with a clinical decision prescribing tool, Drugs4dent, to improve prescribing. The outcome is aimed to be improved dental antibiotic use, and transforming the access to drug knowledge for dentists.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016662</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Brett Manley</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Improving Outcomes for Preterm Infants Through Randomised Clinical Trials</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,354,074.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology</Fields_of_Research>
        <Res_KW1>very preterm birth </Res_KW1>
        <Res_KW2>neonatal intensive care (nicu)</Res_KW2>
        <Res_KW3>neonatal respiratory distress syndrome</Res_KW3>
        <Res_KW4>neonatology</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Babies who are born early (premature) can face many health challenges. My research focuses on ways to improve how we care for premature babies in the first days and weeks of life, especially by supporting their breathing. I also want to explore new ways of doing research studies in premature babies so that we can get better at answering the most important questions. By improving the way we care for premature babies early in their lives, we can improve their health into childhood and even beyond.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016667</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Amanda Wade</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Implementation research to improve hepatitis C testing and treatment in rural and regional Australia</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation</Fields_of_Research>
        <Res_KW1>hepatitis c virus </Res_KW1>
        <Res_KW2>population health</Res_KW2>
        <Res_KW3>primary care</Res_KW3>
        <Res_KW4>access to health care</Res_KW4>
        <Res_KW5>cost-effectiveness</Res_KW5>
        <Plain_Description>I will use implementation research to increase access to hepatitis C testing and treatment in primary care in Western Victoria, and eliminate hepatitis C as a public health threat. Using data from this and a similar project in Cairns, I will determine which interventions are cost-effective in regional settings. Finally, I will help underserved regional areas in Australia to have better access to cost-effective testing and treatment in primary care, especially for people who inject drugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016668</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Dianna Magliano</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Identifying opportunities to reverse the diabetes epidemic: surveillance of diabetes, its complications and mortality </Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | disease surveillance</Fields_of_Research>
        <Res_KW1>diabetic complications </Res_KW1>
        <Res_KW2>diabetic vascular complications</Res_KW2>
        <Res_KW3>type 1 diabetes mellitus (insulin-dependent diabetes mellitus)</Res_KW3>
        <Res_KW4>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW4>
        <Res_KW5>end-stage kidney disease</Res_KW5>
        <Plain_Description>Diabetes is a serious disease causing deadly, disabling and costly complications. We need data to help us manage this pandemic. My research will tell us which complications are increasing and who are most at risk, in Australia and worldwide. It will also tell us which interventions are most effective. Together, this understanding will improve care for people with diabetes. It will ensure that interventions are well targeted which will in turn limit the global health expenditure on diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016686</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Xu Dong Zhang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Harnessing long noncoding RNAs for cancer diagnosis and treatment</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology</Fields_of_Research>
        <Res_KW1>cell biology </Res_KW1>
        <Res_KW2>cancer cell biology</Res_KW2>
        <Res_KW3>cancer research</Res_KW3>
        <Res_KW4>rna</Res_KW4>
        <Res_KW5>colon cancer mechanisms</Res_KW5>
        <Plain_Description>Cancer cells exploit a newly discovered class of molecules for their growth and resistance to treatment. This research program will develop a better understanding of how these molecules influence cancer initiation, progression, and treatment response. It will also uncover new biomarkers that reveal the presence of cancer, as well as new molecular targets for anti-cancer drugs. Findings from this research will pave the way towards earlier detection of cancer and more effective cancer treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016688</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Suzanne Miller</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Targeted neuroprotective treatments for fetal and neonatal brain injury</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health</Fields_of_Research>
        <Res_KW1>cerebral palsy </Res_KW1>
        <Res_KW2>cerebral palsy treatments</Res_KW2>
        <Res_KW3>very preterm birth</Res_KW3>
        <Res_KW4>fetal growth restriction</Res_KW4>
        <Res_KW5>low birth weight infant</Res_KW5>
        <Plain_Description>Neonatal brain injury is common in infants born preterm, with fetal growth restriction, or who suffer a severe lack of oxygen at birth. Having previously identified the neuropathology specific to these complications, I will now examine targeted neuroprotective treatments that address the specific mechanisms of brain injury. The results of my preclinical studies will inform clinical trials offering new therapies to reduce neonatal brain injury and prevent life-long neurodevelopment deficits.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016695</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Alison Ritter</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Improving alcohol and other drug policy by focussing on values</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,437,110.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>human society | policy and administration | public policy | human society | policy and administration | health policy | health sciences | health services and systems | health systems</Fields_of_Research>
        <Res_KW1>public health policy </Res_KW1>
        <Res_KW2>substance use</Res_KW2>
        <Res_KW3>illicit drug use</Res_KW3>
        <Res_KW4>policy analysis</Res_KW4>
        <Res_KW5>ethical issues</Res_KW5>
        <Plain_Description>What should governments do about alcohol and illicit drugs? The policies that are chosen need to be informed by evidence and reflect the goals and values of communities. This program of work on the role of values in policy development will result in more effective and value-aligned alcohol and illicit drug policies such that the harms experienced across communities from these substances can be reduced.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016698</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Gail Matthews</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Strengthening Australian Infectious Disease Clinical Research with a focus on vulnerable populations</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,256,790.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases</Fields_of_Research>
        <Res_KW1>hepatitis c infection </Res_KW1>
        <Res_KW2>hepatitis b infection</Res_KW2>
        <Res_KW3>human immunodeficiency virus (hiv)</Res_KW3>
        <Res_KW4>covid-19</Res_KW4>
        <Res_KW5>injecting drug use</Res_KW5>
        <Plain_Description>This research aims to study treatments for infectious diseases that affect particularly vulnerable communities including people who inject drugs and people living with HIV. It focuses on finding solutions that will aid progress towards elimination of hepatitis B and C, and towards managing the pandemics of HIV and COVID-19, through the establishment of high quality international collaborative clinical research.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016706</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Anne-Marie Laslett</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Alcohol's harm to others</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>human society | policy and administration | health policy</Fields_of_Research>
        <Res_KW1>alcohol </Res_KW1>
        <Res_KW2>health surveys</Res_KW2>
        <Res_KW3>health services research</Res_KW3>
        <Res_KW4>family studies</Res_KW4>
        <Res_KW5>child maltreatment</Res_KW5>
        <Plain_Description>This project aims to measure alcohol's harms to others, beyond the drinker, within families, communities, societies and public services. Using a new Australian survey, in-depth interviews and health, crime and welfare system datasets, the project will study how individuals, health and social services, systems and policies respond to problems caused by others’ drinking. The study will model how reduced heavy drinking will decrease harm from others' drinking, in Australia and internationally.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016719</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Kirsten McCaffery</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Transforming health literacy in Australia: a partnership approach</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,882,170.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | other health sciences | other health sciences not elsewhere classified</Fields_of_Research>
        <Res_KW1>health literacy </Res_KW1>
        <Res_KW2>shared clinical decision making</Res_KW2>
        <Res_KW3>decision support</Res_KW3>
        <Res_KW4>evidence-based health care</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>This program will develop interventions to build health literacy and shared decision making. It will also improve the health system’s capacity to meet the communication needs of people with low health literacy. This program will produce co-designed and tested evidence-based interventions that combine behavioural science with digital innovation and knowledge translation for scalable interventions to improve health literacy nationally and internationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016726</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Ivo Mueller</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>P. vivax Serological Testing &amp; Treatment: a novel intervention to facilitate malaria elimination</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,249,688.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiology not elsewhere classified</Fields_of_Research>
        <Res_KW1>plasmodium </Res_KW1>
        <Res_KW2>malaria control</Res_KW2>
        <Res_KW3>diagnostic applications</Res_KW3>
        <Res_KW4>relapse prevention</Res_KW4>
        <Res_KW5>mathematical modelling</Res_KW5>
        <Plain_Description>This research program aims to develop the diagnostic tools and clinical trials evidence to prove that a new public health intervention, P. vivax Serological Test and Treat (SeroTAT) can facilitate PV elimination in vivax endemic countries world-wide. To achieve this, we will develop a new class of malaria point-of-care sero-diagnostic test that can identify those most at risk of recurrent vivax malaria, and prove that treating these people will significantly reduce P. vivax transmission.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016729</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Wentao Li</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving Labour Induction Outcomes</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology</Fields_of_Research>
        <Res_KW1>induction of labour </Res_KW1>
        <Res_KW2>obstetrics</Res_KW2>
        <Res_KW3>birth</Res_KW3>
        <Res_KW4>perinatal</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>About 1 in 3 Australian women have an induction of labour - an artificial intervention to stimulate the onset of labour when indicated. We know who should have induction of labour and when, but not much about how (which method to use) and where (stay in hospital or at home) to induce labour. In this program, I will lead one international collaborative project, one pragmatic multi-centre clinical trial, and one multi-centre observational study to provide unequivocal answers to these questions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016730</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Orchard</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Screening of athletes for cardiovascular disesase and prevention of sudden death</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$635,170.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>preventive screening </Res_KW1>
        <Res_KW2>athlete training programs</Res_KW2>
        <Res_KW3>cardiac arrhythmia</Res_KW3>
        <Res_KW4>electrocardiogram (ecg)</Res_KW4>
        <Res_KW5>sports medicine</Res_KW5>
        <Plain_Description>Sudden cardiac death (SCD) in athletes is a rare but tragic event. Screening programs to prevent SCD are recommended but data are lacking for some groups (indigenous Australians, female athletes) and across sports. The project will develop Australia’s first national registry of athlete screening ECGs, focus on under-represented groups, and make comparisons across sports. The ultimate goal is to improve the accuracy and quality of screening programs to prevent SCD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016732</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Frank Caruso</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Leveraging Nanoparticle Platforms to Advance Nanomedicine</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,137,110.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | industrial biotechnology | nanobiotechnology | biomedical and clinical sciences | medical biotechnology | nanomedicine | engineering | nanotechnology | nanomaterials</Fields_of_Research>
        <Res_KW1>nanotechnology </Res_KW1>
        <Res_KW2>biomaterials</Res_KW2>
        <Res_KW3>drug delivery systems</Res_KW3>
        <Res_KW4>cellular interactions</Res_KW4>
        <Res_KW5>protein interactions</Res_KW5>
        <Plain_Description>Nanoparticles (NPs) afford a revolutionary approach of packaging and delivering medicines to target specific sites within patients. This proposal will address current limitations in NP-based medicines, by understanding and engineering the performance of NPs, and through their reproducible and scalable synthesis. With a focus on cancer, and infectious and neurological diseases, this research will progress nanomedicines towards preclinical studies and commercialisation to improve health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016756</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Maria Makrides</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>N-3 (Omega-3) precision nutrition: preventing prematurity and enhancing cognitive development of very preterm children</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$3,525,097.84</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | clinical nutrition</Fields_of_Research>
        <Res_KW1>maternal and child health </Res_KW1>
        <Res_KW2>omega-3 fatty acids</Res_KW2>
        <Res_KW3>pregnancy</Res_KW3>
        <Res_KW4>nutritional therapy</Res_KW4>
        <Res_KW5>premature infant</Res_KW5>
        <Plain_Description>Being born too soon can be devastating for children and their families. My work is designed to overcome omega-3 deficiency in Australian pregnant women to prevent some of those early births.  For babies born more than 11 weeks before their due date, my research aims to maximise developmental benefits by feeding extra omega-3 fats in the neonatal unit to match what would have been received in the womb.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016792</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Bridget Barber</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Malaria volunteer infection studies for the advancement of antimalarial therapeutics</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,345,834.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases</Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>clinical research</Res_KW3>
        <Res_KW4>antimalarial</Res_KW4>
        <Res_KW5>disease pathogenesis</Res_KW5>
        <Plain_Description>At QIMR Berghofer I will lead malaria volunteer infection studies to advance the development of antimalarial therapeutics. This will include studies to characterise the PK/PD profile of existing antimalarials to optimise dose selection, evaluate the transmission blocking activity of new and existing antimalarials, and evaluate strategies to boost antimalarial immunity. These studies will inform antimalarial treatment strategies worldwide.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016801</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Anushka Patel</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Prevention of cardiometabolic conditions in diverse populations</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,762,266.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>cardiovascular disease prevention </Res_KW1>
        <Res_KW2>diabetes prevention</Res_KW2>
        <Res_KW3>chronic heart failure (chf)</Res_KW3>
        <Res_KW4>women's health</Res_KW4>
        <Res_KW5>pharmacotherapy</Res_KW5>
        <Plain_Description>Cardiometabolic conditions (including heart disease and diabetes) are a leading cause of premature death and poor health in Australia and globally. My research will focus on identifying effective preventive treatments and methods to deliver these treatments to high-risk populations in Australia and other countries in our region, particularly to groups that have not previously had their needs adequately addressed. A focus will be on novel use of affordable and effective preventive drug therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016803</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Colin Masters</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Alzheimer's disease: causes, natural history, early diagnosis and prevention</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,937,110.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | neurosciences | central nervous system</Fields_of_Research>
        <Res_KW1>alzheimer disease </Res_KW1>
        <Res_KW2>dementia</Res_KW2>
        <Res_KW3>genetic risk factors</Res_KW3>
        <Res_KW4>amyloid beta-protein</Res_KW4>
        <Res_KW5>neurodegeneration</Res_KW5>
        <Plain_Description>Alzheimer’s disease (AD) is a devastating illness for a large number of people in our aging community. We have discovered the major causes of AD from our work over the past 40 years. We are now poised to develop disease modifying therapies (both pharmacological and non-pharmacological) and apply these therapies for prevention. We have defined when and where in the brain AD starts. Armed with this knowledge, we can implement diagnostic and therapeutic strategies for prevention.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016819</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Adam Deane</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Dietary protein to improve outcomes from critical illness</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,029,753.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | clinical nutrition | biomedical and clinical sciences | clinical sciences | intensive care</Fields_of_Research>
        <Res_KW1>intensive care medicine </Res_KW1>
        <Res_KW2>critical care medicine</Res_KW2>
        <Res_KW3>enteral nutrition</Res_KW3>
        <Res_KW4>metabolism</Res_KW4>
        <Res_KW5>randomised controlled trial (rct)</Res_KW5>
        <Plain_Description>Critically ill patients are admitted to an intensive care unit (ICU) to receive life support therapies but suffer rapid and severe muscle wasting.    Dr Deane will evaluate whether increasing dietary protein using existing formula or specific amino acid supplements reduces muscle wasting.     This program will determine whether there is a pragmatic and inexpensive solution for a condition that results in considerable mortality and morbidity to a large number of Australians each year.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016820</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Ricky Johnstone</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Deregulated epigenetics and transcription in cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics)</Fields_of_Research>
        <Res_KW1>epigenetics </Res_KW1>
        <Res_KW2>cancer biology</Res_KW2>
        <Res_KW3>cancer immunology</Res_KW3>
        <Res_KW4>gene transcription</Res_KW4>
        <Res_KW5>cancer therapy</Res_KW5>
        <Plain_Description>The Investigator grant will support Prof. Ricky Johnstone, a world leader in cancer research.  His work focusses on how genes are regulated in normal and cancer cells through a process called epigenetics, and how de-regulated gene expression can result in cancer onset and progression. He and his team will determine how manipulating the proteins and pathways that control the expression of genes can inhibit cancer cell growth and survival, and regulate how our immune system responds to cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016822</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Christopher Semsarian</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Translating Genomics into Improved Care of Inherited Heart Disease and Sudden Death Families</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,099,688.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>cardiovascular disease </Res_KW1>
        <Res_KW2>sudden cardiac death</Res_KW2>
        <Res_KW3>cardiomyopathy</Res_KW3>
        <Res_KW4>genetics</Res_KW4>
        <Res_KW5>inherited</Res_KW5>
        <Plain_Description>Inherited heart diseases are caused by errors in genes we are born with. These genetic errors can lead to heart muscle and rhythm disorders, which can cause sudden cardiac death in the young. This proposed research will use the latest clinical, genetic, and cellular approaches to identify what these genetic errors are, how these errors cause these clinical diseases, and how we can use this new knowledge to improve the care of patients with inherited heart diseases and prevent sudden death.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016825</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Louisa Degenhardt</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Improving Knowledge and Interventions to reduce and prevent substance use related harms</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,937,110.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | health sciences | epidemiology | major global burdens of disease</Fields_of_Research>
        <Res_KW1>addiction </Res_KW1>
        <Res_KW2>data linkage</Res_KW2>
        <Res_KW3>behavioural epidemiology</Res_KW3>
        <Res_KW4>adolescent health</Res_KW4>
        <Res_KW5>mental health</Res_KW5>
        <Plain_Description>I will study the epidemiology of illicit drug use, and improve estimates of substance use and mental disorders and health burden; and study prospective associations between disorders and harms. I will lead globally focused work on the epidemiology and harms of illicit drugs, and coverage of interventions to reduce harm; and examine interventions to address drug use, including treatment of opioid dependence and other interventions to reduce harm among people who use illicit drugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016826</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Juliet French</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Illuminating the dark genome in cancer</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,256,790.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics</Fields_of_Research>
        <Res_KW1>functional genomics </Res_KW1>
        <Res_KW2>rna</Res_KW2>
        <Res_KW3>somatic mutation</Res_KW3>
        <Res_KW4>genetic association</Res_KW4>
        <Res_KW5>enhancer elements</Res_KW5>
        <Plain_Description>Research into the genetic basis of cancer has largely focused on the 2% of human DNA that codes for proteins (what most people refer to as "genes"). In the last decade, it has become clear that a large proportion of DNA outside these genes (referred to as noncoding regions) is functional and can harbour genetic and epigenetic alterations that can promote the development of cancer. This research program will explore the contribution of these noncoding regions to cancer development.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016827</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Shabih Shakeel</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Capturing atomic snapshots to visualise epigenetic silencing machinery for identification of novel therapeutic targets</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics)</Fields_of_Research>
        <Res_KW1>structural biology </Res_KW1>
        <Res_KW2>electron microscopy</Res_KW2>
        <Res_KW3>protein structure</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>gene silencing</Res_KW5>
        <Plain_Description>Heterochromatin, a tightly packed form of DNA prevents genes from being turned on. We know very little about heterochromatin biology at molecular level, despite its critical role in gene silencing. Through cryo-electron microscopy (cryoEM), I will study the protein complexes that lead to heterochromatin formation and maintenance. This information will enable the rational design of a targeted drug discovery program to treat diseases caused by epigenetic dysregulation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016833</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Valentina Lorenzetti</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Using MRI tools to map and mitigate brain harms in chronic cannabis use</Grant_Title>
        <Admin_Institution>Australian Catholic University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,115,278.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | biological psychology not elsewhere classified</Fields_of_Research>
        <Res_KW1>cannabis </Res_KW1>
        <Res_KW2>addictive behaviours</Res_KW2>
        <Res_KW3>hippocampus</Res_KW3>
        <Res_KW4>magnetic resonance imaging (mri)</Res_KW4>
        <Res_KW5>mental health</Res_KW5>
        <Plain_Description>Australia has one of the highest rates of cannabis dependence, and 28% of users report high distress and mental illness. Yet, the neurobiology of cannabis use is unclear. I will fill this knowledge gap by combining advanced brain imaging tools with large longitudinal datasets to map the brain mechanisms which predate, predict and underpin chronic cannabis use, and by trialling new interventions that directly target and mitigate brain dysfunction in chronic cannabis use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016841</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Fabienne Brilot</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Understanding the autoimmune response against the brain to improve diagnosis and therapy of neuroimmunological disorders</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system</Fields_of_Research>
        <Res_KW1>neuroimmunology </Res_KW1>
        <Res_KW2>antibody</Res_KW2>
        <Res_KW3>diagnostic assay</Res_KW3>
        <Res_KW4>multiple sclerosis (ms)</Res_KW4>
        <Res_KW5>sars-cov-2</Res_KW5>
        <Plain_Description>Neuroimmunological disorders include neurological and psychiatric disorders affecting the brain, spinal cord, and nerves. Overall, they can affect up to 1% of the human population. They almost always result in a poor quality of life for children and adults and are a high cost burden for the community. The research program will explore the dysregulation of the immune system in these patients and will design new diagnostic and therapeutic approaches.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016851</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Lucia Romani</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Optimising strategies for control of neglected tropical diseases</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,493,326.67</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | rural and remote health services | health sciences | epidemiology | disease surveillance | health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>epidemiology </Res_KW1>
        <Res_KW2>population health</Res_KW2>
        <Res_KW3>tropical disease</Res_KW3>
        <Res_KW4>infectious diseases</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Neglected tropical diseases (NTDs) are a group of health conditions that affect the poorest of the poor, particularly in remote and rural areas. They affect the most vulnerable communities and cause substantial, chronic health harms impairing personal and social development. Several debilitating NTDs are common in remote indigenous communities and Pacific islands. I propose a series of studies to investigate new strategies to control NTDs in large populations where these diseases are endemic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016866</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Claire O'Callaghan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>A pathway to new symptomatic drug therapies in dementia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | cognitive neuroscience | psychology | biological psychology  | psychopharmacology | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases</Fields_of_Research>
        <Res_KW1>dementia </Res_KW1>
        <Res_KW2>cognitive neuroscience</Res_KW2>
        <Res_KW3>brain imaging</Res_KW3>
        <Res_KW4>neuropharmacology</Res_KW4>
        <Res_KW5>noradrenaline</Res_KW5>
        <Plain_Description>The cognitive symptoms of dementia can be devastating for patients and their families. The drugs that are currently available to treat these symptoms are limited and they do not work for everyone. My program will identify new drug treatment options for cognitive symptoms, and, establish faster ways to help us translate these drugs into clinical practice – so that people with dementia can benefit from novel treatment options as soon as possible.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016876</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Andrew Gardner</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Repetitive Neurotrauma and the Risk for Dementia in Former Athletes</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | other health sciences | other health sciences not elsewhere classified</Fields_of_Research>
        <Res_KW1>ageing </Res_KW1>
        <Res_KW2>cognition</Res_KW2>
        <Res_KW3>magnetic resonance imaging (mri)</Res_KW3>
        <Res_KW4>dementia</Res_KW4>
        <Res_KW5>neurotrauma</Res_KW5>
        <Plain_Description>Contact and collision sports have been popular in Australia for generations, and many millions of people, worldwide, played these sports during their youth. There is tremendous societal concern about whether exposure to concussions and repetitive blows to the head during youth leads to accelerated brain aging and risk for neurological disease later in life. This project will make important advancements in medical and scientific knowledge relating to the long-term brain health of former athletes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016884</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Timothy Mercer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Building RNA therapies to re-program gene expression.</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,756,790.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics</Fields_of_Research>
        <Res_KW1>messenger rna (mrna) </Res_KW1>
        <Res_KW2>rna</Res_KW2>
        <Res_KW3>gene expression</Res_KW3>
        <Res_KW4>rna processing</Res_KW4>
        <Res_KW5>gene therapy</Res_KW5>
        <Plain_Description>Gene mutations cause a wide range of inherited diseases. The delivery of mRNA therapies can replace mutated genes. However, mRNA therapies must be correctly expressed in the diseased tissue and match the expression of the mutated gene. I propose to build a toolkit of RNA structures that control expression of mRNA therapies in different tissues. This will allow their correct expression of mRNA therapies in disease tissues and a new opportunity to treat these currently incurable diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016894</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Richard Birkinshaw</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Using advanced structural biology to exploit BCL2 effector proteins for new tailored therapies.</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,476,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling)</Fields_of_Research>
        <Res_KW1>structural biology </Res_KW1>
        <Res_KW2>apoptosis</Res_KW2>
        <Res_KW3>bcl-2</Res_KW3>
        <Res_KW4>bax</Res_KW4>
        <Res_KW5>mitochondria</Res_KW5>
        <Plain_Description>This research aims to identify new cancer drugs like venetoclax, which has revolutionised leukemia therapy by targeting one of eight BCL2 family proteins involved in cell death. Using Australia’s leading facilities, eg. the National Drug Discovery Center and Australian Synchrotron, this research will investigate the structure and function of three additional BCL2 proteins. This is expected to lead to new classes of drugs that can treat diseases where current therapies fail.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016907</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Raina MacIntyre</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>BREATHE EASY - respiratory protection against airborne threats</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,390,896.36</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health systems</Fields_of_Research>
        <Res_KW1>respiratory viruses </Res_KW1>
        <Res_KW2>biological sciences</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>population health</Res_KW4>
        <Res_KW5>occupational health and safety</Res_KW5>
        <Plain_Description>MacIntyre is a leading international researcher &amp; woman with a 15-year track record of mask research. This will enable critical research on masks; aerosols &amp; how they are blocked by masks; and development of a novel, sustainable mask to meet global needs. These are seamlessly connected within a new NHMRC CRE, BREATHE on mitigation of airborne threats to health, which she leads. She has strong policy and industry links to ensure this research results in global solutions in respiratory protection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016908</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Wai-Hong Tham</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Antibody-based therapies against infectious diseases</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,105,736.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents</Fields_of_Research>
        <Res_KW1>falciparum malaria </Res_KW1>
        <Res_KW2>coronavirus</Res_KW2>
        <Res_KW3>antibody therapy</Res_KW3>
        <Res_KW4>structural biology</Res_KW4>
        <Res_KW5>host/pathogen interaction</Res_KW5>
        <Plain_Description>Infectious diseases have resulted in devastating mortality in human populations throughout history. Antibody-based therapies have revolutionised modern medicine and will be important for the prevention and treatment of diseases caused by some of the world’s deadliest pathogens. Our program builds on a deep understanding of the molecular interactions between human and pathogen and leverages advanced antibody platforms to develop novel antibody therapies against malaria and COVID-19.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016909</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Ms Louisa Picco</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Optimising the investment in real-time prescription drug monitoring</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>opioid analgesia </Res_KW1>
        <Res_KW2>opioid dependence</Res_KW2>
        <Res_KW3>addiction prevention</Res_KW3>
        <Res_KW4>health policy</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>Opioid prescribing has increased substantially in recent times and is associated with significant harms. Various approaches have been adopted to prevent these harms, however research has shown some approaches add to harms. This research aims to better understand the impact of prescription drug monitoring programs on clinical decision-making and how these impact patient and population level outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016930</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Timpson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Anti-fibrotic targeting and biosensor imaging in pancreatic cancer (PC): taking cancer targeting to new dimensions</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,882,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall)</Fields_of_Research>
        <Res_KW1>pancreatic cancer </Res_KW1>
        <Res_KW2>fibrosis</Res_KW2>
        <Res_KW3>imaging</Res_KW3>
        <Res_KW4>extracellular matrix</Res_KW4>
        <Res_KW5>biosensor</Res_KW5>
        <Plain_Description>Pancreatic cancer is a devastating disease in which high levels of dense tissue (otherwise know as fibrosis) surrounds the tumour and effectively protects the tumour from efficient drug delivery and penetrance, causing poor drug response. In this program of work, we outline how we can target this dense impenetrable fibrotic tissue to effectively improve drug delivery and response in this aggressive disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016947</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Ianthe Boden</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Preventing pulmonary complications after major surgery</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$574,120.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | anaesthesiology | biomedical and clinical sciences | clinical sciences | surgery | health sciences | allied health and rehabilitation science | physiotherapy</Fields_of_Research>
        <Res_KW1>pre-operative care </Res_KW1>
        <Res_KW2>respiratory infection</Res_KW2>
        <Res_KW3>physiotherapy</Res_KW3>
        <Res_KW4>surgical outcomes research</Res_KW4>
        <Res_KW5>patient education</Res_KW5>
        <Plain_Description>Contracting a chest infection after major surgery can be catastrophic. Despite the seriousness of this complication, we know little about how common it is, how much it costs hospitals, and how it impacts a person’s recovery after surgery. My research will provide world-first data on the impact of chest infections after major surgery, treatment guidelines for clinicians, and online methods to deliver breathing training before surgery - a treatment known to prevent chest infections after surgery.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016951</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Christina Mitchell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Phosphoinositide signalling in disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified</Fields_of_Research>
        <Res_KW1>phosphoinositide 3-kinase </Res_KW1>
        <Res_KW2>endosomes</Res_KW2>
        <Res_KW3>breast cancer</Res_KW3>
        <Res_KW4>receptor trafficking</Res_KW4>
        <Res_KW5>signal transduction</Res_KW5>
        <Plain_Description>Breast cancer is the most common cancer in women. Current treatment protocols are initially effective; however, more than half of patients experience relapse presenting an urgent need for new therapies. Lipid signals within cells can be hyperactivated in breast cancer promoting tumour growth and spread. We have discovered genes that regulate these signals, that when altered lead to poor outcomes in breast cancer. Here we will investigate these events to identify new biomarkers and therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016969</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Jose Villadangos</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Antigen Presentation and Adaptive Immunity</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,749,688.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | protein trafficking | biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | innate immunity</Fields_of_Research>
        <Res_KW1>antigen presentation </Res_KW1>
        <Res_KW2>t cell immunity</Res_KW2>
        <Res_KW3>protein trafficking</Res_KW3>
        <Res_KW4>inflammation</Res_KW4>
        <Res_KW5>metabolism</Res_KW5>
        <Plain_Description>The research program I will carry out during this fellowship will characterise how the immune system detects and starts responses against pathogens and cancer cells. I will describe proteins and intracellular processes required to fulfil this function, which may be harnessed to develop more effective vaccines against infections, protect critically ill patients from hospital acquired infections, prevent autoimmunity and fight cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016991</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Abdul Rahman Ihdayhid</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Patient-Specific CT-Derived Computational Modelling to Optimise Outcomes in Aortic Stenosis</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$444,472.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>aortic stenosis </Res_KW1>
        <Res_KW2>computed tomography</Res_KW2>
        <Res_KW3>coronary blood flow</Res_KW3>
        <Res_KW4>computer simulation</Res_KW4>
        <Res_KW5>heart valve disease</Res_KW5>
        <Plain_Description>Transcatheter aortic valve replacement (TAVR) has revolutionised the treatment of aortic stenosis by offering a less invasive alternative to open heart surgery.  This study aims to use non-invasive images from cardiac CT to develop a novel, personalised technique that allow clinicians to perform 3D simulation of aortic valve implantation that predicts short and long term clinical outcomes.  These results will provide new tools to make TAVR safer, more durable and accessible to more patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016995</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Shaun Gregory</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>A multidisciplinary approach to reducing complications with extracorporeal membrane oxygenation</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,376,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | medical devices</Fields_of_Research>
        <Res_KW1>biomedical engineering </Res_KW1>
        <Res_KW2>blood flow</Res_KW2>
        <Res_KW3>task-related training</Res_KW3>
        <Res_KW4>left ventricular assist device (lvad)</Res_KW4>
        <Res_KW5>cardiopulmonary bypass</Res_KW5>
        <Plain_Description>Critically-ill patients with heart and/or lung failure (including COVID19) may require advanced life support using a device called ECMO. Current ECMO systems are riddled with complications related to the patient-device interface, such as a poor surgical connection and a lack of regular and life-like clinical training. This project will improve the ECMO-patient interface through better devices and improved clinical training, and measure improvements in patient outcomes using large databases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017001</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Carol Pollock</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Discovery and validation of antifibrotic therapies for kidney disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology</Fields_of_Research>
        <Res_KW1>fibrosis </Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>diabetic nephropathy</Res_KW3>
        <Res_KW4>tubulointerstitial inflammation</Res_KW4>
        <Res_KW5>kidney failure</Res_KW5>
        <Plain_Description>Kidney failure is increasing by 6-12% annually, directly costing up to $1.8B pa. Despite optimum treatment of patients with chronic kidney disease, dialysis, kidney transplant or premature death ensues. This program will assess new treatments for which we have promising preliminary data &amp; dissect differences in the processes leading to kidney recovery vs irreparable damage after kidney injury. Consequently, new therapies will be developed and the next generation of scientists will be trained.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017012</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Laura Diamond</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Smart technology for hip osteoarthritis: a personalised real-world ‘move’ into the future</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$630,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | rehabilitation engineering | health sciences | sports science and exercise | biomechanics | biomedical and clinical sciences | clinical sciences | orthopaedics</Fields_of_Research>
        <Res_KW1>osteoarthritis </Res_KW1>
        <Res_KW2>biomedical engineering</Res_KW2>
        <Res_KW3>biomechanics</Res_KW3>
        <Res_KW4>musculoskeletal disorders</Res_KW4>
        <Res_KW5>activities of daily living</Res_KW5>
        <Plain_Description>My program will design and test a new treatment for hip osteoarthritis (OA). The team I lead has proven that people with hip OA load their hip in a detrimental way during daily activities, and that hip load can be improved with laboratory-based movement retraining. To translate changes into everyday life, retraining must now happen in the real-world. My program will partner authentically with stakeholders to co-develop a body-worn smart device for personalised self-management in the real-world.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017023</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Jean Yang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Statistical bioinformatics at single cell resolution</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,682,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>mathematical sciences | statistics | statistical data science | biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | biological sciences | bioinformatics and computational biology | bioinformatic methods development</Fields_of_Research>
        <Res_KW1>bioinformatics </Res_KW1>
        <Res_KW2>applied statistics</Res_KW2>
        <Res_KW3>gene expression</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>information processing and learning</Res_KW5>
        <Plain_Description>This program will generate a framework and innovative bioinformatics tools to extract disease-associated signatures from multiple-modality single cell platforms for large cohort studies. Our strategy is based on contextual focus machine learning methods and novel statistical models to identify stable relationships among clinical and molecular measurements with robust predictive power across multiple platforms. This will accelerate the process of translational significant biomedical research.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017033</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Eliza Hawkes</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Optimising novel therapies to improve lymphoma patient outcomes</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours</Fields_of_Research>
        <Res_KW1>lymphoma </Res_KW1>
        <Res_KW2>non-hodgkin lymphoma</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>molecular biology</Res_KW4>
        <Res_KW5>diagnostic imaging</Res_KW5>
        <Plain_Description>Lymphomas are blood cancers that can be cured in some patients, but current treatments cause major side effects and many patients still die from this devastating disease. My research brings together clinical trials testing new therapies that manipulate the immune system, studies of blood and biopsy abnormalities, and new types of scans, in patients receiving these and standard treatments, with studies of real-world registry data, to improve treatment options and outcomes for lymphoma patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017060</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Gibbs</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Circulating tumour DNA informed management of early-stage colorectal cancer and pancreas cancer</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,529,302.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers</Fields_of_Research>
        <Res_KW1>colorectal cancer </Res_KW1>
        <Res_KW2>pancreatic cancer</Res_KW2>
        <Res_KW3>adjuvant therapy</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>cancer prognosis</Res_KW5>
        <Plain_Description>Colorectal or pancreas cancer is treated with surgery, then potentially chemotherapy, with that decision informed by examination of the cancer tissue that has been removed. This remains an imprecise way of estimating risk of recurrence and possible benefit from chemotherapy. My initial studies show that a blood test for circulating tumour DNA is a far more precise way of determining recurrence risk. I am leading 4 randomised studies looking to prove the benefit of ctDNA informed management.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017070</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Paul Gregorevic</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Using muscle-directed gene delivery to study and treat disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical physiology | cell physiology</Fields_of_Research>
        <Res_KW1>musculoskeletal disorders </Res_KW1>
        <Res_KW2>cell signalling</Res_KW2>
        <Res_KW3>gene therapy</Res_KW3>
        <Res_KW4>skeletal muscle hypertrophy</Res_KW4>
        <Res_KW5>skeletal muscle wasting</Res_KW5>
        <Plain_Description>Effective therapeutics are urgently required to combat the debilitating effects of skeletal muscle-related disease. This program of research will examine how cellular mechanisms control the functionality of skeletal muscle in health and disease, to pursue the development of innovative muscle-directed therapeutics to eradicate the loss of skeletal muscle mass and function as a cause of morbidity and early death, and combat other serious non-muscle diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017080</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicolas Hart</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving Outcomes for People with Bone Metastases</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | sports medicine | health sciences | allied health and rehabilitation science | rehabilitation | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy)</Fields_of_Research>
        <Res_KW1>bone metastasis </Res_KW1>
        <Res_KW2>breast cancer</Res_KW2>
        <Res_KW3>prostate cancer</Res_KW3>
        <Res_KW4>exercise therapy</Res_KW4>
        <Res_KW5>rehabilitation</Res_KW5>
        <Plain_Description>MOST people with advanced cancer will develop bone metastases – where cancer spreads to bone. This leads to devastating physical and mental problems including bone fragility, bone pain and muscle weakness, along with distress, anxiety and depression. My previous work has proven that carefully prescribed exercise is SAFE for these high-risk people. Now, I aim to establish the clinical effectiveness of supervised and targeted exercise to strengthen muscle, rescue bone loss, and improve function.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017081</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Edward Litton</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving outcomes for ICU survivors with anaemia</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,129,998.28</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | intensive care</Fields_of_Research>
        <Res_KW1>critical care </Res_KW1>
        <Res_KW2>critical illness</Res_KW2>
        <Res_KW3>anaemia</Res_KW3>
        <Res_KW4>intensive care</Res_KW4>
        <Res_KW5>intensive care medicine</Res_KW5>
        <Plain_Description>More than 170,000 Australians require intensive care treatment each year. At discharge, nearly half are anaemic. This impairs recovery, increasing the risk of prolonged and repeated hospitalisation. My research has identified promising anaemia treatments. This Fellowship will allow me to generate high quality evidence to guide practice and policy with the aim of improving recovery after ICU. I will also develop new blood tests that will enable these treatments to be personalised.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017086</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Irina Vetter</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Mechanistic and pharmacological insights into peripheral sensory neuron function in physiological and pathological pain</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,956,790.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | neurosciences | peripheral nervous system | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology</Fields_of_Research>
        <Res_KW1>ion channels </Res_KW1>
        <Res_KW2>nociceptive system</Res_KW2>
        <Res_KW3>electrophysiology</Res_KW3>
        <Res_KW4>peptides</Res_KW4>
        <Res_KW5>sensory nerves</Res_KW5>
        <Plain_Description>Chronic pain is a major health issue in Australia and globally. Many currently used pain killers are associated with serious side effects or do not provide adequate relief for patients. One promising approach to develop better drugs is to directly modify activity of peripheral pain-sensing nerves, which often respond abnormally in pain states. This proposal seeks to better understand the molecular mechanisms of pain to facilitate future development of mechanism-based therapeutics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017125</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Luke Ney</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Fear extinction as an experimental model for PTSD treatments and course</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | biological psychology not elsewhere classified | psychology | biological psychology  | psychophysiology | psychology | clinical and health psychology | clinical psychology</Fields_of_Research>
        <Res_KW1>fear </Res_KW1>
        <Res_KW2>posttraumatic stress disorder (ptsd)</Res_KW2>
        <Res_KW3>conditioning</Res_KW3>
        <Res_KW4>memory</Res_KW4>
        <Res_KW5>psychological treatment</Res_KW5>
        <Plain_Description>Treating psychiatric disorders such as posttraumatic stress disorder (PTSD) is challenging because the biological and cognitive processes involved in the disorders are unclear. This project will benchmark current experimental models of PTSD against real world clinical outcomes, such as treatment success and disease course. The project will design new and data-informed methods for experimentally modelling processes involved PTSD, leading to novel tools that will help to improve PTSD treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017131</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Michael Berk</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Development of a bench to bedside platform for novel therapy development for psychiatric disorders</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,249,688.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology</Fields_of_Research>
        <Res_KW1>psychiatric disorders </Res_KW1>
        <Res_KW2>bipolar affective disorder</Res_KW2>
        <Res_KW3>depression</Res_KW3>
        <Res_KW4>bipolar depression</Res_KW4>
        <Res_KW5>schizophrenia and related disorders</Res_KW5>
        <Plain_Description>My vision for the next five years is to conceptualise, coordinate and lead a program for the bench to bedside development, validation and translation of new, evidence-based therapies for the most prevalent and disabling neuropsychiatric disorders, in particular depression, bipolar disorder, and schizophrenia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017138</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Pamali Fonseka</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Extracellular vesicles-based drug delivery for cancer therapy</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified</Fields_of_Research>
        <Res_KW1>breast cancer </Res_KW1>
        <Res_KW2>cancer metastasis</Res_KW2>
        <Res_KW3>cell-cell communication</Res_KW3>
        <Res_KW4>chemotherapy</Res_KW4>
        <Res_KW5>drug delivery</Res_KW5>
        <Plain_Description>This research program aims to develop a novel treatment for metastatic breast cancer with the use of milk derived packages, an agent with anti-cancer properties. Late-stage breast cancer patients suffer from treatment failure and severe side effects from chemotherapy. Loading drugs into these packages will enhance the delivery, treatment response and limit the side effects. This will ultimately result in positive impact on the quality of life of cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017139</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Hiba Jebeile</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Optimising metabolic and mental health in the management of adolescent obesity</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$605,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | clinical nutrition</Fields_of_Research>
        <Res_KW1>diets for weight loss </Res_KW1>
        <Res_KW2>sub-clinical eating disorders</Res_KW2>
        <Res_KW3>binge eating</Res_KW3>
        <Res_KW4>dietary intervention</Res_KW4>
        <Res_KW5>dietary lifestyle</Res_KW5>
        <Plain_Description>Effective treatment for adolescent obesity is vital. However, a subset of adolescents with obesity are vulnerable to eating disorders. This research brings together a collaboration of obesity and eating disorder researchers, clinicians and consumers to understand: 1) The prevalence of mental health concerns in adolescents with obesity; 2) How to identify adolescents at risk of developing an eating disorder; and 3) How to optimise obesity treatment to improve both physical and mental health</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017140</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr David Waddington</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Advancing dynamic MRI to enable adaptive lung radiotherapy</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$628,510.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>physical sciences | medical and biological physics | medical physics</Fields_of_Research>
        <Res_KW1>magnetic resonance imaging (mri) </Res_KW1>
        <Res_KW2>lung cancer</Res_KW2>
        <Res_KW3>biomedical engineering</Res_KW3>
        <Res_KW4>radiotherapy</Res_KW4>
        <Res_KW5>medical imaging</Res_KW5>
        <Plain_Description>MRI-Linacs are cutting-edge treatment machines that use magnetic resonance imaging (MRI) to image tumour anatomy and biological function with unrivalled quality while radiation therapy is performed with a linear accelerator (Linac). This program will use MRI technology to dynamically track moving lung tumours and identify radioresistant tumour tissue responsible for treatment failure. MRI-Linac advances will enable lung cancer radiation treatments with unprecedented accuracy and efficacy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017170</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Julie Brimblecombe</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Implementation research: Delivering impact at the health-food retail interface for healthy food environments, with Indigenous communities</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,256,790.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | social determinants of health | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander diet and nutrition</Fields_of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>nutrition</Res_KW2>
        <Res_KW3>population</Res_KW3>
        <Res_KW4>food</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>How food is promoted, priced and made available in food retail impacts consumer behaviour and subsequently population health. In partnership with communities, Aboriginal health services, the retail sector and policy-makers, I will generate new knowledge on determinants of, and effective strategies to address, dietary inequity for Aboriginal and Torres Strait Islander Peoples through a focus on the remote store environment, practice and policy, and establish a global remote store collaborative.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017176</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Brittany Mitchell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Understanding the Genetic Basis of Treatment Response for Depression</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</Fields_of_Research>
        <Res_KW1>mental health </Res_KW1>
        <Res_KW2>depression</Res_KW2>
        <Res_KW3>pharmacogenomics</Res_KW3>
        <Res_KW4>clinical psychology</Res_KW4>
        <Res_KW5>statistical genetics</Res_KW5>
        <Plain_Description>Depression is the most common psychiatric disorder and is most commonly trated with antidepressant medicationd and psychological therapy. However, many people discontinue treatment due to experiencing adverse side effects or experiencing no remission in symptoms. I aim to identify genetic factors that influence depression treatment response by analyzing large-scale genetic data. These insights could be used to understand who is most likely to benefit from certain types of treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017197</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Edward Holmes</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>A Metagenomics Platform to Prevent Future Pandemics</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,937,110.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology</Fields_of_Research>
        <Res_KW1>virology </Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>emerging diseases</Res_KW3>
        <Res_KW4>evolution</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>Genome sequence data has transformed the study of emerging diseases. However, large-scale metagenomic data are cumbersome to analyse and have not been widely used for virus surveillance. This research programme will transform our understanding of the disease threat to Australian and global populations by developing a new bioinformatics pipeline to rapidly and identify viruses of potential public health impact and by performing a metagenomic survey of viruses at the animal-human interface.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017220</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Scott Mueller</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Neural regulation of immunity</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,582,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | peripheral nervous system | biomedical and clinical sciences | immunology | cellular immunology</Fields_of_Research>
        <Res_KW1>sympathetic nervous system </Res_KW1>
        <Res_KW2>neuroimmunology</Res_KW2>
        <Res_KW3>immune response</Res_KW3>
        <Res_KW4>cellular interactions</Res_KW4>
        <Res_KW5>t cells</Res_KW5>
        <Plain_Description>Immune responses are essential for the body to fight infections and cancer. It is well appreciated that communication occurs between the nervous system and the immune system, but how this occurs is unclear. Using new tools, genomics and highly advanced imaging, this project will define interactions between the nervous system and the immune system that can be precisely targeted to improve therapies and vaccines for infectious diseases and cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017223</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Karin Jandeleit-Dahm</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Innovative screening and treatment approaches for diabetic complications</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology</Fields_of_Research>
        <Res_KW1>diabetic complications </Res_KW1>
        <Res_KW2>diabetic vascular complications</Res_KW2>
        <Res_KW3>diabetic nephropathy</Res_KW3>
        <Res_KW4>atherosclerosis</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Diabetes is complicated by damage to the kidney leading to kidney failure and injury to blood vessels leading to heart attacks, strokes and amputations. My program will validate novel biomarkers for earlier detection and will develop novel and better treatments for diabetic complications, including in the Indigenous population. I will initiate clinical trials and translate into practice. As a clinician/ scientist my mission is to reduce the high health burden of diabetes and its complications.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017225</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Julie Wixey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Detection and treatment of brain injury in growth restricted newborns</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | paediatrics not elsewhere classified</Fields_of_Research>
        <Res_KW1>fetal growth restriction </Res_KW1>
        <Res_KW2>neuroprotection</Res_KW2>
        <Res_KW3>brain injury</Res_KW3>
        <Res_KW4>inflammation</Res_KW4>
        <Res_KW5>newborn</Res_KW5>
        <Plain_Description>Babies that grow slowly before birth are more likely to suffer brain damage. There is no way to prevent this brain damage, it is difficult to detect, and there are no treatments. These babies often face a challenging life, with many problems including autism, ADHD, or cerebral palsy. My work will provide new knowledge on not only tests to detect brain damage to identify these babies earlier, this project will also explore treatments to improve life-long outcomes for these children.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017229</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Sarah McGuinness</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving strategies to combat preventable infections</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care</Fields_of_Research>
        <Res_KW1>infectious diseases </Res_KW1>
        <Res_KW2>gastrointestinal infections</Res_KW2>
        <Res_KW3>qualitative methods</Res_KW3>
        <Res_KW4>travel health</Res_KW4>
        <Res_KW5>preventive health</Res_KW5>
        <Plain_Description>People living in and visiting resource-poor settings are at increased risk of exposure to infections spread through food, water, mosquitoes and the environment. Preventive strategies that should reduce infection exposure often have limited success in the real world. My research aims to understand and overcome the barriers that limit the effectiveness and uptake of key preventive strategies (such as improved water supplies and vaccination), to improve health outcomes in vulnerable populations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017233</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Giselle Yeo</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Functional amplification of stem cells for tissue repair</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall)</Fields_of_Research>
        <Res_KW1>adult stem cells </Res_KW1>
        <Res_KW2>tropoelastin</Res_KW2>
        <Res_KW3>elastin</Res_KW3>
        <Res_KW4>extracellular matrix</Res_KW4>
        <Res_KW5>tissue repair</Res_KW5>
        <Plain_Description>Stem cells are increasingly being used to treat a diverse range of diseases. However, for such therapies to be clinically feasible and widely accessible, a large supply of quality stem cells are needed. Current methods of manufacturing stem cells are inadequate and expensive. This work aims to develop a safe, cost-effective, robust and more efficient way of propagating and preparing stem cells, by exploiting the potent, versatile actions of a human elastic protein on cell lifespan and behaviour.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017256</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Michelle Haber</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Unlocking precision medicine for 'incurable' child cancers</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers</Fields_of_Research>
        <Res_KW1>combination therapy </Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>drug discovery</Res_KW3>
        <Res_KW4>molecular diagnostics</Res_KW4>
        <Res_KW5>molecular oncology</Res_KW5>
        <Plain_Description>Although personalised medicine programs for children with cancer are better matching drugs to their molecular targets, the outlook remains dismal for patients with aggressive high-risk disease. I will develop new optimised combination therapies for treating these children, develop a new drug to prevent and treat childhood cancer, and develop new diagnostics to better predict treatment response and optimise personalised therapy, with the singular goal of improving patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017257</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Matthew Ritchie</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Building best-in-class bioinformatics tools to drive next generation biomedical research</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,256,790.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches)</Fields_of_Research>
        <Res_KW1>bioinformatics </Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>gene expression</Res_KW3>
        <Res_KW4>data analysis</Res_KW4>
        <Res_KW5>sequencing</Res_KW5>
        <Plain_Description>To get a complete picture of disease, the analysis of data obtained from cutting edge biotechnologies applied to clinical samples is essential. To do this successfully, advanced statistical methods are needed. I will develop new software tools and curate large collections of molecular information to improve understanding of healthy ageing and disease processes. The tools will be freely available to researchers anywhere and will drive new discoveries and disease treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017267</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Andrew Bivard</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Beyond translation: Integrating clinical trials and intelligent health systems for stroke</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>acute stroke </Res_KW1>
        <Res_KW2>ischaemic stroke</Res_KW2>
        <Res_KW3>stroke outcome</Res_KW3>
        <Res_KW4>telemedicine</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Over the next 5 years my research will generate new knowledge with new clinical trials, novel AI-driven stroke assessment tools , and integrated telehealth technologies to enhance rural and regional stroke care. My research will leverage globally unique imaging and biobank data capabilities and my extensive national and international clinical trials network. These will drive the next phase of my successful track record of clinical translation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017278</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Julie Ayre</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Evaluation and implementation of a digital health literacy tool to improve written health information</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>health literacy </Res_KW1>
        <Res_KW2>patient education</Res_KW2>
        <Res_KW3>health services research</Res_KW3>
        <Res_KW4>health care worker education</Res_KW4>
        <Res_KW5>health informatics</Res_KW5>
        <Plain_Description>Providing health information that all people can easily understand is a key step towards a fair and safe public health system, and one that empowers people to become active participants in their own health care. However, we currently lack sophisticated and scalable tools to achieve this goal. This project will evaluate a new online text-editing tool that helps health care providers write health information more simply, and provide strategies to increase its uptake within health organisations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017279</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Kavitha Kothur</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Biomarker discovery informs precision medicine in childhood epilepsy </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$605,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system</Fields_of_Research>
        <Res_KW1>epilepsy </Res_KW1>
        <Res_KW2>genetic testing</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>inflammatory cytokines</Res_KW4>
        <Res_KW5>epilepsy surgery</Res_KW5>
        <Plain_Description>Epilepsy is a common problem affecting 3% of the general population, and is associated with comorbidities, affects the quality of life and poses safety risks. However, if diagnosed and treated appropriately, seizures can be reversed, improving morbidity and mortality. My program will generate novel biomarkers on a large clinical registry of refractory epilepsy patients to increase understanding of underlying disease processes and to provide patient specific precision medicine.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017282</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof George Paxinos</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Linking Brains: Histology, MRI, Connectivity and Functional Maps of Humans and Mice</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,437,110.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified</Fields_of_Research>
        <Res_KW1>neuroanatomy </Res_KW1>
        <Res_KW2>neuroanatomical connections</Res_KW2>
        <Res_KW3>neuroimaging</Res_KW3>
        <Res_KW4>neuroanatomical tracing</Res_KW4>
        <Res_KW5>neuroscience</Res_KW5>
        <Plain_Description>This project uses imaging techniques to produce a new generation of brain atlases. It will advance our understanding of the organisation and connections of the human brain as well as that of the most commonly used animal to model human disease––the mouse. The atlases will inform the development of psychotherapeutic drugs and result in more accurate interventions on the human brain. The new maps will assist those who study the brain of patients with diseases such as Alzheimer’s and Parkinson’s.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017284</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Sebastian Duchene</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Evolutionary genomics to inform outbreak responses</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biological sciences | evolutionary biology | phylogeny and comparative analysis | biological sciences | bioinformatics and computational biology | bioinformatic methods development</Fields_of_Research>
        <Res_KW1>genetic epidemiology </Res_KW1>
        <Res_KW2>infectious diseases</Res_KW2>
        <Res_KW3>evolution</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>Genomics has been essential to track recent pandemics, including those of COVID-19, Ebola, and drug-resistant bacteria. This project will develop methods to integrate epidemiological and genomic data, for a comprehensive system of infectious disease surveillance that will constantly update estimates of pathogen introductions and infectious spread. Implementation of these techniques in public  health will dramatically increase the value of information for pandemic preparedness and mitigation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017289</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Valentina Rodriguez Paris</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Determining cellular competency in the mammary gland </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death</Fields_of_Research>
        <Res_KW1>calcium signalling </Res_KW1>
        <Res_KW2>calcium channels</Res_KW2>
        <Res_KW3>calcium imaging</Res_KW3>
        <Res_KW4>lactation</Res_KW4>
        <Res_KW5>mammary gland cancer</Res_KW5>
        <Plain_Description>A mother’s ability to produce a nutritionally complete source of food for her baby is of central importance to human health. However, we understand very little about the cells in the breast that produce and secrete milk. I will visualise and quantify the function of individual cells in this tissue to better understand their behaviours and to improve our knowledge of the cellular functions and characteristics that can contribute to the development and progression of breast cancers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017295</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Kristie Weir</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>One size does not fit all: achieving patient-centred deprescribing through evidence-based, individualised interventions </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>prescribing </Res_KW1>
        <Res_KW2>patient/doctor communication</Res_KW2>
        <Res_KW3>patient preference</Res_KW3>
        <Res_KW4>decision making</Res_KW4>
        <Res_KW5>communication</Res_KW5>
        <Plain_Description>Reducing medicines (deprescribing) through stopping medicines or taking less medicines is a positive intervention that improves health outcomes. Deprescribing should be tailored and patient-centred, but it is complex and unclear how this can be achieved. This body of work will explore and develop evidence-based tools to enable individualised communication about deprescribing. This will ensure patients and GPs make good decisions about medicines use in older age.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017299</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Maximilien Evrard</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Deciphering the rules of T cell residency across intestinal compartments</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | immunology not elsewhere classified</Fields_of_Research>
        <Res_KW1>cd8 t cells </Res_KW1>
        <Res_KW2>t cell memory</Res_KW2>
        <Res_KW3>t cell development</Res_KW3>
        <Res_KW4>mucosal immunology</Res_KW4>
        <Res_KW5>gastrointestinal infections</Res_KW5>
        <Plain_Description>Tissue-resident memory T cells (TRM) are key for immune protection against infection at barrier sites such as the gut. While much of our understanding of gut TRM comes from studies on the small intestine, how these cells develop and function in the large intestine is unknown. This project aims to identify and modulate molecular pathways by which the intestinal microenvironment influences TRM development specifically in the small or large intestine to enhance immune protection against infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017302</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Scott Teasdale</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Dietitian-led intervention for physical health disparities in people living with severe mental illness</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | biomedical and clinical sciences | nutrition and dietetics | clinical nutrition</Fields_of_Research>
        <Res_KW1>mental illness </Res_KW1>
        <Res_KW2>early psychosis</Res_KW2>
        <Res_KW3>nutrition</Res_KW3>
        <Res_KW4>clinical dietetic practice</Res_KW4>
        <Res_KW5>body weight changes</Res_KW5>
        <Plain_Description>Nutrition is a critical underlying issue for the significantly higher rates of chronic diseases, such as heart disease, experienced by people living with severe mental illness. Best practice nutrition intervention is yet to be determined. This project builds on promising pilot projects to determine the most effective interventions and to translate this into practice by formalising a clinical care process for dietitians and a resource for consumers to advocate for best practice nutrition support.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017325</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Melissa Southey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Delivering Precision Medicine to Population-based Cancer Prevention</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,249,688.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer genetics</Fields_of_Research>
        <Res_KW1>breast cancer </Res_KW1>
        <Res_KW2>prostate cancer</Res_KW2>
        <Res_KW3>inheritance</Res_KW3>
        <Res_KW4>biological risk factors</Res_KW4>
        <Res_KW5>risk prediction</Res_KW5>
        <Plain_Description>My program will build upon my landmark studies that have demonstrated cancer risk factors that are modifications of DNA (epigenomic) rather than mutation of DNA (genomic) by building new, accurate prediction tools for cancer risk in the general population. This research program will advance cancer risk screening by including both epigenomic and genomic assessment and make it widely available in Australia to prevent cases of cancer and to develop new medicines for those who do develop cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017335</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Nicole La Gruta</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Gatekeepers of optimal T cell immune function in health and aging-related decline</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,682,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | immunology | cellular immunology | biological sciences | biochemistry and cell biology | signal transduction</Fields_of_Research>
        <Res_KW1>t cells </Res_KW1>
        <Res_KW2>ageing</Res_KW2>
        <Res_KW3>t cell receptor</Res_KW3>
        <Res_KW4>t cell activation</Res_KW4>
        <Res_KW5>receptor signalling</Res_KW5>
        <Plain_Description>T cells protect from infectious disease and cancers, and boosting T cell activation is the goal of current immunotherapies. In older individuals, T cells become dysfunctional placing the elderly at much greater risk. However, precisely what is required for effective T cell activation, and what goes wrong in older individuals, remains poorly understood. This study will advance fundamental knowledge around T cell activation, critical for the ongoing development and optimisation of immunotherapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017353</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Emily Lelliott</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Uncovering new targets for cancer immunotherapy through multiplexed genomic screens in cytotoxic T cells</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | tumour immunology</Fields_of_Research>
        <Res_KW1>cancer immunotherapy </Res_KW1>
        <Res_KW2>cancer immunology</Res_KW2>
        <Res_KW3>haematological malignancy</Res_KW3>
        <Res_KW4>solid tumours</Res_KW4>
        <Res_KW5>cellular immunology</Res_KW5>
        <Plain_Description>Immunotherapy is a modern approach to treat cancer and works by training the immune system, particularly T cells, to attack cancer cells. Immunotherapies are proving to be very successful in treating certain cancers, however, not all patients respond positively to this treatment for reasons that are still unclear. This project will identify the genetic factors that determine whether T cells have the capacity to fight cancer and discover new ways to improve patient responses to immunotherapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017370</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Reza Nosrati</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Fallopian tube on-a-chip for understanding human reproduction</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | reproduction | engineering | fluid mechanics and thermal engineering | microfluidics and nanofluidics | engineering | biomedical engineering | biomedical instrumentation</Fields_of_Research>
        <Res_KW1>fertility </Res_KW1>
        <Res_KW2>reproduction</Res_KW2>
        <Res_KW3>epithelial cells</Res_KW3>
        <Res_KW4>sperm function</Res_KW4>
        <Res_KW5>cell culture</Res_KW5>
        <Plain_Description>Infertility is on the rise, affecting >180 million individuals worldwide. However, our knowledge of fertilisation is still insufficient and advances in treatment methods are infrequent. This project aims to develop new microfluidic technologies that closely represent the physiology and function of the female fallopian tube to directly study human reproduction. The project expects to bring new insights into unknown causes of infertility and improve treatment methods worldwide.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017373</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Shuai Li</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reducing the Breast Cancer Burden in Young Women</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$638,056.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified</Fields_of_Research>
        <Res_KW1>breast cancer aetiology </Res_KW1>
        <Res_KW2>epidemiology</Res_KW2>
        <Res_KW3>cancer epidemiology</Res_KW3>
        <Res_KW4>risk assessment</Res_KW4>
        <Res_KW5>risk factors</Res_KW5>
        <Plain_Description>I aim to reduce the breast cancer burden in young women by finding out the causes of breast cancer in young women and how cancer risk can be accurately predicted and prevented. I will also investigate the future health of young women diagnosed with breast cancer so that health support is provided to young survivors.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017382</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Francine Marques</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Targeting the gut microbiota to treat cardiovascular disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$815,278.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>blood pressure </Res_KW1>
        <Res_KW2>metabolites</Res_KW2>
        <Res_KW3>dietary fibre</Res_KW3>
        <Res_KW4>cardiovascular disease prevention</Res_KW4>
        <Res_KW5>diet</Res_KW5>
        <Plain_Description>After four decades of research, we now know the association between fibre intake and lower blood pressure is dependent on our gut microbes. While our bodies are incapable of digesting some types of fibre, it feeds the community of ‘good’ bacteria, resulting in the release of substances that can lower blood pressure. In the next 5 years, I will establish how these substances lower blood pressure and test their use to treat patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017383</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Kate Seib</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>A comprehensive vaccine-based strategy to combat gonorrhoea</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,082,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology</Fields_of_Research>
        <Res_KW1>neisseria gonorrhoeae </Res_KW1>
        <Res_KW2>sexually-transmitted infections (sti)</Res_KW2>
        <Res_KW3>vaccine development</Res_KW3>
        <Res_KW4>antibody</Res_KW4>
        <Res_KW5>vaccination immunology</Res_KW5>
        <Plain_Description>The sexually transmitted infection gonorrhoea has a significant impact on global health, with 100 million cases/year, many of which are associated with infertility and increased HIV transmission. Due to increasing antimicrobial resistance and the absence of a vaccine, the WHO has classified gonorrhoea an urgent threat to public health that requires immediate action. My research aims to develop a vaccine to prevent gonorrhoea from becoming an untreatable ‘superbug’ in the near future.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017388</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Mark Plummer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Sickly sweet: managing high blood glucose during and post critical illness</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$447,128.72</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | intensive care</Fields_of_Research>
        <Res_KW1>hyperglycaemia </Res_KW1>
        <Res_KW2>diabetes mellitus</Res_KW2>
        <Res_KW3>critical care medicine</Res_KW3>
        <Res_KW4>intensive care medicine</Res_KW4>
        <Res_KW5>diabetes prevention</Res_KW5>
        <Plain_Description>High blood sugar levels occur frequently during critical illness even in patients without a history of diabetes. High blood sugar levels are associated with increased mortality in ICU and an increased risk of developing diabetes in survivors.   My research will;   (i) determine the efficacy of a new drug to manage high sugar levels in the ICU,   (ii) identify mechanisms of how high blood sugar levels in ICU lead to diabetes, and,   (iii) determine whether this can be prevented with screening programs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017404</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Feargal Ryan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Developing microbiome-based interventions to improve vaccine immunogenicity</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biological sciences | biochemistry and cell biology | systems biology | biological sciences | microbiology | microbial ecology</Fields_of_Research>
        <Res_KW1>systems biology </Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>microbial ecology</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>vaccine biology</Res_KW5>
        <Plain_Description>Effective vaccination is critical for combating infectious disease. However, vaccine immune responses are highly variable between individuals and populations (e.g. lower in the elderly). New evidence suggests bacteria in our gut microbiome may be responsible. This program of work will allow us to understand how gut bacteria modulate activity of the immune system in response to vaccination. This knowledge will be crucial to both future vaccine development and improving vaccines currently in use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017405</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Michele Sterling</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Better health outcomes after road traffic injury</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,351,142.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified</Fields_of_Research>
        <Res_KW1>motor vehicle accidents </Res_KW1>
        <Res_KW2>whiplash injuries</Res_KW2>
        <Res_KW3>neck pain</Res_KW3>
        <Res_KW4>rehabilitation</Res_KW4>
        <Res_KW5>pain</Res_KW5>
        <Plain_Description>Chronic pain is the leading cause of disability worldwide with 30% caused by a road traffic injury. My research will produce new knowledge under three aims. To: 1) Gain new insights into the development of chronic pain, 2) Test novel early treatments to prevent chronic pain after road traffic injury and 3) Implement early risk-screening models of care in the clinical and injury compensation environments. The outcomes will drive change in the assessment and treatment of road traffic injury.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017417</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Kaufman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Applying communication and social science to improve vaccine confidence and uptake</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | health sciences | public health | preventative health care | health sciences | health services and systems | implementation science and evaluation</Fields_of_Research>
        <Res_KW1>vaccination </Res_KW1>
        <Res_KW2>community intervention</Res_KW2>
        <Res_KW3>social and behavioural research</Res_KW3>
        <Res_KW4>health promotion</Res_KW4>
        <Res_KW5>measurement</Res_KW5>
        <Plain_Description>COVID-19 has put vaccination in the spotlight like never before. It is more important than ever to understand why some people don't vaccinate and what to do about it.   This research will:   1) Use surveys to understand access and acceptance barriers to vaccination, and   2) Provide tools and training for community leaders to use to advocate for vaccination.  The outcome will be to help more people feel comfortable about getting routine and COVID-19 vaccines in Australia and the Western Pacific Region.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017420</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Axel Kallies</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Targeting T cell differentiation and function to treat cancer and chronic disease </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,494,678.07</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | immunology not elsewhere classified | biomedical and clinical sciences | immunology | tumour immunology | biomedical and clinical sciences | clinical sciences | infectious diseases</Fields_of_Research>
        <Res_KW1>t cells </Res_KW1>
        <Res_KW2>molecular biology</Res_KW2>
        <Res_KW3>immunotherapy</Res_KW3>
        <Res_KW4>gene transcription</Res_KW4>
        <Res_KW5>cell differentiation</Res_KW5>
        <Plain_Description>Chronic diseases, including persistent viral infections and cancer, are major health burdens and among the most difficult to treat. T cells play a central role in disease control; however, their function is often impaired by a process termed ‘exhaustion’. Immunotherapies aimed at reinvigorating exhausted T cells have revolutionised cancer treatment. In this project, I will identify molecular pathways that control T cells with the goal to pave the way for new immunotherapies for chronic diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017436</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Matthew Grigg</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Addressing the threat of emerging zoonotic malaria in our region</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,526,800.96</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases</Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>zoonotic infectious disease</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>malaria transmission</Res_KW4>
        <Res_KW5>zoonotic disease</Res_KW5>
        <Plain_Description>The monkey malaria parasite P. knowlesi (Pk) increasingly infects humans across Southeast Asia. A multidisciplinary approach will evaluate why Pk cases are rising, improve laboratory detection methods, assess preventative treatments, and inform public health programs. Pk genetic analyses will explore causes of severe disease and geographical infection patterns. Evaluating human interaction with mosquitos, monkeys, and land-use, will generate regional Pk risk prediction maps for targeted control.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017438</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Mimi Tang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Innovative interventions to reduce the personal and societal burden of food allergy</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,710,808.85</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | allergy | biomedical and clinical sciences | paediatrics | infant and child health | health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>food allergy </Res_KW1>
        <Res_KW2>treatment strategies</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>immunotherapy</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>Food allergy causes severely reduced quality of life and psychological distress for allergic children and their families. My vision is to free children and families from the burdens of living with food allergy.   This 5 year program of research will:   (i) identify and evaluate new treatments that induce remission of allergy, bringing a long-term solution that will transform the lives of allergic children and families;   (ii) deliver innovative tools that improve the way food allergy is managed now.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017450</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Emma Thomas</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving equity, access, and quality of cardiac rehabilitation services</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | allied health and rehabilitation science not elsewhere classified</Fields_of_Research>
        <Res_KW1>telemedicine </Res_KW1>
        <Res_KW2>cardiac rehabilitation</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>translational research</Res_KW4>
        <Res_KW5>secondary prevention</Res_KW5>
        <Plain_Description>Cardiac rehabilitation (CR) enables people who have suffered a heart event to self-manage their condition and improve their quality of life.However, many eligible patients (70%) do not attend. Telehealth-delivered CR can reduce access barriers, is safe, effective and is well-liked by patients. However, there is a practice-gap in translating these findings into practice. This project aims to provide a major health system impact by supporting the expanded use of telehealth across CR services.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017461</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Samuel Robinson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>New Toxin Tools for Dissecting Pain</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | neurosciences | peripheral nervous system | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology</Fields_of_Research>
        <Res_KW1>pain </Res_KW1>
        <Res_KW2>toxins</Res_KW2>
        <Res_KW3>peptides</Res_KW3>
        <Res_KW4>ion channels</Res_KW4>
        <Res_KW5>receptors</Res_KW5>
        <Plain_Description>There is worldwide demand for new and creative pain treatment strategies. The aim of my research is to identify new pain-causing toxins from animal venoms and to use them as tools to improve our understanding and, ultimately treatment, of pain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017463</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Cindy Ma</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Novel approaches to understand and treat human allergic diseases</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,756,790.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | allergy | biomedical and clinical sciences | immunology | cellular immunology</Fields_of_Research>
        <Res_KW1>cd4 </Res_KW1>
        <Res_KW2>t cells</Res_KW2>
        <Res_KW3>th2 differentiation</Res_KW3>
        <Res_KW4>cellular immunology</Res_KW4>
        <Res_KW5>lymphocyte differentiation</Res_KW5>
        <Plain_Description>Allergic diseases affect ~1 in 3 Australians and carry significant health and financial burdens. Primary immunodeficiencies (PIDs) result from damaging mutations in genes that affect the development and function of immune cells. In addition to life-threatening infections, PID patients often suffer from severe allergies. I will investigate immune cells from PID patients and patients with allergy to reveal mechanisms of disease and novel approaches to understand and treat these conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017476</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Lachlan Harris</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Prolonging survival in glioblastoma through targeting of quiescent glioma stem cells.  </Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$605,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology</Fields_of_Research>
        <Res_KW1>adult stem cells </Res_KW1>
        <Res_KW2>glioma</Res_KW2>
        <Res_KW3>combination therapy</Res_KW3>
        <Res_KW4>cell proliferation</Res_KW4>
        <Res_KW5>chemotherapy</Res_KW5>
        <Plain_Description>Most people diagnosed with the brain cancer glioblastoma die within 15-months. The cancer is so deadly because of slowly dividing cancer stem cells that resist treatment and cause patient relapse. My strategy is to eliminate these resistant cells by focusing on unique features of their biology, for example, by targeting the fact that these cells have increased expression of surface proteins. This project will test targeted molecules to establish an evidence base for Phase 1 trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017477</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Peter Savas</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>An immunogenomic approach to breast cancer in young women</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$574,120.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | solid tumours</Fields_of_Research>
        <Res_KW1>breast cancer </Res_KW1>
        <Res_KW2>translational research</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>microenvironment</Res_KW4>
        <Res_KW5>oncology</Res_KW5>
        <Plain_Description>Breast cancer causes the highest number of disease related deaths in adult women under the age of 45. It is a difficult problem that is also becoming more common. To understand this disease better, we need a comprehensive and detailed approach. Using samples taken from real patients, we will apply the most sophisticated technologies available to us for revealing how and why a cancer develops. This will ultimately lead to better ways to treat, detect and prevent breast cancer in young women.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017479</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tamera Corte</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Transforming Outcomes for Pulmonary Fibrosis</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,954,074.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases</Fields_of_Research>
        <Res_KW1>pulmonary fibrosis </Res_KW1>
        <Res_KW2>respiratory</Res_KW2>
        <Res_KW3>lung disease</Res_KW3>
        <Res_KW4>disease progression</Res_KW4>
        <Res_KW5>individualising management</Res_KW5>
        <Plain_Description>Pulmonary Fibrosis (PF) is a group of devastating conditions with scarring of the lung tissue - the most common has a survival of only 2-5 years. This research program will develop new techniques to understand the causes of PF; improve early and accurate diagnosis; correctly identify patients whose PF is more likely to progress rapidly, and those most likely to respond to treatment; and optimise delivery of PF care across Australia. This will enable more personalised approaches to treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017481</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Nila Dharan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>The impact of chronic viral infections on molecular ageing processes and associated clinical outcomes</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases</Fields_of_Research>
        <Res_KW1>clinical research </Res_KW1>
        <Res_KW2>prospective cohort study</Res_KW2>
        <Res_KW3>viral infection</Res_KW3>
        <Res_KW4>ageing</Res_KW4>
        <Res_KW5>human immunodeficiency virus (hiv)</Res_KW5>
        <Plain_Description>Older people with certain chronic virus infections age more quickly and have more ageing-related medical problems than people without chronic virus infections. This research will study key chronic virus infections – HIV and cytomegalovirus (a very common virus) – to better understand the biological processes that increase the risk of ageing-related medical conditions. The aim of this research is to discover novel screening and prevention measures to promote healthy ageing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017485</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Freya Fowkes</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Eliminating Malaria in the Asia-Pacific </Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,256,790.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | disease surveillance</Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>implementation</Res_KW2>
        <Res_KW3>immune surveillance</Res_KW3>
        <Res_KW4>epidemiology</Res_KW4>
        <Res_KW5>randomised controlled trial (rct)</Res_KW5>
        <Plain_Description>In the Asia-Pacific, more than two billion people are at risk of malaria, a parasitic disease transmitted by mosquitoes. I will work with malaria endemic partners to provide evidence for the most effective malaria prevention strategies and improve surveillance so that every last malaria infection is detected, treated and eliminated. My program aims to change policy and advance progress towards the goal of malaria elimination in the Asia-Pacific by 2030.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017498</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Katherine Lee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>A program of substantive and methodological research and capacity building in biostatistics</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,219,468.85</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>mathematical sciences | statistics | applied statistics</Fields_of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>biostatistics</Res_KW2>
        <Res_KW3>neonatal</Res_KW3>
        <Res_KW4>applied statistics</Res_KW4>
        <Res_KW5>paediatric</Res_KW5>
        <Plain_Description>Adaptive platform designs are revolutionising how clinical trials are conducted. The proposed program of biostatistical and substantive research and capacity building in these study designs will not only lead to advances in statistical methodology and child health, but will ensure that Australia has the biostatistical skills and understanding to support cutting-edge clinical and public health research into the future.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017499</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jiajia Zhou</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Single molecular antigen rapid test (SMART)</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | biomedical imaging | engineering | biomedical engineering | medical devices</Fields_of_Research>
        <Res_KW1>nanotechnology </Res_KW1>
        <Res_KW2>optical imaging</Res_KW2>
        <Res_KW3>diagnostic techniques</Res_KW3>
        <Res_KW4>instrumentation</Res_KW4>
        <Res_KW5>covid-19</Res_KW5>
        <Plain_Description>This project aims to investigate the role of the spike protein of the COVID-19 virus in binding antibodies and host cells. The project will use new knowledge to develop a Single Molecular Antigen Rapid Test (SMART). Expected outcomes include a better understanding of virus functions and their structural correlation at the molecular level, being able to visualise spike-induced cellular interactions, and a device that can detect multiple virus antigens, sensitively and very efficiently.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017504</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Aletta Schutte</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Novel approaches to improve blood pressure control</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,382,170.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care</Fields_of_Research>
        <Res_KW1>hypertension </Res_KW1>
        <Res_KW2>control of blood pressure</Res_KW2>
        <Res_KW3>cardiovascular disease prevention</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>dietary salt</Res_KW5>
        <Plain_Description>High blood pressure (BP) is the top killer of people in Australia, but only 1 in 3 adults with high BP has it under control. My vision is to rapidly improve BP control using four novel scalable approaches. My program will evaluate the effectiveness of highly promising interventions to lower BP: a salt substitute; a BP awareness campaign in hardware stores; using wearable cuffless BP monitoring; and a simplified treatment model with single pill combination therapy in primary care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017506</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Simon Rosenbaum</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Protecting physical &amp; mental health of trauma-exposed populations</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion</Fields_of_Research>
        <Res_KW1>physical activity </Res_KW1>
        <Res_KW2>traumatic stress</Res_KW2>
        <Res_KW3>exercise</Res_KW3>
        <Res_KW4>refugee health</Res_KW4>
        <Res_KW5>posttraumatic stress disorder (ptsd)</Res_KW5>
        <Plain_Description>Traumatic experiences are a risk factor for poor physical and mental health.     This research program will generate critical knowledge on how lifestyle factors (physical activity, diet and sleep) impact mental and physical health, in people exposed to trauma. This includes emergency service workers, veterans and people from refugee and asylum seeker backgrounds.     Results will inform how lifestyle programs can be integrated into routine care of people exposed to trauma (with, and at risk of PTSD).</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017515</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Tara Richman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Multi-omic landscape of platelet function in disease</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genetics not elsewhere classified</Fields_of_Research>
        <Res_KW1>mitochondria </Res_KW1>
        <Res_KW2>mitochondrial dna (mtdna)</Res_KW2>
        <Res_KW3>energy metabolism</Res_KW3>
        <Res_KW4>platelet activation</Res_KW4>
        <Res_KW5>platelet function</Res_KW5>
        <Plain_Description>Platelets enable blood clotting and would healing during vascular injury requiring high levels of energy to be maintained during circulation in preparation for activation. The energy centre of the cell is packaged within platelets but its function is not well defined. This project will uncover how dysfunction in the energy centre affects the platelets and how this can be translated to diagnosis and treatments for patients with excessive bleeding or clotting leading to stroke or heart attack.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017517</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Miaomiao Liu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>New method to identify disease-associated drug targets</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | proteomics and metabolomics | chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | biological sciences | biochemistry and cell biology | receptors and membrane biology</Fields_of_Research>
        <Res_KW1>therapeutic target </Res_KW1>
        <Res_KW2>mass spectrometry</Res_KW2>
        <Res_KW3>membrane protein</Res_KW3>
        <Res_KW4>drug targeting</Res_KW4>
        <Res_KW5>protein targeting</Res_KW5>
        <Plain_Description>This project aims to develop mass spectrometry-based methods to identify or characterise new targets for drug discovery. The application of the methods in target identification will allow finding of unknown protein targets for bioactive compounds and will revolutionise and dramatically accelerate the drug discovery process. Furthermore, adapting to studying membrane proteins will result in finding novel therapeutic ligands that target MPs, the most important class of drug targets.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017521</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Alexis Whitton</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Targeting anhedonia to improve clinical and functional outcomes in depression</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | psychology | cognitive and computational psychology | learning, motivation and emotion</Fields_of_Research>
        <Res_KW1>depression </Res_KW1>
        <Res_KW2>antidepressants</Res_KW2>
        <Res_KW3>emotion</Res_KW3>
        <Res_KW4>learning</Res_KW4>
        <Res_KW5>mood disorders</Res_KW5>
        <Plain_Description>Anhedonia (loss of pleasure) is a key driver of disability in people with depression because it impairs functioning and responds poorly to treatment. This research aims to improve our understanding of anhedonia’s underlying causes and will evaluate whether a novel intervention improves symptoms and functioning for people with anhedonic depression. By informing new treatment approaches for anhedonia, the findings would make significant progress toward reducing the global burden of depression.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017527</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Robin Cash</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Next Generation Therapeutic Brain Stimulation for Depression and beyond </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</Fields_of_Research>
        <Res_KW1>neuroimaging </Res_KW1>
        <Res_KW2>transcranial magnetic stimulation (tms)</Res_KW2>
        <Res_KW3>neuropsychiatry</Res_KW3>
        <Res_KW4>functional magnetic resonance imaging (fmri)</Res_KW4>
        <Res_KW5>treatment-resistant</Res_KW5>
        <Plain_Description>With millions of people suffering from depression and other mental illnesses, there is an urgent need for more effective treatments. I aspire to make possible a future in which dysfunctional brain circuits are routinely delineated using a person’s brain scans and treated using innovative brain stimulation therapeutics. My program will fundamentally advance the brain stimulation personalisation technology that I have developed and accelerate its clinical translation to improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017537</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicole Hill</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Averting suicide contagion and suicide clusters in young people</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$642,052.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | health services and systems | health and community services</Fields_of_Research>
        <Res_KW1>suicide prevention </Res_KW1>
        <Res_KW2>youth</Res_KW2>
        <Res_KW3>mental health services</Res_KW3>
        <Res_KW4>health surveillance</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>Suicide is the leading cause of death in young Australians. Young people who are exposed to suicide are at significant risk of suicide themselves. The proposed research will transform suicide prevention policy by building the evidence base identifying who is at risk of suicide contagion and clusters and building a suite of practical resources that can be implemented and utilised by stakeholders and decision makers to avert further deaths in communities impacted by multiple suicide losses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017538</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrew Toner</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving outcomes after high-risk surgery</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$452,575.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | anaesthesiology</Fields_of_Research>
        <Res_KW1>chronic pain </Res_KW1>
        <Res_KW2>surgical outcomes research</Res_KW2>
        <Res_KW3>systemic inflammation</Res_KW3>
        <Res_KW4>risk prediction</Res_KW4>
        <Res_KW5>anaesthesia</Res_KW5>
        <Plain_Description>Complications after operations are common and can result in chronic health problems or death. In this project, a large clinical trial will test whether treatment with a local anaesthetic drug, lidocaine, reduces the development of chronic pain one year after high-risk breast cancer surgery. Parallel studies will also assess the impact of enhanced ward monitoring after all types of high-risk operations and the role of inflammation in driving poor surgical outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017575</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Anna Singleton</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Scalable Survivorship Support after Cancer (CanSupport): Evaluation of a co-designed and automated eHealth intervention to support cancer survivors in primary care</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | digital health</Fields_of_Research>
        <Res_KW1>public health </Res_KW1>
        <Res_KW2>health services research</Res_KW2>
        <Res_KW3>health promotion</Res_KW3>
        <Res_KW4>electronic health information</Res_KW4>
        <Res_KW5>population health</Res_KW5>
        <Plain_Description>After cancer treatment, survivors need ongoing health support but access is limited. As an emerging survivorship researcher, my vision is to improve survivors’ access to support and health. I will expand my earlier breast cancer work to co-design a new support program for prostate, colorectal and lung cancer survivors sent via text messages called CanSupport, test if it improves support access and health in a primary care clinical trial and collect information to inform national roll-out.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017578</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Christopher Draper-Joyce</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Structural biology and protein engineering to accelerate rational development of novel antipsychotics</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$605,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology</Fields_of_Research>
        <Res_KW1>membrane protein </Res_KW1>
        <Res_KW2>molecular pharmacology</Res_KW2>
        <Res_KW3>schizophrenia</Res_KW3>
        <Res_KW4>structural biology</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>Schizophrenia is a debilitating psychiatric disorder that affects ~1% of the population, with a projected global economic burden of ~US$6trillion by 2030. Unfortunately, most schizophrenia patients discontinue antipsychotic treatment within the initial months of starting due to two key reasons: debilitating side effects and lack of efficacy. My research program is focused on solving these major bottlenecks with cutting-edge techniques and platforms for drug discovery at both new and old targets.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017580</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Simon Finfer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Improving sepsis outcomes using precision medicine</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,937,110.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | intensive care</Fields_of_Research>
        <Res_KW1>intensive care medicine </Res_KW1>
        <Res_KW2>sepsis</Res_KW2>
        <Res_KW3>immune modulation</Res_KW3>
        <Res_KW4>corticosteroids</Res_KW4>
        <Res_KW5>resuscitation</Res_KW5>
        <Plain_Description>Sepsis occurs when your body’s response to infection damages its own tissues and organs, if not prevented or treated promptly it may be fatal. It affects 55,000 Australians each year causing 7,000 deaths. Survivors commonly suffer long term health problems. My research focusses on improving the design and conduct of clinical trials that will match the right treatments to the right patients at the right time thus reducing death and disability from sepsis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017583</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Lidia Engel</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Fair resource allocation decisions in old age – enhancing the quality-adjusted life year (QALY) framework</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$553,973.20</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | aged health care | economics | applied economics | health economics</Fields_of_Research>
        <Res_KW1>economic evaluation </Res_KW1>
        <Res_KW2>health economics</Res_KW2>
        <Res_KW3>ageing</Res_KW3>
        <Res_KW4>quality of life</Res_KW4>
        <Res_KW5>patient preference</Res_KW5>
        <Plain_Description>People aged 65 years and over, a rapidly growing age group, are significant users of health and aged care services. Funding decisions for services are guided by cost-effectiveness evidence, using quality-adjusted life years (QALYs) as a measure of effectiveness. Yet the methods used to derive QALYs in older adults are flawed. My research will provide evidence on how to improve the estimation of QALYs in older adults, promoting fairer and socially accepted funding decisions for older adults.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017605</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Franz Babl</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Improving Emergency Department Identification and Care for Children with Sepsis</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,256,790.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | emergency medicine</Fields_of_Research>
        <Res_KW1>emergency medicine </Res_KW1>
        <Res_KW2>sepsis</Res_KW2>
        <Res_KW3>paediatric</Res_KW3>
        <Res_KW4>young children</Res_KW4>
        <Res_KW5>infection</Res_KW5>
        <Plain_Description>Sepsis is a severe infection of major national concern due to its morbidity and mortality. Early identification and optimal management of children at risk of sepsis in emergency departments are yet to be determined. My program will develop methods to identify these children, expand our understanding of sepsis causes and identify the most efficacious intravenous fluid for management. The goal is to improve sepsis care for children by filling evidence gaps for national/international guidelines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017609</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Dion Stub</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Integration of Pre-hospital and Hospital cardiac clinical registries to investigate novel therapeutics and systems of care in cardiac emergencies</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,461,112.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>acute myocardial infarction (ami) </Res_KW1>
        <Res_KW2>cardiac arrest</Res_KW2>
        <Res_KW3>shock</Res_KW3>
        <Res_KW4>acute coronary syndromes</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>The cardiac emergencies of cardiac arrest and heart attack continue to be a major challenge, with unacceptably high mortality and morbidity. Best outcomes are seen when systems of care integrating pre-hospital and hospital care are optimized. My research team involves the collaboration of Ambulance Victoria, with hospital based cardiac clinical registries, allowing for the unique opportunity to perform pragmatic clinical trials, to improve therapies in patients who currently have poor outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017628</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Rachel Menzies</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Targeting death anxiety with an online intervention to improve outcomes in anxiety-related disorders</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology</Fields_of_Research>
        <Res_KW1>anxiety disorders </Res_KW1>
        <Res_KW2>internet service delivery</Res_KW2>
        <Res_KW3>psychological treatment</Res_KW3>
        <Res_KW4>cognitive behaviour therapy</Res_KW4>
        <Res_KW5>treatment efficacy</Res_KW5>
        <Plain_Description>High rates of anxiety disorders are a global issue, with dire need for scalable treatment. Death anxiety has been shown to underpin many anxiety-related disorders, making it a vital treatment target. This research program will examine the world's first online evidence-based intervention for death anxiety. It will provide evidence of whether interventions targeting death anxiety improve existing mental health symptoms, reduce relapse, and prevent development of new disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017630</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Leanne Robinson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Innovative public health strategies for the elimination of malaria and lymphatic filariasis</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,256,790.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | disease surveillance</Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>filariasis</Res_KW2>
        <Res_KW3>health surveillance</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>vector control</Res_KW5>
        <Plain_Description>My vision is to improve the health of communities that have a high, yet often unrecognised, burden of parasitic vector-borne diseases, particularly malaria and lymphatic filariasis. My collaborative program of research will reduce the burden of these chronic debilitating infections in low-income countries, especially Papua New Guinea, by developing and testing new public health strategies and directly informing policy to target these infections more accurately, efficiently and effectively.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017642</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Liliana Laranjo</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Digital health to support behaviour change and chronic disease prevention in the community: What works, for whom, and in what context?</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$636,434.15</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | health services and systems | general practice | health sciences | health services and systems | digital health</Fields_of_Research>
        <Res_KW1>health informatics </Res_KW1>
        <Res_KW2>health behaviours</Res_KW2>
        <Res_KW3>cardiovascular disease prevention</Res_KW3>
        <Res_KW4>primary care</Res_KW4>
        <Res_KW5>population health</Res_KW5>
        <Plain_Description>The use of technology like apps to support health care and lifestyle behaviours is becoming increasingly common. However, the research to date is either non-existent or unclear as to which ones work best to improve health outcomes. I will address this gap by synthesising existing research and evaluating novel technologies such as artificial intelligence to better understand how digital technologies can be best used to improve health behaviours and prevent chronic disease in the community.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017646</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Miles Prince</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Novel approaches to the treatment and monitoring of patients with incurable haematological cancers</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$974,844.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | immunology | tumour immunology</Fields_of_Research>
        <Res_KW1>non-hodgkin lymphoma </Res_KW1>
        <Res_KW2>t cell immunotherapy</Res_KW2>
        <Res_KW3>targeted therapy</Res_KW3>
        <Res_KW4>cancer immunotherapy</Res_KW4>
        <Res_KW5>haematological malignancy</Res_KW5>
        <Plain_Description>This project will focus on 2 largely incurable forms of blood cancer; T cell lymphoma (TCL) and acute myeloid leukemia (AML). We will join international collaborators contributing to large databases to examine the causes and predictors of outcome of TCL.  I will undertake completely novel clinical trials using non-chemotherapy therapies which will include the scale-up in our laboratory of genetically engineered human immune cells called CART cells specifically designed for treating TCL and AML.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017651</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Piero Perucca</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Translating Epilepsy Genetics Advances into Improved Patient Care</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,376,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases</Fields_of_Research>
        <Res_KW1>epilepsy </Res_KW1>
        <Res_KW2>neuroscience</Res_KW2>
        <Res_KW3>genetics</Res_KW3>
        <Res_KW4>antiepileptic drugs</Res_KW4>
        <Res_KW5>epilepsy surgery</Res_KW5>
        <Plain_Description>Many epilepsies are now known to be genetic. The time has come to use this knowledge in the management of people with epilepsy to improve their treatment outcomes. I will develop a research program that will translate the progress in epilepsy genetics in the past 20 years into better patient care by using genetic data to accurately classify epilepsies of unknown type and guide epilepsy surgery. I will also set up a platform to study therapies targeting genetic abnormalities causing epilepsy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017661</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Benjamin Rogers</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Optimised Outpatient Parenteral Antimicrobial Therapy</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$440,075.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases</Fields_of_Research>
        <Res_KW1>antimicrobial resistance </Res_KW1>
        <Res_KW2>antimicrobial therapy</Res_KW2>
        <Res_KW3>bacterial infection</Res_KW3>
        <Res_KW4>clinical pharmacology</Res_KW4>
        <Res_KW5>community care</Res_KW5>
        <Plain_Description>Treatment of many complicated infections can now occur in the community rather than hospital. The approach of giving antibiotics in the home setting is preferred by patients and health services. However, practical challenges impact on which antibiotics are available for use in the home setting. Further, as this is a relatively new field, research on the best possible treatments and strategies to overcome practical challenges to antibiotic administration in the home setting are urgently needed.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017679</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Ming  Li</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Platform Technologies for Antibiotic Resistance Diagnostics at Single-Cell Resolution</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | fluid mechanics and thermal engineering | microfluidics and nanofluidics</Fields_of_Research>
        <Res_KW1>biomedical engineering </Res_KW1>
        <Res_KW2>biotechnology</Res_KW2>
        <Res_KW3>antibiotic resistance</Res_KW3>
        <Res_KW4>cell separation</Res_KW4>
        <Res_KW5>drug screening</Res_KW5>
        <Plain_Description>My research aims to advance our understanding of antibiotic resistance in bacterial populations at the single-cell level. Examining the differences between individual bacterial cells in response to antibiotics is essential to provide fundamental insights into heterogeneous resistance, an important player precipitating the antibiotic crisis. Expected outcomes include improved knowledge of bacterial heterogeneity, informing antibiotic usage, and a new tool for more accurate resistance testing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017694</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof John Kaldor</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Design and evaluation of novel interventions for infectious diseases of global importance</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,633,294.56</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>infectious diseases </Res_KW1>
        <Res_KW2>community intervention study</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>evaluation studies</Res_KW4>
        <Res_KW5>social disadvantage</Res_KW5>
        <Plain_Description>I will set up a new centre to conduct studies on how to prevent sexually transmitted infections and neglected tropical diseases in the countries most affected by these conditions. I will trial novel uses and new agents for mass drug administration, which involves treating whole populations when disease rates are high, rather than trying to find those with the infection. I will also evaluate innovative methods for tracking the impact of programs and strategies aimed at control of these diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017719</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Courtney Ryder</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Transforming Injury for Aboriginal and Torres Strait Islander Children through Innovative Knowledge Gain and Co-designed Intervention</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$642,650.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | injury prevention | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing</Fields_of_Research>
        <Res_KW1>aboriginal health </Res_KW1>
        <Res_KW2>aboriginal child</Res_KW2>
        <Res_KW3>injury</Res_KW3>
        <Res_KW4>injury prevention</Res_KW4>
        <Res_KW5>injury epidemiology</Res_KW5>
        <Plain_Description>Indigenous children have high rates of injury, these rates are not decreasing and create burden in the community. My research program will address this through collaborating with Indigenous communities in South Australia and working with Big Data to understand the injury burden for Indigenous children, detect areas for improvement, and co-design an injury intervention for Indigenous children to decrease injury and improve health and wellbeing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017734</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Louise Owen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Lungs for life: a programme of clinical trials to improve respiratory outcomes for premature babies</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,345,834.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology</Fields_of_Research>
        <Res_KW1>prematurity </Res_KW1>
        <Res_KW2>premature infant</Res_KW2>
        <Res_KW3>bronchopulmonary dysplasia</Res_KW3>
        <Res_KW4>respiratory distress syndrome (rds)</Res_KW4>
        <Res_KW5>resuscitation</Res_KW5>
        <Plain_Description>Almost 1 in 10 babies in Australia are born early (preterm). They often need help to breathe at birth, and for days and weeks afterwards. Some will go on to have long-term problems with their lungs.  My research looks at how we can improve the outlook for preterm babies, by finding better ways to support their breathing, right from their first breath. Improving how we care for preterm babies immediately after birth can improve their lung health, as newborns, as children and through to adulthood.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017742</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Emily Banks</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Large scale evidence, microsimulation and translation to address contemporary challenges in tobacco control and cardiovascular disease</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$2,937,110.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care</Fields_of_Research>
        <Res_KW1>chronic illness prevention </Res_KW1>
        <Res_KW2>cigarette smoking</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>cardiovascular disease prevention</Res_KW4>
        <Res_KW5>survivorship</Res_KW5>
        <Plain_Description>Chronic diseases, including cardiovascular disease (CVD), cancer, dementia, chronic kidney disease and chronic lung disease, are highly preventable and threaten Australia's continuing improvements in life expectancy. The proposed research will generate and translate large-scale evidence to drive improvement in tobacco control, electronic cigarettes and CVD, for the general and Aboriginal and Torres Strait Islander populations, including through creation of an enduring CVD microsimulation model.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017774</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Yuerui Lu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Advanced intravascular optical imaging in vivo for future precise diagnosis and treatment therapies</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | engineering | nanotechnology | nanophotonics | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>diagnostic imaging </Res_KW1>
        <Res_KW2>optical imaging</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>lens development</Res_KW5>
        <Plain_Description>This interdisciplinary project aims to develop a new optical imaging modality using the high-speed and focus-tunable micro-lenses I recently invented. The device will be small enough to be inserted into blood vessels to provide high-quality images with unprecedented resolution and image depth. Artificial intelligence will be implemented for high-speed and real-time image processing. This will help specialists better visualise and understand the causes of heart attacks and how to prevent them.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017798</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Prashanthan Sanders</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Managing the First Pillar for Atrial Fibrillation and Stroke</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,117,519.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>atrial fibrillation </Res_KW1>
        <Res_KW2>stroke</Res_KW2>
        <Res_KW3>lifestyle factors</Res_KW3>
        <Res_KW4>cardiac arrhythmia</Res_KW4>
        <Res_KW5>embolism</Res_KW5>
        <Plain_Description>This program will develop and evaluate a standardised approach to the management of lifestyle/risk factors for atrial fibrillation (AF) and stroke. Management of AF is currently not standardised and therefore leads to highly variable patient outcomes. Advancing risk factor modification as the primary AF management pillar, this program seeks to establish a new paradigm of upstream interventions for the prevention and treatment of AF and stroke, and formulate optimal delivery strategies for care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017818</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Bobby Porykali</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>A holistic approach to achieving best health outcomes through culturally appropriate self-determined pathways into employment for Aboriginal and Torres Strait Islander people</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$666,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander peoples, society and community | aboriginal and torres strait islander community-based research | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social determinants of health | indigenous studies | aboriginal and torres strait islander education | embedding aboriginal and torres strait islander knowledges, histories, culture, country, perspectives and ethics in education</Fields_of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>social determinants of health</Res_KW2>
        <Res_KW3>employment</Res_KW3>
        <Res_KW4>community intervention study</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>This project will achieve best health outcomes for Aboriginal and Torres Strait Islander peoples by developing holistic culturally appropriate pathways into self-determined employment. The longer people remain unemployed the more likely they suffer from a range of health problems and premature deaths. By improving employment outcomes, we will improve the set of circumstances that individuals, families, and communities are born, grow, live and work. This will promote good health and wellbeing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017828</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Jagnoor Jagnoor</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Turning the tide: co-developing drowning prevention interventions</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | behavioural epidemiology | health sciences | public health | injury prevention | health sciences | health services and systems | implementation science and evaluation</Fields_of_Research>
        <Res_KW1>injury prevention </Res_KW1>
        <Res_KW2>health policy</Res_KW2>
        <Res_KW3>injury control</Res_KW3>
        <Res_KW4>health inequalities</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Drowning is a leading cause of injury deaths. In the last 30 years, we have developed a good understanding of how we can prevent drowning incidents and deaths, but we have not implemented our knowledge to its full potential. Using robust methods and through a consultative process, I will work with communities and policy stakeholders in Australia and India to develop and implement, evidence-led drowning prevention solutions for populations most susceptible to drowning.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017844</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Joanne Kemp</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Understanding and reducing hip osteoarthritis burden in young adults and adolescents</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,576,390.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | rheumatology and arthritis | health sciences | allied health and rehabilitation science | physiotherapy | biomedical and clinical sciences | clinical sciences | sports medicine</Fields_of_Research>
        <Res_KW1>hip replacement </Res_KW1>
        <Res_KW2>arthritis</Res_KW2>
        <Res_KW3>physiotherapy</Res_KW3>
        <Res_KW4>sports medicine</Res_KW4>
        <Res_KW5>musculoskeletal disorders</Res_KW5>
        <Plain_Description>Hip pain is common in young adults, causing substantial burden and representing early hip arthritis. My research program will reduce the burden of hip pain in younger adults at risk of/with early hip arthritis. I will capture the natural history of hip disease and develop effective interventions, determining how to best treat hip pain in younger adult, and identify who is at risk of hip arthritis to stop the progression of hip pain to hip osteoarthritis and the need for hip replacement.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017876</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Imogen Bell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Harnessing innovative digital technologies to enhance youth mental health care</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$648,985.62</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</Fields_of_Research>
        <Res_KW1>adolescent health </Res_KW1>
        <Res_KW2>clinical psychology</Res_KW2>
        <Res_KW3>internet service delivery</Res_KW3>
        <Res_KW4>mental health</Res_KW4>
        <Res_KW5>psychological treatment</Res_KW5>
        <Plain_Description>There is a growing youth mental health crisis. Mental ill-health remains the leading cause of death in young people. Of the one in four who suffer, only a quarter receive adequate care. To overcome this crisis, more accessible and effective treatments need to be developed. My research program will develop, evaluate and implement a new generation of treatments that harness advanced digital technologies to provide better care to young people.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017877</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Joshua Ooi</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Targeted regulatory T cells to treat autoimmune diseases</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,256,790.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | autoimmunity</Fields_of_Research>
        <Res_KW1>autoimmunity </Res_KW1>
        <Res_KW2>t cells</Res_KW2>
        <Res_KW3>regulatory t cells</Res_KW3>
        <Res_KW4>autoimmune disease</Res_KW4>
        <Res_KW5>cell therapy</Res_KW5>
        <Plain_Description>Autoimmune diseases occur when the immune system attacks a person's own body. These diseases affect more than a million Australians and hundreds of millions worldwide. There are no cures and current treatments cause significant side effects.  This novel research program will use genetic engineering to develop a potent cell-based therapy that specifically treats the cause of disease. This new therapy has the potential to cure autoimmune diseases and restore the lives of many patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017879</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof J Hudson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Improving outcomes for children with anxiety disorders</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</Fields_of_Research>
        <Res_KW1>primary school-aged children </Res_KW1>
        <Res_KW2>anxiety disorders</Res_KW2>
        <Res_KW3>mental health</Res_KW3>
        <Res_KW4>internet service delivery</Res_KW4>
        <Res_KW5>early intervention</Res_KW5>
        <Plain_Description>Children whose mental health difficulties are identified early, and effectively addressed, reap the benefits across their lifespan. This has profound benefits for the child and the child’s family as well as significant social benefits. We need to invest in improving outcomes for children with anxiety to make an enduring difference to the mental health of all Australians. This work will improve access to, and delivery of evidence-based care and will improve treatments for children with anxiety.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017897</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephen Tong</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Translating new therapeutics and diagnostics for stillbirth and preeclampsia</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology | biomedical and clinical sciences | reproductive medicine | reproduction</Fields_of_Research>
        <Res_KW1>pre-eclampsia </Res_KW1>
        <Res_KW2>stillbirth</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>pregnancy</Res_KW4>
        <Res_KW5>fetal growth restriction</Res_KW5>
        <Plain_Description>Stillbirth and preeclampsia are terrible diseases of pregnancy that can claim the life of the mother, or her unborn baby.     Here, I propose large programs of research that will avidly hunt for new treatments and diagnostics to tackle both conditions. We will develop a blood test that may save babies from stillbirth. We will find new drugs in the laboratory to treat preeclampsia and test them in successive international clinical trials - mainly South Africa where the disease is sadly rife.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017898</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof David Ziegler</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Novel Therapeutic Strategies for Childhood Brain Cancer</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,878,395.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy)</Fields_of_Research>
        <Res_KW1>brain tumours </Res_KW1>
        <Res_KW2>anti-tumour drugs</Res_KW2>
        <Res_KW3>oncology</Res_KW3>
        <Res_KW4>paediatric</Res_KW4>
        <Res_KW5>tumour biology</Res_KW5>
        <Plain_Description>Brain cancer is the single disease causing the most deaths in childhood, as well as significant disability and long-term health problems for survivors, warranting urgent improvement to treatments.  My program seeks to improve outcomes for children with the most aggressive brain tumours by developing new targeted treatment strategies, investigating immunotherapies, and developing strategies to allow effective drugs to penetrate into the brain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017903</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Enyuan Cao</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Harnessing novel lymph-resident targets and lymph-specific therapeutics to fight inflammation </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences</Fields_of_Research>
        <Res_KW1>pharmaceutics </Res_KW1>
        <Res_KW2>drug delivery</Res_KW2>
        <Res_KW3>lymphatics</Res_KW3>
        <Res_KW4>obesity</Res_KW4>
        <Res_KW5>inflammation</Res_KW5>
        <Plain_Description>The mesenteric lymphatic system plays vital roles in regulating dietary lipid transport and immune activation. Lymphatic dysfunction impairs these processes, and is detrimental in both obesity-associated metabolic disease and inflammatory bowel disease. This proposal will uncover the mechanisms driving mesenteric lymphatic dysfunction and associated inflammation. This knowledge will be used to establish lymph-specific therapeutics to enhance treatment outcomes in chronic inflammation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017912</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Kirstie Bertram</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Linking microbiome, inflammation, HIV target cells </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology</Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>mucosal immunity</Res_KW2>
        <Res_KW3>dendritic cell</Res_KW3>
        <Res_KW4>t cells</Res_KW4>
        <Res_KW5>epidermal barrier</Res_KW5>
        <Plain_Description>New HIV infections are now clearly associated with an inflamed genital tract (in both females and males) and the microbiome of these sites. What is unclear is the immune cell constitution of these inflamed tissues that may be the main drivers of increased disease. I have developed in my lab techniques to isolate and interrogate immune cells from human genital tissue and how they interact with HIV. I will connect the immune cell environment with inflammation and the microbiome.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017916</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Krystyna Gieniec</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Tumour-stroma crosstalk in breast cancer: Deciphering and disrupting communications between cancer cells and cancer-associated fibroblasts</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | biological sciences | biochemistry and cell biology | signal transduction</Fields_of_Research>
        <Res_KW1>fibroblasts </Res_KW1>
        <Res_KW2>stromal cells</Res_KW2>
        <Res_KW3>breast cancer</Res_KW3>
        <Res_KW4>calcium signalling</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>Breast cancer can be described as a play with many acts and actors. For approx. 20% of women diagnosed with this disease, there are no targeted therapies and for many more, recurrence and metastasis are major obstacles. Whilst tumour cells take centre stage in the diagnosis and treatment of this disease, it is now understood that fibroblasts play an important supporting role. Using novel methods to view and study this disease, my work will help to define the next generation of cancer therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017929</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Najoua Lalaoui</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Investigating the interplay between cell death and inflammation in human diseases</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,256,790.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | biological sciences | biochemistry and cell biology | cell development, proliferation and death | biological sciences | biochemistry and cell biology | signal transduction</Fields_of_Research>
        <Res_KW1>cell death </Res_KW1>
        <Res_KW2>cell signalling</Res_KW2>
        <Res_KW3>tissue necrosis factor (tnf)</Res_KW3>
        <Res_KW4>inflammation</Res_KW4>
        <Res_KW5>mouse models</Res_KW5>
        <Plain_Description>Cell death is a mechanism that allows old cells to be replaced by new cells or occurs during tissue damage. In some contexts, dying cells release inflammatory molecules that can be beneficial or detrimental to the body. This proposal aims to study the complex interplay between cell death and inflammation. Understanding the involvement of these processes in cancer and inflammatory diseases is essential to identify novel treatment strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017942</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof David Evans</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Developing and Applying Mendelian Randomization Methods to Facilitate Drug Discovery and Solve Intractable Problems in Medical Research</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,307,786.44</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological methods | biological sciences | bioinformatics and computational biology | statistical and quantitative genetics</Fields_of_Research>
        <Res_KW1>statistical genetics </Res_KW1>
        <Res_KW2>genetic epidemiology</Res_KW2>
        <Res_KW3>complex disease</Res_KW3>
        <Res_KW4>genetic association</Res_KW4>
        <Res_KW5>biostatistics</Res_KW5>
        <Plain_Description>Mendelian randomization is a way of using genetic data to test whether particular environmental exposures, biological molecules or drug targets cause disease. The purpose of this Investigator Award is to create new statistical methods and software that use Mendelian randomization to facilitate drug discovery, and to use the Mendelian randomization paradigm to solve high value questions in medical research that have so far proven intractable to other research approaches.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017952</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Sandra Cooper</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Innovating pathways to embed novel RNA technologies into clinical practise</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,287,110.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics)</Fields_of_Research>
        <Res_KW1>clinical genetics </Res_KW1>
        <Res_KW2>cancer predisposition</Res_KW2>
        <Res_KW3>molecular diagnostics</Res_KW3>
        <Res_KW4>splicing</Res_KW4>
        <Res_KW5>aboriginal health</Res_KW5>
        <Plain_Description>Genetic rare disorders affect 1 in 100 individuals. A precise genetic diagnosis is the key to personalised healthcare, disease prevention, and sometimes a cure or treatment.  For the 50% of families undiagnosed after DNA testing, the answer can lie in their RNA.  I will lead an evidence-based national strategy to embed RNA diagnostics in clinical practise, vastly improving diagnoses of families living with genetic rare disorders and revolutionising their personalised health care options.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017962</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Lianne Schmaal</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Identifying clinically relevant neurobiological markers of depression and suicidal behaviours</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,256,790.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</Fields_of_Research>
        <Res_KW1>depression </Res_KW1>
        <Res_KW2>suicide</Res_KW2>
        <Res_KW3>neuroimaging</Res_KW3>
        <Res_KW4>prediction</Res_KW4>
        <Res_KW5>longitudinal</Res_KW5>
        <Plain_Description>Depression and suicide have a devastating impact on lives and communities. To develop more effective treatments, we need to gain a better understanding of the biological mechanisms underlying depression and suicide. This research program aims to identify brain markers that can assist in the diagnosis of depression and suicidal thoughts and behaviours and predict who is at risk for poor clinical outcomes over time.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017971</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Marco Herold</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Using advanced CRISPR tools to improve clinical therapies for poor prognostic lymphomas</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,205,736.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biological sciences | biochemistry and cell biology | cell development, proliferation and death</Fields_of_Research>
        <Res_KW1>genetic screening </Res_KW1>
        <Res_KW2>bcl-2</Res_KW2>
        <Res_KW3>lymphoma</Res_KW3>
        <Res_KW4>tumour suppression</Res_KW4>
        <Res_KW5>oncogenes</Res_KW5>
        <Plain_Description>Treatment outcomes for certain aggressive blood cancers have not improved in recent years. Many patients do not respond and novel treatments are desperately required. My program aims to fill this gap by using sophisticated lymphoma models and unique molecular tools to discover new treatments and therapy resistance factors, and to test a new drug for clinical application. Outcomes of this work could improve life quality and chances for a cure for blood cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017974</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Jie Tang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Fighting Cancer Relapse: Developing an Oral Cancer Vaccine Generating Memory T Cells</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | nanotechnology | nanomaterials | engineering | biomedical engineering | biomaterials</Fields_of_Research>
        <Res_KW1>nanotechnology </Res_KW1>
        <Res_KW2>vaccine vectors</Res_KW2>
        <Res_KW3>adjuvant</Res_KW3>
        <Res_KW4>colorectal cancer prevention</Res_KW4>
        <Res_KW5>oral administration</Res_KW5>
        <Plain_Description>Colorectal cancer (CRC) is the world's second most fatal cancer with a high rate of relapse. This project aims to develop an oral vaccine for preventing CRC recurrence by boosting the local gut immune response, which is at the frontline in powerful anti-cancer defence. This oral vaccine is based on cutting-edge research in immunology and nanomaterials, enabling robust and persistent protection against CRC recurrence, and enables convenient oral intake for maximal patient acceptance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018015</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Jacqui Webster</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Increasing the impact of food policy research in Australia and globally </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,932,170.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>public health policy </Res_KW1>
        <Res_KW2>dietary sodium</Res_KW2>
        <Res_KW3>community development</Res_KW3>
        <Res_KW4>food</Res_KW4>
        <Res_KW5>public health impact</Res_KW5>
        <Plain_Description>My research will identify the critical factors required to support adoption and implementation of food policies by governments in Australia and globally. It will inform strategies to support researchers to strengthen the impact of future food policy research. This will ensure that  evidence-based policies are to improve diets are adopted and implemented reducing the health and economic burden of diet-related diseases and meaning government funding for food policy research is well spent.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018064</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof William Tarnow-Mordi</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Advancing perinatal health in Australia through international randomised studies to reduce death and disability.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,437,110.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiology not elsewhere classified</Fields_of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>perinatal</Res_KW2>
        <Res_KW3>neonatal</Res_KW3>
        <Res_KW4>meta-analysis</Res_KW4>
        <Res_KW5>obstetrics</Res_KW5>
        <Plain_Description>Clinical trials have made big advances in treatment in all areas in Australia and worldwide. However most trials for high-risk babies and their mothers are too small to find improvements in healthy survival as quickly as we would like. We will work with stakeholders across the world to create a new kind of trial that will run at least ten times larger and faster, at one tenth the cost, saving thousands more lives and millions more dollars in Australia and overseas</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018071</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Wei</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Early intervention for therapeutic benefit in AML: a national program of clinical trials</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,029,302.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology</Fields_of_Research>
        <Res_KW1>acute myeloid leukaemia (aml) </Res_KW1>
        <Res_KW2>targeted therapy</Res_KW2>
        <Res_KW3>myeloid leukaemia</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>AML is a lethal blood cancer capable of developing resistance to therapy. Relapsing disease is the major barrier to improving outcome. I will build on my success in delivering new AML therapies by developing a national program of trials using technologies to detect returning disease at its earliest stages complemented by novel drugs to target AML with precision intent. A multidisciplinary team will elucidate mechanisms of resistance and validate alternative approaches to extend patient survival.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018077</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Dean Picone</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Saving lives with better blood pressure measurement</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>blood pressure </Res_KW1>
        <Res_KW2>hypertension</Res_KW2>
        <Res_KW3>cardiovascular physiology</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>reliability</Res_KW5>
        <Plain_Description>The research program aims to address problems related to inaccurate measurement of blood pressure (BP). I will use advanced analysis techniques to develop a better way to measure BP. Other program elements include examining the accuracy of BP measurement in high-risk patients and promotion best practice measurement methods and devices through translational research. Overall, the aim of the program is to minimise the burden of preventable cardiovascular disease in Australia and globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018081</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Ravi Savarirayan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>New therapies for skeletal dysplasia</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,605,432.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics)</Fields_of_Research>
        <Res_KW1>translational research </Res_KW1>
        <Res_KW2>clinical genetics</Res_KW2>
        <Res_KW3>skeletal dysplasia</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>individualising management</Res_KW5>
        <Plain_Description>Inherited disorders of the skeleton are common with significant health impacts. My research has enabled treatment of these conditions at their genetic source. This program will assess whether drug treatment of infants with achondroplasia will decrease the 50-fold higher risk of sudden death by relieving pressure on the spinal cord, and assess whether treatment of children with metaphyseal dysplasia will relieve pain, improve skeletal deformity and eliminate the need for invasive surgery.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018082</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Leopold Aminde</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Estimating the health equity and productivity impacts of dietary salt reduction in people with chronic kidney disease in Australia</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological modelling | health sciences | public health | preventative health care</Fields_of_Research>
        <Res_KW1>hypertension </Res_KW1>
        <Res_KW2>dietary sodium</Res_KW2>
        <Res_KW3>kidney disease</Res_KW3>
        <Res_KW4>burden of disease</Res_KW4>
        <Res_KW5>health economics</Res_KW5>
        <Plain_Description>Excess salt intake increases blood pressure and puts persons at risk of complications like chronic kidney disease (CKD) that kills one in ten Australians. CKD contributes to health inequalities and has a major impact on quality of life and productivity, and the future impacts in Australia are unknown. This project will evaluate long-term impacts of strategies to reduce population salt intake on CKD burden, to guide policies that improve the quality of life of all Australians.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018098</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Carl Walkley</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Understanding and exploiting A-to-I RNA editing</Grant_Title>
        <Admin_Institution>St Vincents Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genetics not elsewhere classified</Fields_of_Research>
        <Res_KW1>rna binding proteins </Res_KW1>
        <Res_KW2>rna</Res_KW2>
        <Res_KW3>innate immunity</Res_KW3>
        <Res_KW4>mouse genetics</Res_KW4>
        <Res_KW5>cell biology</Res_KW5>
        <Plain_Description>This project will determine how changes to a type of RNA modification, termed Adenosine-to-Inosine (A-to-I) RNA editing, cause disease. Reduced A-to-I editing causes development of autoimmune disease and brain diseases. Too much editing is seen in cancer. I will use animal models to understand how changes in A-to-I editing cause disease. This will be important to provide knowledge of how these diseases occur and identify new ways to treat them.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018101</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Liping Huang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Scaling the effects of salt substitute on cardiovascular risk reduction population-wide</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>dietary salt </Res_KW1>
        <Res_KW2>cardiovascular disease prevention</Res_KW2>
        <Res_KW3>high blood pressure</Res_KW3>
        <Res_KW4>modelling</Res_KW4>
        <Res_KW5>control of blood pressure</Res_KW5>
        <Plain_Description>In a world-first trial, we showed that switching regular salt for a reduced-sodium, added-potassium ‘salt substitute’ can lower blood pressure and prevent premature death. ‘Salt substitutes’ are safe and low-cost but are not widely used. Over the next 5-years I will do the work required to upscale their use in Australia and around the world. I will do this by building tools that show governments the health gains, cost-benefits and practical ways they can scale national uptake of salt substitute.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018105</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Caleb Dawson </CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Decoding the instructions for immune cell function</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death</Fields_of_Research>
        <Res_KW1>macrophage biology </Res_KW1>
        <Res_KW2>t cells</Res_KW2>
        <Res_KW3>breast cancer</Res_KW3>
        <Res_KW4>confocal microscopy</Res_KW4>
        <Res_KW5>immune regulation</Res_KW5>
        <Plain_Description>Each organ sends many different signals to its immune cells to instruct them in varied and critical functions that impact health and disease. These signals are complex and there is a lack of tools to study them, so how they act to instruct immune cell function remains largely unknown. I will combine cutting-edge molecular and imaging technologies to discover how the breast instructs its immune cells and reveal new ways to control breast cancer, treat inflammation and improve infant health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018108</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Mei Ling Yap</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Harnessing big data to improve access to care and outcomes in REcent Migrants And Refugees diagnosed with Cancer (REMARC)</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$493,090.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified</Fields_of_Research>
        <Res_KW1>cancer control </Res_KW1>
        <Res_KW2>refugee health</Res_KW2>
        <Res_KW3>equity</Res_KW3>
        <Res_KW4>migrant health</Res_KW4>
        <Res_KW5>radiotherapy</Res_KW5>
        <Plain_Description>Cancer is one of the leading causes of death in Australia. There have been 4.5 million migrants and refugees to Australia in the last 30 years. This research program uses big data to study whether recent migrants and refugees diagnosed with cancer access the right treatments and the impacts of a cancer diagnosis on these people’s lifespan and employment. Our research will highlight current gaps and the policy changes needed to improve the lives of people diagnosed with cancer in this population.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018114</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Ksenia Skvortsova</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Investigating the epigenetic control of female-biased autoimmune disorders</Grant_Title>
        <Admin_Institution>Garvan Institute of Medical Research</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$574,120.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics)</Fields_of_Research>
        <Res_KW1>epigenetics </Res_KW1>
        <Res_KW2>dna methylation</Res_KW2>
        <Res_KW3>autoimmune disease</Res_KW3>
        <Res_KW4>x chromosome inactivation</Res_KW4>
        <Res_KW5>b cells</Res_KW5>
        <Plain_Description>Our immune system is a complex network of cells that defend us from infections. In 5-8% of people, the immune system goes awry and mistakenly attacks the body’s healthy tissues, leading to autoimmune disease. Remarkably, 80% of autoimmunity patients are women, however, the molecular mechanisms behind this bias remain unknown. Using cutting-edge technologies, I will define female-specific mechanisms leading to autoimmunity, which will provide tools for diagnostics and drug target prioritisation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018118</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Heidi Staudacher</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Food, mood and microbes: Improving mental health through diet</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | clinical nutrition | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)</Fields_of_Research>
        <Res_KW1>mental health </Res_KW1>
        <Res_KW2>diet</Res_KW2>
        <Res_KW3>molecular microbiology</Res_KW3>
        <Res_KW4>dietary intervention</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Mental health conditions like depression are a major cause of reduced quality of life. Unfortunately, medications are suboptimal for many people with the condition. Research shows changing your diet can improve depression. A Mediterranean diet rich in wholegrain cereals, fruit, vegetables and olive oil is particularly beneficial. However, we do not know how this diet improves depression symptoms and we need to identify ways to provide clear information about it to the people who need it most.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018144</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephanie Brown</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Driving change in the health sector to reduce the impact of intergenerational trauma and family violence</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | social determinants of health | health sciences | epidemiology | social epidemiology | health sciences | health services and systems | implementation science and evaluation</Fields_of_Research>
        <Res_KW1>trauma </Res_KW1>
        <Res_KW2>aboriginal mental health</Res_KW2>
        <Res_KW3>refugee health</Res_KW3>
        <Res_KW4>domestic violence</Res_KW4>
        <Res_KW5>lived experiences</Res_KW5>
        <Plain_Description>Intergenerational trauma and family violence are global public health issues with major impacts on the health and wellbeing of children, families and communities. My research will provide robust evidence about lived experiences of intergenerational trauma and family violence in priority populations to inform early intervention and health system reform. Co-designed intervention studies will provide evidence about ways to embed culturally safe, trauma-informed approaches into practice.     </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018157</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Frank Iorfino</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Harnessing digital technologies to improve the quality of youth mental health services</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$574,564.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services</Fields_of_Research>
        <Res_KW1>youth </Res_KW1>
        <Res_KW2>computer-based decision support</Res_KW2>
        <Res_KW3>prediction</Res_KW3>
        <Res_KW4>mood disorders</Res_KW4>
        <Res_KW5>outcomes research</Res_KW5>
        <Plain_Description>Mental disorders are the leading cause of disability and death among young people. While youth mental health services have improved access to care, many challenges contribute to ongoing service inefficiencies and poor clinical outcomes at high costs to society. This research program aims to address these challenges by making use of modern digital technologies to provide services with decision-support tools designed to make youth mental health care more personalised, dynamic and proactive.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018163</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Kistler</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Atrial fibrillation: improving outcomes through lifestyle and ablation</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,941,085.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>atrial fibrillation </Res_KW1>
        <Res_KW2>atrial arrhythmias</Res_KW2>
        <Res_KW3>congestive heart failure</Res_KW3>
        <Res_KW4>obesity</Res_KW4>
        <Res_KW5>alcohol</Res_KW5>
        <Plain_Description>Atrial fibrillation(AF) is the most common heart rhythm disorder and an epidemic of cardiovascular disease. AF is associated with stroke, mortality and heart failure. Ablation involves passing wires into the heart and delivering tiny burns to cure AF. Increasingly lifestyle factors such as weight loss and alcohol reduction have also been shown to reduce AF. The research plan explores yoga, medicated weight loss and new ablation techniques to improve outcomes in people with AF.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018167</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Belinda Parker</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Targeting crosstalk in the tumour microenvironment for precision cancer therapy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,082,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets</Fields_of_Research>
        <Res_KW1>metastatic progression </Res_KW1>
        <Res_KW2>breast cancer</Res_KW2>
        <Res_KW3>prostate cancer</Res_KW3>
        <Res_KW4>microenvironment</Res_KW4>
        <Res_KW5>interferon (ifn)</Res_KW5>
        <Plain_Description>Cancer spread remains very difficult to target therapeutically. My research focus has been modelling the cellular interactions that occur during cell spread to develop markers that predict the effectiveness of existing therapies and to uncover new biological targets for treating aggressive cancer types. I now aim to drive this research into the clinical setting by utilising unique humanised models and interrogating patient samples to enable science-guided therapies for cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018182</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Nadine Foster</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Musculoskeletal pain: getting the right patient to the right treatment at the right time</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,832,580.96</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | pain | biomedical and clinical sciences | clinical sciences | rheumatology and arthritis | health sciences | allied health and rehabilitation science | physiotherapy</Fields_of_Research>
        <Res_KW1>musculoskeletal disorders </Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>health economics</Res_KW3>
        <Res_KW4>low back pain</Res_KW4>
        <Res_KW5>osteoarthritis</Res_KW5>
        <Plain_Description>Common painful conditions affecting the bones and joints such as low back pain and arthritis cause more disability than any other condition, and the scale of the problem is rising. Health care is struggling to meet the demand, commonly offering treatments of limited value to patients who don't need them, whilst not providing access to effective care for those who do. This program will reduce uncertainty about treatment effectiveness and ensure patients get access to the care they need.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018187</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Paula Miotto</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Leveraging liver-derived extracellular vesicles to identify new therapies for type 2 diabetes</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell metabolism</Fields_of_Research>
        <Res_KW1>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </Res_KW1>
        <Res_KW2>endocrine factors</Res_KW2>
        <Res_KW3>lipid metabolism</Res_KW3>
        <Res_KW4>insulin resistance</Res_KW4>
        <Res_KW5>fatty liver disease</Res_KW5>
        <Plain_Description>Type 2 diabetes is characterised by impairments in glycemic control, compromised insulin secretion, and insulin resistance. There is an urgent clinical need to develop new strategies to normalise blood glucose levels. This investigator grant aims to identify novel insulin-independent therapeutic targets that can improve glycemic control. This project will use preclinical models to validate the efficacy of these targets, setting the stage for the development of new treatments for type 2 diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018194</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Gemma Figtree</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Innovative solutions towards reducing heart attacks- beyond classical risk factors</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,029,302.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>coronary artery disease </Res_KW1>
        <Res_KW2>atherosclerosis</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>drug discovery</Res_KW4>
        <Res_KW5>heart attack</Res_KW5>
        <Plain_Description>I am a cardiologist driven by the increasing number of heart attack patients who ask “why me?”. Fourteen-27% of patients with life-threatening heart attacks have no standard modifiable risk factors. By focussing on this growing group with no risk factors, I will discover and translate new biomarkers, develop new drugs to reduce heart attacks, derive new clinical pathways, and improve outcomes with broader benefits to all patients susceptible to coronary artery disease and heart attack.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018204</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Angela Nickerson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Advancing Refugee Mental Health</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,756,790.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology</Fields_of_Research>
        <Res_KW1>refugee health </Res_KW1>
        <Res_KW2>posttraumatic stress disorder (ptsd)</Res_KW2>
        <Res_KW3>traumatic stress</Res_KW3>
        <Res_KW4>psychological treatment</Res_KW4>
        <Res_KW5>cognitive behaviour therapy</Res_KW5>
        <Plain_Description>The number of refugees worldwide has reached unprecedented levels. Refugees show high rates of psychological disorders due to exposure to war, trauma and persecution. Despite this, many do not seek help or fail to respond to treatment. This research program proposes to increase knowledge about the factors contributing to PTSD and help-seeking. This will lead to the development of two new interventions to improve mental health outcomes in refugees.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018214</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Man Lee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reconstructing the megakaryocyte lipidome to control platelet production: Applications for thrombocytopenia or thrombocytosis</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death</Fields_of_Research>
        <Res_KW1>platelets </Res_KW1>
        <Res_KW2>lipids</Res_KW2>
        <Res_KW3>haematopoiesis</Res_KW3>
        <Res_KW4>thrombocytopenia</Res_KW4>
        <Res_KW5>stem cell biology</Res_KW5>
        <Plain_Description>Platelets are cell fragments critical for blood clotting. Too few, results in bleeding disorders and too many, can block blood supply to organs. Both are life threatening. Current treatments are limited and have side effects. There is an urgent need to identify new ways to counteract both extreme conditions. We recently identified important lipids that are needed for platelet production. Here, we aim to increase or decrease these lipid levels to determine if we can control platelet production.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018220</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Susana Nery</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Optimizing strategies for control of neglected tropical diseases</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,756,790.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological methods | health sciences | epidemiology | epidemiology not elsewhere classified | health sciences | public health | public health not elsewhere classified</Fields_of_Research>
        <Res_KW1>tropical disease </Res_KW1>
        <Res_KW2>community intervention study</Res_KW2>
        <Res_KW3>helminth infection</Res_KW3>
        <Res_KW4>scabies</Res_KW4>
        <Res_KW5>trachoma</Res_KW5>
        <Plain_Description>My research program will optimize strategies for control of neglected tropical diseases which are closely associated with poverty, affecting 2 billion of people globally.   The specific aims of this research program are: 1) optimising programs for control of intestinal worms; 2) integration of control programs to increase their impact and 3) defining the public health role of a new and promising medication, moxidectin.   Findings will be used to inform policy makers and improve existing guidelines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018222</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Rebecca Rockett (nee Sedwell)</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Pathogen Genomics Dual Utility to Deliver Personalised Medicine and Precision Public Health</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases</Fields_of_Research>
        <Res_KW1>functional genomics </Res_KW1>
        <Res_KW2>medical virology</Res_KW2>
        <Res_KW3>molecular virology</Res_KW3>
        <Res_KW4>public health</Res_KW4>
        <Res_KW5>respiratory infection</Res_KW5>
        <Plain_Description>Novel treatments for COVID-19 have rapidly been developed and are used to prevent severe SARS-CoV-2 infection in patients with underlying health conditions. The SARS-CoV-2 virus is evolving rapidly and this has led to variants that can reduce the effectiveness of novel antiviral treatments. This grant will develop genomic tools to predict the optimal SARS-CoV-2 therapeutic needed whilst monitoring for viral resistance in patients that fail antiviral therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018244</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicola Waddell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Leveraging genomics to unravel tumour complexity and improve patient outcomes</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,382,170.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | sequence analysis</Fields_of_Research>
        <Res_KW1>dna sequencing </Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>medical genomics</Res_KW3>
        <Res_KW4>cancer</Res_KW4>
        <Res_KW5>tumour-specific targeting</Res_KW5>
        <Plain_Description>Cancer is the cause of 1 in 8 deaths worldwide. Cancer occurs due to errors or mutations in the DNA of normal cells. I will identify the mutations in tumour cells to determine:  i) How a tumour develops and how complex it is  ii) How a tumour may be treated to kill the cancer  The work studies a variety of cancer types including mesothelioma, melanoma, oesophageal and breast cancer. The overall vision is to apply some of the research findings or approaches into patient care to improve patient survival</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018256</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Wenyi Li</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>A rapid synthetic molecular evolution platform for novel antimicrobials against infections</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$630,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | chemical sciences | medicinal and biomolecular chemistry | proteins and peptides</Fields_of_Research>
        <Res_KW1>antibiotic resistance </Res_KW1>
        <Res_KW2>drug discovery</Res_KW2>
        <Res_KW3>novel therapeutic agents</Res_KW3>
        <Res_KW4>synthetic peptides</Res_KW4>
        <Res_KW5>mechanism of action</Res_KW5>
        <Plain_Description>Infections caused by antimicrobial resistant bacteria are rapidly increasing worldwide, with 106 million new cases annually. Antimicrobial peptides are a promising therapeutic to tackle the shortage of antibiotics. However, conventional development of antimicrobial peptides is limited by inadequate preparation of large parallel libraries and ineffective bioactivity tests. I will develop novel approaches via computational modelling and smart synthesis to identify therapeutic to combat infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018340</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Fabienne Mackay</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Breakthrough research paving the way for the development of transformative immunotherapies for SLE.</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | autoimmunity</Fields_of_Research>
        <Res_KW1>gut immunity </Res_KW1>
        <Res_KW2>autoantibodies</Res_KW2>
        <Res_KW3>lupus</Res_KW3>
        <Res_KW4>metabolites</Res_KW4>
        <Res_KW5>pathology</Res_KW5>
        <Plain_Description>Lupus is a debilitating autoimmune disease which is very hard to treat. Patients with lupus have a leaky gut but the role of this medical anomaly in driving disease is not known. Breakthrough data from our group showed that modifying the biology of immune cells in the gut, restores gut health and protects against lupus. We propose to harness the biological mechanisms underpinning this new therapeutic effect for the development of transformative and much needed new therapies for lupus.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018360</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Eleni Giannoulatou</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving the genetic diagnosis of cardiovascular disease</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,526,390.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | translational and applied bioinformatics</Fields_of_Research>
        <Res_KW1>medical genomics </Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>dna sequencing</Res_KW3>
        <Res_KW4>cardiovascular disease</Res_KW4>
        <Res_KW5>gene mutations</Res_KW5>
        <Plain_Description>Cardiovascular disease (CVD) claims 17.9 million lives each year and has remained the leading cause of death globally for the last 20 years. Using genomic technologies and novel computational methodology, I will improve the rate of genetic diagnosis of cardiovascular disease and provide better understanding of the disease mechanism. This research program will enable personalised management and treatment, and improved risk assessment for CVD patients and their families.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018363</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Thomas Preiss</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>RNA-level gene regulation</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$2,437,110.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biomedical and clinical sciences | medical biotechnology | medical molecular engineering of nucleic acids and proteins | biological sciences | genetics | genome structure and regulation</Fields_of_Research>
        <Res_KW1>messenger rna (mrna) </Res_KW1>
        <Res_KW2>rna binding proteins</Res_KW2>
        <Res_KW3>rna processing</Res_KW3>
        <Res_KW4>rrna</Res_KW4>
        <Res_KW5>protein synthesis</Res_KW5>
        <Plain_Description>Genetic information resides in the DNA of our genome; however, to use this information it must be transcribed into chemically related RNA molecules, collectively known as the transcriptome. While different body cells carry the same genome, they differ widely in their transcriptome composition. To understand how cells properly utilise their transcriptomes, I will characterise the marks and binding partners found on RNA in the context of cardiac and cancer biology.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018376</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Pierre Qian</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Development of novel ablation technologies for the treatment of ventricular tachycardia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases)</Fields_of_Research>
        <Res_KW1>microwave </Res_KW1>
        <Res_KW2>ionising radiation</Res_KW2>
        <Res_KW3>ventricular tachycardia</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>sympathetic nerves</Res_KW5>
        <Plain_Description>Rhythm disorders from the main pumping chambers of the heart (ventricular arrhythmias, VA) cause 1 in4 of all deaths from heart disease. VA can be treated effectively by finding and destroying the circuits within heart scar tissue that perpetuate VA (ablation). The study innovates new technology and minimally invasive approaches to reduce the risk of VA for patients with heart disease, prolonging longevity and improving quality of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018383</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Polizzotto</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Simplified Immunotherapies for Global Oncology</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$2,878,395.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy)</Fields_of_Research>
        <Res_KW1>human papillomavirus (hpv) </Res_KW1>
        <Res_KW2>human immunodeficiency virus (hiv)</Res_KW2>
        <Res_KW3>kaposi's sarcoma</Res_KW3>
        <Res_KW4>epstein-barr virus (ebv)</Res_KW4>
        <Res_KW5>cancer genetics</Res_KW5>
        <Plain_Description>Around 1 in 5 cancers worldwide are caused by infections. These are particularly important in the developing world, where they account for the majority of cancer cases and deaths, often in young people. This grant continues my world-leading work in developing drugs to treat and prevent cancers caused by infections, and in understanding their origins. I focus on simple but effective drugs that can be used in developing countries, to ensure my new treatments can be used by those in greatest need.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018391</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Meg Jardine</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Addressing unmet needs in chronic disease through innovations in trial design and delivery</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,257,170.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology</Fields_of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>chronic diseases</Res_KW3>
        <Res_KW4>chronic cardiovascular disease</Res_KW4>
        <Res_KW5>quality assurance</Res_KW5>
        <Plain_Description>This program will utilise innovative designs and new digital capabilities to address some of the challenges in completing randomized trials in chronic disease. Trial designs will be informed by clinical practice and a good understanding of clinician and consumer attitudes to proposed trials.   These approaches will facilitate large, simple randomized quality assurance studies and trials embedded in clinical practice, leading to improvements in clinical outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018420</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Jue Sheng Ong</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Expanding genetic causal inference analyses to evaluate cancer risk factors in diverse populations</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | statistical and quantitative genetics</Fields_of_Research>
        <Res_KW1>complex genetic disease </Res_KW1>
        <Res_KW2>genetic analysis</Res_KW2>
        <Res_KW3>genetic risk factors</Res_KW3>
        <Res_KW4>genetic susceptibility</Res_KW4>
        <Res_KW5>genetic epidemiology</Res_KW5>
        <Plain_Description>My research studies the use of statistical models applied to large-scale genetic data to help us understand what causes diseases such as cancers. Using these models, I investigate whether the genetic background underlying cancers can give us clues about whether the observed relationship between a range of putatively modifiable risk factors and common cancers is causal in European populations. I am also investigating whether the same genetic relationship is present in other populations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018431</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Jacob Gratten</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Towards improved clinical outcomes for common brain disorders using large-scale statistical genomics</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,356,790.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | neurogenetics | biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biological sciences | bioinformatics and computational biology | genomics and transcriptomics</Fields_of_Research>
        <Res_KW1>statistical genetics </Res_KW1>
        <Res_KW2>autism spectrum disorders</Res_KW2>
        <Res_KW3>parkinson disease</Res_KW3>
        <Res_KW4>neurogenetics</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>The social and economic costs of common brain disorders, such as autism spectrum disorder and Parkinson’s disease, are enormous. My research aims to generate new knowledge on these conditions by using advanced statistical methods to integrate large-scale genetics and genomics with deep clinical and lifestyle data. Ultimately, this is expected to underpin improved clinical outcomes and quality of life through prevention, earlier diagnosis, and safer evidence-based treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018432</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Jose Alquicira Hernandez</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Characterisation of the genetic architecture of autoimmune disease at single-cell resolution</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology)</Fields_of_Research>
        <Res_KW1>control of gene expression </Res_KW1>
        <Res_KW2>autoimmune disease</Res_KW2>
        <Res_KW3>genetic variation</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>functional genomics</Res_KW5>
        <Plain_Description>Autoimmune disorders represent a considerable burden for the healthcare system, affecting up to 9% of the human population. Genetic factors are the most significant contributors to autoimmune disease risk; however, their effects on individual immune cells remain unknown. My research seeks to characterise the functional impact of genetic factors in pathological cell states and their role in mediating autoimmunity to ultimately improve the treatment of autoimmune conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018440</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Alexander Swarbrick</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Dissecting the cellular ecosystems and therapeutic vulnerabilities of breast cancer</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,205,736.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | systems biology</Fields_of_Research>
        <Res_KW1>breast cancer </Res_KW1>
        <Res_KW2>cancer biology</Res_KW2>
        <Res_KW3>gene expression</Res_KW3>
        <Res_KW4>cancer immunology</Res_KW4>
        <Res_KW5>cancer treatment</Res_KW5>
        <Plain_Description>Solid cancers are complex cellular ‘ecosystems’ in which the growth and drug response of the tumour is controlled by cell interactions. We will use single cell genomics to understand the nature and interactions of cells that make up breast cancers. This will help us to better understand the role of specific cell types in the development of cancers and find improved ways to treat cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018461</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Fabian Rehm</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Engineering protein diagnostics/therapeutics via next-generation enzymatic and genetic code expansion approaches</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | synthetic biology | biological sciences | biochemistry and cell biology | enzymes</Fields_of_Research>
        <Res_KW1>antibody engineering </Res_KW1>
        <Res_KW2>protein engineering</Res_KW2>
        <Res_KW3>drug conjugation</Res_KW3>
        <Res_KW4>protein expression</Res_KW4>
        <Res_KW5>molecular pharmacology</Res_KW5>
        <Plain_Description>The use of protein conjugates for therapeutic or diagnostic applications is widespread. However, currently employed protein modifying technologies are largely non-specific and result in a mixture of conjugates. It is difficult to predict how such mixtures perform in a clinical setting and typically a substantial fraction underperforms. To address these issues, the proposed project aims to establish a platform for generating new types of highly defined protein conjugates.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018465</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Graham Gee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Supporting healing and recovery for Aboriginal and Torres Strait Islander survivors of childhood sexual abuse </Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,568,756.02</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social, emotional, cultural and spiritual wellbeing</Fields_of_Research>
        <Res_KW1>trauma </Res_KW1>
        <Res_KW2>sexual abuse</Res_KW2>
        <Res_KW3>recovery</Res_KW3>
        <Res_KW4>aboriginal health</Res_KW4>
        <Res_KW5>wellbeing</Res_KW5>
        <Plain_Description>Child sexual abuse is a form of violence that occurs across nations and cultures worldwide. Collective efforts are being made to address this issue within Victorian Aboriginal and Torres Strait Islander communities. This research will generate new knowledge about survivors lived experiences of healing and recovery, identify current therapeutic practices, and build training and education resources that support Aboriginal organisations to better meet the healing and recovery needs of survivors.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018477</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Y C Gary Lee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Transforming Care and Outcomes for Patients with Pleural Effusion</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,205,736.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases</Fields_of_Research>
        <Res_KW1>adult respiratory diseases </Res_KW1>
        <Res_KW2>mesothelioma</Res_KW2>
        <Res_KW3>respiratory infection</Res_KW3>
        <Res_KW4>respiratory medicine</Res_KW4>
        <Res_KW5>lung neoplasms</Res_KW5>
        <Plain_Description>My world-leading program brings together clinicians, scientists and allied health researchers to advance knowledge and care of pleural effusions (fluid build-up in the chest), a neglected condition that affects 60,000 Australians a year. Our consumer-driven research will use multicentre randomised trials, multidisciplinary (diet, exercise, psychology) approaches and cutting-edge laboratory techniques to improve diagnosis and treatment of pleural effusions esp those from cancer and infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018497</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Dr Felix Ng</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Microvascular dysfunction in acute ischemic stroke: The next frontier in stroke reperfusion </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$655,150.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified</Fields_of_Research>
        <Res_KW1>cerebral ischaemia </Res_KW1>
        <Res_KW2>ischaemia/reperfusion</Res_KW2>
        <Res_KW3>treatment</Res_KW3>
        <Res_KW4>microvascular</Res_KW4>
        <Res_KW5>recovery</Res_KW5>
        <Plain_Description>Ischemic stroke is due to an abrupt blockage in a major brain artery. Over half of patients who receive acute treatment do not improve for unclear reasons. We will study how dysfunction of microcirculation (microscopic vessels in the brain) leads to complications and reduces treatment effectiveness. Ultimately, the aim is to develop a new therapy targeting the microvessels that can augment the benefit of reperfusion treatments in stroke.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018514</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Scolyer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Melanoma: Getting the Diagnosis and Treatment Right for Better Patient Outcomes</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,937,110.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers | biomedical and clinical sciences | clinical sciences | pathology (excl. oral pathology) | biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis</Fields_of_Research>
        <Res_KW1>malignant melanoma </Res_KW1>
        <Res_KW2>oncology</Res_KW2>
        <Res_KW3>pathology</Res_KW3>
        <Res_KW4>diagnosis</Res_KW4>
        <Res_KW5>cancer treatment</Res_KW5>
        <Plain_Description>Melanoma is a major Australian health problem. Prevention, early diagnosis and appropriate treatment remain the linchpins of disease control. Over the past decade, new drug therapies have improved previously dismal outcomes for metastatic melanoma patients. This research proposal will integrate molecular and immune profiling with clinical and patient factors, and personalised treatment strategies, to transform melanoma diagnosis, risk prediction and treatment across all stages of the disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018534</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Guy Marks</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Innovation for global lung health</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,649,688.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases</Fields_of_Research>
        <Res_KW1>tuberculosis </Res_KW1>
        <Res_KW2>lung disease</Res_KW2>
        <Res_KW3>air pollution</Res_KW3>
        <Res_KW4>public health</Res_KW4>
        <Res_KW5>asthma</Res_KW5>
        <Plain_Description>This program of work is dedicated to mitigating the global burden of ill-health due to lung disease. I have focused on the major respiratory diseases that are responsible for death and disability worldwide, noncommunicable chronic respiratory disease (asthma and COPD) and tuberculosis, and air pollution, a major environmental cause of ill-health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018537</APP_ID>
        <Date_Announced>2022-10-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Anthony Keech</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Innovative clinical trials: improving care and health outcomes</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,937,110.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified</Fields_of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>cardiovascular</Res_KW2>
        <Res_KW3>diabetes mellitus</Res_KW3>
        <Res_KW4>perinatal</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Ground-breaking clinical trials intended to advance care and improve health outcomes nationally and internationally will be undertaken. The focus will include trials and new methods in cardiovascular disease and diabetes particularly. Evidence synthesis for reliable guidelines and policy decisions will be conducted. Projects will link basic science research with clinical outcomes to improve our understanding of disease and treatment mechanisms.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015556</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Julia Sarant</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Hearing Health Evidence Based Support Services</Sub_Type>
        <Grant_Title>Hearing loss, the silent enemy of good health: Effectiveness, cost-effectiveness, and potential economic and social impact of interventions to promote treatment to facilitate improved hearing</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$541,448.90</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | preventive medicine | public health and health services | primary health care | applied economics | health economics | </Fields_of_Research>
        <Res_KW1>hearing loss</Res_KW1>
        <Res_KW2>hearing aids</Res_KW2>
        <Res_KW3>referral practices</Res_KW3>
        <Res_KW4>behavioural intervention</Res_KW4>
        <Res_KW5>health economics</Res_KW5>
        <Plain_Description>Hearing loss impacts many adults of all ages, and 7 in 10 adults aged over 70 years. Despite significant associated health, well-being and financial costs, referrals for hearing care, hearing aid adoption and use are very low. This project will identify barriers to medical referral for hearing care and barriers to hearing aid uptake and use and will design and evaluate the feasibility and cost-effectiveness of interventions to address these, leading to improved health outcomes for Australians.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015700</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Prof Piers Dawes</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Hearing Health Evidence Based Support Services</Sub_Type>
        <Grant_Title>Improving access to the hearing services program for people from culturally and linguistically diverse backgrounds</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$902,757.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>other medical and health sciences | medical and health sciences not elsewhere classified | public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>hearing</Res_KW1>
        <Res_KW2>hearing aids</Res_KW2>
        <Res_KW3>health inequalities</Res_KW3>
        <Res_KW4>social and cultural issues</Res_KW4>
        <Res_KW5>access to health care</Res_KW5>
        <Plain_Description>Hearing loss affects 1 in 5 people, impacting communication, quality of life, education and employment, social activities, and physical and mental health. People can get effective help for hearing loss. But people from culturally and linguistically diverse communities are less likely to get help. We will work with people from culturally and linguistically diverse communities to co-design accessible, equitable and culturally safe hearing services to preserve and protect hearing health. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015711</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Christina Bryant</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Hearing Health Evidence Based Support Services</Sub_Type>
        <Grant_Title> Implementation and Evaluation of a Co-designed Program Targeting the Psychosocial and Emotional Impacts of Hearing Conditions in Adults </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$496,103.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | otorhinolaryngology | psychology | health, clinical and counselling psychology | </Fields_of_Research>
        <Res_KW1>hearing loss</Res_KW1>
        <Res_KW2>psychosocial adjustment</Res_KW2>
        <Res_KW3>audiology</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>mental health</Res_KW5>
        <Plain_Description>Hearing conditions have many psychosocial consequences and the most common forms of management (e.g., hearing aids) do not appropriately address these concerns. This project will develop an online Hearing Wellbeing Program (HWP) to improve the psychological, social, and emotional wellbeing of people with hearing conditions. The project will test the feasibility of implementing the HWP and then assess the program for its effectiveness in improving the wellbeing of people with hearing conditions. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015735</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Valerie Sung</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Hearing Health Evidence Based Support Services</Sub_Type>
        <Grant_Title>Building on newborn hearing screening success: towards national standards and data management</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,436,994.31</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>paediatrics and reproductive medicine | paediatrics | neurosciences | sensory systems | public health and health services | preventive medicine | </Fields_of_Research>
        <Res_KW1>databases</Res_KW1>
        <Res_KW2>hearing</Res_KW2>
        <Res_KW3>child</Res_KW3>
        <Res_KW4>aboriginal health</Res_KW4>
        <Res_KW5>health outcomes</Res_KW5>
        <Plain_Description>Australia’s universal newborn hearing screening enables early hearing loss identification, access to hearing devices and early intervention. But we do not know how hearing programs improve child outcomes, who do not access services, and whether postnatal screening occurs. We will establish the prerequisites of a national child hearing database to ensure screening/interventions improve child outcomes, ensure no deaf or hard-of-hearing child ‘falls through the cracks’, and facilitate research.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015748</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Melanie Ferguson</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Hearing Health Evidence Based Support Services</Sub_Type>
        <Grant_Title>Empowering adults with hearing loss by increasing informed choice, accessibility, and uptake of hearing healthcare</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$683,027.43</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | otorhinolaryngology | </Fields_of_Research>
        <Res_KW1>audiology</Res_KW1>
        <Res_KW2>hearing aids</Res_KW2>
        <Res_KW3>aural rehabilitation</Res_KW3>
        <Res_KW4>computer-based decision support</Res_KW4>
        <Res_KW5>behaviour change</Res_KW5>
        <Plain_Description>The problem. Four million Australians have hearing loss. Yet many do not seek help, and are unaware of the hearing healthcare options that are available. This leads to many people not obtaining the hearing healthcare they need.  Our solution. We will co-create a tailored online decision aid to explain the pros and cons of available hearing health options. We anticipate this approach to decision-making will increase uptake of hearing healthcare and improve the lives of many adults with hearing loss. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015750</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Christopher Brennan-Jones</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Hearing Health Evidence Based Support Services</Sub_Type>
        <Grant_Title>Prevalence of hearing loss in Aboriginal children caused by otitis media from birth to 5 years of age and evidence of the effectiveness of health promotion programs: evidence to inform national policy</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,123,133.74</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | </Fields_of_Research>
        <Res_KW1>aboriginal health</Res_KW1>
        <Res_KW2>hearing loss</Res_KW2>
        <Res_KW3>otitis media</Res_KW3>
        <Res_KW4>child health</Res_KW4>
        <Res_KW5>health promotion</Res_KW5>
        <Plain_Description>This project will provide the first estimates of the number of Aboriginal children who have ear infections and hearing loss from 0 to 5 years of age and will demonstrate the feasibility of screening for ear infections and hearing loss from 2 months of age. It will also test, for the first time, the effectiveness of a health promotion intervention to resolve ear infections and prevent hearing loss without the need for surgery. If effective, this intervention can be implemented nationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015793</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Dr Jacqueline Stephens</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Hearing Health Evidence Based Support Services</Sub_Type>
        <Grant_Title>Pathways For Aboriginal and Torres Strait Islander Hearing Health: The PATHWAY Project</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,155,685.70</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | </Fields_of_Research>
        <Res_KW1>child health</Res_KW1>
        <Res_KW2>aboriginal health</Res_KW2>
        <Res_KW3>otitis media</Res_KW3>
        <Res_KW4>referral practices</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>All children have the right to hear well, but Aboriginal and Torres Strait Islander children have inequitable access to hearing healthcare. Multifaceted strategies are needed which consider people’s first-hand experiences in the co-design of solutions. This project will generate evidence  of culturally appropriate methods to build a strategy which optimises the complex and difficult to navigate hearing health patient pathway experienced by Aboriginal and Torres Strait Islander children. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015794</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrew Ford</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Hearing Health Evidence Based Support Services</Sub_Type>
        <Grant_Title>Hearables and behavioural activation for mental distress and social isolation in hearing impaired older adults</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$571,966.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | otorhinolaryngology | clinical sciences | psychiatry (incl. psychotherapy) | clinical sciences | geriatrics and gerontology | </Fields_of_Research>
        <Res_KW1>hearing</Res_KW1>
        <Res_KW2>mental health promotion</Res_KW2>
        <Res_KW3>psychotherapy</Res_KW3>
        <Res_KW4>hearing aids</Res_KW4>
        <Res_KW5>depression</Res_KW5>
        <Plain_Description>Age-related hearing loss is common and may lead to depression, social isolation, loneliness, and reduced quality of life.  Hearing aids are expensive and simpler, cost-effective hearing amplification devices (hearables) may offer an alternative treatment strategy. This trial will test if hearables in addition to a pragmatic psychological intervention (behavioural activation) improves mood, quality of life, mental distress and social isolation in older adults with mild to moderate hearing loss.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015803</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Nerina Scarinci</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Hearing Health Evidence Based Support Services</Sub_Type>
        <Grant_Title>Improving the psychosocial and emotional well-being of adults with hearing loss through co-designed evidence-based services: ACE2.0</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$527,012.40</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>clinical sciences | rehabilitation and therapy (excl. physiotherapy) | </Fields_of_Research>
        <Res_KW1>hearing</Res_KW1>
        <Res_KW2>communication skills</Res_KW2>
        <Res_KW3>aural rehabilitation</Res_KW3>
        <Res_KW4>psychosocial</Res_KW4>
        <Res_KW5>qualitative methods</Res_KW5>
        <Plain_Description>Hearing loss affects a person’s ability to communicate and to socialise. Community members will partner with researchers to develop an innovative and contemporary education and support program to help adults with hearing loss and their family overcome the everyday communication, social, and emotional difficulties they experience. The solution will be rolled out and evaluated in hearing services across Australia and subsequently be made available to all Australians with hearing loss.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015740</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Dr Catherine Franklin</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Improving health of people with intellectual disability</Sub_Type>
        <Grant_Title>Bridge to Better Health: A Cluster Randomised Controlled Trial for Capacity Building in Intellectual Disability Health for General Practice</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,497,939.40</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | care for disabled | nursing | clinical nursing: primary (preventative) | public health and health services | primary health care | </Fields_of_Research>
        <Res_KW1>intellectual disability</Res_KW1>
        <Res_KW2>general practice</Res_KW2>
        <Res_KW3>nursing</Res_KW3>
        <Res_KW4>health service accessibility</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>We will improve preventive health outcomes for people with intellectual disability by supporting general practice nurses to do health assessments with their patients with intellectual disability. We will provide access to a specialist intellectual disability nurse, training on conducting a health assessment, intellectual disability health training and access to online resources. This intervention is designed to be able to be rolled out nationwide and will be evaluated using a randomised trial.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015753</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Dr Elizabeth Palmer</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Improving health of people with intellectual disability</Sub_Type>
        <Grant_Title>GeneEQUAL: equitable and accessible genomic healthcare for people with intellectual disability</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,556,865.18</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>genetics | genomics | public health and health services | care for disabled | </Fields_of_Research>
        <Res_KW1>medical genomics</Res_KW1>
        <Res_KW2>genetic counselling</Res_KW2>
        <Res_KW3>intellectual disability</Res_KW3>
        <Res_KW4>health inequalities</Res_KW4>
        <Res_KW5>health literacy</Res_KW5>
        <Plain_Description>The GeneEQUAL team are:  •	self-advocates   •	researchers  •	clinicians.   We will talk with:  •	people with intellectual disability   •	their families   •	their doctors.   We will ask them about genomic health care.  Genomic health care is genetic tests and genetic counselling.  We will write guides and resources so that genomic healthcare will:   •	include everyone respectfully  •	help people make healthcare choices  •	help people understand about their health conditions  •	help people get the right treatments and support.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015902</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jenny Downs</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Improving health of people with intellectual disability</Sub_Type>
        <Grant_Title>Reducing potentially preventable hospitalisations and building health literacy for children and adolescents with intellectual disability</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,537,414.30</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | care for disabled | </Fields_of_Research>
        <Res_KW1>intellectual disability</Res_KW1>
        <Res_KW2>hospitalisation</Res_KW2>
        <Res_KW3>socioeconomic</Res_KW3>
        <Res_KW4>developmental disorders</Res_KW4>
        <Res_KW5>primary care</Res_KW5>
        <Plain_Description>Children with intellectual disability have high health care needs but access to primary care services can be hampered by difficulties they and their carers face day to day, leading to potentially preventable hospitalisations. We will examine use of health services in hospital and primary care settings for these children, the enablers and barriers to using primary care services, and how health service use can be optimised for better care and be available across the community.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015929</APP_ID>
        <Date_Announced>2022-10-21T00:00:00</Date_Announced>
        <CIA_Name>Prof Sandra Eades</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2021 Improving health of people with intellectual disability</Sub_Type>
        <Grant_Title>Equitable access to health and disability services for Aboriginal and Torres Strait Islander children with intellectual disability</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$792,020.13</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | public health and health services | care for disabled | </Fields_of_Research>
        <Res_KW1>intellectual disability</Res_KW1>
        <Res_KW2>child development</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>health services</Res_KW4>
        <Res_KW5>diagnosis</Res_KW5>
        <Plain_Description>This project will improve the health and wellbeing of Indigenous children with intellectual disability (ID) by recommending effective models of care to ensure appropriate, timely diagnoses and access to high-quality health and disability services. National Disability Insurance Scheme data and interviews with families, adolescents with ID, and healthcare and disability services will be analysed to identify barriers and facilitators to meeting the healthcare needs of Indigenous children with ID.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021932</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Natacha Omer</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Natural killer cell immunotherapy in paediatric sarcomas </Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$102,238.25</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>natural killer cells </Res_KW1>
        <Res_KW2>cancer immunotherapy</Res_KW2>
        <Res_KW3>cell therapy</Res_KW3>
        <Res_KW4>sarcoma</Res_KW4>
        <Res_KW5>paediatric</Res_KW5>
        <Plain_Description>Sarcomas account for 10% of childhood cancers. It is a group of cancers arising from the bone or soft tissue with less than 30% chance of cure when it has spread or comes back despite intensive and possibly mutilating therapies. Natural killer (NK) cells are a type of immune cells known for their ability to kill cancer cells. This project aims to prove that our immune cells can be used to treat sarcomas by selecting the appropriate NK cells for the patients based on their receptor expression.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021941</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Xi May Zhen</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Overweight and obesity in young adults with type 1 and type 2 diabetes: mortality, pregnancy outcomes, and novel glycaemic interventions</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | </Fields_of_Research>
        <Res_KW1>type 1 diabetes mellitus (insulin-dependent diabetes mellitus) </Res_KW1>
        <Res_KW2>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW2>
        <Res_KW3>weight loss</Res_KW3>
        <Res_KW4>overweight/obesity</Res_KW4>
        <Res_KW5>pregnancy outcome</Res_KW5>
        <Plain_Description>This project aims to explore the impact of overweight and obesity on long-term outcomes and pregnancy outcomes in young people with type 1 diabetes, and to make comparisons with young-onset type 2 diabetes. Furthermore, this project aims to produce highly novel randomised trial data on the efficacy of novel glycaemic and obesity interventions in people with overweight/obesity and type 1 dabetes/young-onset type 2 diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021945</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Josephine Warren</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Evaluation and diagnosis of cardiac allograft vasculopathy post heart transplant using novel Cardiac CT techniques. </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>cardiac transplantation </Res_KW1>
        <Res_KW2>cardiac ischaemia</Res_KW2>
        <Res_KW3>functional computed tomography</Res_KW3>
        <Res_KW4>cardiac dysfunction</Res_KW4>
        <Res_KW5>microvascular disease</Res_KW5>
        <Plain_Description>Heart transplantation is reserved for patients with terminal heart failure. Cardiac allograft vasculopathy (CAV) is a leading cause of death post-transplant, due to progressive narrowing in the heart arteries. As CAV is often asymptomatic, screening with invasive coronary angiography (ICA) is required.     Non-invasive testing with Cardiac CT may be a suitable alternative to ICA in this population, and newer techniques examining the effect of blockages on blood flow may improve its accuracy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021950</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Mr Harrison Hansford</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>The ZEUs (ZopiclonE for acUte low back pain) trial: A multi-site, double blind, randomised controlled trial of zopiclone for acute low back pain</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$85,964.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | pain | </Fields_of_Research>
        <Res_KW1>low back pain </Res_KW1>
        <Res_KW2>sleep</Res_KW2>
        <Res_KW3>pain mechanisms</Res_KW3>
        <Res_KW4>pharmaceutical treatment</Res_KW4>
        <Res_KW5>primary care</Res_KW5>
        <Plain_Description>Low back pain (LBP) is the leading cause of disability globally and all commonly prescribed medications for acute LBP are not effective or cause serious side effects. Effective treatments for acute LBP are urgently needed. Muscle relaxants medicines such as Zopiclone, a safe sleep drug, appear to be safe and effective for acute LBP, although considerable uncertainty remains. My study, ZEUs, will be the definitive, double-blind placebo controlled randomised trial testing Zopiclone in acute LBP.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021953</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Sarah Heynemann</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Ethics of cancer trials phD </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$117,310.58</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>philosophy and religious studies | applied ethics | bioethics | philosophy and religious studies | applied ethics | medical ethics | biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | </Fields_of_Research>
        <Res_KW1>bioethics </Res_KW1>
        <Res_KW2>cancer</Res_KW2>
        <Res_KW3>cancer research</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>ethical issues</Res_KW5>
        <Plain_Description>This project seeks to understand how recent changes to the manner in which cancer research is designed and undertaken may influence the way research results are interpreted and used across the modern cancer treatment landscape. Interviews and surveys will be undertaken with research experts, cancer doctors and patients about their views on this topic and analysed with respect to new implications which emerge of an ethical nature as well as the way in which research contributes to new knowledge.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021964</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Lawrence Kasherman</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Improving outcomes and experiences of Culturally and Linguistically Diverse patients affected by cancer participating in survivorship programs</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$98,470.17</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | </Fields_of_Research>
        <Res_KW1>survivorship </Res_KW1>
        <Res_KW2>cancer follow-up</Res_KW2>
        <Res_KW3>migrant health</Res_KW3>
        <Res_KW4>patient outcomes</Res_KW4>
        <Res_KW5>qualitative research</Res_KW5>
        <Plain_Description>Cancer survivors who have completed treatment are at risk of complications for several years. Although cancer survivorship clinics have been established around Australia, migrants of culturally and linguistically diverse (CALD) backgrounds, experience unique challenges in navigating local health systems in the survivorship setting. This research aims to highlight the substantial unmet needs specific to CALD populations that are yet to be addressed in the current Australian healthcare system.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021983</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Phillip Nguyen</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Clonal determinants of immune evasion to allogeneic stem cell transplant in acute myeloid leukaemia</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | </Fields_of_Research>
        <Res_KW1>haematology </Res_KW1>
        <Res_KW2>cancer biology</Res_KW2>
        <Res_KW3>cancer genetics</Res_KW3>
        <Res_KW4>cancer immunology</Res_KW4>
        <Res_KW5>haematological malignancy</Res_KW5>
        <Plain_Description>Patients with acute myeloid leukaemia (AML) who relapse after first line treatment have a very poor clinical outcome. A stem cell transplant offers the opportunity for cure, however up to half of patients receiving this cellular immunotherapy have disease resistance or recurrence. This project will use a cutting-edge barcoding technique to track the genetic and non-genetic changes in each leukaemia cell over time to determine the mechanisms of immune evasion by AML.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021986</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Steven Nicolaides</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Immune Related Adverse Events of the Gastrointestinal System and Investigation of Novel diagnostics and Therapeutics</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>colitis </Res_KW1>
        <Res_KW2>immunotherapy</Res_KW2>
        <Res_KW3>ultrasound</Res_KW3>
        <Res_KW4>faecal</Res_KW4>
        <Res_KW5>cancer immunotherapy</Res_KW5>
        <Plain_Description>This research project will explore the utility of intestinal ultrasound as a diagnostic tool of immune checkpoint inhibitor colitis. It will also explore the utility of faecal microbiota transplant in the management of immune checkpoint inhibitor colitis. It is expected that intestinal ultrasound will prove to provide an accurate and non invasive way of diagnosing this condition. It is also expected that faecal transplant will be effective in managing difficult to treat cases of this condition.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021994</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Elisabeth Ng</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Primary Aldosteronism: New Strategies for Diagnosis and Management</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$98,470.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>hypertension </Res_KW1>
        <Res_KW2>hyperaldosteronaemia</Res_KW2>
        <Res_KW3>cardiovascular disease</Res_KW3>
        <Res_KW4>adrenal endocrinology</Res_KW4>
        <Res_KW5>indigenous australians</Res_KW5>
        <Plain_Description>Primary aldosteronism (PA) is a common and curable form of high blood pressure, requiring multiple tests for diagnosis. Lack of capacity for testing has led to delayed diagnosis and suboptimal outcomes, especially among Indigenous Australians whose rate of PA is unknown. Treatment options for PA are also limited at present. My research will establish modern tools, efficient pathways and novel therapies to improve health outcomes for all Australians with PA.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022019</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Hannah Gordon</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Characterising the perinatal, neonatal and school-age childhood outcomes associated with diabetes in pregnancy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified | </Fields_of_Research>
        <Res_KW1>gestational diabetes </Res_KW1>
        <Res_KW2>control of diabetes</Res_KW2>
        <Res_KW3>pregnancy complications</Res_KW3>
        <Res_KW4>early childhood</Res_KW4>
        <Res_KW5>diabetes mellitus</Res_KW5>
        <Plain_Description>Diabetes in pregnancy is common and can lead to complications for mother and baby. Using population-based data from Victoria, this dissertation seeks firstly to assess the long-term developmental and educational outcomes for children born to diabetic mothers. Management of diabetes confers improved perinatal outcomes, and so this thesis will secondarily assess the efficacy of lesser used medications, such as metformin, with the view to improving treatment of diabetes in pregnancy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022072</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Suyi Ooi</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Advanced magnetic resonance imaging (MRI) biomarkers  for prediction of clinical outcomes after a first seizure</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$102,238.25</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>seizures </Res_KW1>
        <Res_KW2>epilepsy</Res_KW2>
        <Res_KW3>cognitive outcome</Res_KW3>
        <Res_KW4>magnetic resonance imaging (mri)</Res_KW4>
        <Res_KW5>prediction</Res_KW5>
        <Plain_Description>After someone has their first seizure, we are unable to accurately predict who will go on to have further seizures (e.g., epilepsy) despite routine investigations. Cognitive and social problems often predate the first seizure. This project will develop a prediction tool using MRI brain scan markers, that can be used in the clinic after someone experiences their first seizure. This may provide patients with a more accurate diagnosis, individualise treatment and prevent cognitive deterioration.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022097</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Avraham Travers</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>CD8+ T cell tolerance within the tumour draining lymph node as a novel immunotherapy target in colorectal cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$94,702.08</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>cancer immunology </Res_KW1>
        <Res_KW2>cancer immunotherapy</Res_KW2>
        <Res_KW3>immune tolerance</Res_KW3>
        <Res_KW4>colorectal cancer</Res_KW4>
        <Res_KW5>colorectal cancer treatment</Res_KW5>
        <Plain_Description>Immunotherapy, a type of cancer treatment, achieves remarkable outcomes for some patients, though unfortunately not everyone benefits. An immune process called peripheral tolerance (PT) may be preventing the immune system from fighting cancer cells and reducing the benefit of immunotherapy. Our project aims to find out if PT is present in colorectal cancer and how it relates to patient outcomes. We will also define how to breach PT and explore new treatments in order to overcome this hurdle.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022099</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Gia Tang</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>The impact of gender affirming hormone therapy on scalp hair pattern and distribution </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | clinical sciences | dermatology | </Fields_of_Research>
        <Res_KW1>gender </Res_KW1>
        <Res_KW2>testosterone</Res_KW2>
        <Res_KW3>estradiol</Res_KW3>
        <Res_KW4>hair cells</Res_KW4>
        <Res_KW5>hormone therapy</Res_KW5>
        <Plain_Description>Scalp hair loss in transgender individuals commencing testosterone for gender transition is poorly studied but has significant impacts on quality of life. Using novel artificial intelligence-assisted camera technology (HairMetrix), I will firstly document changes in scalp hair with gender affirming hormone therapy in trans men and in trans women. Following this, I will undertake the first randomised clinical trial to prevent hair loss in trans men starting testosterone therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022102</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Minh Huan Dang</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Defining new therapeutic targets for ANCA-associated vasculitis </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | biomedical and clinical sciences | immunology | autoimmunity  | </Fields_of_Research>
        <Res_KW1>vasculitis </Res_KW1>
        <Res_KW2>neutrophils</Res_KW2>
        <Res_KW3>autoimmunity</Res_KW3>
        <Res_KW4>glomerulonephritis</Res_KW4>
        <Res_KW5>experimental glomerulonephritis</Res_KW5>
        <Plain_Description>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is an autoimmune disease that causes inflammation of small blood vessels. It often leads to severe kidney and lung inflammation and kidney impairment. While experimental disease models have identified new therapeutic options, they have multiple limitations that are hindering therapeutic progress. This work will optimise new disease models, define key mechanisms and identify new therapeutic targets in ANCA-associated vasculitis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022109</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Shuyu Wang</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Advancing precision therapies for epilepsy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>epilepsy </Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>intractable epilepsy syndromes</Res_KW3>
        <Res_KW4>antiepileptic drugs</Res_KW4>
        <Res_KW5>neurogenetics</Res_KW5>
        <Plain_Description>Precision therapies targeting genetic abnormalities causing epilepsy may improve the outcomes of the medical treatment of epilepsy, which have remained unchanged for decades. My project will evaluate the existing information for precision therapies in epilepsy and study potential precision approaches in patients with two severe genetic epilepsies. The results of this project may provide a pathway to realising the promise of precision medicine, ultimately improving epilepsy treatment outcomes.      </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022116</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Ms Stefanie Dimov</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>The impact of post-school transitions on the mental health of young people with developmental disabilities</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$93,827.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>mental health </Res_KW1>
        <Res_KW2>disability</Res_KW2>
        <Res_KW3>school policies</Res_KW3>
        <Res_KW4>employment</Res_KW4>
        <Res_KW5>developmental disorders</Res_KW5>
        <Plain_Description>Young people with developmental disabilities have poorer experiences of post-school transition and worse mental health compared to young people without disability. This PhD project will analyse survey data and conduct inclusive interviews with young people with development disabilities. The findings will provide evidence on the impact of post-school transitions on the mental health of young people with developmental disabilities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022137</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Briony Shaw</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Novel approaches to transfusion to improve supportive care for patients with blood cancers</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>haematological malignancy </Res_KW1>
        <Res_KW2>blood transfusion</Res_KW2>
        <Res_KW3>frailty</Res_KW3>
        <Res_KW4>cancer care</Res_KW4>
        <Res_KW5>supportive care</Res_KW5>
        <Plain_Description>The burden of blood cancers is increasing with an ageing Australian population. With new treatments available, many older and more frail patients are accessing treatment for their disease. Transfusion is a mainstay of supportive care for people with blood cancers and one aspect of care that can be potentially be performed in the home. My research study involves the use of novel monitoring devices to monitor patients receiving transfusion, and to pilot a program to transfuse patients at home.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022142</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Rahul Muthalaly</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Cardiovascular risk reduction in stroke survivors </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | health sciences | health services and systems | health systems | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>cardiovascular disease prevention </Res_KW1>
        <Res_KW2>acute stroke</Res_KW2>
        <Res_KW3>health services</Res_KW3>
        <Res_KW4>stroke prevention</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Many people who survive a stroke suffer heart disease in the next 10 years due to a high burden of vascular risk factors. Research in heart disease has identified effective ways to control these risk factors. Stroke survivors do not receive as much attention to these factors compared to heart attack survivors.   The aim of our project is to implement a cardiologist-led clinic to reduce the risk of heart disease in stroke survivors. We will also classify risk in stroke survivors using new tools.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022150</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Rajan Rehan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Novel Insights into Ischemia and No Obstructive Coronary Artery Disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$98,470.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>coronary artery disease </Res_KW1>
        <Res_KW2>microvascular disease</Res_KW2>
        <Res_KW3>platelet function</Res_KW3>
        <Res_KW4>cardiac ischaemia</Res_KW4>
        <Res_KW5>vasospasm</Res_KW5>
        <Plain_Description>Patients with Ischemia and No Obstructive Coronary Artery Disease (INOCA) are under-diagnosed and under-treated in current clinical practice. These patients continue to experience recurrent angina, a poor quality of life and adverse cardiovascular outcomes. This project aims to improve our understanding of the burden of disease and the factors that drive its occurrence and progression. Our investigations will help inform future practice for INOCA patients, including a novel diagnostic pathway.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022155</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Mr Karan Rao</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Investigating methods to optimise and streamline transcatheter aortic valve implantation (TAVI)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$98,470.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>aortic stenosis </Res_KW1>
        <Res_KW2>conduction block</Res_KW2>
        <Res_KW3>aged care</Res_KW3>
        <Res_KW4>cost-effectiveness</Res_KW4>
        <Res_KW5>pacemaker</Res_KW5>
        <Plain_Description>Transcatheter aortic valve implantation (TAVI) is a minimally invasive alternative to surgery for aortic valve narrowing. A common complication of TAVI is heart block (HB) requiring a pacemaker, which is hard to anticipate. This project investigates novel predictors of HB after TAVI, by monitoring patients for 2 years with an implantable heart monitor. Finally, we will evaluate the viability of safe &amp; early discharge in low risk patients, with aims to reduce length of stay, and streamline TAVI.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022156</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Lottie Morison</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Improving outcomes for children with complex communication needs</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$99,112.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | other health sciences | other health sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>speech pathologist </Res_KW1>
        <Res_KW2>speech and language development</Res_KW2>
        <Res_KW3>motor speech disorders</Res_KW3>
        <Res_KW4>phenotype</Res_KW4>
        <Res_KW5>genetics</Res_KW5>
        <Plain_Description>Speech &amp; language disorders impact literacy, social &amp; work outcomes. The investigation of human genes can help us to understand why some children have speech &amp; language disorders. My projects are: 1) Describe the speech &amp; language profile of 2 genetic disorders (Batten Disease &amp; Kleefstra Syndrome) 2) Complete a high-tech speech therapy trial in the genetic disorder Angelman's Syndrome 3) Create a high-tech therapy decision-making resource for speech pathologists.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022163</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Omali Pitiyarachchi</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Dora Lush Basic Science Research</Sub_Type>
        <Grant_Title>Moving Towards Personalising Treatment for Patients with Pancreatic Cancer Using a Patient-Derived Tumour Explant Model </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$98,470.17</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | chemotherapy | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>pancreatic cancer </Res_KW1>
        <Res_KW2>oncology</Res_KW2>
        <Res_KW3>chemotherapy</Res_KW3>
        <Res_KW4>stroma</Res_KW4>
        <Res_KW5>tumour biology</Res_KW5>
        <Plain_Description>Patients with pancreatic cancer (PC) have a poor prognosis. Our team has developed a world-first laboratory model of PC which we can use to test different chemotherapy drugs on a sample of a patient's tumour ("explant") with results available within 3 weeks. The overall aim of my PhD is to show our model can be used as a reliable indicator of how a patient will respond to different drug treatments, and search for reasons why some patients have tumours that don't respond ("chemoresistance").</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022167</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Youlin Koh</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Selective Serotonin Reuptake Inhibitors And Depression in Atrial Fibrillation: The SAD-AF randomised controlled trial</Grant_Title>
        <Admin_Institution>Melbourne Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>atrial fibrillation </Res_KW1>
        <Res_KW2>depression</Res_KW2>
        <Res_KW3>serotonin</Res_KW3>
        <Res_KW4>cardiology</Res_KW4>
        <Res_KW5>quality of life</Res_KW5>
        <Plain_Description>The SAD-AF study is  trial of serotonin-based antidepressants in people with intermittent atrial fibrillation (AF) and at least moderate symptoms of depression, to improve AF-related quality of life. AF is an irregular rhythm arising from the upper chambers of the heart, and can cause symptoms of chest pain, breathlessness and feelings of depression or anxiety. We believe that commonly prescribed serotonin-based antidepressants may improve AF-related symptoms and reduce the time spent in AF.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022178</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Yanna Ko</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>The role of the Gut Microbiome in Irritable Bowel Syndrome and its therapeutic potential</Grant_Title>
        <Admin_Institution>University of Western Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$94,702.08</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>irritable bowel syndrome (ibs) </Res_KW1>
        <Res_KW2>microbiology</Res_KW2>
        <Res_KW3>microbiological safety</Res_KW3>
        <Res_KW4>dietary factors</Res_KW4>
        <Res_KW5>clinical dietetic practice</Res_KW5>
        <Plain_Description>Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. IBS patients have an altered gut microbiome, but the potential of targetting microbiome changes to treat IBS is unclear. This PhD will evaluate faecal microbiota transplantation as a novel method of restoring healthy gut bacteria in IBS treatment and the role of dietary modifications. It will also lead to the creation of Australia’s first microbiome bank for IBS patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022186</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Miss Rachael Farquhar</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Investigating the effectiveness of systems-oriented implementation research and partnerships in malaria-endemic settings</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$93,827.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health systems | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>health systems</Res_KW2>
        <Res_KW3>decision making</Res_KW3>
        <Res_KW4>collaboration</Res_KW4>
        <Res_KW5>population health</Res_KW5>
        <Plain_Description>Malaria control interventions are falling short of impact and long-term sustainability as they lack systems integration and effective cross-program coordination. My research will provide evidence on; a) feasibility and acceptability of new vivax-specific tools, b) effectiveness of systems-oriented implementation research and c) impact of research partnerships in PNG. This research will be critical to embed the coordination and systems approach required to achieve malaria elimination.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022193</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Antonia Kolovos</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Saving sight: Novel stratification instruments for glaucoma</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$98,470.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | </Fields_of_Research>
        <Res_KW1>glaucoma </Res_KW1>
        <Res_KW2>primary open angle glaucoma</Res_KW2>
        <Res_KW3>risk prediction</Res_KW3>
        <Res_KW4>risk factors</Res_KW4>
        <Res_KW5>clinical patient management</Res_KW5>
        <Plain_Description>Glaucoma is the leading cause of irreversible blindness globally. Predictors of disease progression remain poorly understood, and monitoring is time and resource intensive. This project seeks to create an innovative predictive risk calculator which can be used to identify individuals at the highest risk of vision loss. The outcomes of this project will directly address existing gaps in knowledge and clinical practice, and propose new approaches to glaucoma monitoring and resource allocation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022228</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Ms Nina Leggett</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Digital health to assist recovery after critical illness</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$99,112.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | intensive care  | health sciences | allied health and rehabilitation science | physiotherapy | health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>patient outcomes </Res_KW1>
        <Res_KW2>survivorship</Res_KW2>
        <Res_KW3>recovery</Res_KW3>
        <Res_KW4>critical care</Res_KW4>
        <Res_KW5>telemedicine</Res_KW5>
        <Plain_Description>People who survive an Intensive Care Unit (ICU) admission often have physical and mental complications and poor health outcomes. Previous ICU recovery research is limited to in-person follow-up. Digital solutions may be a powerful mediator of ICU recovery by improving access to specialised recovery programs. This research aims to understand acceptability of digital programs, and develop and test these. This research will improve outcomes for ICU survivors, and will inform larger-scale research.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022235</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Juliana Kanawati</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Three-Dimensional (3D) Printing to Refine Cardiac Assessment and Procedures</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$113,542.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>arrhythmia </Res_KW1>
        <Res_KW2>cardiac disease</Res_KW2>
        <Res_KW3>cardiac electrophysiology</Res_KW3>
        <Res_KW4>magnetic resonance imaging (mri)</Res_KW4>
        <Res_KW5>computed tomography</Res_KW5>
        <Plain_Description>3D printing in cardiovascular medicine is still in its infancy. There is great scope for clinical applications of this technology and its use in developing the field of personalised medicine. First, this technique needs to be refined and established. Studies to demonstrate effectiveness are required before this technology can become implemented into guidelines and widely adopted. The proposed research is expected to establish the optimal 3D printing strategy in cardiovascular medicine.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022237</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Justin Chua</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Defining the landscape of ANCA-associated vasculitides in Australia and providing a foundation for improved care</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | biomedical and clinical sciences | immunology | autoimmunity  | biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | </Fields_of_Research>
        <Res_KW1>vasculitis </Res_KW1>
        <Res_KW2>clinical epidemiology</Res_KW2>
        <Res_KW3>databases</Res_KW3>
        <Res_KW4>quality of care</Res_KW4>
        <Res_KW5>glomerular disease</Res_KW5>
        <Plain_Description>ANCA-associated vasculitis is caused by the body attacking itself in small blood vessels affecting multiple organs, leading to deaths and ill health. A registry is being established to capture more information about this condition in Australia, to gain insight into the extent of the disease locally and identify improvements to treatment. The plan is to link the data with an existing European registry to attain more meaningful results, to investigate how to better treat this condition worldwide.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022238</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Michael Moso</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Nanoparticle and gene therapy approaches to HIV cure</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | medical biotechnology | nanomedicine | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>gene therapy</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>medical virology</Res_KW4>
        <Res_KW5>anti-latency drugs</Res_KW5>
        <Plain_Description>Current treatment for HIV is able to suppress but not eradicate HIV infection. This is because HIV is able to infect long-lived immune cells and maintain a reservoir of latent infection. One promising approach to target this reservoir is a form of gene therapy using CRISPR/Cas9. CRIPSR is able to target sequences of DNA, including HIV. This project aims to develop a therapeutic approach using CRISPR/Cas9 and explore novel mechanisms for gene therapy delivery using nanoparticle technology.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022240</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Antonia Clarke</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Aboriginal and Torres Strait Islander Health Research</Sub_Type>
        <Grant_Title>Community, Country, and Cognition: A multi-jurisdictional assessment of dementia affecting Aboriginal and Torres Strait Islander Peoples</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | major global burdens of disease | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>dementia </Res_KW1>
        <Res_KW2>indigenous australians</Res_KW2>
        <Res_KW3>clinical epidemiology</Res_KW3>
        <Res_KW4>cardiovascular disease</Res_KW4>
        <Res_KW5>health service utilisation</Res_KW5>
        <Plain_Description>This study will be the first to evaluate nationwide dementia rates between Aboriginal and Torres Strait Islander and non-Aboriginal people. Guided by community-identified priorities, the study will evaluate risk factors for Aboriginal and non-Aboriginal Australians living with or developing dementia in NSW and Central Australia. This study will inform clinical practice and policy development to benefit dementia care for Aboriginal Australians across urban, regional, and remote settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022244</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Yvonne Kong</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Platelet biomarkers of thrombotic risk in type 2 diabetes</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$98,470.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>diabetes mellitus </Res_KW1>
        <Res_KW2>platelet activation</Res_KW2>
        <Res_KW3>platelet function</Res_KW3>
        <Res_KW4>cardiovascular complications</Res_KW4>
        <Res_KW5>cardiovascular disease prevention</Res_KW5>
        <Plain_Description>Patients with diabetes face an increased risk of diseases linked to abnormal blood clotting, such as heart attacks and strokes. Our initial studies show platelets from patients with diabetes, which are hyperactive, produce more inflammatory proteins such as CXCL3. This opens new opportunities for drugs to block platelet inflammation to prevent heart attacks, with potentially fewer bleeding side-effects compared to traditional treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022247</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Mr Yunduo Zhao</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Dora Lush Basic Science Research</Sub_Type>
        <Grant_Title>Coronary artery mimicking blood clot test: A point-of-care prothrombotic prediction device for patient-specific diagnosis </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$80,864.92</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | biomechanical engineering | </Fields_of_Research>
        <Res_KW1>coronary artery disease </Res_KW1>
        <Res_KW2>thrombosis</Res_KW2>
        <Res_KW3>haemodynamics</Res_KW3>
        <Res_KW4>platelets</Res_KW4>
        <Res_KW5>arterial flow dynamics</Res_KW5>
        <Plain_Description>This biomedical engineering program aims to develop a patient-specific biochip to diagnose and predict blood clot tendency at an earlier stage. The point-of-care prothrombotic prediction device will be suitable for patients with high blood clot risks such as diabetes and, more recently, the COVID-19. It also serves as a testing platform for new anti-platelet and anti-coagulant drugs, and as a way for surgeons to screen patients for anti-thrombotic before operating to avoid uncontrolled bleeding.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022273</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Natasha Gorrie</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Understanding the phenotypic expression of early disease and genetics of cardiac amyloidosis</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>amyloid </Res_KW1>
        <Res_KW2>transthyretin</Res_KW2>
        <Res_KW3>clinical genetics</Res_KW3>
        <Res_KW4>heart failure</Res_KW4>
        <Res_KW5>ischaemic stroke</Res_KW5>
        <Plain_Description>Cardiac amyloid is a multi-system disorder with poor survival that presents as heart failure, rhythm issues or strokes. New treatments improving survival are available but costly. The prevalence of genetic mutations, the best test and how to diagnose early disease is unclear. Cardiac amyloid patients and families will have genetic testing and cardiac imaging to identify the prevalence of mutations, the best and earliest diagnostic tests and better explain heart changes associated with strokes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022274</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Douglas Tjandra</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Predicting progression of intestinal metaplasia to gastric cancer</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>dysplasia </Res_KW1>
        <Res_KW2>gastric cancer</Res_KW2>
        <Res_KW3>surveillance</Res_KW3>
        <Res_KW4>cancer screening</Res_KW4>
        <Res_KW5>endoscopy</Res_KW5>
        <Plain_Description>Stomach cancer is a rare type of cancer in Australia which is often diagnosed late and has a poor survival. Intestinal metaplasia is a change in the stomach which precedes cancer in some people. However, the best way to monitor patients with this condition is not known. This project will try to understand why some people develop stomach cancer, and how we should monitor patients with intestinal metaplasia. This will include developing a world-first model in the lab using cells from patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022279</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Ms Ellie Medcalf</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Generating the trial evidence end-users prefer: adding value to the analysis of a randomised controlled trial of patient-led surveillance for subsequent melanoma (MEL-SELF)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$67,902.83</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological methods | mathematical sciences | statistics | biostatistics | biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | </Fields_of_Research>
        <Res_KW1>randomised controlled trial (rct) </Res_KW1>
        <Res_KW2>epidemiological research methods</Res_KW2>
        <Res_KW3>melanoma</Res_KW3>
        <Res_KW4>biostatistics</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>Common ways of determining the success of new treatments for health problems do not always offer the most useful knowledge to patients and doctors. This research explores new ways of analysing research results. In doing so, it aims to enhance the benefits of new treatments to patients, doctors, and policy makers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022284</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Rabia Khalid</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Understanding the interplay between eating disorders and weight management therapy</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$85,964.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | clinical nutrition | psychology | clinical and health psychology | counselling psychology | </Fields_of_Research>
        <Res_KW1>overweight/obesity </Res_KW1>
        <Res_KW2>eating disorders</Res_KW2>
        <Res_KW3>diets for weight loss</Res_KW3>
        <Res_KW4>behavioural intervention</Res_KW4>
        <Res_KW5>psychology</Res_KW5>
        <Plain_Description>We need better evidence to make sure that weight management therapy for obesity does not lead to eating disorders development. We aim to (1) identify which persons are at risk of eating disorders (2) break down the building blocks of weight management therapies and compare if these ‘blocks’ increase eating disorder risk (3) describe what healthcare professionals and patients think about these issues (4) describe the pathway to eating disorder development during weight management therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022301</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Jeremy Hill</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Towards ending tuberculosis and leprosy in the Pacific – implementing the PEARL study in South Tarawa, Kiribati</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | major global burdens of disease | health sciences | public health | preventative health care | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>tuberculosis </Res_KW1>
        <Res_KW2>population screening</Res_KW2>
        <Res_KW3>disease prevention</Res_KW3>
        <Res_KW4>epidemiology</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>South Tarawa, the capital of Kiribati, has the highest rates of tuberculosis (TB) and leprosy in the Pacific. My project will partner with the Kiribati government to offer community-based screening, treatment and prevention for TB and leprosy to the entire population. We will measure the impact of this intervention on incidence and transmission rates of TB and leprosy in South Tarawa, demonstrating a pathway for future disease elimination in the whole of Kiribati and other remote settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022307</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Karen Liddle</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Precision diagnosis for children with hearing loss: optimising utilisation of imaging and genetic testing</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$113,542.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | community child health  | </Fields_of_Research>
        <Res_KW1>child development </Res_KW1>
        <Res_KW2>congenital hearing loss</Res_KW2>
        <Res_KW3>genetic testing</Res_KW3>
        <Res_KW4>neuroimaging</Res_KW4>
        <Res_KW5>genetic counselling</Res_KW5>
        <Plain_Description>Hearing loss (HL) is relatively common in Australian newborns. Early and accurate detection and diagnosis of hearing loss optimizes care and developmental outcomes. Over 50% of HL is genetic with >120 genes known. Imaging findings and genetic testing can enhance our understanding of the cause, providing families with precise diagnoses and family planning information. Up to 12% of genetic HL is due to an inner ear abnormality associated with specific genes, but genetic testing is rarely offered.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022340</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Abera Saeed</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Novel retinal imaging biomarkers for the assessment and prevention of diabetes complications  </Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$124,846.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | vision science | </Fields_of_Research>
        <Res_KW1>diabetes </Res_KW1>
        <Res_KW2>diabetic retinopathy</Res_KW2>
        <Res_KW3>optical imaging</Res_KW3>
        <Res_KW4>retina</Res_KW4>
        <Res_KW5>diabetic complications</Res_KW5>
        <Plain_Description>PREDICT is a major study of type 2 diabetes complications. Whilst diabetes management has improved tremendously, our ability to identify those at risk of the sight- and life-threatening complications of the disease has not. Our goal is to develop better ways of estimating the risk of complications. We will use the rich data collected in PREDICT to determine if simple eye scans can be used for improved prediction. We will test new eye scanning technology and artificial intelligence methods.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022345</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Shejil Kumar</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>The effects of osteoanabolic pharmacotherapy and osteogenic exercise on bone and muscle outcomes in postmenopausal osteoporosis: exploring the bone/muscle interface</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | </Fields_of_Research>
        <Res_KW1>osteoporosis </Res_KW1>
        <Res_KW2>musculoskeletal disorders</Res_KW2>
        <Res_KW3>exercise</Res_KW3>
        <Res_KW4>bone mineral density</Res_KW4>
        <Res_KW5>muscle function</Res_KW5>
        <Plain_Description>Bone fractures, particularly in women after menopause, result in significant health-related disability. We need to get more benefit from current therapies for osteoporosis (bone fragility). We will investigate the effects of combining exercise with bone-building medication on improving bone mass and whether bone-building medication can improve muscle and physical function, which may lend to reduction in falls. We are conducting a multi-centre study to help address these important questions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022346</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Danielle Hutchinson</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>PhD Community Sentiment Tool</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$108,973.75</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | behavioural epidemiology | </Fields_of_Research>
        <Res_KW1>behavioural epidemiology </Res_KW1>
        <Res_KW2>public health</Res_KW2>
        <Res_KW3>cultural perceptions</Res_KW3>
        <Res_KW4>epidemiological research methods</Res_KW4>
        <Res_KW5>community</Res_KW5>
        <Plain_Description>Widespread beliefs and opinions held by a community about a topic is known as "community sentiment". It is critical to understand community sentiment about public health measures as it will affect compliance. Artificial intelligence can be used to analyse sentences, phrases and words in open-source media and social media to measure community sentiment. This can be done in many languages and locations in real time to inform health policy. It can be adapted to any language, area or health issue.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022364</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Russell Gear</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Comparing the Efficacy and Acceptability of Genomic Testing and Skin Biopsy in Diagnosing Monogenic Skin Disease </Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$124,846.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | biomedical and clinical sciences | clinical sciences | dermatology | </Fields_of_Research>
        <Res_KW1>medical genomics </Res_KW1>
        <Res_KW2>dermatology</Res_KW2>
        <Res_KW3>cost-effectiveness</Res_KW3>
        <Res_KW4>attitudes</Res_KW4>
        <Res_KW5>patient preference</Res_KW5>
        <Plain_Description>A skin biopsy is currently the first-line diagnostic-investigation for individuals with suspected genetic skin diseases. It would be valuable to determine whether this invasive procedure could be replaced with a saliva sample and genomic testing. This proposal aims to measure the cost-effectiveness, diagnostic yield and clinical impact of these test modalities, in addition to examining the attitudes of relevant stakeholders – including patients, families and clinicians.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022368</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Justin Phan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Dora Lush Basic Science Research</Sub_Type>
        <Grant_Title>Assessing the cardiac arrhythmia profile of cancer therapeutics</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$113,542.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>action potential </Res_KW1>
        <Res_KW2>adverse drug reactions</Res_KW2>
        <Res_KW3>cardiac electrophysiology</Res_KW3>
        <Res_KW4>cardiovascular complications</Res_KW4>
        <Res_KW5>sudden cardiac death</Res_KW5>
        <Plain_Description>Heart rhythm disorders or arrhythmias can result from cancer treatment. A lab-based study will assess the mechanisms of cancer-treatment induced long QT syndrome, which can result in fatal arrhythmias.  A clinical study will recruit patients treated with medications that use the immune system to fight cancer. A side effect of these medications includes heart inflammation and arrhythmias. This study will develop methods to diagnose heart inflammation and markers that indicate arrhythmia risk.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022377</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Smitha Kumble</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Critical evaluation of the diagnostic utility of whole genome and transcriptome sequencing and the training of physicians in the deployment of frontier diagnostic technologies in healthcare</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$94,702.08</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>genetic testing </Res_KW1>
        <Res_KW2>diagnostic methods</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>rna</Res_KW4>
        <Res_KW5>clinical competence / skills</Res_KW5>
        <Plain_Description>Rare diseases are largely uncommon but collectively, they result in significant morbidity. Most rare disease is genetic in origin and the majority of children with rare disease remain undiagnosed following genetic testing.    This project focuses on increasing diagnoses in children with rare disease through novel testing strategies such as combined genome and RNA sequencing, as well as improving their overall care by upskilling and improving genomic literacy in medical specialists.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022380</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Emma Tay</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Prescription Drug Monitoring Program in New South Wales: A mixed methods study of implementation processes, stakeholder experiences, and program impact</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$94,702.08</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health informatics and information systems | health sciences | health services and systems | primary health care | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>health services research </Res_KW1>
        <Res_KW2>clinical decision making</Res_KW2>
        <Res_KW3>patient safety</Res_KW3>
        <Res_KW4>drugs of dependence</Res_KW4>
        <Res_KW5>medications</Res_KW5>
        <Plain_Description>Harm from high-risk prescription medicines including opioids is a public health concern. Prescription Drug Monitoring Programs (PDMP) are electronic systems that monitor these high-risk medicines and warn health care professionals when a patient is at risk. This research project will investigate how the NSW PDMP (SafeScript NSW) was implemented and will explore health care providers' and consumers' experiences and perceptions of the new PDMP tool in NSW.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022387</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Miss Nga Yan Tse</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Functional connectivity-guided transcranial magnetic stimulation (TMS) treatment for young people with major depression</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$85,964.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>transcranial magnetic stimulation (tms) </Res_KW1>
        <Res_KW2>functional imaging</Res_KW2>
        <Res_KW3>major depressive disorder</Res_KW3>
        <Res_KW4>adolescence</Res_KW4>
        <Res_KW5>psychiatric illness</Res_KW5>
        <Plain_Description>Transcranial magnetic stimulation (TMS) is a Medicare-subsidised treatment for depression that normalises brain changes. However, neuroimaging studies of adolescent depression has generated inconsistent results, hindering the development of better TMS treatment for this age group. This study aims to establish a robust understanding of the neurobiology underlying adolescent depression and integrate this knowledge to improve TMS treatment efficacy for young people suffering from major depression.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022391</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Aashray Gupta</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Evidence Supporting Strategies for Coronary Artery Revascularisation</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$106,006.33</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | surgery | </Fields_of_Research>
        <Res_KW1>coronary artery disease </Res_KW1>
        <Res_KW2>clinical outcome</Res_KW2>
        <Res_KW3>coronary artery bypass surgery</Res_KW3>
        <Res_KW4>mortality</Res_KW4>
        <Res_KW5>clinical research</Res_KW5>
        <Plain_Description>My PhD project examines the quality and safety of treatments for coronary artery disease (CAD) and seeks to demonstrates the outcomes from these in various patient groups including in women and indigenous populations. New techniques in Coronary Artery Bypass Surgery (CABG) have been refined, but the comparisons between these and stenting is limited. With the help of artificial intelligence and medical machine learning, this project will provide novel data to improve patient survival globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022415</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Aleece MacPhail</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Predicting and preventing sepsis in patients with haematological malignancy</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>sepsis </Res_KW1>
        <Res_KW2>haematological malignancy</Res_KW2>
        <Res_KW3>supportive care</Res_KW3>
        <Res_KW4>prognostic indicators</Res_KW4>
        <Res_KW5>infection control</Res_KW5>
        <Plain_Description>Sepsis is overwhelming reaction to severe infection. Patients with haematological malignancy (blood cancers) have reduced immunity to infection and many develop sepsis. The treatments available for blood cancers have improved in recent years, but the risk of dying from sepsis is still high. My research program will help understand which patients are at the highest risk of sepsis, and whether we can prevent sepsis with immunoglobulin (antibody) treatment or improved hospital hygiene strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022417</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Joshua Wong</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Heart Failure Prevention in Cancer Survivors by Recognition and Treatment of Subclinical Disease</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>cardiovascular disease prevention </Res_KW1>
        <Res_KW2>heart failure</Res_KW2>
        <Res_KW3>cancer follow-up</Res_KW3>
        <Res_KW4>cardioprotection</Res_KW4>
        <Res_KW5>echocardiography</Res_KW5>
        <Plain_Description>Cancer survivors have an increased risk of heart failure (HF) due to chemotherapy toxicity &amp; shared risks between cancer &amp; heart disease.     Subclinical heart failure (SBHF) are changes in echocardiography occurring prior to symptoms, allowing initiation of cardioprotective therapies (medications, exercise) - reducing the risk of overt HF.     We aim to detect SBHF in cancer survivors &amp; evaluate impact of early cardioprotection. We expect this will improve functional capacity &amp; delay/prevent overt HF.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022424</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Alex Stoyanov</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Detection of autoantibodies using novel bioluminescent systems</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | autoimmunity  | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>anti-receptor autoimmunity </Res_KW1>
        <Res_KW2>neuroimmunology</Res_KW2>
        <Res_KW3>autoimmune disease</Res_KW3>
        <Res_KW4>autoantibodies</Res_KW4>
        <Res_KW5>diagnostic assay</Res_KW5>
        <Plain_Description>This research aims to develop new and improved laboratory tests to identify and measure antibodies and other markers in the bloodstream that are associated with autoimmune diseases, including a number of different neurological conditions. More accurate detection of these markers is important to allow early diagnosis and treatment of autoimmune diseases, and prevent their complications including long term disability.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022453</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Mr John Chetwood</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Optimising Biologics in Inflammatory Bowel Disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$124,846.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>inflammatory bowel disease (ibd) </Res_KW1>
        <Res_KW2>crohn's disease</Res_KW2>
        <Res_KW3>ulcerative colitis</Res_KW3>
        <Res_KW4>therapeutic drug monitoring</Res_KW4>
        <Res_KW5>microbiology</Res_KW5>
        <Plain_Description>There is no cure for inflammatory bowel disease (IBD), &amp; the underpinning mechanisms involved in disease development are poorly understood. Patients often progress on first line treatment and need ‘biologic’ therapy to control their disease, thereby keeping them healthy and improving their quality of life. My research aims to evaluate the clinical and cellular issues of IBD,  and personalise treatments based on the individual which will help decide treatment strategies to keep patients healthy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022454</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Ms Georgia Carstensen</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Novel policy approaches to reduce the supply and availability of tobacco products</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$70,495.25</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>human society | policy and administration | health policy | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>public health policy </Res_KW1>
        <Res_KW2>tobacco control</Res_KW2>
        <Res_KW3>tobacco</Res_KW3>
        <Res_KW4>smoking cessation</Res_KW4>
        <Res_KW5>policy analysis</Res_KW5>
        <Plain_Description>This research aims to reduce tobacco smoking in Australia. Tobacco is widely available to purchase, making it difficult for smokers to quit and easy for young people to start. I will find new options for reducing availability of tobacco by looking at models used in other countries for harmful products. I will develop new policy options for reducing tobacco supply and gain feedback from the public and other stakeholders, which I will use to make policy recommendations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022463</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Catherine Banks</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Targeted and stem cell therapeutics for Cystic Fibrosis sinus disease </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | otorhinolaryngology | biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>cystic fibrosis </Res_KW1>
        <Res_KW2>cystic fibrosis transmembrane regulator (cftr)</Res_KW2>
        <Res_KW3>rhinosinusitis</Res_KW3>
        <Res_KW4>stem cell transplantation</Res_KW4>
        <Res_KW5>endoscopic surgery</Res_KW5>
        <Plain_Description>Despite advances in treatment for Cystic Fibrosis, (CF) there is currently no cure. The sinonasal airway provides valuable insights into the lower airway. The impact of modulators on the sinonasal airway before and after treatment in the paediatric CF population will be studied. A rabbit sinus model will be developed to further define the essential preclinical steps to deliver rabbits own corrected airway stem-cells to renew the damaged cells within the sinus and lung.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022470</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Chun Mei Thng</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Investigating Novel Prevention and Treatment Strategies for for Gonococcal Control</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$117,310.58</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | venereology | biomedical and clinical sciences | medical microbiology | medical microbiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>neisseria gonorrhoeae </Res_KW1>
        <Res_KW2>vaccination immunology</Res_KW2>
        <Res_KW3>treatment strategies</Res_KW3>
        <Res_KW4>disease prevention</Res_KW4>
        <Res_KW5>antibiotic resistance</Res_KW5>
        <Plain_Description>Gonorrhoea infection can lead to long term health problems including infertility. Cases of gonorrhoea continue to increase and antibiotic-resistant strains have been reported, prompting WHO to declare an urgent need for new strategies to prevent the spread of untreatable gonorrhoea. My study focuses on this priority by generating new knowledge towards alternative strategies for gonococcal disease control including vaccine development and non-antibiotic strategies to treat gonorrhoea.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022471</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Adam Peterson</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Human amnion epithelial cell derived novel therapeutics in inflammatory bowel disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$106,006.33</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | immunology | immunology not elsewhere classified | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | </Fields_of_Research>
        <Res_KW1>inflammatory bowel disease (ibd) </Res_KW1>
        <Res_KW2>crohn's disease</Res_KW2>
        <Res_KW3>ulcerative colitis</Res_KW3>
        <Res_KW4>stem cell therapy</Res_KW4>
        <Res_KW5>regenerative medicine</Res_KW5>
        <Plain_Description>We will examine the potential therapeutic properties of extracellular vesicles, particles that carry messages between cells, that can be harvested from human amnion epithelial cells, a type of stem cell found in the amniotic membrane. We will then apply this as a treatment for perianal fistulising Crohn’s disease, a difficult to manage type of inflammatory bowel disease (IBD) with a higher risk of poor outcomes. Our goal is to establish a novel new therapy for patients suffering with IBD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022495</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Sarah Donoghue</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Towards treatment of intellectual disability caused by errors in the chromatin machinery</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$102,238.25</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry and metabolomics not elsewhere classified | </Fields_of_Research>
        <Res_KW1>behaviour genetics </Res_KW1>
        <Res_KW2>metabolomics</Res_KW2>
        <Res_KW3>acetylation</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>histone deacetylase</Res_KW5>
        <Plain_Description>Disorders that influence the expression of genes may be influenced by the metabolic environment in the cell.  This research aims to characterise the metabolic environment and to see if there may be potential treatments for these metabolic disorders by supplementing deficient nutrients/substrates.  In addition, we would be interested in characterising the biomarkers of these conditions to see if there are other chemicals that might be helpful to track treatment for these conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022510</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Yasmin Mohamed</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Vaccine Champions and Vaccine Communication program</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$105,686.67</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | public health | health promotion | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>vaccination </Res_KW1>
        <Res_KW2>community intervention</Res_KW2>
        <Res_KW3>social and behavioural research</Res_KW3>
        <Res_KW4>health promotion</Res_KW4>
        <Res_KW5>measurement</Res_KW5>
        <Plain_Description>The Vaccine Champions and Vaccine Communication (VCVC) program aims to increase the number of people getting the COVID-19 vaccine and to build confidence in vaccines by empowering healthcare providers, community, faith, and industry leaders to become vaccine “champions” within their communities, in three Western Pacific countries. Champions will run vaccine information sessions in the community, addressing concerns and misconceptions. This research will assess the impact of the VCVC program.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022517</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Patricia Khoo</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Novel bacteria as a therapy for inflammatory bowel disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$98,470.17</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>inflammatory bowel disease (ibd) </Res_KW1>
        <Res_KW2>mucosal immunology</Res_KW2>
        <Res_KW3>pathogenic bacteria</Res_KW3>
        <Res_KW4>translational research</Res_KW4>
        <Res_KW5>probiotics</Res_KW5>
        <Plain_Description>Inflammatory bowel disease (IBD) is an incurable disease, affecting 1 in 200 Australians and is thought to be related to an imbalance between protective and harmful bacteria in our gut. Despite years of research, a large proportion of these bacteria remain unknown or poorly understood. Our team has succeeded in identifying a vast number of new species. I will use novel techniques to further understand the relationship between these bacteria and IBD, and lead the development of a new treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022530</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Megan Frohlich</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Application of novel personalised medicine tools to understand treatment mechanisms in Primary Ciliary Dyskinesia </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$124,846.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | biomedical and clinical sciences | medical physiology | medical physiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>adult respiratory diseases </Res_KW1>
        <Res_KW2>mucociliary clearance</Res_KW2>
        <Res_KW3>functional magnetic resonance imaging (fmri)</Res_KW3>
        <Res_KW4>cell culture</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>Primary Ciliary Dyskinesia (PCD) is a rare genetic condition mostly affecting the respiratory tract, causing recurrent respiratory infections eventually leading to scarred and dilated airways. Research on the best treatment for patients with PCD is scarce. This study will use medical imaging and mini airway organs created in a lab from cells collected from the nose of PCD patients to measure the impact of treatments in patients with PCD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022548</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Dr Melissa Shields</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Better Vision for Patients with Ocular Toxoplasmosis</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$136,151.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | </Fields_of_Research>
        <Res_KW1>eye </Res_KW1>
        <Res_KW2>retinal disease</Res_KW2>
        <Res_KW3>toxoplasmosis</Res_KW3>
        <Res_KW4>biological therapy</Res_KW4>
        <Res_KW5>clinical decision making</Res_KW5>
        <Plain_Description>Toxoplasma gondii is a parasite that causes the eye disease called ocular toxoplasmosis. There are no medications that can rid the body of the parasite, and there is no vaccine that prevents an infection. The goal of my research is to improve vision outcomes in patients with ocular toxoplasmosis. I will investigate a new treatment that targets inflammatory molecules to protect the eye tissues, and I will develop clinical algorithms to identify patients who would benefit most from treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022557</APP_ID>
        <Date_Announced>2022-11-17T00:00:00</Date_Announced>
        <CIA_Name>Mr Michael Dymock</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Designing Bayesian clinical trials to enhance clinician- and consumer-directed decision-making</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$93,827.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>mathematical sciences | statistics | biostatistics | health sciences | other health sciences | other health sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>biostatistics</Res_KW2>
        <Res_KW3>randomised controlled trial (rct)</Res_KW3>
        <Res_KW4>translational research</Res_KW4>
        <Res_KW5>informed decision making</Res_KW5>
        <Plain_Description>Clinical trials are designed to answer scientific research questions. It is therefore hard for clinicians and consumers to use the trial results for their own decision-making. This is because the research question does not consider their individual preferences and so may not be helpful to them. To change this, we need a better way to evaluate and report trial results to make decision-making easier. This project will use advanced statistics to design better clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018592</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Prof Ricky O'Brien</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2022 Synergy Grants</Sub_Type>
        <Grant_Title>Reducing the impact of radiation on the heart for cancer and cardiac disease patients</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | </Fields_of_Research>
        <Res_KW1>radiation </Res_KW1>
        <Res_KW2>cardiology</Res_KW2>
        <Res_KW3>ventricular tachycardia</Res_KW3>
        <Res_KW4>lung cancer</Res_KW4>
        <Res_KW5>radiotherapy</Res_KW5>
        <Plain_Description>This program will develop the integrated technology and perform datamining, animal and human studies to provide a comprehensive understanding on the response of substructures in the heart to radiation. This work will benefits patients receiving radiation therapy for cancer treatments where we aim to minimise cardiac complications post treatment. Our work will also benefit patients with advanced ventricular tachycardia where radiation is being used to reduce the number of painful ICD shocks.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018642</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Prof Glenn Marshall</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2022 Synergy Grants</Sub_Type>
        <Grant_Title>Improving outcomes for high-risk child and adolescent cancer: from discovery to individualised treatment within a consumer partnership</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | psychology | clinical and health psychology | counselling psychology | </Fields_of_Research>
        <Res_KW1>cancer therapy </Res_KW1>
        <Res_KW2>experimental therapeutics</Res_KW2>
        <Res_KW3>consumer participation</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>mental health</Res_KW5>
        <Plain_Description>Cancer is the commonest disease causing death in children. New anticancer drugs are developed against one adult cancer gene target. Anticancer drugs work best in combination to overcome resistance. Our network of scientists and doctors have developed a diagnostic platform to better match the drug to the gene target for high risk child cancer. We will develop effective child cancer-specific combination therapy, accurate diagnostics for resistance and integrate consumers in the research pathway.  

</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018654</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Prof James Beeson</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2022 Synergy Grants</Sub_Type>
        <Grant_Title>Accelerating to zero: targeting roadblocks to achieve malaria elimination</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | disease surveillance | biological sciences | microbiology | infectious agents | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>plasmodium</Res_KW2>
        <Res_KW3>malaria vaccine</Res_KW3>
        <Res_KW4>drug resistance</Res_KW4>
        <Res_KW5>surveillance</Res_KW5>
        <Plain_Description>This Synergy Grant addresses major knowledge and translation gaps that are key roadblocks to achieving malaria elimination. The new knowledge, tools, and strategies developed in this program through innovative and targeted research is responsive to global priorities and will directly inform policy and health practices, as well as driving future innovation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018668</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Prof Sharon Naismith</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2022 Synergy Grants</Sub_Type>
        <Grant_Title>Synergise, Integrate and Enhance Sleep Research to Transform Brain Ageing (SIESTA)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>sleep disturbance </Res_KW1>
        <Res_KW2>alzheimer disease</Res_KW2>
        <Res_KW3>sleep disorders</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>treatment strategies</Res_KW5>
        <Plain_Description>Modifiable risk factors account for up to 40% of dementia risk, and sleep disturbance (SD) has emerged as a viable new target. This project will assess SD, cognitive decline and dementia pathology using methods including novel blood-based biomarkers. This project will also develop scalable digital health solutions addressing SD, and assess the impact of interventions on SD and dementia biomarkers, in order to translate findings into clinical practice and substantially reduce dementia risk.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018970</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Francis Mitrou</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2022 Synergy Grants</Sub_Type>
        <Grant_Title>Improving Aboriginal health by understanding the influence of early life environments and contacts with health and social service systems over time and across generations</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | </Fields_of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>child development</Res_KW2>
        <Res_KW3>data linkage</Res_KW3>
        <Res_KW4>epidemiology</Res_KW4>
        <Res_KW5>family studies</Res_KW5>
        <Plain_Description>This project is a partnership between researchers, the Aboriginal community and government to provide evidence for policy and practice addressing high priority health conditions for Aboriginal children and families. It will use a longitudinal linked dataset based on a population representative sample of Aboriginal children and their families (the 2000/02 Western Australian Aboriginal Child Health Survey) and government data across health, education, child protection, and justice domains.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019056</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Prof Maria Kavallaris</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2022 Synergy Grants</Sub_Type>
        <Grant_Title>Advancing the treatment of brain cancer in children</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | </Fields_of_Research>
        <Res_KW1>brain tumours </Res_KW1>
        <Res_KW2>blood-brain barrier</Res_KW2>
        <Res_KW3>drug delivery</Res_KW3>
        <Res_KW4>brain imaging</Res_KW4>
        <Res_KW5>child</Res_KW5>
        <Plain_Description>Brain cancers are the number one cause of cancer related death in children. Treatment for this group of cancers is aggressive and includes chemotherapy, surgery and radiotherapy. This research will develop innovative nano-sized drug carriers to deliver therapies and imaging agents to detect and kill brain tumours. If successful, this work has the potential to markedly change treatment strategies to improve the survival of paediatric brain cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019247</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tamara Mackean</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2022 Synergy Grants</Sub_Type>
        <Grant_Title>How can health districts and networks cultivate anti-racist hospitals?</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | </Fields_of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>hospitals</Res_KW2>
        <Res_KW3>health inequalities</Res_KW3>
        <Res_KW4>access to health care</Res_KW4>
        <Res_KW5>organisational processes</Res_KW5>
        <Plain_Description>The aim of this research is to enable local health networks and districts in Australia to tackle systemic racism in hospitals. Specifically, this research will use tools and frameworks to improve quality of hospital care and reduce health inequities for Aboriginal and Torres Strait Islander people. This work will be undertaken by a team of researchers with expertise and skills across public health, social science and Indigenous ways of working.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019251</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Prof Jose Polo</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2022 Synergy Grants</Sub_Type>
        <Grant_Title>Using complex models of human trophoblast to study placental biology and disease</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biomedical and clinical sciences | reproductive medicine | reproductive medicine not elsewhere classified | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>placenta </Res_KW1>
        <Res_KW2>stem cell biology</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>implantation</Res_KW4>
        <Res_KW5>transposons</Res_KW5>
        <Plain_Description>In this synergy grant, a multidisciplinary team of researchers in stem cell biology, placenta , epigenetics, embryonic implantation and computational science will work together to study the placenta using different artificial models. This will allow us to understand how early placenta is formed in humans, how it interacts with the cells of the uterus of the mother and unveil the genetic and toxicity insults that contribute to problems in pregnancy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019252</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Coral Gartner</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2022 Synergy Grants</Sub_Type>
        <Grant_Title>The Interdisciplinary Tobacco Endgame Research Network (INTER-Net)</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | economics | applied economics | behavioural economics | human society | policy and administration | health policy | </Fields_of_Research>
        <Res_KW1>tobacco control </Res_KW1>
        <Res_KW2>public health policy</Res_KW2>
        <Res_KW3>health economics</Res_KW3>
        <Res_KW4>behavioural science</Res_KW4>
        <Res_KW5>smoking</Res_KW5>
        <Plain_Description>Tobacco smoking remains the leading preventable cause of early death and disease globally. Australia has been a global leader in implementing policies that have reduced smoking to one of the lowest rates in the world. This multidisciplinary research program will examine promising new approaches to minimising smoking in Australia using methods from epidemiology and applied statistics, health policy, law, the social sciences, and economics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019260</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Prof Ian Hickie</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2022 Synergy Grants</Sub_Type>
        <Grant_Title>Rhythms and blues: Personalising care for body clock dysfunction in mood disorders</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>circadian rhythms </Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>clinical genetics</Res_KW3>
        <Res_KW4>biosensor</Res_KW4>
        <Res_KW5>psychiatry</Res_KW5>
        <Plain_Description>This project aims to improve our knowledge about how problems with “body clocks” might lead to mood disorders like depression and bipolar disorder. We expect this research will (1) lead to better ways to measure body clock function, (2) reveal more clearly how body clocks are affected in mood disorders, (3) help clinicians predict whose mood disorder will persist or get worse over time, and (4) guide clinicians about what treatments can help improve people’s body clocks and mental health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024704</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr David Lane</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Bionics Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$175,939.06</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024700</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Marcia Fearn</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>National Ageing Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$269,730.58</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024693</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Raja Choudhury</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$601,540.31</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024706</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Ms Sonja Bates</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Garvan Institute of Medical Research</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$20,101.50</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024696</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Andrea Richardson</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Florey Institute of Neuroscience and Mental Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,292,024.30</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024689</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Cherry Yu</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,883,201.91</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024690</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Ms Nadine Barnes</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,593,844.69</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024710</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Callum Hensman</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>VCS Foundation Limited</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$63,114.25</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024709</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Catherine Hayden</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$6,934,493.84</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024708</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Michael Frommer</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>The Sax Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$184,164.39</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024707</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Kerry Jenson</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>The George Institute for Global Health</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$258,543.90</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024688</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Mrs Julie Taranto</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>ANZAC Research Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$171,289.22</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024705</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Marc Campitelli</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,331,279.62</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024703</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Colleen Elso</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>St Vincents Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,037,103.52</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024702</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Leanne Sutherland</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$497,425.26</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024701</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Stephanie Miller</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Royal Brisbane and Women's Hospital Foundation</Admin_Institution>
        <State>QLD</State>
        <Sector>Health</Sector>
        <Total>$29,439.81</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024699</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicole Donker</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$4,424,388.24</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024698</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Ms Valerie Jakrot</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Melanoma Institute Australia</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$39,698.94</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024697</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Rosalba Drummond</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Institute for Breathing and Sleep</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$95,889.16</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024695</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Mrs Jane Estoesta</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Family Planning NSW</Admin_Institution>
        <State>NSW</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$42,119.90</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024694</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Ms Ramona Grimm</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Children's Medical Research Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$25,035.49</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024692</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Michelle Rutledge</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Centenary Institute of Cancer Medicine and Cell Biology</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$57,851.71</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024691</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Alysha Cameron</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2022</Grant_Title>
        <Admin_Institution>Cancer Council VIC</Admin_Institution>
        <State>VIC</State>
        <Sector>Charities and Philanthropic</Sector>
        <Total>$90,363.19</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024644</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Lucy Sheehan-Hennessy</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$102,012.25</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024674</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Emilie Corrick</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$144,622.53</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024684</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Mrs Fiona Miotti</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$202,370.44</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024637</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Ms Nadine Barnes</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$57,829.43</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024660</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Jodie Ellis</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$97,071.72</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024664</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Marcia Fearn</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>National Ageing Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$9,786.63</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024667</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Leanne Sutherland</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$18,048.07</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024679</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Ms Debbie Docherty</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$602,991.01</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024636</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Haley Jacobi</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Bond University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$18,837.17</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024659</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Erin Semon</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$71,925.76</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024638</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Raja Choudhury</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$21,825.67</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024641</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Kara Spilstead</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$85,548.21</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024645</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Andrea Richardson</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Florey Institute of Neuroscience and Mental Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$46,878.49</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024635</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Cherry Yu</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$68,328.17</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024669</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Sheila Hamilton-Brown</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Swinburne University of Technology</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$13,942.99</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024687</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Manijah Hakim</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Western Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$8,983.15</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024686</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrew Gaff</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Victoria University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$6,462.70</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024685</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Monica Birrento</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$31,506.56</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024683</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Katherine Waldron</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$46,186.43</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024682</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Jodie Lamont</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$51,116.05</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024681</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Nicole Makoviney</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$620,924.34</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024680</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Mark Geier</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$77,776.86</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024678</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Wade Moore</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$906,177.32</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024677</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Catherine Hayden</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$251,604.08</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024676</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Ekaterina Ovsyanikova</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$481,962.12</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024675</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Ms Judy Alexander</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$130,703.58</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024673</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Michael Frommer</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>The Sax Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$6,682.03</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024672</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Kerry Jenson</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>The George Institute for Global Health</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$9,380.74</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024671</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Marc Campitelli</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$120,868.74</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024670</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr David Lane</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Bionics Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$6,383.59</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024668</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Colleen Elso</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>St Vincents Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$37,629.20</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024666</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Jane Holt</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$30,889.62</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024665</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Ms Katie York</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$37,493.21</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024663</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Kerrie Carr</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Murdoch University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$10,468.90</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024662</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicole Donker</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$160,529.97</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024661</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Michelle McMurtrie</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$791,822.05</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024646</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Lynette Farquhar</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$64,069.82</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024632</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Mrs Julie Taranto</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>ANZAC Research Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$6,214.88</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024650</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Georgina Caruana</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$57,388.74</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024649</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Mr Javier Balanzategui</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$34,394.03</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024642</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Ms Sharon York</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Edith Cowan University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$12,060.51</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024640</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Dr Jananee Raguragavan</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$36,015.20</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024639</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Mrs Hemali Seneviratne</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Charles Darwin University</Admin_Institution>
        <State>NT</State>
        <Sector>University</Sector>
        <Total>$6,363.38</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2024634</APP_ID>
        <Date_Announced>2022-11-25T00:00:00</Date_Announced>
        <CIA_Name>Katherine Hammersley</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2022 Equipment Grant</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$95,923.66</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Fields_of_Research>Not Applicable</Fields_of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2016736</APP_ID>
        <Date_Announced>2022-12-05T00:00:00</Date_Announced>
        <CIA_Name>Prof Lisa Jamieson</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Dental health, mental health and economic productivity; a child longitudinal study </Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,499,998.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | community child health  | </Fields_of_Research>
        <Res_KW1>child health </Res_KW1>
        <Res_KW2>dental health</Res_KW2>
        <Res_KW3>dental health surveys</Res_KW3>
        <Res_KW4>population health</Res_KW4>
        <Res_KW5>health economics</Res_KW5>
        <Plain_Description>Working with partners across each State and Territory to ensure local tailoring and national implementation, we will undertake NCOHS-2 – oral epidemiological examinations and questionnaire data on approximately 32,000 Australian children aged 5 to 14 years – then compare against NCOHS-1 data to test, model, evaluate and disseminate evidence that will enable important questions around child oral health, social and emotional wellbeing, school performance and economic productivity to be answered.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017219</APP_ID>
        <Date_Announced>2022-12-05T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Peter Hibbert</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Improving the health system’s response when patients are harmed: a mixed-methods study</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,496,179.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | patient safety | </Fields_of_Research>
        <Res_KW1>patient safety </Res_KW1>
        <Res_KW2>adverse events</Res_KW2>
        <Res_KW3>health services research</Res_KW3>
        <Res_KW4>injury</Res_KW4>
        <Res_KW5>health care evaluation</Res_KW5>
        <Plain_Description>When patients are harmed, it is imperative that health care organisations respond to and learn from them and prevent other patients suffering a similar incident. However, there is no evidence that systems for managing incidents reduce more incidents causing harm to patients.  We will work closely with four jurisdiction's health systems to research current practices, test interventions that are occurring in health services, and undertake a world-first simulation trial using artificial intelligence.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2017496</APP_ID>
        <Date_Announced>2022-12-05T00:00:00</Date_Announced>
        <CIA_Name>Dr Yaqoot Fatima</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Sleep for Strong Souls (3S): Multisectoral partnership and co-designed solutions to improve the sleep health of First Nations Adolescents</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$783,055.32</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | </Fields_of_Research>
        <Res_KW1>indigenous australians </Res_KW1>
        <Res_KW2>sleep</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>service delivery</Res_KW4>
        <Res_KW5>capacity building</Res_KW5>
        <Plain_Description>1 in 3 Aboriginal and Torres Strait Islander adolescents struggle with poor sleep, yet their sleep health needs remains unmet. In collaboration with community members, the project team and partner organisations are working together to co-design a sleep health program and resources, build local capacity, and embed culturally responsive and context responsive sleep health care in preventive programs and health system to meet the sleep health needs of First Nations adolescents.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018981</APP_ID>
        <Date_Announced>2022-12-05T00:00:00</Date_Announced>
        <CIA_Name>Dr Zephanie Tyack</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>NAVICARE: Implementing, scaling up and sustaining a co-designed care navigation model to improve mental health service access in regional Australia</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$727,470.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | human society | social work | counselling, wellbeing and community services | health sciences | health services and systems | rural and remote health services | </Fields_of_Research>
        <Res_KW1>mental health services </Res_KW1>
        <Res_KW2>mental health promotion</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>health economics</Res_KW4>
        <Res_KW5>rural and remote health services</Res_KW5>
        <Plain_Description>One in five Australians experience mental ill health each year. In regional Australia, mental health services are harder to access than in urban areas. We developed a new model of care with regional communities to address this. A local person assists people in navigating how to access the best mental health care, which has been shown to be beneficial. This project will evaluate the new model of care in multiple regional sites in Queensland and potential scaling up across Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019034</APP_ID>
        <Date_Announced>2022-12-05T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Dietze</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Determining the impact of the Melbourne Supervised Injecting Rooms on health and social outcomess </Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,499,966.40</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>overdose </Res_KW1>
        <Res_KW2>injecting drug use</Res_KW2>
        <Res_KW3>heroin dependence</Res_KW3>
        <Res_KW4>drug use</Res_KW4>
        <Res_KW5>addiction</Res_KW5>
        <Plain_Description>The Melbourne Supervised Injecting Room opened in North Richmond in 2018 and has since become one of the busiest in the world. A second MSIR will open in Melbourne's Central Business District. By establishing SIRX, a prospective cohort of MSIR service users, this study will provide new highest-quality evidence about the effectiveness of the MSIRS to inform ongoing policy and practice around supervised injecting facilities over the coming decade.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019085</APP_ID>
        <Date_Announced>2022-12-05T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jo Robinson</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Can an aftercare service reduce suicide risk in young people? An effectiveness-implementation evaluation</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,225,326.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>suicide prevention </Res_KW1>
        <Res_KW2>suicide</Res_KW2>
        <Res_KW3>adolescent health</Res_KW3>
        <Res_KW4>evaluation</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>This project responds to rising rates of youth suicide. It will evaluate a youth aftercare service designed to support young people who have presented to the emergency department with suicide risk. The project will employ different methodologies to understand the acceptability and effectiveness of the service from the perspectives of young people, families and professionals. It represents a partnership between the University of Melbourne, Orygen and the Victorian Department of Health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019735</APP_ID>
        <Date_Announced>2022-12-05T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof James Wood</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2022 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Integrating mathematical modelling and public health surveillance to improve control of epidemic and pandemic respiratory infections in Australia</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,009,784.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | disease surveillance | health sciences | epidemiology | epidemiological modelling | </Fields_of_Research>
        <Res_KW1>covid-19 </Res_KW1>
        <Res_KW2>health surveillance</Res_KW2>
        <Res_KW3>mathematical modelling</Res_KW3>
        <Res_KW4>decision support</Res_KW4>
        <Res_KW5>respiratory viruses</Res_KW5>
        <Plain_Description>Australia has had a highly successful response to COVID-19 by global standards but this success relied on real-time development of public health responses including new surveillance of trends and interventions and analysis through newly developed models. We seek to embed efficient and relevant surveillance and real-time analysis within jurisdictional responses to COVID-19 and other important respiratory infections, through partnerships with NSW, ACT and QLD health departments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018793</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Stephen Blake</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Engineered tumour-homing bacteria that safely turn up the heat on immunologically cold colorectal cancers</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$808,254.27</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>immunotherapy </Res_KW1>
        <Res_KW2>colorectal cancer treatment</Res_KW2>
        <Res_KW3>cd40/ cd40l interactions</Res_KW3>
        <Res_KW4>molecular microbiology</Res_KW4>
        <Res_KW5>acute liver injury</Res_KW5>
        <Plain_Description>The most prevalent colorectal cancer subtype has a low mutational burden and does not respond well to immunotherapies. The immune agonist anti-CD40 can drive immune infiltration into this cancer subtype and can reduce tumour burden in a mouse model that faithfully recapitulates the disease, however induces severe toxicity.  This project will determine if expressing CD40 agonists in probiotic bacteria can be used to reduce this toxicity and effectively suppress colorectal cancer growth.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018797</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Revill</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting the hepatitis B e antigen as a novel therapeutic approach</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,400,226.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>hepatitis b virus </Res_KW1>
        <Res_KW2>hepatitis b infection</Res_KW2>
        <Res_KW3>novel therapeutic agents</Res_KW3>
        <Res_KW4>antibody therapy</Res_KW4>
        <Res_KW5>novel therapies</Res_KW5>
        <Plain_Description>There is no cure for chronic hepatitis B virus disease. The secreted hepatitis B e antigen (HBeAg) is a major cause of chronic infection, and its removal by host immune responses improves patient health. Current antiviral therapy does not specifically target this protein. We have developed novel methods to reducing HBeAg levels in a mouse model of HBV persistence. This proposal will progress these findings towards a novel therapeutic approach to treat HBeAg-+ve chronic hepatitis B.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018825</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Roger Pocock</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Characterization of the Germline Regulatory Landscape</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,156,248.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>developmental biology </Res_KW1>
        <Res_KW2>developmental genetics</Res_KW2>
        <Res_KW3>genetics</Res_KW3>
        <Res_KW4>germ cells</Res_KW4>
        <Res_KW5>gene transcription</Res_KW5>
        <Plain_Description>Human fertility requires the generation of gametes (oocytes and sperm) that combine to produce an embryo. The aim of this research program is to identify genes and proteins that control gamete production. The biochemical pathways under study could be targeted by drugs. Therefore, new knowledge generated in this project has the potential to identify processes and pathways that are directly relevant to reproduction-related disease, infertility and in vitro fertilization.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018833</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Eduardo Eyras</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Accelerating messenger RNA (mRNA) therapeutics by cracking the epitranscriptomic code</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,556,956.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | genomics and transcriptomics | information and computing sciences | machine learning | deep learning | biological sciences | biochemistry and cell biology | synthetic biology | </Fields_of_Research>
        <Res_KW1>messenger rna (mrna) </Res_KW1>
        <Res_KW2>rna processing</Res_KW2>
        <Res_KW3>sequencing</Res_KW3>
        <Res_KW4>artificial neural networks</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>The remarkable efficacy of SARS-CoV-2 vaccines based on messenger RNA (mRNA) has highlighted the extraordinary potential of mRNA technologies and has secured the promise of mRNA as a therapeutic modality for multiple diseases. This research project builds on a recent breakthrough from my research that enables an unprecedented characterisation of the chemical composition of individual mRNA molecules to uphold this promise and accelerate mRNA exploration and design for therapeutic development.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018835</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Elizabeth Gardiner</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Molecular pathways that control platelet production</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$883,019.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>platelets </Res_KW1>
        <Res_KW2>haematopoiesis</Res_KW2>
        <Res_KW3>thrombocytopenia</Res_KW3>
        <Res_KW4>ribosome biogenesis</Res_KW4>
        <Res_KW5>haemorrhage</Res_KW5>
        <Plain_Description>Platelets are small cells that circulate by the millions in the bloodstream and are primarily responsible for sealing a blood vessel when the vessel is damaged. The mechanisms controlling platelet production are not well understood. We have discovered that by inhibiting ribosomal biogenesis, we can rapidly increase platelet production. This will be of enormous benefit in clinical settings where platelets are low and catastrophic bleeding is likely.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018880</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Abderrahman Hachani</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Dissecting the intracellular lifestyle of lethal Staphylococcus aureus</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$870,337.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | </Fields_of_Research>
        <Res_KW1>staphylococcus aureus </Res_KW1>
        <Res_KW2>intracellular bacterial infections</Res_KW2>
        <Res_KW3>cell death</Res_KW3>
        <Res_KW4>septicaemia</Res_KW4>
        <Res_KW5>antimicrobial resistance</Res_KW5>
        <Plain_Description>Staphylococcus aureus (golden staph) cause infection of the bloodstream, a serious condition with a high death toll in patients. Despite years of research, it is still unclear how these bacteria hide into human cells to escape our immune system and current antibiotics. Here, we propose a research programme to understand the molecular strategies used by golden staph to cause these serious infections. Our findings will help design new drugs to treat severe bacterial infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018888</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Arjun Muralidharan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting molecular ageing pathways for the treatment of chronic pain</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$828,285.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>chronic pain </Res_KW1>
        <Res_KW2>neuropathic pain</Res_KW2>
        <Res_KW3>pain mechanisms</Res_KW3>
        <Res_KW4>pain minimisation</Res_KW4>
        <Res_KW5>pain transmission</Res_KW5>
        <Plain_Description>One in five Australians lives with chronic pain and this prevalence rises to one in three people over the age of 65. Available treatments for pain are often ineffective and associated with dose-limiting side effects. This project aims to explore a potential new avenue of pain research, and the knowledge gained is expected to provide a breakthrough understanding of the interplay between chronic pain and cellular ageing, and nonetheless will lay the groundwork for numerous applications.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018895</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Johnson Mak</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Unmask HIV latency through disruption of HIV synapses</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,224,430.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical virology  | biological sciences | biochemistry and cell biology | protein trafficking | information and computing sciences | computer vision and multimedia computation | computer vision | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>protein trafficking</Res_KW2>
        <Res_KW3>synapse</Res_KW3>
        <Res_KW4>calcium</Res_KW4>
        <Res_KW5>image processing</Res_KW5>
        <Plain_Description>HIV synapses enable cell-cell transmission to overcome anti-retroviral therapeutics and broadly neutralising anti-HIV antibodies. Our ground-breaking report on the Ca2+-HIV synapse biology will: (i) improve efficiency of HIV therapeutics; and (ii) show how HIV latently infected cells can be sensitised for destruction. A cross-disciplinary approach involving molecular virology, cell biology, and machine learning will be used to accelerate our discovery for its application at the clinic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018897</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof John Bertram</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Preventing a nephron deficit in premature offspring</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,255,941.85</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | foetal development and medicine | </Fields_of_Research>
        <Res_KW1>premature birth </Res_KW1>
        <Res_KW2>nephron endowment</Res_KW2>
        <Res_KW3>maternal nutrition</Res_KW3>
        <Res_KW4>lactation</Res_KW4>
        <Res_KW5>kidney development</Res_KW5>
        <Plain_Description>Many premature babies are born with a low number of functional units (nephrons) in their kidneys and an increased risk of developing chronic kidney disease. Strategies to prevent a nephron deficit in preterm offspring are required. We have found that manipulating maternal nutrition during lactation can rescue a nephron deficit. We will determine the multidimensional impact of dietary macronutrients on maternal milk composition and nephron endowment following premature birth.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018916</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof David Godler</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Assessing benefits of extended genomic newborn screening at population scale in infants from Generation Victoria</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,812,607.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>newborn screening </Res_KW1>
        <Res_KW2>imprinting</Res_KW2>
        <Res_KW3>intellectual disability</Res_KW3>
        <Res_KW4>x linked disorder</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>There are over 7,000 rare diseases with the average age of diagnosis being 4 years. Newborn screening using genomics could identify these children at a younger age and deliver new therapies at birth to offer the most chance of health benefits. We will test effectiveness of a novel genomic workflow called EpiGNs to detect harmful changes to genes on the whole-of-state birth cohort (GenV) of 100,000 infants. This will enable its implementation as a new model for genomic newborn screening.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018919</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Juan Carlos Polanco</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Regulators of Tau Pathology Induced by Exosomal and Vesicle-free Tau Seeds</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$923,434.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>alzheimer disease </Res_KW1>
        <Res_KW2>neuroscience</Res_KW2>
        <Res_KW3>molecular neuroscience</Res_KW3>
        <Res_KW4>protein aggregation</Res_KW4>
        <Res_KW5>vesicle-associated proteins</Res_KW5>
        <Plain_Description>In Alzheimer’s disease, misfolded forms of the protein tau known as seeds propagate from neuron to neuron allowing for spreading and progression of tau pathology. We discovered novel genes that regulate this process. We will dissect how these regulators enable the disease, and whether their manipulation can modulate or stop tau pathology in cells and in brains. We expect that by understanding how different tau seeds cause tau pathology, our research will also reveal novel therapeutic targets.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018947</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Daniel Kolarich</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Personalising diagnosis and treatment of Pseudomonas aeruginosa infection</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$880,844.25</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | glycobiology | </Fields_of_Research>
        <Res_KW1>pseudomonas aeruginosa infection </Res_KW1>
        <Res_KW2>glycobiology</Res_KW2>
        <Res_KW3>immunoglobulin (ig)</Res_KW3>
        <Res_KW4>antibody therapy</Res_KW4>
        <Res_KW5>glycoproteins</Res_KW5>
        <Plain_Description>We will develop a novel blood test that measures the antibody glycocode and informs on the individual immune status of patients. This new test will improve and significantly accelerate personalised diagnosis and treatment of patients suffering from infection with Pseudomonas aeruginosa, a pathogen classified by the World Health Organisation at the highest threat level due to it becoming increasingly resistant to last resort antibiotics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018951</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Vicki Whitehall</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>New Approaches for Sensitising Metastatic Colorectal Cancer to Immunotherapy</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,419,345.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>colorectal cancer </Res_KW1>
        <Res_KW2>colorectal cancer treatment</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>novel therapies</Res_KW4>
        <Res_KW5>cancer prognosis</Res_KW5>
        <Plain_Description>Immunotherapy is an approach that takes advantage of the body’s own immune system to attack cancer cells. This therapy that has produced long term benefit for patients with many different types of advanced cancers, but has had limited benefit for patients with bowel cancer. In this application we are using cutting edge techniques to identify new ways to use immunotherapy to improve outcomes for patients with advanced bowel cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018980</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Nichollas Scott</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Defining the roles of O-linked glycosylation on Burkholderia virulence</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$512,466.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>glycosylation </Res_KW1>
        <Res_KW2>burkholderia</Res_KW2>
        <Res_KW3>proteomics</Res_KW3>
        <Res_KW4>protein modification</Res_KW4>
        <Res_KW5>mass spectrometry</Res_KW5>
        <Plain_Description>Burkholderia infections are associated with high mortality rates especially within immunocompromised individuals. Due to this there is an urgent need to identify bacterial factors which can be targeted to reduce the disease burden of these infections. Within this grant we aim to identify how a specific set of proteins, glycoproteins, contribute to Burkholderia virulence with the goal to identify next generation vaccines and anti-microbial targets.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018988</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stuart Mazzone</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A novel brain circuit inhibiting airway interoceptive processing</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,116,663.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | sensory systems | biomedical and clinical sciences | neurosciences | autonomic nervous system  | </Fields_of_Research>
        <Res_KW1>vagus nerve </Res_KW1>
        <Res_KW2>cough</Res_KW2>
        <Res_KW3>sensory function</Res_KW3>
        <Res_KW4>autonomic nervous system</Res_KW4>
        <Res_KW5>airway diseases</Res_KW5>
        <Plain_Description>The air passages and lungs are exposed to the external environment through the air that is breathed. It is therefore important that they can sense danger signals present in air, such as toxins or irritants, that might compromise breathing. This sensory system is poorly described. We will investigate brain circuits regulating airway irritant detection when air quality is compromised by smoke arising from bush fires. The findings will inform the severe health impacts of environmental pollutants.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018997</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Dale Nyholt</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Novel biomarkers and drug targets for pharmacoresistant epilepsy</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,967,753.56</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacogenomics | biological sciences | genetics | neurogenetics | </Fields_of_Research>
        <Res_KW1>epilepsy </Res_KW1>
        <Res_KW2>drug resistant</Res_KW2>
        <Res_KW3>pharmacogenetics</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>antiepileptic drugs</Res_KW5>
        <Plain_Description>In one-third of epilepsy patients, currently available antiepileptic drugs (AEDs) do not control seizures. Recurrent seizures threaten life and impair its quality; hence, there is a clear need to discover new AEDs. In addition, there is currently no way to accurately predict which and how individuals will respond to a specific or any AED. The proposed research aims identify new AED targets and predict the right (and wrong) drugs for an epilepsy patient from the outset.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019011</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Nafiseh Atapour</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Thalamic plasticity following cortical damage: recovery of vision </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$892,044.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>brain injury </Res_KW1>
        <Res_KW2>adult neurogenesis</Res_KW2>
        <Res_KW3>neural regeneration</Res_KW3>
        <Res_KW4>recovery</Res_KW4>
        <Res_KW5>task-related training</Res_KW5>
        <Plain_Description>This project will investigate how neuroplasticity can contribute to vision recovery in adult brain, following damage to one of its key nodes. Normally, such lesions render the person blind, but some slight improvement occurs over time. We will test the extent to which newborn neurons can be integrated to other parts of this circuit in a manner that explains the partial recovery of vision, and whether a rehabilitation therapy can boost this process.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019014</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Chrishan Samuel</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Engineering bone marrow-derived stromal cells to express anti-fibrotic cargo as a treatment for chronic kidney disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$981,260.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | </Fields_of_Research>
        <Res_KW1>nephrology </Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>therapeutics</Res_KW3>
        <Res_KW4>stem cell therapy</Res_KW4>
        <Res_KW5>combination therapy</Res_KW5>
        <Plain_Description>Although a number of organs can repair themselves from mild injury, when subjected to persistent injury, they fail to do so. As a result, they undergo organ scarring (fibrosis) and a progressive loss of function. As current therapies fail to effectively stop this scarring process, we aim to engineer human bone marrow-derived stromal cells to express an anti-fibrotic agent (serelaxin), to deliver the therapeutic potential of this combination therapy as a treatment of chronic kidney disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019024</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Iain Comerford</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing and understanding Tr1 cells in inflammation</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$866,880.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>inflammation </Res_KW1>
        <Res_KW2>experimental autoimmune encephalomyelitis (eae)</Res_KW2>
        <Res_KW3>cd4</Res_KW3>
        <Res_KW4>airway inflammation</Res_KW4>
        <Res_KW5>regulatory t cells</Res_KW5>
        <Plain_Description>Inflammation that is inappropriately directed causes a range of important human diseases and current therapies for these diseases are limited. New methods or identification of new mechanisms that can be exploited to control persistent inflammation are therefore urgently required. In this project we will explore the biology of Type-I regulatory T cells (Tr1 cells), which appear to play an important role in the control of inflammation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019032</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Luc Furic</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Codon bias and the role of tRNA modifications in cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$934,787.32</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | biological sciences | bioinformatics and computational biology | proteomics and metabolomics | </Fields_of_Research>
        <Res_KW1>protein synthesis </Res_KW1>
        <Res_KW2>rna processing</Res_KW2>
        <Res_KW3>messenger rna (mrna)</Res_KW3>
        <Res_KW4>proteome analysis</Res_KW4>
        <Res_KW5>cancer cell biology</Res_KW5>
        <Plain_Description>Cancer is characterised by high rate of cell growth and proliferation. Cancer cells need to increase their biomass to divide and this is dependent on the the synthesis of proteins. We have recently discovered that transfer RNAs, the small molecules carrying the building blocs required for protein synthesis, are chemicaly modified and that these modifications could be targeted to strongly inhibit tumour growth and progression in a wide array of cancers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019058</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ulrike Kappler</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>How does metabolic conditioning of the host environment enhance persistence of Haemophilus influenzae infections?</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$786,583.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry and metabolomics not elsewhere classified | biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>bacterial respiratory diseases </Res_KW1>
        <Res_KW2>infectious diseases</Res_KW2>
        <Res_KW3>haemophilus influenzae</Res_KW3>
        <Res_KW4>metabolism</Res_KW4>
        <Res_KW5>host/pathogen interaction</Res_KW5>
        <Plain_Description>To thrive, bacterial pathogens infecting humans require access to high quality nutrients, but our understanding of pathogen nutrition is limited. We will examine how virulence of the respiratory pathogen Haemophilus influenzae (NTHi) is determined by nutrient availability in the human respiratory tract and how the presence of NTHi changes the way human cells detect infection. The project will identify targets for the development of novel types of antimicrobials that starve NTHi of key nutrients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019079</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Lindsea Booth</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Shedding new light on vagal nerve stimulation</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$853,380.10</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | autonomic nervous system  | </Fields_of_Research>
        <Res_KW1>vagus nerve </Res_KW1>
        <Res_KW2>autonomic nervous system</Res_KW2>
        <Res_KW3>parasympathetic nervous system</Res_KW3>
        <Res_KW4>inflammation</Res_KW4>
        <Res_KW5>septic shock</Res_KW5>
        <Plain_Description>Inflammation is a complex response to injury and overactivation of inflammation can lead to damage to the host. Stimulating the vagus nerve (VNS) is known to have powerful anti-inflammatory effects but the mechanisms are not well understood. We will use cutting-edge molecular tools in a pre-clinical model of inflammation to allow us to selectively target branches of the vagus nerve going to specific organs and will determine the contribution of each organ to the anti-inflammatory effect of VNS.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019087</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Mark Larsen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Interrupting suicides in public places: Using CCTV to understand, detect, and respond to behaviours prior to a suicide attempt</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$839,422.65</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>suicide prevention </Res_KW1>
        <Res_KW2>suicide</Res_KW2>
        <Res_KW3>image analysis</Res_KW3>
        <Res_KW4>artificial neural networks</Res_KW4>
        <Res_KW5>intervention</Res_KW5>
        <Plain_Description>Suicide is a leading cause of death, and 30% of all suicides occur in public places. Despite this frequency, we lack an understanding of the key behaviours people exhibit prior to a suicide attempt in different public settings, and we lack the tools to identify these behaviours at the scale needed for those responsible for those public sites to meaningfully respond. This project will characterise, detect, and respond to behaviours which precede suicide attempts in public places in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019093</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jennifer Flegg</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Improving estimates of antimalarial drug resistance</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$866,114.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>mathematical sciences | statistics | time series and spatial modelling | mathematical sciences | statistics | applied statistics  | </Fields_of_Research>
        <Res_KW1>applied statistics </Res_KW1>
        <Res_KW2>mathematical modelling</Res_KW2>
        <Res_KW3>disease modelling</Res_KW3>
        <Res_KW4>drug resistance</Res_KW4>
        <Res_KW5>falciparum malaria</Res_KW5>
        <Plain_Description>Antimalarial drugs are essential for the elimination of malaria. Resistance to all currently available antimalarials, including the pivotal artemisinin derivatives, has emerged and is spreading. This project aims to generate the first data-driven, predictive maps of the changing landscape of artemisinin resistance in Asia. These maps fill in the gaps where no information is available and can be used by health agencies to guide new polices about where and when the drug is appropriate to use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019097</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Brendon Chua</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A metabolic enzyme as a target for controlling tumourigenesis</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,131,088.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | innate immunity | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>macrophages </Res_KW1>
        <Res_KW2>cd8 t cells</Res_KW2>
        <Res_KW3>t cell immunity</Res_KW3>
        <Res_KW4>lipid metabolism</Res_KW4>
        <Res_KW5>cancer control</Res_KW5>
        <Plain_Description>Cancer is the leading cause of death in Australia and globally. The majority of cancers are associated with metabolic alterations in tumours. We have identified a key role for an enzyme involved in fatty acid metabolism which impairs immune responses involved in tumour-control and drives cancer. This research aims to investigate key mechanisms of how this enzyme promotes tumour progression and establish the development of inhibitors of this enzyme that can be applied to different cancers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019100</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Thiruma Valavan Arumugam</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Finding Biomarkers and Treatments for Vascular Dementia</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,229,540.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>vascular dementia </Res_KW1>
        <Res_KW2>neuroinflammation</Res_KW2>
        <Res_KW3>mild cognitive impairment</Res_KW3>
        <Res_KW4>neuronal cell death</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Vascular dementia (VaD) occurs as a result of brain hypoperfusion and represents the second most common type of dementia after Alzheimer's disease. Currently, no specific treatments for VaD exist due to incomplete understanding of the underlying pathophysiology. We are studying inflammasomes as a new therapeutic target to treat VaD. In the next 5 years, this project expects to discover translatable preclinical targets and therapies to treat VaD, and novel biomarkers to diagnosis VaD in humans.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019101</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Stacey Edwards</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Combining genetics and genomics to tackle ovarian cancer.</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,129,198.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>molecular biology </Res_KW1>
        <Res_KW2>cancer genetics</Res_KW2>
        <Res_KW3>rna</Res_KW3>
        <Res_KW4>chromatin</Res_KW4>
        <Res_KW5>ovarian cancer</Res_KW5>
        <Plain_Description>Recent studies have identified DNA markers within the human genome that are associated with an increased risk of ovarian cancer. Most of these markers are located in noncoding regions, therefore the key genes driving risk are not known. This proposal will identify the target genes at all ovarian cancer risk regions and assess gene function in cancer development. Understanding how DNA variation contributes to ovarian cancer will provide new avenues for future prevention or treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019139</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Brooke Pereira</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Repurposing the in-clinic PCSK9 inhibitor evolocumab to enhance Gemcitabine/Abraxane chemotherapy in pancreatic cancer guided by single-cell intravital imaging</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$532,570.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>cancer cell biology </Res_KW1>
        <Res_KW2>pancreatic cancer</Res_KW2>
        <Res_KW3>imaging</Res_KW3>
        <Res_KW4>cancer metastasis</Res_KW4>
        <Res_KW5>biosensor</Res_KW5>
        <Plain_Description>During pancreatic cancer development, cancer cells undergo metabolic rewiring in order to survive, grow and spread. This Ideas Grant will use advanced animal imaging and unique patient-derived pancreatic cancer specimens to explore targeting PCSK9 with drugs already in the clinic, in combination with chemotherapy. This new dual therapy could significantly improve treatment response in this devastating disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019152</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Angela Devine</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Multi-species malaria transmission modelling to inform policy decisions</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,041,498.87</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>economics | applied economics | health economics  | health sciences | epidemiology | epidemiological modelling | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>malaria transmission </Res_KW1>
        <Res_KW2>mathematical modelling</Res_KW2>
        <Res_KW3>economic evaluation</Res_KW3>
        <Res_KW4>malaria</Res_KW4>
        <Res_KW5>decision making</Res_KW5>
        <Plain_Description>Most malaria cases are caused by two parasite species. While many countries with malaria have both species, decisions about treatment and control of malaria rely on data and mathematical models on one species. Working with policy makers, we have built a novel model that includes both species. This model will explore how species interact and determine how to allocate money on strategies that will maximise health benefits, ensuring that we reach malaria elimination as quickly as possible.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019153</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Steven Kho</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The newly-discovered splenic Plasmodium reservoir as a target to reduce global malaria burden</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,564,455.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical microbiology | medical parasitology  | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>organ-specific</Res_KW2>
        <Res_KW3>genetics</Res_KW3>
        <Res_KW4>differential gene expression</Res_KW4>
        <Res_KW5>splenectomy</Res_KW5>
        <Plain_Description>We have recently discovered that the spleen is the major reservoir for malaria parasites in natural human malaria infections. There are significant concerns that this previously-unrecognised reservoir underlies the major challenges we face to eliminate this disease. We will use the world’s only collection of spleen and blood samples from untreated human infections, to study the splenic malaria reservoir, uncover its biology and identify new ways to improve malaria elimination strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019160</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Des Richardson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Pharmaceutical Development of Innovative "Trojan Horse" Anti-Cancer Agents that Inhibit Desmoplasia by Reprogramming Signalling</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$599,828.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences | </Fields_of_Research>
        <Res_KW1>pharmaceutical </Res_KW1>
        <Res_KW2>pharmaceutical treatment</Res_KW2>
        <Res_KW3>pharmaceutics</Res_KW3>
        <Res_KW4>molecular pharmacology</Res_KW4>
        <Res_KW5>anticancer drug action</Res_KW5>
        <Plain_Description>We discovered the new PPPT agents that reprogram Sonic Hedgehog Signalling to Inhibit Desmoplasia.    Another breakthrough is that these agents totally prevent myoglobin (Mb) oxidation, which was an issue with our clinically trialled agent, DpC    Underlining Innovation, no other drug currently available prevents deleterious Mb oxidation, targets the deadly "Triad of Death" (metastasis, Pgp resistance, primary tumour growth), and &amp; inhibits bidirectional oncogenic signalling that leads to desmoplasia</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019167</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Katharina Ronacher</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Oxidised Cholesterols as Key Regulators of Host Immunity to Tuberculosis</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,515,176.90</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | </Fields_of_Research>
        <Res_KW1>mycobacterium tuberculosis </Res_KW1>
        <Res_KW2>tuberculosis</Res_KW2>
        <Res_KW3>oxysterols</Res_KW3>
        <Res_KW4>granuloma</Res_KW4>
        <Res_KW5>bacterial respiratory diseases</Res_KW5>
        <Plain_Description>Despite available antibiotics we have failed to eradicate TB.  It is therefore critically important to elucidate the host immune factors that are required for effective containment of the bacteria that cause TB. We have identified that oxidised cholesterols play a critical role in attracting immune cells and containing the infection. This project will deliver further insights into this pathway which can ultimately be targeted with drugs to prevent the development of TB.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019196</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Sarah Spencer</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The Mental Health Impact of Childhood SARS-CoV-2</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$765,560.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | psychology | biological psychology  | social and affective neuroscience | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>sars-cov-2 </Res_KW1>
        <Res_KW2>brain development</Res_KW2>
        <Res_KW3>mental health</Res_KW3>
        <Res_KW4>depression</Res_KW4>
        <Res_KW5>amygdala</Res_KW5>
        <Plain_Description>Children have key differences in ACE2, the receptor by which SARS-CoV-2 enters host cells, that may make them especially vulnerable to lasting brain damage. We show that a single ACE2 inhibition in juvenile rats leads to lasting anxiety- and depressive-like behaviour and associated brain changes. We hypothesize these effects will be worse the younger COVID-19 occurs. We will reveal the potential for COVID-19 to critically impact children, changing the approach to child health in this pandemic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019231</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Margaret Sunde</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Firing up oncolytic vectors: viral based strategies to repurpose necroptosis</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$748,283.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | molecular medicine | biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>cell death </Res_KW1>
        <Res_KW2>tumour immunotherapy</Res_KW2>
        <Res_KW3>molecular virology</Res_KW3>
        <Res_KW4>herpes simplex virus (hsv)</Res_KW4>
        <Res_KW5>structural biology</Res_KW5>
        <Plain_Description>Necroptosis is an inflammatory form of cell death that could be harnessed to turn on the immune response and fight tumours. This research will study necroptosis signalling and adapt existing approved oncolytic viruses to deliver proteins that initiate necroptosis specifically within the tumour. Melanoma and colorectal cancer models will be used for proof-of-principle. These second-generation therapeutics could work in concert with existing immunotherapies to provide superior cancer control.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019254</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Briffa</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Size matters: ECM regulation in pregnancy success</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$646,541.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>mouse models </Res_KW1>
        <Res_KW2>developmental genetics</Res_KW2>
        <Res_KW3>implantation</Res_KW3>
        <Res_KW4>extracellular matrix</Res_KW4>
        <Res_KW5>placentation</Res_KW5>
        <Plain_Description>Complications affect ~15% of pregnancies. Appropriate regulation of cellular environment is required for correct implantation and placental formation, but disease will occur if it is defective. To diagnose and treat pregnancy complications we must first understand how implantation and the placenta form. This project will investigate mouse models with abnormal implantation and placental development. It will determine how and why disease occurs and investigate potential therapeutic interventions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019264</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Lipin Loo</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Novel Targeted Therapies for Chronic Pain</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,028,104.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>chronic pain </Res_KW1>
        <Res_KW2>pain mechanisms</Res_KW2>
        <Res_KW3>cell therapy</Res_KW3>
        <Res_KW4>targeted therapy</Res_KW4>
        <Res_KW5>gene silencing</Res_KW5>
        <Plain_Description>Using single cell sequencing technology, we have identified several drivers underlying spinal hyperexcitability in neuropathic pain. Here we will confirm our findings with new spatial technology that reconstructs the spinal anatomical map and assess the effectiveness of 1) boosting inhibition via cell transplants and 2) suppressing hyperexcitability via CRISPR.  Our work leverages new functional genomic technologies to rapidly deliver new safe, effective pain management approaches to the clinic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019271</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Pankaj Sah</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Neural circuits that control movement: from mice to humans</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,070,796.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>movement </Res_KW1>
        <Res_KW2>parkinson disease</Res_KW2>
        <Res_KW3>cellular nervous system</Res_KW3>
        <Res_KW4>neural pathways</Res_KW4>
        <Res_KW5>neural regulation</Res_KW5>
        <Plain_Description>Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting nearly 1% of individuals older than 60, one of the fastest growing neurological disorders, generating a substantial burden patients, and caregivers, with the total cost to the community in excess of $10 billion / year. Many patients with PD  develop Freezing of gait. This grant aim to understand what causes freezing of gait in PD and  new ways treat the effects of PD on gait and movement.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019296</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Deborah Marsh</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>An Achilles’ heel of ovarian cancer: targeting ARID1A mutant tumours</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,199,273.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>cancer biology </Res_KW1>
        <Res_KW2>cancer cell biology</Res_KW2>
        <Res_KW3>ovarian cancer</Res_KW3>
        <Res_KW4>gynaecological cancers</Res_KW4>
        <Res_KW5>molecular biology</Res_KW5>
        <Plain_Description>Five-year survival for most women with ovarian cancer is poor, with drug resistance a major problem, especially once relapsed. Outcomes are particularly dismal for the sub-type ovarian clear cell carcinoma that is particularly drug resistant. We are looking beyond the DNA to the “epigenome” to target factors involved in changing the landscape of DNA in order to identify new therapies to treat ovarian cancer, overcome chemoresistance and extend the lives of women with this malignancy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019329</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Samantha Ginn</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Exploiting the gene transfer synergies of AAV and LNP to achieve highly efficient genome editing in the human liver</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,350,007.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </Fields_of_Research>
        <Res_KW1>gene delivery </Res_KW1>
        <Res_KW2>adeno-associated virus</Res_KW2>
        <Res_KW3>liver disease</Res_KW3>
        <Res_KW4>hepatocytes</Res_KW4>
        <Res_KW5>messenger rna (mrna)</Res_KW5>
        <Plain_Description>Genome editing is set to revolutionise the face of modern medicine. This project will develop a cutting-edge genome editing treatment carefully designed for therapeutic readiness. The team will exploit privileged access to explanted patient and donor livers as well as elite gene delivery systems to advance an innovative approach that will provide the foundations for a future clinical trial in children with severe and potentially fatal urea cycle disorders without further preclinical studies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019352</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stavros Selemidis</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A therapeutic solution for respiratory RNA viruses that corrects the patient’s TLR7-dependent inflammatory response</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,448,333.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>toll-like receptors </Res_KW1>
        <Res_KW2>acute inflammation</Res_KW2>
        <Res_KW3>acute lung injury</Res_KW3>
        <Res_KW4>influenza virus</Res_KW4>
        <Res_KW5>sars-cov-2</Res_KW5>
        <Plain_Description>Respiratory virus infections such as COVID-19 and influenza cause mild to severe complications in humans, often resulting in patient death. With limitations in current treatments, there is an urgent need for novel therapeutics to combat these and other viruses. We propose a drug strategy that attacks a critical point in the viral pathogenesis process. With the knowledge of this control point, we developed a drug and will evaluate its efficacy for treating COVID-19, influenza and the common cold.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019360</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Hamish King</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Gene regulatory mechanisms by autoimmune risk loci in primary human cells</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,499,871.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genome structure and regulation | biological sciences | genetics | genetic immunology  | biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>functional genomics </Res_KW1>
        <Res_KW2>gene regulation</Res_KW2>
        <Res_KW3>complex genetic disease</Res_KW3>
        <Res_KW4>autoimmune disease</Res_KW4>
        <Res_KW5>b cells</Res_KW5>
        <Plain_Description>The genetic causes of autoimmune disease (where the immune system attacks our own body) are poorly understood. While many small changes in patient DNA are linked with autoimmunity, for more than 90% of these mutations we do not know which genes or cells are affected. We will discover the genes controlled by autoimmune-specific DNA changes and how they disrupt immune cell function. This will discover how autoimmune diseases develop and provide information needed to develop new treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019361</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Yanchuan Shi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The Role of Salt in Obesity Development</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$860,943.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biological sciences | biochemistry and cell biology | cell metabolism | </Fields_of_Research>
        <Res_KW1>hypothalamus </Res_KW1>
        <Res_KW2>neuropeptide y (npy)</Res_KW2>
        <Res_KW3>dietary salt</Res_KW3>
        <Res_KW4>energy balance</Res_KW4>
        <Res_KW5>obesity</Res_KW5>
        <Plain_Description>Modern diets high in sugar and fat have contributed significantly to the prevalence of obesity. However, tackling obesity by lowering dietary fat content in our diets has not succeeded to the degree that we expected. As a result, obesity is on the rise. Recently, my team has discovered that high salt intake, often present in a high fat diet, could be a key and overlooked factor that potentially contributes to the development and progression of obesity, especially combined with high fat feeding.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019372</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stefan Thor</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Developing an in vitro human sleep system</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$599,036.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>neurodevelopment </Res_KW1>
        <Res_KW2>neurodevelopmental disorders</Res_KW2>
        <Res_KW3>gene regulation</Res_KW3>
        <Res_KW4>hypothalamus</Res_KW4>
        <Res_KW5>sleep</Res_KW5>
        <Plain_Description>This project aims to understand the formation of cells in the brain that are critical for controlling sleep. These sleep neurons are often affected in sleep disorders such as narcolepsy, a condition involving sudden attacks of sleep that affects 1/2,000 humans. By understanding how sleep neurons develop within the brain we will be able to generate sleep neurons from stem cells. This will pave the way for future bench-to-clinic transplantation experiments to alleviate narcolepsy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019383</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Anai Gonzalez Cordero</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Stimulating Biomimetic Neuroplasticity to Develop New Cell Therapy for Blindness.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$790,265.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | vision science | </Fields_of_Research>
        <Res_KW1>stem cell transplantation </Res_KW1>
        <Res_KW2>vision loss</Res_KW2>
        <Res_KW3>photoreceptors</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>neuroplasticity</Res_KW5>
        <Plain_Description>The loss of light-sensing photoreceptors is a leading cause of blindness. Severe cases have no treatments, and we thus aim to develop effective cell therapy by transplantation of photoreceptors to restore vision. We can generate millions of these cells from stem cell generated mini-retinas (organoids), but transplantation outcomes are still ineffective. Here we will test whether electrical stimulation improves photoreceptor transplantation in animal models to rescue sight and treat blindness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019404</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Vaughan Macefield</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Microelectrode recordings from the vagus nerve in awake humans</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,246,924.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | autonomic nervous system  | </Fields_of_Research>
        <Res_KW1>vagus nerve </Res_KW1>
        <Res_KW2>parasympathetic nervous system</Res_KW2>
        <Res_KW3>microneurography</Res_KW3>
        <Res_KW4>baroreceptors</Res_KW4>
        <Res_KW5>orthostatic hypotension</Res_KW5>
        <Plain_Description>The vagus nerve is an important nerve that controls the heart, lungs and gut. It exits the brain and travels with the carotid arteries and jugular veins in the neck. As such it has defied direct investigation in humans, but here we have developed a means of inserting metal microelectrodes into this nerve and recording signals going to and from the brain. This approach promises to provide much needed information on how the organ control provided by the vagus nerve is affected in disease states.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019416</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Nathalie Dehorter</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The Neurokinin 3 Receptor is a New Target for the Treatment of Autism Spectrum Disorder.</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$996,128.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>autism </Res_KW1>
        <Res_KW2>neuron</Res_KW2>
        <Res_KW3>neuropeptides</Res_KW3>
        <Res_KW4>brain development</Res_KW4>
        <Res_KW5>electrophysiology</Res_KW5>
        <Plain_Description>No treatment has been shown to be effective in treating the core symptoms of autism spectrum disorder. We have discovered a molecule, named NK3R, which plays a key role in the development of autism. Studying how this molecule works in mouse models of autism will help us to better understand the disorder and enable us to identify the signs of abnormal brain function. The outcomes of this 4-year research will ultimately enable us to propose new strategies to treat the symptoms of autism.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019420</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Harman</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Human anogenital mononuclear phagocytes in tranmission of HIV</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$802,780.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>cellular immunology</Res_KW2>
        <Res_KW3>dendritic cell</Res_KW3>
        <Res_KW4>flow cytometry</Res_KW4>
        <Res_KW5>confocal microscopy</Res_KW5>
        <Plain_Description>Dendritic cells (DC) are the first cells to interact with HIV and the program has discovered three that transmit the virus. This proposal will define the receptors these DCs use to bind HIV and how they activate the immune system which is important information for vaccine design. Using new technologies that the research program has pioneered, the proposal will also define how HIV transmission occurs in human inflamed tissue for the first time which will lead to better prophylactic treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019437</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Christine Chaffer</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting phenotypic plasticity to treat chemotherapy-resistant cancer</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$929,996.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </Fields_of_Research>
        <Res_KW1>breast cancer metastases </Res_KW1>
        <Res_KW2>cancer treatment</Res_KW2>
        <Res_KW3>cancer cell biology</Res_KW3>
        <Res_KW4>cancer chemotherapy</Res_KW4>
        <Res_KW5>epithelial-mesenchymal transition (emt)</Res_KW5>
        <Plain_Description>Some cancer cells are very aggressive. Those cells are the reason why cancers become resistant to chemotherapy. If we can eradicate the aggressive cells we can improve survival outcomes for patients. We have identified a new target, SULF1, that is required for cancer cells to be aggressive and evade chemotherapy.  We now aim to show that by targeting SULF1 we can stop cancers from spreading and make them susceptible to chemotherapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019442</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Elizabeth Westrupp</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Improving parent and child emotion regulation in early childhood to reduce population rates of child mental illness</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,392,462.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>psychology | applied and developmental psychology | applied and developmental psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>parenting </Res_KW1>
        <Res_KW2>mental health promotion</Res_KW2>
        <Res_KW3>child development</Res_KW3>
        <Res_KW4>community intervention study</Res_KW4>
        <Res_KW5>child behaviour</Res_KW5>
        <Plain_Description>The project develops and trials a new smartphone intervention that will radically redesign models for parenting support and the prevention of child mental illness. We aim to engage both mothers and fathers of children 2-4 years, and will optimise parent and child outcomes: (a) tailoring parenting resources to be relevant to specific parenting situations; (b) including Indigenous-led, culturally-derived content; and (c) using machine learning to personalise the delivery of 3 types of support.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019447</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr ALI MOTAZEDIAN</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding clonal hierarchy and tissue reconstitution post injury</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$691,296.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>experimental haematology </Res_KW1>
        <Res_KW2>adult stem cells</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>plasticity</Res_KW4>
        <Res_KW5>t cell development</Res_KW5>
        <Plain_Description>Millions of blood cells are made by the body every day in specialised organ compartments. T-cells are white blood cells and make up an important part of the immune system that fights infections and cancer. In this study, we aim to find out how blood stem cells turn into T-cells as they move through different organ compartments. We are trying to understand how the blood system is regenerated after damage from cancer therapies by stem cell transplants to improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019455</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jessica Frith</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing the therapeutic potential of mesenchymal stromal cells by priming via surface microtopographies</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$836,365.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | engineering | biomedical engineering | biomaterials  | </Fields_of_Research>
        <Res_KW1>cell therapy </Res_KW1>
        <Res_KW2>autocrine/paracrine regulation</Res_KW2>
        <Res_KW3>biomaterials</Res_KW3>
        <Res_KW4>nanotechnology</Res_KW4>
        <Res_KW5>biomedical engineering</Res_KW5>
        <Plain_Description>Mesenchymal stromal cells (MSCs) promote tissue repair, but lose their beneficial properties during the production process outside the body. We have found that culturing MSCs on surfaces with microscale patterns alters their properties. We will investigate how these surfaces improve the therapeutic activity of MSCs and develop a technology to allow this to be done at a large scale. Our discoveries will enable higher quality MSCs to be produced for therapies for a wide range of diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019477</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Carsten Schmitz-Peiffer</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Developing PKCepsilon-Degrading PROTACs as Dual-Action Agents to Treat Type 2 Diabetes</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$825,490.65</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>medicinal chemistry </Res_KW1>
        <Res_KW2>protein kinase c (pkc)</Res_KW2>
        <Res_KW3>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW3>
        <Res_KW4>drug design</Res_KW4>
        <Res_KW5>ubiquitin-mediated proteolysis</Res_KW5>
        <Plain_Description>Type 2 diabetes (T2D) is reaching epidemic proportions worldwide, and involves poor insulin production and decreased insulin sensitivity. This  collaboration between diabetes researchers and medicinal chemists will translate basic science, demonstrating that inhibiting one enzyme can improve both these defects, into the generation of lead compounds that block this target. We will test inhibitors in models of T2D, providing  proof-of-principle for their further development.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019488</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Gregory Monteith</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A calcium influx pathway regulates adaptive cancer drug tolerance</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$690,303.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacology and pharmaceutical sciences not elsewhere classified | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </Fields_of_Research>
        <Res_KW1>molecular pharmacology </Res_KW1>
        <Res_KW2>pharmacology</Res_KW2>
        <Res_KW3>calcium signalling</Res_KW3>
        <Res_KW4>calcium imaging</Res_KW4>
        <Res_KW5>calcium channels</Res_KW5>
        <Plain_Description>New drugs for the treatment of melanoma, lung and other cancers has revolutionised therapeutic approaches for many patients. However, in many cases, cancers become tolerant and eventually completely resistant to these new therapies. This project team has identified a specific new drug target that may hold the key to preventing or reversing the tolerance to these therapies. This grant will focus on defining the therapeutic opportunities that this new drug target offers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019492</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Leann Tilley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Hijacking enzymes that charge tRNAs: a new strategy for development of anti-malarials.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$758,942.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | enzymes | biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>infectious diseases </Res_KW1>
        <Res_KW2>medical parasitology</Res_KW2>
        <Res_KW3>antimalarial</Res_KW3>
        <Res_KW4>antimicrobial resistance</Res_KW4>
        <Res_KW5>structural biology</Res_KW5>
        <Plain_Description>New drugs are desperately needed to treat drug-resistant pathogens. We have discovered a class of inhibitor molecules, called “nukes”, that target enzymes powered by the energy molecule, ATP. “Nukes” induce the enzymes to generate their own inhibitors, via a mechanism that we call “reaction hijacking”. This project will investigate the design principles for making bespoke “nukes”, which will have applications in curing malaria, as well as infections with antimicrobial resistant bacteria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019552</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Zaklina Kovacevic</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Unlocking the potential of cancer associated fibroblasts to defeat pancreatic cancer.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$636,920.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>pancreatic cancer </Res_KW1>
        <Res_KW2>fibroblasts</Res_KW2>
        <Res_KW3>cell metabolism</Res_KW3>
        <Res_KW4>cancer chemotherapy</Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>There are key knowledge gaps in understanding the complex metabolism of the pancreatic cancer tumour microenvironment and how this influences poor response to current therapies. My research will directly address this by characterizing how the pancreatic cancer tumour microenvironment evolves as cancer progresses and its response to current therapies. This will inform development of more effective treatment strategies that can overcome resistance and improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019558</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Margaret Hibbs</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Dysregulated lymphatic vasculature in the pathogenesis of bronchopulmonary dysplasia</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,490,644.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | </Fields_of_Research>
        <Res_KW1>bronchopulmonary dysplasia </Res_KW1>
        <Res_KW2>lymphangiogenesis</Res_KW2>
        <Res_KW3>angiogenesis</Res_KW3>
        <Res_KW4>lung development</Res_KW4>
        <Res_KW5>vascular endothelium</Res_KW5>
        <Plain_Description>Bronchopulmonary dysplasia is a severe lung disease that is a main cause of disability and death in premature infants and there is no cure. We have found that a factor that enhances the growth of lung lymphatic vessels, essential fluid channels, protects the lung from structural and functional damage. We will used advanced research methods to define the role of these vessels in this disease to turn our discovery into new treatments that can help these tiny lungs develop and function normally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019572</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Michelle Tate</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting pyroptosis to limit the severity of influenza virus infections</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,062,685.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>influenza virus </Res_KW1>
        <Res_KW2>host/pathogen interaction</Res_KW2>
        <Res_KW3>inflammation</Res_KW3>
        <Res_KW4>immunomodulation</Res_KW4>
        <Res_KW5>innate immunity</Res_KW5>
        <Plain_Description>Highly pathogenic influenza A virus infections are associated with highly mortality rates. To facilitate the development of improved treatments for severe IAV infections, this project will advance our fundamental knowledge of the mechanisms by which the host and virus interact and elucidate how the host's immune system can be therapeutically modulated to limit disease severity. These studies are crucial to ensure we are better prepared for the next pandemic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019595</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Tamar Sztal</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The role of genetic compensation in modifying disease severity and potential therapeutic application</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$640,308.90</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>developmental biology </Res_KW1>
        <Res_KW2>developmental genetics</Res_KW2>
        <Res_KW3>transcriptional regulation</Res_KW3>
        <Res_KW4>disease modelling</Res_KW4>
        <Res_KW5>zebrafish</Res_KW5>
        <Plain_Description>Harmful mutations in the genome have significant impacts on health and survival. Recent studies have identified individuals with mutations, that are expected to cause disease, yet they are remarkably asymptomatic. Growing evidence suggests this is due to compensatory activation of other genes, masking the effects of damaging mutations. This project examines the trigger for this compensation to determine its relevance in preventing disease and potential use in genetic therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019655</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Dineika Chandrananda</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Tracking transcriptional evolution in breast cancer using circulating tumour DNA</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$663,211.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies | </Fields_of_Research>
        <Res_KW1>solid tumours </Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>gene expression</Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>Tumours shed small amounts of DNA into the patient’s bloodstream. Therefore, a simple blood test gives us a window to study the cancer, offering a non-invasive alternative to tissue biopsies. This project will use circulating tumour DNA in blood to study how cancer evolves and becomes resistant to treatment in advanced breast cancer where only 25% of patients survive beyond five years. Our method is generalisable across tumour types and has the potential to transform real-time cancer monitoring.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019670</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Matthew Page</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Novel methods to improve reporting and peer review of systematic reviews of health evidence</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$552,225.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | epidemiology | epidemiological methods | mathematical sciences | statistics | biostatistics | </Fields_of_Research>
        <Res_KW1>meta-analysis </Res_KW1>
        <Res_KW2>evidence-based</Res_KW2>
        <Res_KW3>methodology</Res_KW3>
        <Res_KW4>guidelines</Res_KW4>
        <Res_KW5>intervention study</Res_KW5>
        <Plain_Description>Systematic reviews focus on the totality of available evidence on a given question, and often underpin healthcare decision making. However, the reporting of many systematic reviews is suboptimal. This amounts to wasted research effort, and systematic reviews that cannot reliably inform clinical and public health guidelines. This proposal will develop guidance and web apps to help researchers produce systematic reviews that better meet the needs of stakeholders, hence improving health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019689</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Catherine Satzke</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>On target and on time, advancing molecular diagnosis of complicated childhood pneumonia for better patient outcomes and vaccine strategies</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,133,729.65</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | </Fields_of_Research>
        <Res_KW1>pneumonia </Res_KW1>
        <Res_KW2>streptococcus pneumoniae</Res_KW2>
        <Res_KW3>molecular diagnosis</Res_KW3>
        <Res_KW4>antibiotics</Res_KW4>
        <Res_KW5>vaccine</Res_KW5>
        <Plain_Description>During pleural infection fluid pools in the lung. Identifying the bacterial cause is important, so children can receive the right antibiotics. Our new laboratory test can better identify bacteria than traditional methods. We will use our test to determine which bacteria are causing pleural infection in Asian children and how our test will improve clinical care. We will apply other molecular methods to determine how many cases could be prevented by pneumococcal vaccines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019722</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Carsten Schmitz-Peiffer</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting Impaired Glucose Sensing in the Brain to Improve Glucose Homeostasis in T2D</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$961,576.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>hypothalamus </Res_KW1>
        <Res_KW2>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW2>
        <Res_KW3>obesity</Res_KW3>
        <Res_KW4>protein kinase c (pkc)</Res_KW4>
        <Res_KW5>molecular neuroscience</Res_KW5>
        <Plain_Description>New drugs working in novel ways are needed to treat type 2 diabetes, because current treatments fail to prevent the progression of the disease. We showed that an enzyme, PKCe, interferes with the the sensitivity of the brain to glucose, so that it fails to respond to rising glucose levels. We will investigate how this enzyme prevents the brain from controlling blood glucose levels, and will also test whether blocking PKCe is able to improve glucose sensing, paving the way for drug development.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019729</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Pouya Faridi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Determination of “actionable vaccine targets” for breast cancer immunotherapy</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,377,141.75</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - proteins and peptides (incl. medical proteomics) | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>proteomics </Res_KW1>
        <Res_KW2>human leukocyte antigen (hla)</Res_KW2>
        <Res_KW3>antigen presentation</Res_KW3>
        <Res_KW4>breast cancer</Res_KW4>
        <Res_KW5>cancer immunotherapy</Res_KW5>
        <Plain_Description>In recent years, immunotherapy brings hopes for treatment of incurable cancer. However, understanding the right target for immunotherapy is critical and challenging. We have developed new technologies and will explore new classes of antigens that can form targets of vaccines and immunotherapy in breast cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019765</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Ana Traven</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing metabolism to improve the outcomes of deadly fungal infections</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$955,684.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | mycology  | </Fields_of_Research>
        <Res_KW1>mycology </Res_KW1>
        <Res_KW2>medical mycology</Res_KW2>
        <Res_KW3>candida</Res_KW3>
        <Res_KW4>fungal infection</Res_KW4>
        <Res_KW5>fungal pathogenesis</Res_KW5>
        <Plain_Description>Life-threatening infections are complications of surgery, chemotherapy and organ transplantations. Therapies are limited and mortality is high. This project studies how metabolic adaptations could be harnessed to provide energy for effective immune responses and maintaining the function of vital organs during life-threatening fungal infection. We expect that the knowledge gained in this project will inform therapeutic innovations aimed at improving patient survival of serious fungal infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019767</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Martina Sanderson-Smith</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Characterising a novel toxin regulatory mechanism from the new hypervirulent Streptococcal pyogenes M1uk lineage in Australia</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,058,650.97</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>streptococcus pyogenes </Res_KW1>
        <Res_KW2>group a streptococcal disease</Res_KW2>
        <Res_KW3>bacterial pathogenesis</Res_KW3>
        <Res_KW4>bacterial virulence factors</Res_KW4>
        <Res_KW5>bacterial toxins</Res_KW5>
        <Plain_Description>Group A Streptococcus (GAS) is a strictly human pathogen that ranks among the top 10 infectious disease killers. A new variant of GAS expressing a novel set of bacterial toxins has emerged in the United Kingdom, known as M1UK.  The M1UK  lineage is associated with increases in invasive disease. We have now detected that this new GAS M1UK lineage has arrived in Australia. This proposal will define the disease mechanisms underlying this new health threat to Australian and global health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019780</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Philip Ahring</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>GABA-A receptor variants in developmental and epileptic encephalopathy: a bench to bedside approach.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,240,955.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacogenomics | </Fields_of_Research>
        <Res_KW1>intractable epilepsy syndromes </Res_KW1>
        <Res_KW2>gamma-aminobutyric acid (gaba) receptors</Res_KW2>
        <Res_KW3>antiepileptic drugs</Res_KW3>
        <Res_KW4>genetic analysis</Res_KW4>
        <Res_KW5>pharmacological intervention</Res_KW5>
        <Plain_Description>Developmental epileptic encephalopathies (DEE) are a group of severe brain disorders characterised by childhood seizures that are often treatment resistant. We identified that hyperactivity in GABA-A receptors (the major inhibitory protein of the brain) caused by novel mutations are responsible for treatment resistant DEE. With a team of scientists, geneticists, and neurologists we aim to decipher the role of these receptors in brain networks and translate our discoveries to the clinic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019804</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Christopher Reid</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Testing a preventative strategy for sudden unexpected death in epilepsy (SUDEP) in mouse models based on human genetics</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$917,002.71</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | neurosciences | central nervous system  | biological sciences | genetics | neurogenetics | </Fields_of_Research>
        <Res_KW1>epilepsy </Res_KW1>
        <Res_KW2>cardiac arrhythmia</Res_KW2>
        <Res_KW3>ion channels</Res_KW3>
        <Res_KW4>electrophysiology</Res_KW4>
        <Res_KW5>sudden death</Res_KW5>
        <Plain_Description>What causes sudden unexpected death in epilepsy (SUDEP) in unclear, although irregular heart rhythm is suspected to play a role. We recently found that genetic changes in the heart could help identify epilepsy patients who are at higher risk of SUDEP. By introducing these genetic changes in research models, we can understand how the heart responds in events leading up to SUDEP, and if improving heart function with currently available therapies can reduce SUDEP risk.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019818</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Xin-Ming Chen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Inspire the bright side of kidney fibroblasts to prevent and cure chronic kidney disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$895,653.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>renal fibrosis </Res_KW1>
        <Res_KW2>fibroblasts</Res_KW2>
        <Res_KW3>drug delivery</Res_KW3>
        <Res_KW4>tissue regeneration</Res_KW4>
        <Res_KW5>cell therapy</Res_KW5>
        <Plain_Description>Chronic kidney disease (CKD) is a worldwide public health problem. Current clinical strategies for CKD are largely ineffective. Kidney transplantation and dialysis are the only options for the management of end stage kidney disease (ESKD), which results in a significant personal and societal burden. This project will innovatively promote the good function but hinder the bad role of kidney fibroblasts thereby conferring renal protection in CKD through targeting En-1 gene function.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019831</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Ms Hayley Williams</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Healing Spirit, Healing Minds: Co-designed healing program to promote social and emotional wellbeing of Aboriginal and Torres Strait Islander youth.</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$886,931.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social, emotional, cultural and spiritual wellbeing | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health promotion | indigenous studies | aboriginal and torres strait islander peoples, society and community | aboriginal and torres strait islander community-based research | </Fields_of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>aboriginal mental health</Res_KW2>
        <Res_KW3>mental health promotion</Res_KW3>
        <Res_KW4>community-based</Res_KW4>
        <Res_KW5>participatory action research</Res_KW5>
        <Plain_Description>The Healing Spirits, Healing Minds project will co-design and evaluate a healing program under the leadership of First Nations youth that are most at risk of suffering from undetected and under-supported suicidal ideations and behaviours. The resulting program is anticipated to incorporate peer mentorship with activities focused on 1) promoting empowerment and wellbeing, 2) building social connections, 3) facilitating emotional regulation, and 4) encouraging help seeking behaviours.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019843</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof David Croucher</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting metastatic pancreatic cancer via selective inhibition of oncogenic JNK</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$775,663.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>cell signalling </Res_KW1>
        <Res_KW2>cancer metastasis</Res_KW2>
        <Res_KW3>pancreatic cancer</Res_KW3>
        <Res_KW4>mouse models</Res_KW4>
        <Res_KW5>c-jun/jnk kinase</Res_KW5>
        <Plain_Description>Pancreatic cancer is one of the most lethal forms of human cancer. The current standard-of-care chemotherapies are known to be largely ineffective against advanced disease and new treatment options are urgently needed.    We have developed a novel drug (K12) that selectively inhibits the metastatic function of JNK in breast cancer, and shown that this oncogenic pathway is conserved in pancreatic cancer. We will now test the utility of our novel drug as a treatment for metastatic pancreatic cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019853</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Frederic Hollande</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Developing novel therapeutic strategies and predictive biomarkers in Pancreatic Cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,230,897.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>pancreatic cancer </Res_KW1>
        <Res_KW2>targeted therapy</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>signalling pathways</Res_KW4>
        <Res_KW5>dna barcoding</Res_KW5>
        <Plain_Description>Pancreatic cancers are frequent and have extremely poor outcomes. Very few treatments are available for patients with this disease. Candidate drugs have recently emerged to block specific genetic modifications found in this cancer, but tumour cells can often evade these treatments. Here, we will combine innovative genetic and cellular analyses to design specific drug combinations preventing the ability of pancreatic cancers to escape treatment and thus improving the treatment of this disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019859</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Natasa Gisev</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Identifying modifiable health and social determinants of 'deaths of despair': learning from the past to shape new interventions</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,027,327.70</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>avoidable deaths </Res_KW1>
        <Res_KW2>suicide</Res_KW2>
        <Res_KW3>drug utilisation</Res_KW3>
        <Res_KW4>data linkage</Res_KW4>
        <Res_KW5>health care utilisation</Res_KW5>
        <Plain_Description>Deaths of despair (due to alcohol, other substances, and suicide) have risen dramatically in Australia and globally over the last 20 years. These are avoidable deaths given timely and targeted intervention. Using population-based data linkage, novel machine learning methods, and mathematical modelling, we will examine risk factors, and model the impact of potential interventions to reduce deaths of despair to inform targeted strategies and policies to prevent these premature deaths occurring.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019867</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Yi Wang</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A new brain circuit of GPR75 to regulate metabolism</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$643,424.26</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical physiology | systems physiology  | </Fields_of_Research>
        <Res_KW1>overweight/obesity </Res_KW1>
        <Res_KW2>hypertension</Res_KW2>
        <Res_KW3>glucose homeostasis</Res_KW3>
        <Res_KW4>energy balance</Res_KW4>
        <Res_KW5>hypothalamus</Res_KW5>
        <Plain_Description>The increasing prevalence of obesity represents a major public health crisis worldwide. In Australia, almost two-thirds of adults are overweight or obese. GPR75 is a gene recently identified to play an important role in body weight regulation. Indeed, humans and mice carrying loss-of-function mutations of GPR75 are protected from obesity. This proposal will determine the specific site of action, and underlying mechanism of GPR75-induced protection against obesity, and its related hypertension.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019871</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Barry Slobedman</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Novel regulation of a fundamental host defence pathway by human herpesviruses</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$925,288.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>herpes simplex virus (hsv) </Res_KW1>
        <Res_KW2>cytomegalovirus (cmv) infection</Res_KW2>
        <Res_KW3>virus pathogenesis</Res_KW3>
        <Res_KW4>immune evasion</Res_KW4>
        <Res_KW5>viral infection</Res_KW5>
        <Plain_Description>Human cytomegalovirus (HCMV) and herpes simplex virus (HSV) often cause serious disease. Eg, HCMV is the leading infectious cause of birth defects and a major complication in transplant patients, and HSV causes cold sores that can be life-threatening in those with a compromised immune system. We have identified a novel way that these viruses can control the host response to infection. This research proposal will investigate this control to identify potential ways to control viral disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019889</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Kim Loh</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A novel therapeutic target for obesity: Salt-inducible kinase 3 (SIK3)</Grant_Title>
        <Admin_Institution>St Vincents Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$987,440.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical physiology | cell physiology | biological sciences | biochemistry and cell biology | systems biology | </Fields_of_Research>
        <Res_KW1>protein kinases </Res_KW1>
        <Res_KW2>energy metabolism</Res_KW2>
        <Res_KW3>cell metabolism</Res_KW3>
        <Res_KW4>energy expenditure</Res_KW4>
        <Res_KW5>thermogenesis</Res_KW5>
        <Plain_Description>The overconsumption of high calorie foods together with sedentary lifestyle are key reasons for the obesity epidemic. The brain plays an important role in controlling the amount of energy intake and expenditure. However, how the brain controls these physiological processes remain poorly understood. In this proposal, we aim to study a new molecule in the brain to control appetite and body weight and establish this molecule as a potential new therapeutic target for the treatment of obesity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019904</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Mathias Francois</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Endothelial origin of left ventricular non compaction</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,094,172.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>endothelial cells </Res_KW1>
        <Res_KW2>congenital heart disease</Res_KW2>
        <Res_KW3>transcription factor</Res_KW3>
        <Res_KW4>embryo development</Res_KW4>
        <Res_KW5>morphogenesis</Res_KW5>
        <Plain_Description>Primary cardiac myopathies refers to inheritable heart diseases, characterised by weak heart muscles. A common form of these disorders is left ventricular non-compaction (LVNC).  By enlarge our understanding of the cellular origin of these cardiac defects is still unknown. This proposal will investigate how defects in blood vessel formation during embryogenesis is a cause of LVNC. This work will help to risk-stratify patients with LVNC cardiac disease to better manage adverse outcome.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019912</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Samir Taoudi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding how platelets prevent fetal and neonatal stroke</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$744,803.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>platelets </Res_KW1>
        <Res_KW2>abnormal embryogenesis</Res_KW2>
        <Res_KW3>stroke prevention</Res_KW3>
        <Res_KW4>neonatal survival</Res_KW4>
        <Res_KW5>intracerebral haemorrhage</Res_KW5>
        <Plain_Description>Stroke is caused by either abnormal clotting or by unchecked bleeding; both result in devastating damage to the brain, causing death or life-long disability. Newborn children with low platelet numbers are at high risk of bleeding-associated stroke, yet we do not understand why. We hypothesize that the cause is rooted in early development. We will identify when these problems arise and define therapeutic strategies for the prevention or amelioration of neonatal stroke.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019920</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ellen Menkhorst</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Uncovering and detecting placental dysfunction in late-onset preeclampsia</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,222,195.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>placenta </Res_KW1>
        <Res_KW2>pregnancy complications</Res_KW2>
        <Res_KW3>hypertension</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>lipid metabolism</Res_KW5>
        <Plain_Description>Preeclampsia is a life-threatening disease of pregnancy with grave immediate and life-long consequences for the mother and baby. The root cause of preeclampsia is an unhealthy placenta which releases toxins into the maternal blood causing maternal organ damage. This project will identify early pregnancy biomarkers to detect women who are at risk of developing preeclampsia and discover the key molecular mechanisms which drive preeclampsia, leading to new preventative treatment options.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019925</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Nicolle Packer</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Metformin, gut epithelium and microbiome in the prevention of colorectal cancer</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$847,242.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | microbiology not elsewhere classified | biological sciences | biochemistry and cell biology | glycobiology | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>colorectal cancer </Res_KW1>
        <Res_KW2>molecular microbiology</Res_KW2>
        <Res_KW3>glycobiology</Res_KW3>
        <Res_KW4>proteome analysis</Res_KW4>
        <Res_KW5>neoplasia</Res_KW5>
        <Plain_Description>Prevention of colorectal cancer (CRC) saves lives. Metformin, a safe drug clinically used as an anti-diabetic therapy, has been shown to suppress cancer. Yet, its successful implementation as a CRC preventative is limited by a lack of knowledge on how metformin elicits these anti-cancer effects. Our project will provide a holistic understanding of how metformin impacts the colon lining, its microbiome and CRC development.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019931</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Kay Double</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The first tool to quantify brain copper during life</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,087,644.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | </Fields_of_Research>
        <Res_KW1>medical imaging </Res_KW1>
        <Res_KW2>positron emission tomography (pet)</Res_KW2>
        <Res_KW3>copper</Res_KW3>
        <Res_KW4>neurodegeneration</Res_KW4>
        <Res_KW5>parkinson disease</Res_KW5>
        <Plain_Description>Copper is essential for brain health but serious diseases result from either too much, or too little, copper in the brain. Unfortunately we do not have a method to measure brain copper levels.  This limits our ability to understand the role of copper in these disorders and to deliver safe, effective treatments to patients.  We are developing a technology to directly measure brain copper levels during life to solve these important problems.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019934</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr John Schjenken</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Novel determinants of male fertility carried by seminal fluid extracellular vesicles</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$899,842.25</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | reproduction  | biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>reproductive biology </Res_KW1>
        <Res_KW2>male reproduction</Res_KW2>
        <Res_KW3>sperm function</Res_KW3>
        <Res_KW4>reproductive immunology</Res_KW4>
        <Res_KW5>fertility</Res_KW5>
        <Plain_Description>A father's influence over reproductive outcome goes beyond the provision of sperm. Our research has shown that signals carried by seminal fluid influence the likelihood of conception and pregnancy, but the identity and regulation of these signals is unknown. This research will define novel drivers of fertility and expand our understanding of the biological events at conception. Ultimately, these findings will inform the development of therapeutics that address the rising burden of infertility.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019948</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Richard Young</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing a native corticosteroid-binding globulin to treat life-threatening septic shock</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,235,442.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified | </Fields_of_Research>
        <Res_KW1>glucocorticoids </Res_KW1>
        <Res_KW2>septic shock</Res_KW2>
        <Res_KW3>binding protein</Res_KW3>
        <Res_KW4>morbidity</Res_KW4>
        <Res_KW5>mortality</Res_KW5>
        <Plain_Description>Septic shock is a maladaptive response to overwhelming infection that leads to organ failure and death. Corticosteroid-binding globulin (CBG) is a blood protein with unique properties to deliver the body’s natural anti-inflammatory hormone, glucocorticoid, to threatened organs - but its excessive depletion in septic shock triples the risk of dying. Our experiments in mouse models of sepsis are important next steps towards the use of CGB therapy to prevent deterioration and death in patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019968</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Leszek Lisowski</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Developing Therapeutic Engineered Virus-Like Particles to Target Genetic Diseases of the Retina</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,094,135.32</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | medical biotechnology | medical molecular engineering of nucleic acids and proteins | biomedical and clinical sciences | ophthalmology and optometry | vision science | </Fields_of_Research>
        <Res_KW1>gene therapy </Res_KW1>
        <Res_KW2>lentiviral vector</Res_KW2>
        <Res_KW3>retinal disease</Res_KW3>
        <Res_KW4>molecular biology</Res_KW4>
        <Res_KW5>genetic engineering</Res_KW5>
        <Plain_Description>Inherited retinal disease is a leading cause of blindness among working-aged adults. Advances in diagnosis have identified mutations in genes which can cause these diseases. The project aims to develop and construct personalised gene therapy treatments for patients with inherited retinal diseases. The team will combine customised gene editing tools to fix their particular gene mutation together with a delivery system that specifically target the affected cell type.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019970</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Miriam Matamales</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The neural bases of inhibitory learning and disorders of action control</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$486,802.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | behavioural neuroscience | </Fields_of_Research>
        <Res_KW1>cognitive dysfunction </Res_KW1>
        <Res_KW2>basal ganglia</Res_KW2>
        <Res_KW3>striatum</Res_KW3>
        <Res_KW4>dopamine</Res_KW4>
        <Res_KW5>impulse control disorder</Res_KW5>
        <Plain_Description>Several mental disorders including Tourette syndrome and obsessive-compulsive disorder, share a common feature, that is, the repeated urge to engage in behavioural sequences that are counterproductive or damaging. This proposal will study the neural bases of naturally-occurring processes for behaviour change by which subjects learn to inhibit maladaptive actions. The findings will help develop effective therapeutic interventions that promote inhibitory learning in affected individuals.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019988</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David Lynn</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A human experimental model to assess whether the gut microbiota regulates specific and non-specific immune responses to vaccination</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,579,475.25</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | immunology not elsewhere classified | biological sciences | biochemistry and cell biology | systems biology | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>vaccine biology </Res_KW1>
        <Res_KW2>microbial ecology</Res_KW2>
        <Res_KW3>systems biology</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>vaccination immunology</Res_KW5>
        <Plain_Description>Our hypothesis is that the gut microbiota is a critical and targetable factor regulating specific and non-specific immune responses to vaccination. To assess this, we will investigate the impact of depleting the human gut microbiota on protection mediated by the BCG vaccine against microbes specifically targeted by the vaccine and unrelated infections. This study will lead to new interventions to maximise vaccine mediated protection in vulnerable populations worldwide.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019991</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Megan Galbally</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Transforming the management of perinatal depression through precision medicine to improve outcomes for women and children</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$630,913.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>antidepressants </Res_KW1>
        <Res_KW2>pharmacogenetics</Res_KW2>
        <Res_KW3>perinatal</Res_KW3>
        <Res_KW4>depression</Res_KW4>
        <Res_KW5>pregnancy</Res_KW5>
        <Plain_Description>Pharmacogenetics have increasingly been shown to be relevant to the understanding of outcomes associated with antidepressants. By using a study of 862 women, including 158 taking antidepressants in pregnancy, we propose to use a new novel approach to elucidate how better to manage depression in pregnancy for women and also predict vulnerability to adverse impacts for the infant following antidepressant exposure and whether this can be attributed to variation in pharmacogenetics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2019993</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Julia Pagan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Tuning mitophagy in mitochondrial diseases</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$684,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>ubiquitin-mediated proteolysis </Res_KW1>
        <Res_KW2>mitochondrial disease</Res_KW2>
        <Res_KW3>mitochondrial dynamics</Res_KW3>
        <Res_KW4>cell signalling</Res_KW4>
        <Res_KW5>autophagy</Res_KW5>
        <Plain_Description>The accumulation of damaged mitochondria is detrimental to cells and results in diseases. This fundamental research addresses how cells maintain a healthy mitochondrial population. We have discovered a pathway that maintains healthy mitochondrial numbers in cells. This pathway does not function properly in a devastating disease called mitochondrial DNA depletion disease. In this proposal, we seek to determine strategies to restore mitochondrial function in this disease.    </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020010</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Vivek Gupta</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Let there be light- Modified Serpin as a Dual Function Therapeutic Agent in Glaucoma</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,186,771.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | vision science | </Fields_of_Research>
        <Res_KW1>glaucoma </Res_KW1>
        <Res_KW2>biochemistry</Res_KW2>
        <Res_KW3>mouse models</Res_KW3>
        <Res_KW4>neurodegenerative disorders</Res_KW4>
        <Res_KW5>apoptosis</Res_KW5>
        <Plain_Description>Glaucoma causes blindness and despite our best treatment many patients continue to progress. A new and innovative approach is needed to protect the cells that die in the retina. We have engineered a protease inhibitor – neuroserpin – a protein that is deactivated in the disease. We aim to deliver this molecule to retinal cells using an “artificial virus” approach and determine its usefulness as a novel and innovative therapy in glaucoma.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020020</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Katrina Moss</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A novel approach to reducing the psychosocial burden of infertility treatment</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$652,078.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | reproduction  | psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>in vitro fertilisation (ivf) </Res_KW1>
        <Res_KW2>psychosocial</Res_KW2>
        <Res_KW3>coping techniques</Res_KW3>
        <Res_KW4>social support</Res_KW4>
        <Res_KW5>behavioural intervention</Res_KW5>
        <Plain_Description>One in six Australian couples experience infertility. Up to 75% of patients will report anxiety or depression during reproductive treatment, but less than 20% will receive mental health support. This research will generate new evidence on how coping, social support and mood change across an in vitro fertilization cycle (IVF). It will produce an online coping intervention for patients and information resources for partners and families, leading to better mental health outcomes after IVF.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020035</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Antonio Di Ieva</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Computational analysis and Artificial Intelligence in brain tumour imaging: towards the augmented diagnostics of the future</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,556,663.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | surgery | health sciences | health services and systems | digital health | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>brain tumours </Res_KW1>
        <Res_KW2>magnetic resonance imaging (mri)</Res_KW2>
        <Res_KW3>artificial neural networks</Res_KW3>
        <Res_KW4>neurosurgery</Res_KW4>
        <Res_KW5>connectivity</Res_KW5>
        <Plain_Description>This work will apply computer models, including Artificial Intelligence techniques, to augment expert diagnosis of brain tumours with the aim of better predicting patients’ prognosis, optimising their treatment and thereby improving their outcomes. By the end of this research, a new diagnostic paradigm will be in place: computers will help clinicians and surgeons in their decision-making to ensure the best treatment of patients affected by brain tumours, throughout their journey.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020050</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Karen Sheppard</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A Fat Chance for Melanoma</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,173,377.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>cutaneous melanoma </Res_KW1>
        <Res_KW2>targeted therapy</Res_KW2>
        <Res_KW3>map kinases</Res_KW3>
        <Res_KW4>cell signalling</Res_KW4>
        <Res_KW5>cancer immunology</Res_KW5>
        <Plain_Description>Recently a study in melanoma patients showed that overweight patients did much better on treatment than normal weight patients. This project aims to understand how body fat makes melanoma patients more responsive to therapy. By understanding the biological basis for this association, we can design new therapeutic strategies that will improve the outcomes for melanoma patients and not lead to adverse health effects associated with being overweight.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020077</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Bennet McComish</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Using genomic signatures of natural selection to elucidate the genetic architecture of multiple sclerosis</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$764,770.65</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biological sciences | evolutionary biology | biological adaptation | </Fields_of_Research>
        <Res_KW1>multiple sclerosis (ms) </Res_KW1>
        <Res_KW2>population genetics</Res_KW2>
        <Res_KW3>adaptation</Res_KW3>
        <Res_KW4>complex genetic disease</Res_KW4>
        <Res_KW5>disease prevalence</Res_KW5>
        <Plain_Description>Multiple sclerosis (MS) is more common in people of European descent, and more common further from the equator. It is likely that this pattern has been shaped by natural selection. Identifying genes that increase MS risk and have experienced natural selection will improve our understanding of what causes the disease. We will identify specific genes that are under local selection in response to environmental factors, helping to better target therapies aimed at these risk factors.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020078</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Matthew Watt</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>New ways to treat fatty liver disease: a focus on lipid metabolism</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,441,644.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell metabolism | biomedical and clinical sciences | medical physiology | medical physiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>fat metabolism </Res_KW1>
        <Res_KW2>insulin resistance</Res_KW2>
        <Res_KW3>fatty liver disease</Res_KW3>
        <Res_KW4>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW4>
        <Res_KW5>mouse models</Res_KW5>
        <Plain_Description>Individuals with obesity have increased risk of developing other metabolic diseases including non-alcoholic fatty liver disease and diabetes. This is partially due to impairments in the capacity to burn fat and excessive accumulation of fat in most tissues of the body. We have identified a new pathway by which cells of the body regulate fat breakdown. In this project, we aim to test whether activating this pathway is effective in slowing the development of fatty liver and diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020097</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Nathan Pavlos</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Unlocking the Therapeutic Potential of a New ‘Dual-Action’ Target for Bone and Joint Diseases</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$848,048.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | orthopaedics  | </Fields_of_Research>
        <Res_KW1>osteoclast </Res_KW1>
        <Res_KW2>bone biology</Res_KW2>
        <Res_KW3>osteolysis</Res_KW3>
        <Res_KW4>membrane transport</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>Diseases affecting the bones and joints are devastating to physical function and human health and often feature bone destruction by osteoclasts, giant bone dissolving cells. However, treatments for these diseases remain inadequate. We have discovered a new molecule that blocks osteoclast function and helps build new bone when inhibited. This proposal evaluates the utility of this promising target for the development of new bone preserving drugs for the treatment of bone and joint diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020111</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Hubert Hondermarck</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Predict, prevent and treat bone metastases in prostate cancer</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$599,657.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>prostate cancer </Res_KW1>
        <Res_KW2>bone metastasis</Res_KW2>
        <Res_KW3>neurotrophic factors</Res_KW3>
        <Res_KW4>brain-derived neurotrophic factor (bdnf)</Res_KW4>
        <Res_KW5>cancer treatment</Res_KW5>
        <Plain_Description>Bone metastases are a fear development of prostate cancer that cannot be predicted and for which there is no effective treatment. In this translational and multidisciplinary project, we will develop an innovative strategy to predict, prevent and treat bone metastases. Our idea is based on cancer neurosciences and the targeting of nerves in prostate cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020113</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Brett Graham</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Network level decoding of touch and pain in the spinal cord</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$738,587.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | neurosciences | sensory systems | </Fields_of_Research>
        <Res_KW1>chronic pain </Res_KW1>
        <Res_KW2>spinal cord</Res_KW2>
        <Res_KW3>calcium imaging</Res_KW3>
        <Res_KW4>signal processing</Res_KW4>
        <Res_KW5>neural coding</Res_KW5>
        <Plain_Description>Understanding how touch and pain signals pass through the spinal cord is critical in pain treatment, especially for touch-evoked pain. Our current understanding focuses on small circuits of spinal nerve cells, even though we know touch and pain activate much larger networks to produce signals that reach our brain. This project will decode network-level signalling of touch and pain in the spinal cord by studying activity in large nerve cell networks using imaging and complex systems analysis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020121</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Rachel Sacks-Davis</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Test often, treat early: Are major changes in policy and practice needed to eliminate hepatitis C among people with HIV?</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$618,088.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | health sciences | epidemiology | epidemiology not elsewhere classified | health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>hepatitis c infection </Res_KW1>
        <Res_KW2>mathematical modelling</Res_KW2>
        <Res_KW3>collaboration</Res_KW3>
        <Res_KW4>human immunodeficiency virus (hiv)</Res_KW4>
        <Res_KW5>cohort study</Res_KW5>
        <Plain_Description>Hepatitis C treatment is highly effective, preventing liver-related morbidity and mortality for individuals, as well as onward transmission of hepatitis. However, current limitations on the number of tests per year and restrictions on treatment until chronic hepatitis C infection has been confirmed, mean that treatment is usually delayed for over a year after diagnosis. This proposal aims to estimate potential benefits from allowing more frequent testing and earlier treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020137</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Sherry Wu</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>In vivo genetic engineering of T-cells for cancer treatment using novel exosome mimetic nanoparticles</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$751,076.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>cancer therapy </Res_KW1>
        <Res_KW2>oncology</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>biomedical engineering</Res_KW5>
        <Plain_Description>Despite the promise of using genetically engineered T-cells for treatment of a variety of immune-mediated diseases, current methods are expensive, labour-intensive, result in significant side effects, and have limited availability. In this proposal, we will re-engineer naturally occurring vesicles that are present in our body to allow them to redirect T-cells to specific danger signals. We will examine the therapeutic efficacy of this novel nanotechnology in cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020149</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Anna Trigos</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Spatial analysis to investigate cancer evolution as a complex ecosystem of interacting tumour populations</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$978,228.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer genetics | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>gene expression </Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>prostate cancer</Res_KW3>
        <Res_KW4>data analysis</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>Cancer is a disease where cells grow rapidly, creating tumours. However, all tumour cells are not the same. There can be multiple cell types within a single tumour. These are likely interacting, helping each other grow. We aim to understand which tumour cells are cooperating with each other in prostate cancer that has spread using computational methods. With this, we hope to develop a new type of treatment that works by disrupting how tumour cells talk with each other and thus kill tumours.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020151</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Nicodemus Tedla</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Development of new treatment options for post-sepsis acute lung injury (ALI). </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$989,098.96</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>acute inflammation </Res_KW1>
        <Res_KW2>inflammatory cytokines</Res_KW2>
        <Res_KW3>cell surface receptor</Res_KW3>
        <Res_KW4>cytokine signalling</Res_KW4>
        <Res_KW5>acute lung injury</Res_KW5>
        <Plain_Description>Acute lung injury (ALI) occurs due to uncontrolled inflammation and is a major cause of death in Australia because there are no treatments. We recently found treatment with a new protein called A3 protects mice from this condition. In this project, we will develop A3 into a new class of anti-inflammatory drug and test it in mouse models of ALI that resemble human ALI and validate our results in human cells. This invention will address one of the most important unmet clinical needs worldwide.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020152</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jonathan Noonan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Autoimmunity; Finding the key to chronic atherosclerotic inflammation and plaque rupture</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$982,020.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>atherosclerosis </Res_KW1>
        <Res_KW2>plaque rupture</Res_KW2>
        <Res_KW3>chronic inflammation</Res_KW3>
        <Res_KW4>human</Res_KW4>
        <Res_KW5>animal model</Res_KW5>
        <Plain_Description>Heart disease is the leading cause of death globally, and ~1/3 of all deaths in Australia. Inflammation has been identified as a major cause of heart disease. However, what drives inflammation in heart diseases is not well known. Our research will explore how T cells, a common white blood cell, might cause heart attacks and strokes. By doing so, we will identify new ways in which we can treat inflammation and thereby prevent the massive numbers of deaths caused by heart disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020164</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Matilde Balbi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Assessment and modulation of cortical sensorimotor control for recovery after stroke</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,273,360.02</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>stroke </Res_KW1>
        <Res_KW2>sensorimotor control</Res_KW2>
        <Res_KW3>mouse models</Res_KW3>
        <Res_KW4>neuromodulation</Res_KW4>
        <Res_KW5>cortical plasticity</Res_KW5>
        <Plain_Description>Our goal is to promote the recovery of motor function after stroke. We will create a computational model of the effects of stroke on the motor control system throughout rehabilitation. We will determine whether electrical stimulation can enhance the effect of movement-based therapy on recovery after stroke. We will also adjust our stimulation based on ongoing brain activity. We hypothesise that feedback mediated rehabilitation is a more robust mechanism to activate affected areas.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020169</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrea Stringer</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Protecting vitamin D levels to prevent chemotherapy-induced gastrointestinal mucositis</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$807,368.12</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | toxicology (incl. clinical toxicology)  | </Fields_of_Research>
        <Res_KW1>intestine </Res_KW1>
        <Res_KW2>vitamin d</Res_KW2>
        <Res_KW3>cancer chemotherapy</Res_KW3>
        <Res_KW4>mucositis</Res_KW4>
        <Res_KW5>tissue damage</Res_KW5>
        <Plain_Description>Vitamin D deficiency is common in cancer patients, and is linked to the incidence of many cancers. Maintaining vitamin D levels is key for maximising therapeutic outcomes and preventing chemotherapy- induced mucositis. We will identify cancer patients as ‘at risk’ for vitamin D deficiency, leading to higher incidence and severity of chemotherapy-induced mucositis. We will investigate therapeutic options for maintaining vitamin D levels and preventing chemotherapy-induced mucositis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020173</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Peter Speck</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Bacteriophages: a new paradigm in caring for infected wounds.</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$736,657.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | medical microbiology | medical microbiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>diabetes mellitus </Res_KW1>
        <Res_KW2>bacteriophage</Res_KW2>
        <Res_KW3>staphylococcus aureus</Res_KW3>
        <Res_KW4>antimicrobial resistance</Res_KW4>
        <Res_KW5>health economics</Res_KW5>
        <Plain_Description>We will develop wound dressings carrying bacteriophages (viruses that kill bacteria) as a safe, effective way to treat wound infections. This will have great impact on treatment of diabetic foot ulcer infections, which currently often lead to amputation, which carries extremely high mortality. This work will lead to a new paradigm in wound care and will dramatically improve the lives of people with diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020185</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jenny Gunnersen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>An accessible chronic pain therapeutic target in peripheral sensory nerves</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$677,696.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | peripheral nervous system | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>chronic pain </Res_KW1>
        <Res_KW2>hyperalgesia</Res_KW2>
        <Res_KW3>dorsal root ganglia</Res_KW3>
        <Res_KW4>neuroinflammation</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>Chronic pain is hugely debilitating and its prevention remains an area of unmet clinical need. Nerve injuries result in exaggerated responses to painful, and even mild, stimuli. In pre-clinical models, we have discovered that removing a single protein from neurons, either throughout the nervous system or only in the peripheral nervous system, significantly diminishes injury-induced pain. This research aims to find a way to interfere with the development of chronic pain by targeting this protein.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020192</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Matthew McKay</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Using Big Data to Engineer Highly Immunogenic Hepatitis C Virus Envelopes for the Induction of Broad Neutralising Antibodies</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,143,599.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | sequence analysis | physical sciences | medical and biological physics | biological physics | biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>hepatitis c virus </Res_KW1>
        <Res_KW2>vaccine design</Res_KW2>
        <Res_KW3>sequence analysis</Res_KW3>
        <Res_KW4>antibody</Res_KW4>
        <Res_KW5>mathematical modelling</Res_KW5>
        <Plain_Description>There is an urgent need to develop a preventative vaccine against hepatitis C, a virus that causes chronic life-threatening disease in millions of people globally.  This project will bring together intelligent big data design methods and innovative experimental models to engineer panels of viral antigens for eliciting antibodies capable of neutralising diverse virus strains. The findings can be used to design new hepatitis C vaccines aimed at preventing virus infection and chronic disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020197</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Sara Baratchi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A Bioengineered Model of Calcific Aortic Valve Disease  </Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,045,794.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | mechanobiology | </Fields_of_Research>
        <Res_KW1>biomedical engineering </Res_KW1>
        <Res_KW2>aortic valve</Res_KW2>
        <Res_KW3>disease modelling</Res_KW3>
        <Res_KW4>mechanotransduction</Res_KW4>
        <Res_KW5>haemodynamics</Res_KW5>
        <Plain_Description>Calcific aortic valve disease is a common cause of mortality and morbidity in the elderly. Our limited knowledge of the mechanisms that drive the progression of aortic stenosis is a major obstacle in developing medical treatments for this disease. This project utilises a bioengineered aortic valve model that mimics features found in the early and late stages of this disease. It enables the systematic study of the complex pathology of this disease and serves as a platform for screening drugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020226</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Shelley Forrest</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding neurodegeneration caused by oligodendroglial dysfunction</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,025,253.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>neuropathology </Res_KW1>
        <Res_KW2>histology</Res_KW2>
        <Res_KW3>microtubule associated protein (map)</Res_KW3>
        <Res_KW4>behaviour change</Res_KW4>
        <Res_KW5>brain</Res_KW5>
        <Plain_Description>Globular glial tauopathy (GGT) is a recently described frontotemporal dementia, a debilitating early-onset neurodegenerative disorder. GGT is characterised by abnormal tau protein in oligodendroglia, the main neuron support cell. Previous research has focused on neurons, which cause neurodegeneration and clinical symptoms with little consideration of oligodendroglia. This study will investigate how dysfunction in oligodendroglia causes neurodegeneration in human and preclinical disease models.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020234</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Holly Seale</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Community driven communication and engagement during health crisis periods: co-designing enhanced and transferable strategies</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$589,259.20</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>communications/social research </Res_KW1>
        <Res_KW2>population health</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>communication skills</Res_KW4>
        <Res_KW5>public health policy</Res_KW5>
        <Plain_Description>Communicating crisis information with “hard-to-reach” culturally and linguistically diverse (CALD) communities is a significant challenge. Leveraging existing networks and actors can ensure that information reaches CaLD communities. We will fill a key gap via developing a: (1) communication and engagement strategy that outlines best practices around the identification and support of information intermediaries and (2) a training program that focuses on capacity building with CaLD communities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020251</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anna Calkin</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A Systems Genetics Approach to Defining the Sexual Dimorphism in Exercise-Induced Cardioprotection</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,426,825.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - lipids  | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>exercise </Res_KW1>
        <Res_KW2>cardiovascular disease prevention</Res_KW2>
        <Res_KW3>metabolomics</Res_KW3>
        <Res_KW4>proteomics</Res_KW4>
        <Res_KW5>lipid metabolism</Res_KW5>
        <Plain_Description>Men and women differ in their risk and development of cardiovascular disease (CVD) and their response to the protective effects of exercise; however, we do not fully understand the mechanisms underlying these differences. We propose to generate a cutting-edge research tool that characterises the changes in the heart at rest and in response to exercise in male and females. Using this tool, we will identify novel targets that we will test for their ability to treat CVD in a personalised manner</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020253</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Elke Hacker</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The Burning Question – how safe is sun exposure at low-dose and intensity?</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$741,332.70</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>skin cancer </Res_KW1>
        <Res_KW2>sun protection</Res_KW2>
        <Res_KW3>vitamin d</Res_KW3>
        <Res_KW4>solar ultraviolet (uv) radiation</Res_KW4>
        <Res_KW5>preventive medicine</Res_KW5>
        <Plain_Description>Skin cancers are more common in Australia than all other cancers combined. To reduce their burden, Australians are advised to protect their skin when the sun is strong, but not when the sun is weak.  We will test whether low-intensity sunlight is ‘harmless’ by exposing the skin of volunteers to non-burning doses of UV radiation, and then assessing the effects on their skin cells. The information from these experiments will inform sun protection policies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020285</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stuart Pitson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>New approaches to enhance immunotherapy for brain tumours</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$844,149.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>sphingolipids </Res_KW1>
        <Res_KW2>g protein-coupled receptors</Res_KW2>
        <Res_KW3>t cells</Res_KW3>
        <Res_KW4>glioblastoma</Res_KW4>
        <Res_KW5>brain tumours</Res_KW5>
        <Plain_Description>Primary brain tumours and brain metastases arising from other tumours both have extremely poor patient outcomes. Immunotherapy offers great promise for brain tumour therapy, but is currently limited due to brain tumour-induced immunosuppression. This proposal aims to overcome this problem to improve the potency of brain tumour immunotherapies. Successful outcomes in this work have the potential to dramatically improve the survival outcomes for glioblastoma patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020289</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Celine Valant</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Modulation of the M4 muscarinic receptor for the treatment of schizophrenia</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,807,677.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>muscarinic receptors </Res_KW1>
        <Res_KW2>schizophrenia</Res_KW2>
        <Res_KW3>molecular pharmacology</Res_KW3>
        <Res_KW4>rational drug design</Res_KW4>
        <Res_KW5>protein structure</Res_KW5>
        <Plain_Description>The M4 muscarinic receptor is a promising drug target for treating schizophrenia, with therapeutic outcomes above and beyond any current antipsychotics. Recently, two M4-targeting drugs, xanomeline and emraclidine, have progressed to advanced stages in clinical trials. This project aims to explore the pharmacological outcomes of xanomeline and emraclidine as a novel, first-in-class, dual therapy to ultimately assist in designing more effective and safer drugs for treating schizophrenia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020303</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof John Mariadason</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Exploiting GPX2 deficiency to enhance radiation response in gastrointestinal cancers</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$696,211.55</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | biomedical and clinical sciences | oncology and carcinogenesis | chemotherapy | </Fields_of_Research>
        <Res_KW1>colorectal cancer </Res_KW1>
        <Res_KW2>colorectal cancer treatment</Res_KW2>
        <Res_KW3>colorectal cancer risk</Res_KW3>
        <Res_KW4>irradiation</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Bowel cancer is a major global health problem. Here, we will investigate how loss of protein called GPX2 can on the one hand contribute to the development of this disease, but make cancers sensitive to radiotherapy on the other. By studying the role of this critical protein, this project will deliver important new knowledge into how colorectal cancers arise, enable us to identify patients most likely to benefit from radiotherapy, and to develop a new way to improve response to this treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020305</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Susan Woods</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>HARNESSING TUMOUR SPECIFIC HOMING AND EVOLUTION OF PROBIOTIC BACTERIA TO ENGINEER NEXT-GENERATION BOWEL CANCER TREATMENTS</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$717,084.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>colorectal cancer treatment </Res_KW1>
        <Res_KW2>bacterial genetics</Res_KW2>
        <Res_KW3>probiotics</Res_KW3>
        <Res_KW4>mouse models</Res_KW4>
        <Res_KW5>gastroenterology</Res_KW5>
        <Plain_Description>Bowel cancer kills over 5000 Australians each year. This failure of current treatments shows that a very different approach is needed. We are investigating the use of probiotics engineered to selectively release drugs direct to tumours. This research will help us understand why the probiotics home to tumours and how they change once in the tumour, so that we can better design probiotic treatments to treat bowel cancer in the future.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020315</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Yang LIAO</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A novel algorithm for accurate and efficient alignment of long DNA and RNA sequencing reads</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$153,131.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | </Fields_of_Research>
        <Res_KW1>bioinformatics </Res_KW1>
        <Res_KW2>sequence analysis</Res_KW2>
        <Res_KW3>methodology</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>dna sequencing</Res_KW5>
        <Plain_Description>Long-read sequencing is a new development in DNA/RNA sequencing. It helps to find mutations and other genomic features that can never be found before. Mapping read sequences to the genome is usually the first step in the analysis. We will use many novel concepts to develop a new tool for long-read mapping. Because of its high efficiency and accuracy compared with the current tools, it can strongly enhance the value of long-read sequencing in both research and clinical settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020316</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Michael Buchert</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Dissecting the role of group 2 innate lymphoid cells in gastric cancer </Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,365,646.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | </Fields_of_Research>
        <Res_KW1>gastric cancer </Res_KW1>
        <Res_KW2>innate immunity</Res_KW2>
        <Res_KW3>cancer immunology</Res_KW3>
        <Res_KW4>cancer metastasis</Res_KW4>
        <Res_KW5>cancer detection</Res_KW5>
        <Plain_Description>Gastric inflammation and early gastric cancer (GC) development elicits a rapid expansion of specialised immune cells (ILC2) in the stomach and their dissemination into the bloodstream. This project aims to uncover the impact of the systemic spread of ILC2s on metastatic niche formation and metastatic cancer growth in the context of aggressive GC and to investigate the utility of circulatory ILC2 as diagnostic biomarker for GC in order to achieve better health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020334</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Susan Clark</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Functional impact of CTCF binding site mutations in 3D cancer genome regulation</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$961,787.38</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genome structure and regulation | </Fields_of_Research>
        <Res_KW1>transcriptional regulation </Res_KW1>
        <Res_KW2>chromatin structure</Res_KW2>
        <Res_KW3>de novo mutations</Res_KW3>
        <Res_KW4>promoter analysis</Res_KW4>
        <Res_KW5>antisense rna</Res_KW5>
        <Plain_Description>Understanding what regulates gene expression in normal cells and how this goes wrong in cancer is still one of the biggest challenges in modern biology. This grant is focused on investigating two classes of non-coding somatic mutations in breast and prostate cancer, which we hypothesise disrupt binding of an important DNA regulator (CTCF) and results in deregulation of specific regions of gene expression. Unravelling mechanisms underpinning CTCF site mutations may lead to new cancer treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020371</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Tanya Applegate</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A novel molecular test to determine if a pathogen is alive or dead - a tool to transform infectious disease management and reduce the threat of antimicrobial resistance</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$956,774.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biological sciences | microbiology | infectious agents | biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | </Fields_of_Research>
        <Res_KW1>molecular diagnostics </Res_KW1>
        <Res_KW2>infectious diseases</Res_KW2>
        <Res_KW3>antimicrobial resistance</Res_KW3>
        <Res_KW4>sexually-transmitted infections (sti)</Res_KW4>
        <Res_KW5>clinical diagnosis</Res_KW5>
        <Plain_Description>Antimicrobial resistance is threatening our ability to treat infections globally. Current molecular tests for infectious disease detect both living and dead pathogens contributing to overdiagnosis and treatment. We will use a novel real time molecular assay, adaptable across pathogens, to determine what proportion of sexually transmitted infections are viable as an exemplar. This study could transform our entire public health approach to infectious disease diagnosis and antimicrobial stewardship</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020376</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Nicholas Clemons</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Improving therapeutic responses in oesophageal cancer by overcoming resistance to ferroptosis</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,073,391.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biological sciences | biochemistry and cell biology | cell metabolism | </Fields_of_Research>
        <Res_KW1>cancer therapy </Res_KW1>
        <Res_KW2>cell death</Res_KW2>
        <Res_KW3>metabolism</Res_KW3>
        <Res_KW4>functional genomics</Res_KW4>
        <Res_KW5>oesophageal cancer</Res_KW5>
        <Plain_Description>Compared to normal tissues, oesophageal cancers increase their consumption of nutrients from the surrounding environment and change the way they use these nutrients in order to survive, grow, spread to other organs and resist treatments. This project will identify which nutrients oesophageal cancers depend on to survive, and develop strategies to exploit these dependencies and improve the efficacy of treatments used to combat this disease, thereby improving cure rates and long term outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020377</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Isabelle Lucet</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Elucidating the signalling functions of Transmembrane Pseudokinases as a strategy to develop novel therapeutics modalities</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,320,638.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>structural biology </Res_KW1>
        <Res_KW2>protein kinases</Res_KW2>
        <Res_KW3>eph receptors</Res_KW3>
        <Res_KW4>intracellular signal transduction</Res_KW4>
        <Res_KW5>electron microscopy</Res_KW5>
        <Plain_Description>Cells require highly coordinated communication signals to grow and divide. Any improper signalling responses can lead to conditions, such as cancer and inflammation. Pseudokinases have recently been discovered to play a vital role in the coordination of signals that can lead to cancer. This program aims to elucidate how transmembrane receptor pseudokinases contribute to “out of control” signalling, which will provide novel therapeutic strategies to counteract pseudokinase-driven diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020421</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Melissa Brown</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Overcoming antiseptic and disinfectant resistance in staphylococci</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$941,905.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>multidrug resistance </Res_KW1>
        <Res_KW2>antimicrobial resistance</Res_KW2>
        <Res_KW3>structural biology</Res_KW3>
        <Res_KW4>medicinal chemistry</Res_KW4>
        <Res_KW5>staphylococcus aureus</Res_KW5>
        <Plain_Description>Strains of Staphylococcus aureus (Golden Staph), resistant to almost all available anti-staphylococcal agents, are responsible for serious infections among patients. Resistance has emerged to all classes of antimicrobial agents, including antiseptics and disinfectants. We will increase our understanding of proteins that confer resistance by pumping multiple compounds out of the cell to ultimately be able to block their action.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020423</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Fiona Cousins</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing the protective effects of Interferon epsilon as a therapeutic for endometriosis</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,125,385.96</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | reproductive medicine not elsewhere classified | biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | biomedical and clinical sciences | reproductive medicine | reproduction  | </Fields_of_Research>
        <Res_KW1>endometrium </Res_KW1>
        <Res_KW2>endometriosis</Res_KW2>
        <Res_KW3>women's health</Res_KW3>
        <Res_KW4>uterus</Res_KW4>
        <Res_KW5>cell proliferation</Res_KW5>
        <Plain_Description>Endometriosis is a chronic, debilitating condition that affects 1 in 9 menstruators. People with the disease have limited treatment options and there is no cure. A defective immune response is one of the causes of the disease. This project aims to investigate a new immunomodulator, interferon epsilon (IFNe), which may exert protective effects against the development of endometriosis. We will investigate whether IFNe can be used as an innovative treatment for endometriosis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020434</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Ernst Wolvetang</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A human brain organoid model of acute prenatal hypoxia enables biomarker discovery and drug screening for hypoxic-ischemic encephalopathy.</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,361,482.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>fetal hypoxia </Res_KW1>
        <Res_KW2>encephalopathy</Res_KW2>
        <Res_KW3>brain asphyxia</Res_KW3>
        <Res_KW4>neurological disturbance</Res_KW4>
        <Res_KW5>early brain development</Res_KW5>
        <Plain_Description>A lack of oxygen supply to the baby before and during birth has devastating immediate and long term consequences for brain development. Quantifiying the severity of birth asphyxia in newborns is difficult, little is known about the molecular and cellular processes involved, and effective treatments beyond cooling the newborn do not exist. Here we will use innovative human brain organoid models to address and overcome each of these knowledge and capability gaps.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020443</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Mikael Martino</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Engineered Amphiregulin: A Novel Growth Factor to Promote Tissue Regeneration</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$652,046.52</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biomedical and clinical sciences | medical biotechnology | medical molecular engineering of nucleic acids and proteins | </Fields_of_Research>
        <Res_KW1>regenerative medicine </Res_KW1>
        <Res_KW2>growth factor therapy</Res_KW2>
        <Res_KW3>protein engineering</Res_KW3>
        <Res_KW4>epidermal growth factor receptor (egfr)</Res_KW4>
        <Res_KW5>macrophages</Res_KW5>
        <Plain_Description>Tissue regeneration is facilitated by key proteins that are released by immune cells in injured tissues. These proteins include growth factors, which are promising drugs for regenerative medicine. However, growth factors have found limited clinical success due to poor efficacy and/or side effects. We have developed a novel engineered growth factor that shows significant promise in promoting tissue healing. This project will confirm its safety and efficacy for regenerative medicine applications.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020452</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Grant Drummond</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting interleukin-18-mediated inflammation to treat advanced kidney disease</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,304,466.78</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>kidney disease </Res_KW1>
        <Res_KW2>hypertension</Res_KW2>
        <Res_KW3>renal fibrosis</Res_KW3>
        <Res_KW4>chronic inflammation</Res_KW4>
        <Res_KW5>pharmacological intervention</Res_KW5>
        <Plain_Description>Kidney failure is a leading cause of death and morbidity worldwide. This project will use state-of-the-art technologies to characterise the role of a newly identified molecule (interleukin-18) that contributes to the pathological remodelling that precedes kidney failure. The therapeutic potential of interleukin-18 inhibition will also be tested. This research will define an entirely new mechanism of kidney disease and validate interleukin-18 as a target for new therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020453</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Archa Fox</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Nuclear mechanobiology in cell migration and metastasis</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$645,792.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>mechanotransduction </Res_KW1>
        <Res_KW2>cancer metastasis</Res_KW2>
        <Res_KW3>control of gene expression</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>cell polarity</Res_KW5>
        <Plain_Description>Preventing, diagnosing, and treating metastasis (the appearance of secondary tumors within the body) is the key to reducing death in breast cancer patients. Yet we still do not know exactly how cancer cells leave their tumors and invade into blood vessels to metastasise. Here we will test a new idea that invading breast cancer cells control their genes differently to normal cells, by the cell sensing its environment. This new understanding will help develop new drugs and diagnostic tools.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020454</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Christopher Rayner</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Stratifying low-calorie sweeteners for diabetes risk</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,612,729.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | nutritional science | biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>metabolic syndrome </Res_KW1>
        <Res_KW2>diabetes prevention</Res_KW2>
        <Res_KW3>glucose homeostasis</Res_KW3>
        <Res_KW4>microbiology</Res_KW4>
        <Res_KW5>gut peptides</Res_KW5>
        <Plain_Description>Low calorie sweeteners are not inert sugar supplements. Rather, they are emerging as a risk factor for the development of diabetes. They can enhance sugar absorption from the gut and disrupt bacteria that live there, which can raise blood sugar levels. However, sweeteners are all distinct and are likely to affect blood sugar differently. We will test these differences in innovative human and animal studies to identify which sweeteners are safer options, in an effort to prevent type 2 diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020455</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr David Muller</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>CRACing the role of the Flavivirus NS1 protein</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$814,543.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>dengue virus </Res_KW1>
        <Res_KW2>cholesterol</Res_KW2>
        <Res_KW3>flavivirus</Res_KW3>
        <Res_KW4>viral replication</Res_KW4>
        <Res_KW5>protein trafficking</Res_KW5>
        <Plain_Description>In this proposal, we will investigate the mechanisms by which various forms of the dengue viral protein, NS1 physically interacts with lipids and cholesterol. This is a critically important interaction for efficient viral replication and so understanding the ways in which NS1 engages with these host cell components should provide important clues as to how we can disrupt this interaction and so design potential anti-viral strategies not only for dengue, but also other flaviviruses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020482</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Gregory Moseley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Viral modulation of the host cell: The STAT3 Interface</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$823,296.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>virus </Res_KW1>
        <Res_KW2>host/pathogen interaction</Res_KW2>
        <Res_KW3>viral proteins</Res_KW3>
        <Res_KW4>immune evasion</Res_KW4>
        <Res_KW5>protein interactions</Res_KW5>
        <Plain_Description>This project will examine how viruses that cause major human diseases are able to interact with and control the cells that they infect, specifically through targeting of a central cellular regulator protein called STAT3. We will examine precisely how viruses selectively regulate STAT3 to control multiple processes in our cells that support viral infection and spread, and hence disease. By understanding how viruses do this, the project will identify new potential strategies to combat infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020483</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kate Quinlan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Discovery of eosinophil-derived thermogenic beiging factors to combat obesity</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$518,569.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell metabolism | </Fields_of_Research>
        <Res_KW1>eosinophils </Res_KW1>
        <Res_KW2>overweight/obesity</Res_KW2>
        <Res_KW3>innate immunity</Res_KW3>
        <Res_KW4>adipose tissue</Res_KW4>
        <Res_KW5>gene regulation</Res_KW5>
        <Plain_Description>Obesity is a global problem. We study the signals that control the switch between the accumulation and the burning of fat. A new type of fat, beige fat, is important in burning rather than storing fuel. Our data show that signals from a specialised immune cell – the eosinophil – convert normal fat into beige fat. By identifying the signaling molecules eosinophils produce in mouse and human tissue, we seek to mimic their action, and therapeutically stimulate beige fat to combat obesity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020501</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Irene Gallego Romero</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Comparative human functional genomics of Island Southeast Asia</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$707,834.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>differential gene expression </Res_KW1>
        <Res_KW2>immune regulation</Res_KW2>
        <Res_KW3>population genetics</Res_KW3>
        <Res_KW4>papua new guinea</Res_KW4>
        <Res_KW5>health inequalities</Res_KW5>
        <Plain_Description>To date nearly all studies of how DNA variants impact genes have been carried out in people of European descent. But insights gained from them do not always translate to other populations. By combining measurements of gene expression obtained at a single cell level with samples from Island Southeast Asia, this project will be the first to characterise the genetic differences that impact immune response in these populations, with implications for disease progression and personalised medicine.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020517</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Kirsten Fairfax</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Examining the ‘how’ and ‘why’ of blood cell gene regulation at loci relevant to autoimmune disease </Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$854,575.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology) | </Fields_of_Research>
        <Res_KW1>single nucleotide polymorphism (snp) </Res_KW1>
        <Res_KW2>genetic variation</Res_KW2>
        <Res_KW3>complex genetic disease</Res_KW3>
        <Res_KW4>molecular basis of disease</Res_KW4>
        <Res_KW5>molecular immunology</Res_KW5>
        <Plain_Description>Every person has a distinct DNA code, which is why some people get certain diseases and some don’t. This code is complex and we currently only understand a fraction of what it does. Our research aims to understand which bits of DNA code are important for causing autoimmune diseases. We will do this using new technologies, like subtly changing the DNA code and looking at the effect this has. Understanding how these changes influence disease can benefit clinical diagnosis and drug development.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020532</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Graham Neely</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>New pooled CRISPR screening approaches to study pain and painful venoms </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,343,958.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell neurochemistry | biological sciences | genetics | neurogenetics | </Fields_of_Research>
        <Res_KW1>molecular neuroscience </Res_KW1>
        <Res_KW2>acute pain</Res_KW2>
        <Res_KW3>chronic pain</Res_KW3>
        <Res_KW4>neurotoxins</Res_KW4>
        <Res_KW5>pain</Res_KW5>
        <Plain_Description>It is time to develop new, effective, and non-addictive ways to manage pain, but this can only come from a better basic understanding of pain biology. Here, we develop and apply new pooled CRISPR screening technologies to map the human genome for factors that control pain. Our work here will yield the first genome-scale basic understanding of human pain regulation, and will provide a foundation for rational new painkillers for the 21st century.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020540</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David McGiffin</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Hypothermic machine perfusion of circulatory death hearts for transplantation</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,062,431.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>heart transplantation </Res_KW1>
        <Res_KW2>organ preservation</Res_KW2>
        <Res_KW3>myocardial ischaemia</Res_KW3>
        <Res_KW4>cardiovascular physiology</Res_KW4>
        <Res_KW5>cardiothoracic transplantation</Res_KW5>
        <Plain_Description>Novel technology has been developed to mitigate injury associated with heart preservation during heart transplantation. Preliminary studies show this technology is effective, but its beneficial effects are poorly understood. This project will investigate at a functional and cellular level how this technology improves heart function during heart transplantation. Increasing use of this technology will increase the donor heart pool, and decrease the risk of death following heart transplantation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020543</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Timothy Barnett</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Characterising a novel molecular pathway to reduce penicillin failure for Strep throat</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$819,804.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>group a streptococcal disease </Res_KW1>
        <Res_KW2>antibiotic resistance</Res_KW2>
        <Res_KW3>antibiotic use</Res_KW3>
        <Res_KW4>intracellular bacterial infections</Res_KW4>
        <Res_KW5>bacterial pathogenesis</Res_KW5>
        <Plain_Description>Strep throat is a common bacterial infection caused by Group A Streptococcus (GAS). While GAS is sensitive to penicillin in vitro, 10-20% of infections recur after treatment. We have identified that some GAS strains can replicate in a penicillin-resistant intracellular niche. This project will define this mechanism of resistance to penicillin and other antibiotics, and develop a prototype test to detect resistant infections at the point of care. This will lead to better treatment outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020555</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Daniel Worthley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>HORIZONTAL GENE TRANSFER TO DETECT MUTATION AND REACT TO COLONIC NEOPLASIA</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$800,115.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | </Fields_of_Research>
        <Res_KW1>colorectal cancer </Res_KW1>
        <Res_KW2>bacterial genetics</Res_KW2>
        <Res_KW3>genetic engineering</Res_KW3>
        <Res_KW4>cancer detection</Res_KW4>
        <Res_KW5>bowel cancer</Res_KW5>
        <Plain_Description>Bowel cancer is common and is defined by changes to our genetic material (DNA). In this project we will answer whether bacteria that naturally live in the bowel can be coerced to take up cancer DNA through cutting-edge synthetic design; and whether bacteria could, in the future, detect and then react to bowel polyps and cancer and thus facilitate the detection, prevention and treatment of bowel cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020562</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephen Turner</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>PRC-1 regulation of mature CD8+ T cell effector and memory responses</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$997,141.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | immunology not elsewhere classified | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>cd8 t cells </Res_KW1>
        <Res_KW2>t cell memory</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>influenza virus</Res_KW4>
        <Res_KW5>t cell activation</Res_KW5>
        <Plain_Description>The programming of effective killer T cell immunity is associated requires appropriate gene regulation that ensures acquisition of the specific functions necessary for control of infection and cancer, as well as the establishment of effective immunity. This study will examine how a key factor called PRC1 regulates the induction of optimal protective virus and tumour T responses. This knowledge will contribute to the development of novel treatments for infection, cancer and autoimmune disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020563</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Ruth Arkell</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The influence of genetic variation on foetal alcohol spectrum disorder</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,312,850.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>fetal alcohol syndrome </Res_KW1>
        <Res_KW2>teratology</Res_KW2>
        <Res_KW3>environmental influences</Res_KW3>
        <Res_KW4>cell signalling</Res_KW4>
        <Res_KW5>developmental genetics</Res_KW5>
        <Plain_Description>Drinking alcohol during pregnancy is the most common cause of environmentally induced human birth defects. But there is not a simple linear relationship between the amount of alcohol ingested and the consequence for the unborn child. In this research we will examine how the genetic makeup of an unborn child influences the consequence of maternal alcohol consumption.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020565</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Michael Gantier</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Therapeutic targeting of TLR7 in autoimmunity</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,496,654.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | autoimmunity  | </Fields_of_Research>
        <Res_KW1>toll-like receptors </Res_KW1>
        <Res_KW2>autoimmunity</Res_KW2>
        <Res_KW3>major histocompatibility complex (mhc) class ii</Res_KW3>
        <Res_KW4>oligonucleotide</Res_KW4>
        <Res_KW5>intracellular signal transduction</Res_KW5>
        <Plain_Description>Autoimmune diseases, which are driven by self-reactive autoantibodies, affect approximately 5% of all Australians. While treatments are available to limit disease progression and morbidity, these are non-curative and can have numerous harmful side-effects. Here, we propose an innovative approach to thwart autoimmune disease by targeting how autoantibodies are generated. We have developed a new class of specific therapeutics that have the potential to help treat diverse autoimmune conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020567</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Thomas Burne</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Reverse translation of a rodent cognitive flexibility task</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$503,785.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>animal model </Res_KW1>
        <Res_KW2>cognition</Res_KW2>
        <Res_KW3>translational research</Res_KW3>
        <Res_KW4>metabolic disorders</Res_KW4>
        <Res_KW5>mental health</Res_KW5>
        <Plain_Description>Cognitive dysfunction is prominent in patients with neuropsychiatric and neurodegenerative disorders, yet current treatments have little effect on these symptoms. We need better treatments, but this requires better testing protocols. The goal is to provide a novel cognitive flexibility task for cognitive research in rodents that will help to develop initiatives to prevent, treat and rehabilitate patients with cognitive impairment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020569</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ines Esteves Domingues Pires da Silva</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Liver metastases: a niche of resistance and of therapeutic opportunities for all cancers.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$852,279.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy </Res_KW1>
        <Res_KW2>drug resistance</Res_KW2>
        <Res_KW3>liver metastases</Res_KW3>
        <Res_KW4>malignant melanoma</Res_KW4>
        <Res_KW5>lung cancer</Res_KW5>
        <Plain_Description>Drugs that stimulate immune cells to fight cancer (immunotherapy) have been used in melanoma and other cancers. The majority of melanoma patients resistant to immunotherapy have their melanoma spread to the liver; and we will study the effect of the presence of liver metastases on the immune response, in order to unveil novel mechanisms of resistance and therapeutic targets. Given the global finding across other cancers, our work has potential for impacting a broad range of cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020579</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Grant Logan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A novel pharmaco-genetic treatment for auto-immune kidney disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,248,547.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>gene therapy </Res_KW1>
        <Res_KW2>experimental glomerulonephritis</Res_KW2>
        <Res_KW3>adeno-associated virus</Res_KW3>
        <Res_KW4>vasculitis</Res_KW4>
        <Res_KW5>neutrophils</Res_KW5>
        <Plain_Description>There is mounting evidence that the enzyme DNase I is a novel non-toxic therapeutic for autoimmunity,  an appealing alternative to long-term use of current sub-optimal immunosuppressive drugs that carry significant toxicities. This project will build the translational bridge for application of a “one shot” DNase I therapy in humans with autoimmune kidney disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020587</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Grant Ramm</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A novel proinflammatory mechanism reveals an innovative therapeutic strategy to treat hepatic inflammation in chronic liver disease.</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$950,912.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>hepatic stellate cells </Res_KW1>
        <Res_KW2>hepatic fibrosis</Res_KW2>
        <Res_KW3>haemochromatosis</Res_KW3>
        <Res_KW4>ferritin</Res_KW4>
        <Res_KW5>inflammation</Res_KW5>
        <Plain_Description>We have generated considerable evidence for a role for tissue ferritin as a mediator of inflammation associated with liver fibrosis (scarring). These highly novel and innovative studies will identify the mechanisms associated with H-Ferritin-regulated liver inflammation in hepatic stellate cells (scar-forming cells in the liver) in chronic liver disease, which we will use to develop novel anti-inflammatory therapeutics to inhibit inflammation and fibrosis associated with chronic liver disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020590</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Christina Perry</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Incubation of craving for alcohol: Is exercise a viable intervention?</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$876,991.56</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | behavioural neuroscience | </Fields_of_Research>
        <Res_KW1>alcohol and behaviour </Res_KW1>
        <Res_KW2>neuroscience</Res_KW2>
        <Res_KW3>exercise therapy</Res_KW3>
        <Res_KW4>alcohol use disorders</Res_KW4>
        <Res_KW5>addiction treatment</Res_KW5>
        <Plain_Description>Environmental cues elicit strong craving in people with alcohol use disorder. These cravings increase over longer periods of abstinence, in many cases prompting relapse.  In a preclinical model, we have found that increased compulsion to seek alcohol across abstinence can be prevented with voluntary exercise. In this project we will identify the neural changes responsible for both the increase in craving and the restorative effect of exercise, and test the longevity of exercise benefits.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020606</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephen Rogerson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Monoclonal antibodies to placental malaria antigen VAR2CSA</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$707,364.16</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>plasmodium falciparum </Res_KW1>
        <Res_KW2>malaria</Res_KW2>
        <Res_KW3>antibody</Res_KW3>
        <Res_KW4>monoclonal antibody</Res_KW4>
        <Res_KW5>pregnancy</Res_KW5>
        <Plain_Description>Placental malaria parasites express VAR2CSA protein on the red blood cell surface. From the blood of pregnant women with strong antibody to VAR2CSA, we will isolate antibody-producing B cells. We will test the antibodies produced by the B cells to find antibodies which can block placental infection, can clear or kill infected cells, and react with many strains. The best ones will be tweaked to further improve activity. Optimised monoclonal antibody to VAR2CSA may prevent placental malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020613</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Mireille Lahoud</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Dissecting the regulatory mechanisms controlling antigen processing and presentation in dendritic cells</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,482,413.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>dendritic cell </Res_KW1>
        <Res_KW2>cell surface receptor</Res_KW2>
        <Res_KW3>antigen presenting cells</Res_KW3>
        <Res_KW4>ubiquitination</Res_KW4>
        <Res_KW5>immune regulation</Res_KW5>
        <Plain_Description>Dendritic cells of the immune system utilise specific receptors to sense danger signals from their environment. We identified a DC danger receptor, Clec9A, which recognizes and induces immunity to “dangerous” dead cells eg. infected cells. We will investigate how dendritic cells regulate their responses to “dangerous” dead cells, and the checkpoints that control immune responses. We will use this knowledge to develop novel approaches for vaccines and immunotherapies for improved health outcomes</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020624</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Lars Ittner</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Inhibition failure in Alzheimer’s disease</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,212,345.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>alzheimer disease </Res_KW1>
        <Res_KW2>neurofibrillary tangles</Res_KW2>
        <Res_KW3>amyloid beta-protein</Res_KW3>
        <Res_KW4>dementia</Res_KW4>
        <Res_KW5>mouse models</Res_KW5>
        <Plain_Description>Dementia is a leading cause of death in Australia with a huge socioeconomic burden. Network of the brains executive cells, the neurons, are critical for the normal function of the brain. We hypothesize that distinct populations of neurons are compromised or lost in dementia brains, resulting initially in mild cognitive impairment and progressing to severe dementia. This project aims at understanding how these network fail and will test novel way to prevent or treat the resulting deficits.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020626</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Renly Lim</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Co-designing a consumer-focused digital health system to improve adverse drug event (ADE) detection, management and reporting</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,717,988.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | primary health care | health sciences | public health | health promotion | health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>drug safety </Res_KW1>
        <Res_KW2>adverse drug reactions</Res_KW2>
        <Res_KW3>surveillance</Res_KW3>
        <Res_KW4>patient outcomes</Res_KW4>
        <Res_KW5>patient/professional communication</Res_KW5>
        <Plain_Description>Medicines have many benefits, but can also cause harm. Currently the effects of medicines and any potential harms are not monitored for the majority of people taking medicines. This project will develop a new digital health system that enables consumers and health professionals to actively detect medicine harms, and to report the harms to the medicine regulatory authority in Australia. We will also develop new tools to better communicate medicine safety issues to the public.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020633</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Melissa Churchill</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The use of Pro-apoptotic Drugs to Eliminate HIV in the Brain</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,287,548.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>viral infection</Res_KW2>
        <Res_KW3>central nervous system (cns)</Res_KW3>
        <Res_KW4>anti-latency drugs</Res_KW4>
        <Res_KW5>apoptosis</Res_KW5>
        <Plain_Description>HIV affects >37 M people worldwide and no scalable cure exists. Current approaches to cure HIV utilises drugs that are designed to target and kill HIV-infected cells in the blood. However, the efficacy and possible toxicity of these compounds in the brain is unclear. Our study will use novel animal cohorts and human brain cells to determine the ability of these drugs to target and kill HIV-infected cells in the brain, thus, informing on the suitability of these drugs in people with HIV.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020636</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Kate Anderson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>What Matters to First Nations Kids: Co-designing a wellbeing measure for First Nations children aged 5-11 years (WM2K Project)</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,779,065.70</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander child health and wellbeing | </Fields_of_Research>
        <Res_KW1>aboriginal mental health </Res_KW1>
        <Res_KW2>wellbeing</Res_KW2>
        <Res_KW3>measurement</Res_KW3>
        <Res_KW4>aboriginal child</Res_KW4>
        <Res_KW5>indigenous australians</Res_KW5>
        <Plain_Description>This project gives First Nations Australian children the chance to have a say about what is important to their wellbeing. The project team will engage First Nations children and their primary carers from across the country to co-design a new wellbeing measure that asks questions about what makes a good life for them. The measure will be widely available for use by decision makers to better understand the real impacts of policies and programs to improve the lives of all First Nations children.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020646</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrew Ellisdon</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Molecular mechanisms underlying NF1 dysfunction in tumour growth and disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$939,387.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | information and computing sciences | artificial intelligence | modelling and simulation | biological sciences | biochemistry and cell biology | proteomics and intermolecular interactions (excl. medical proteomics) | </Fields_of_Research>
        <Res_KW1>structural biology </Res_KW1>
        <Res_KW2>electron microscopy</Res_KW2>
        <Res_KW3>protein biochemistry</Res_KW3>
        <Res_KW4>gtp-binding protein</Res_KW4>
        <Res_KW5>protein function</Res_KW5>
        <Plain_Description>Mutations of the neurofibromin tumour suppressor gene cause the common genetic disease neurofibromatosis type 1 and drive numerous cancers including melanoma, breast and brain cancer. We will apply new breakthrough technologies to uncover how the neurofibromin protein is dysregulated at the atomic level and inside the cell. This project will discover new pathways for therapeutic intervention for Australians living with NF1-linked disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020732</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jonathan Mynard</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Next generation technology for paediatric blood pressure monitoring</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,130,880.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | medical devices | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>blood pressure </Res_KW1>
        <Res_KW2>hypertension</Res_KW2>
        <Res_KW3>young children</Res_KW3>
        <Res_KW4>primary school-aged children</Res_KW4>
        <Res_KW5>hypotension</Res_KW5>
        <Plain_Description>Blood pressure (BP) monitoring is critically important in hospitalised children and in those with hypertension, but is impeded by low tolerance to repeated cuff inflation. In this project, a novel cuffless BP device suitable for children will be developed and tested in real clinical settings. The device will overcome the distress and sleep disturbance caused by current devices, enabling more reliable and timely identification of high or low BP levels that can cause permanent brain/kidney damage.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020737</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jonathan Paul</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting Bromodomain and Extra-Terminal (BET) Proteins for Preventing Preterm Birth</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$529,026.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>parturition </Res_KW1>
        <Res_KW2>premature birth</Res_KW2>
        <Res_KW3>fetal membranes</Res_KW3>
        <Res_KW4>gene regulation</Res_KW4>
        <Res_KW5>chromatin</Res_KW5>
        <Plain_Description>Preterm birth is the biggest contributing factor to death and disease among newborns. This application explores the physiological mechanism that controls pregnancy length and is disrupted in preterm birth. We focus on the involvement of key regulatory proteins that can be targeted by drugs and will determine the potential of these drugs to block preterm parturition.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020743</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jacqueline Heraud-Farlow</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>How is immunogenic double-stranded RNA regulated in cells?</Grant_Title>
        <Admin_Institution>St Vincents Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,086,607.70</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biomedical and clinical sciences | immunology | innate immunity | </Fields_of_Research>
        <Res_KW1>rna binding proteins </Res_KW1>
        <Res_KW2>rna</Res_KW2>
        <Res_KW3>inflammatory diseases</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>genetics</Res_KW5>
        <Plain_Description>Fundamental to a functional immune system is the ability to correctly distinguish between material from our own cells and from a virus. Failure to do so results in auto-inflammation. We have identified three new genes that are important for regulating virus-like RNA in our own cells, to prevent inflammation. Understanding these genes provides crucial insights and potential new therapeutic targets for diverse settings from auto-inflammatory disease to cancer, viral immunity and RNA therapeutics</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020750</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anna Coussens</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Translating and field-validating an epigenetic blood test to predict TB infection and disease risk</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$785,406.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>tuberculosis </Res_KW1>
        <Res_KW2>diagnostic</Res_KW2>
        <Res_KW3>risk prediction</Res_KW3>
        <Res_KW4>longitudinal cohort study</Res_KW4>
        <Res_KW5>dna methylation</Res_KW5>
        <Plain_Description>We will deliver a validated DNA blood test which can be used to identify asymptomatic individuals in at-risk communities who are infected with the tuberculosis bacteria and at risk of developing symptomatic disease over 3 years. Community screening asymptomatic individuals with this test has the potential to have the greatest impact on reducing TB cases, by allowing us to better target preventative therapy to those most in need, before they develop disease and transmit the bacteria to others.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020757</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Adam Rose</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting hepatic amino acid transport to combat cardiometabolic disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,363,478.79</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell metabolism | </Fields_of_Research>
        <Res_KW1>amino acid transport </Res_KW1>
        <Res_KW2>lipoprotein metabolism</Res_KW2>
        <Res_KW3>hepatic metabolism</Res_KW3>
        <Res_KW4>lipid metabolism</Res_KW4>
        <Res_KW5>atherosclerosis</Res_KW5>
        <Plain_Description>The overarching idea of this proposal is to find a way to mimic the health benefits of dietary protein restriction while avoiding negative health consequences. To this end, we have invented a way to internally mimic a protein restricted state, and preliminary data have shown that such a strategy can reduce cardiometabolic disease biomarkers.  This proposal seeks to thoroughly understand and to provide key evidence of the effectiveness of this novel drug target against cardiometabolic disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020758</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Abiodun Ogunniyi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A novel dual therapy approach to treatment of multidrug-resistant Gram-negative infections</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$981,046.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | biological sciences | microbiology | infectious agents | biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>multidrug resistance </Res_KW1>
        <Res_KW2>bacterial infection</Res_KW2>
        <Res_KW3>mouse models</Res_KW3>
        <Res_KW4>molecular imaging</Res_KW4>
        <Res_KW5>medical bacteriology</Res_KW5>
        <Plain_Description>This project will use multiple advanced approaches to pinpoint how new derivatives of the anticoccidial drug robenidine kill and exert their specific activities against different superbugs. This study is of utmost significance in the current era of inexorable rise in multidrug resistance. The project will generate critical data that will promote targeted and responsible use of new antimicrobials, in alignment with similar global approaches towards eliminating multidrug resistance development.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020762</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Elizabeth Manning</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Striatal population involvement in OCD symptom domains</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$644,116.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | psychology | biological psychology  | behavioural neuroscience | </Fields_of_Research>
        <Res_KW1>obsessive-compulsive disorder (ocd) </Res_KW1>
        <Res_KW2>animal model</Res_KW2>
        <Res_KW3>behavioural science</Res_KW3>
        <Res_KW4>striatum</Res_KW4>
        <Res_KW5>calcium imaging</Res_KW5>
        <Plain_Description>Obsessive compulsive disorder (OCD) is associated with disturbances in different areas of flexible behaviour, including flexible actions (compulsions), threat responses (obsessions) and decision making. The striatum is a brain region that is critical for flexible behaviour, and that is also over active in OCD. The current proposal will determine how the two distinct functional neural populations in the striatum contribute to different disturbances in flexible behaviour relevant to OCD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020768</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Christopher Dayas</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A new mechanism for targeting stress-related mental health disorders </Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$831,378.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | psychology | biological psychology  | behavioural neuroscience | </Fields_of_Research>
        <Res_KW1>stress </Res_KW1>
        <Res_KW2>hypothalamus</Res_KW2>
        <Res_KW3>calcium imaging</Res_KW3>
        <Res_KW4>depression</Res_KW4>
        <Res_KW5>motivation</Res_KW5>
        <Plain_Description>Australians have faced significant emotional trauma over the past two years. Unfortunately, treatments for stress-induced psychiatric illness remain poor. By establishing a causal role of hypothalamic PVN-CRH cells in stress-induced psychopathology independent of the stress hormones, these studies will significantly shift the current dogma in psychiatry, leading to new studies and therapeutic opportunities for the treatment of stress-related disorders including depression and PTSD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020780</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stuart Ralph</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Does finite slowing of feeding cause artemisinin resistance in malaria?</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$859,736.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>antimalarial </Res_KW1>
        <Res_KW2>malaria control</Res_KW2>
        <Res_KW3>drug resistance</Res_KW3>
        <Res_KW4>malaria</Res_KW4>
        <Res_KW5>malaria drug resistance</Res_KW5>
        <Plain_Description>Drug resistance to the frontline antimalarial artemisinin is a major challenge to addressing the global burden of malaria. Deteriorating artemisinin resistance could lead to this drug becoming unusable, or could be manageable if drug resistance doesn't worsen and spread. We have determined the mechanism that underlies resistance and will test whether this is a finite and manageable process or instead is an escalating system that likely presages worsening prospects for global artemisinin use</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020782</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Yorgi Mavros</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Optimising sleep quality inside insecticide treated mosquito nets in hot overnight environments </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,244,248.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical physiology | human biophysics  | biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>heat stress </Res_KW1>
        <Res_KW2>climate change</Res_KW2>
        <Res_KW3>thermoregulation</Res_KW3>
        <Res_KW4>mosquito-borne disease</Res_KW4>
        <Res_KW5>sleep</Res_KW5>
        <Plain_Description>Nine-five percent of all Malaria transmission occurs within the African region, causing approximately 600 000 deaths per year.  Insecticide-treated bed nets are one of the primary interventions used to stop the spread of malaria.  However, sensations of feeling too hot to sleep comfortably is the primary reason for not using bed nets. By simulating real-world conditions, this project will determine how fans can be used to improve thermal comfort and sleep quality within the bed net enclosure.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020814</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Irina Voineagu</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Identification and functional characterisation of genomic enhancers in the human brain: a steppingstone to clinical translation of genetic data for brain disorders.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$503,855.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>functional genomics </Res_KW1>
        <Res_KW2>gene regulation</Res_KW2>
        <Res_KW3>schizophrenia and related disorders</Res_KW3>
        <Res_KW4>glioma</Res_KW4>
        <Res_KW5>autism spectrum disorders</Res_KW5>
        <Plain_Description>The genetic basis of brain disorders is incompletely understood. An important discovery over the last decade was that genetic variants associated with brain disorders are likely to impact gene expression regulation. The proposed project studies enhancers, the key regulatory elements of the genome that turn genes on and off. The project aims to identify enhancers that play functional roles in brain cells, thereby uncovering how genetic changes lead to brain disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020822</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Danny Wilson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>4D molecular characterisation of C-RIP proteins required for malaria host-cell entry</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$901,642.43</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>invasion biology</Res_KW2>
        <Res_KW3>malaria transmission</Res_KW3>
        <Res_KW4>protein-protein interaction</Res_KW4>
        <Res_KW5>drug targeting</Res_KW5>
        <Plain_Description>We have identified proteins that control the dynamic release of essential antigens required for malaria parasite infection of host red blood cells and will identify druggable interactions between these proteins that can be targeted to kill malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020851</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Erica Sloan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting sympathetic nerves to treat metastatic triple negative breast cancer</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,109,795.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | chemotherapy | </Fields_of_Research>
        <Res_KW1>breast cancer </Res_KW1>
        <Res_KW2>chemotherapy</Res_KW2>
        <Res_KW3>cancer treatment</Res_KW3>
        <Res_KW4>relapse</Res_KW4>
        <Res_KW5>cancer biology</Res_KW5>
        <Plain_Description>Survival from metastatic triple negative breast cancer is terrible. Our new findings suggest that nerves within cancers undermine the beneficial effects of current treatments. This project investigates how blocking nerves improves response to treatment, and will determine how to optimally apply these findings so cancer patients benefit.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020861</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Merlin Crossley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>New approaches to treating hemoglobinopathies</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,508,780.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>transcription factor </Res_KW1>
        <Res_KW2>control of gene expression</Res_KW2>
        <Res_KW3>enhancer elements</Res_KW3>
        <Res_KW4>dna methylation</Res_KW4>
        <Res_KW5>histone deacetylase</Res_KW5>
        <Plain_Description>The genetic disorders ß-thalassemia and sickle cell disease are caused by mutations in the adult globin gene. Fortunately, humans have a second globin gene, the fetal globin gene, which is expressed in utero but turned off after birth. Re-activating expression of this fetal globin gene can alleviate the symptoms of ß-thalassemia and sickle cell disease. We are using new strategies, including sophisticated gene editing, to boost fetal globin output to treat this disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020900</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Chen Davidovich</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>RNA-mediated regulation of chromatin compaction in development and disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$774,339.26</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genome structure and regulation | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>rna binding proteins </Res_KW1>
        <Res_KW2>rna</Res_KW2>
        <Res_KW3>chromatin structure</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>gene regulation</Res_KW5>
        <Plain_Description>Polycomb repressive complexes are enzymatic complexes that safeguard the genome by preventing repressed genes from becoming active. The proposed study aimed at identifying how RNA regulate certain types of polycomb repressive complexes to maintain genes in a compacted state that prevent their expression. The project aims to determine how RNA regulates the formation of compact chromatin structure and to visualize this process in high resolution.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020902</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Mark Mackay</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Designing novel blood and MRI-based predictive tools to understand disease mechanisms, improve recovery and guide targeted interventions following neonatal arterial ischaemic stroke</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,270,873.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | </Fields_of_Research>
        <Res_KW1>stroke </Res_KW1>
        <Res_KW2>neonatal</Res_KW2>
        <Res_KW3>proteomics</Res_KW3>
        <Res_KW4>brain imaging</Res_KW4>
        <Res_KW5>developmental outcomes</Res_KW5>
        <Plain_Description>Around 120 Australian babies suffer a stroke every year but causes are unknown. Almost half experience long-term problems such as cerebral palsy, speech, learning or behavioural difficulties. The study aims to answer the two most important questions that parents ask their doctors: why did my baby have a stroke and how will the stroke affect my baby’s future development? We will do this by looking at blood signatures and use advanced MRI imaging to study brain networks in 50 babies with stroke.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020911</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Daniela Loessner</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting the 4Ms in cancer treatment – matrix, mechanics, microenvironment, metabolism</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$814,599.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | biomaterials  | </Fields_of_Research>
        <Res_KW1>extracellular matrix </Res_KW1>
        <Res_KW2>microenvironment</Res_KW2>
        <Res_KW3>cancer cell biology</Res_KW3>
        <Res_KW4>tissue engineering</Res_KW4>
        <Res_KW5>biomechanics</Res_KW5>
        <Plain_Description>This project addresses a clinical problem with an innovative approach. Pancreatic cancer is one of the deadliest cancers and only 10% of patients survive 5 years after diagnosis. To find better therapies, we need patient-specific models that mimic the biology of tumour tissues and target interactions between different cell types. We will develop a controllable platform for modelling the human disease in the laboratory. We will use our new platform to discover better ways of treating the disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020950</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ling Zhu</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>High-throughput ex vivo screening of human retinal cell specific delivery nanoparticles for gene therapy</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$920,948.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | vision science | </Fields_of_Research>
        <Res_KW1>macular disease </Res_KW1>
        <Res_KW2>nanotechnology</Res_KW2>
        <Res_KW3>ex vivo</Res_KW3>
        <Res_KW4>drug delivery</Res_KW4>
        <Res_KW5>retinal metabolism</Res_KW5>
        <Plain_Description>Using nanoparticles as carriers of therapeutic payloads is one promising way to treat retinal diseases. They can carry significantly larger payloads than viruses. The project combine single-cell RNA sequencing with a barcoded library to perform high-throughput screening for the nanoparticles that will cell-specifically deliver genes. These identified carriers will be used as vectors to introduce the gene constructs or drugs specifically into the target retinal cells to treat retinal diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020961</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jana Vukovic</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting IL-6 trans-signalling in brain injury</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$940,680.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>microglia </Res_KW1>
        <Res_KW2>molecular neuroscience</Res_KW2>
        <Res_KW3>acquired brain injury</Res_KW3>
        <Res_KW4>glia-neuron relationship</Res_KW4>
        <Res_KW5>glia</Res_KW5>
        <Plain_Description>Acquired brain injury is a leading cause of ongoing disability worldwide. Although the damage caused by the primary insult is irreversible, a series of secondary events cause further nerve cell death and exacerbate brain dysfunction. My laboratory has recently uncovered a way to prevent these secondary events by targeting the brain’s immune cells - microglia. Here we will dissect as to how microglia can be manipulated to promote repair following brain injury.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020984</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Brett McKinnon</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Identifying endometriosis risk and disease variability by mapping endometrial stem cell maturation</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$945,439.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>endometriosis </Res_KW1>
        <Res_KW2>endometrium</Res_KW2>
        <Res_KW3>adult stem cells</Res_KW3>
        <Res_KW4>gene transcription</Res_KW4>
        <Res_KW5>in vitro</Res_KW5>
        <Plain_Description>Endometriosis is a poorly categorised disease. Diagnosis is via surgery and patient outcomes are varied. Identifying markers for disease risk and sub grouping would greatly improve treatment for individual patients. Endometriosis grows from endometrial stem cells that enter the peritoneal cavity. We identified altered differentiation increases endometriosis risk and propose to identify factors that cause altered differentiation and the biological signatures that result to improve treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020999</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Paul Dawson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Neuroprotective benefit and safety of preterm neonatal sulphate supplementation</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$966,906.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | intensive care  | </Fields_of_Research>
        <Res_KW1>cerebral palsy treatments </Res_KW1>
        <Res_KW2>very preterm birth</Res_KW2>
        <Res_KW3>neuroprotection</Res_KW3>
        <Res_KW4>neonatal intensive care (nicu)</Res_KW4>
        <Res_KW5>hyposulphataemia</Res_KW5>
        <Plain_Description>Preterm babies become sulphate deficient after birth, increasing the risk of cerebral palsy. Any intervention that prevents cerebral palsy in preterm infants, particularly a simple, low-risk, low-cost intervention would have considerable personal and economic benefits. In this study, we will investigate the impact of sulphate supplementation on brain development in preterm piglets, which will help develop future sulphate therapies in human preterm infants.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021009</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Claudine Bonder</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting desmoglein-2 to reinvigorate anti-tumour immunity</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,159,847.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>cancer cell biology </Res_KW1>
        <Res_KW2>pancreatic cancer</Res_KW2>
        <Res_KW3>melanoma</Res_KW3>
        <Res_KW4>tumour immunology</Res_KW4>
        <Res_KW5>adhesion molecules</Res_KW5>
        <Plain_Description>Pancreatic cancer and melanoma are amongst the deadliest forms of cancer which continue to rise in prevalence. Despite clinical advances, once metastasised, cancer from any organ is universally fatal. The growth and spread of solid tumours requires access to the blood supply as well as control of the immune response. Our work on tumour vasculature, in these most difficult to treat tumours, has identified an adhesion protein on the cancer cells that may help fight this deadly disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021010</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Peter Crouch</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Muscle-directed gene therapy as an adjuvant to neuroprotection: Targeting both ends of the dysfunctional nerve-muscle axis to treat motor neurone disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,122,472.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>amyotrophic lateral sclerosis </Res_KW1>
        <Res_KW2>motor neuron disease (mnd)</Res_KW2>
        <Res_KW3>muscle degeneration</Res_KW3>
        <Res_KW4>treatment strategies</Res_KW4>
        <Res_KW5>skeletal muscle hypertrophy</Res_KW5>
        <Plain_Description>Amyotrophic lateral sclerosis involves nerve cell death and deterioration of the muscles that the nerves control. Effective treatments are lacking. Capitalising on our team’s complementary expertise in neuroscience and muscle physiology, we are developing a multimodal treatment strategy designed to protect nerves and promote muscle re-growth. Targeting both ends of the ‘nerve-muscle axis’ will prevent premature death of people with this disease and stimulate functional recovery.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021029</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Monaghan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title> Enabling remote screening of childhood hearing loss using artificial intelligence</Grant_Title>
        <Admin_Institution>National Acoustic Laboratories</Admin_Institution>
        <State>NSW</State>
        <Sector>Hospitals and Health Services</Sector>
        <Total>$452,713.70</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | otorhinolaryngology | </Fields_of_Research>
        <Res_KW1>congenital hearing loss </Res_KW1>
        <Res_KW2>conductive hearing loss</Res_KW2>
        <Res_KW3>health screening</Res_KW3>
        <Res_KW4>audiology</Res_KW4>
        <Res_KW5>artificial neural networks</Res_KW5>
        <Plain_Description>Children born in Australia are tested to check if they have a hearing loss. This newborn screening doesn't pick up some forms of hearing loss and can't detect a hearing loss that only appears later in life. This project will create a smartphone app parents can use to record their child speaking to check if they may have a hearing loss. The app will provide a simple way for parents, health workers, and teachers to help make sure all children with hearing loss are diagnosed as soon as possible.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021041</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Wayne Tilley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Exploiting sex differences in androgen action to advance a novel treatment for breast cancer.</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,262,967.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>breast cancer </Res_KW1>
        <Res_KW2>androgen receptor</Res_KW2>
        <Res_KW3>oestrogen receptor</Res_KW3>
        <Res_KW4>endocrine therapy</Res_KW4>
        <Res_KW5>immune response</Res_KW5>
        <Plain_Description>We have recently discovered that activation of the androgen receptor (AR) can redirect the cancer-promoting activity of the estrogen receptor (ER) to halt rather than promote breast cancer growth. The current study will establish if AR activating drugs influence the immune system to inhibit growth of ER-driven breast cancers to establish androgen therapy as a more effective treatment strategy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021055</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Kelly Crossley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Reducing the burden of respiratory distress after caesarean delivery.</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,240,465.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical physiology | medical physiology not elsewhere classified | biomedical and clinical sciences | paediatrics | neonatology | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>respiratory physiology </Res_KW1>
        <Res_KW2>cardiovascular physiology</Res_KW2>
        <Res_KW3>airway oedema</Res_KW3>
        <Res_KW4>newborn</Res_KW4>
        <Res_KW5>respiratory diseases</Res_KW5>
        <Plain_Description>Compared with vaginally born babies, babies born at term by caesarean section have a higher risk of needing intensive care due to breathing problems soon after birth. We have recently made a major break-through in understanding why and this project will provide the additional information required to identify effective treatments for these otherwise healthy newborns. Ultimately this research will identify approaches and treatments that will reduce the risk or severity of this breathing problem.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021057</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Sudha Rao</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>SETDB1 Epigenetic checkpoint blockade: A new approach to enhance immune-mediated control</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,280,776.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy </Res_KW1>
        <Res_KW2>cancer immunology</Res_KW2>
        <Res_KW3>gene expression</Res_KW3>
        <Res_KW4>nuclear import</Res_KW4>
        <Res_KW5>novel therapeutic agents</Res_KW5>
        <Plain_Description>SETDB1 is a novel drug target that mediates immunotherapy resistance. We have shown that the nuclear form of SETDB1 is enriched in tissue and blood samples from immunotherapy-resistant metastatic cancers. We have designed a new drug targeting nuclear SETDB1 (MSETC) that targets both cancer cells and simultaneously re-invigorates the immune system. In this project, we will undertake critical molecular pre-clinical studies towards advancing our prototypic drug (MSETC) to the clinic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021063</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Omer Gilan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding and targeting self-renewal in aggressive blood cancers </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$976,222.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>chromatin </Res_KW1>
        <Res_KW2>targeted therapy</Res_KW2>
        <Res_KW3>gene transcription</Res_KW3>
        <Res_KW4>acute leukaemia</Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>The epigenetic protein Menin, is critical for the ability of leukaemia cells to divide indefinitely. Therapies that target this protein are currently in clinical trials, however it is unclear how they work. By studying how resistance to these therapies emerges, we have unexpectedly discovered that they work differently to what was previously thought. This proposal will use new tools to elucidate these findings in order to develop ways to overcome resistance and improve their efficacy.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021074</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Ruth Hubbard</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Organ Transplantation as a Model of Reversible Frailty</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,609,170.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | biomedical and clinical sciences | clinical sciences | nephrology and urology  | biomedical and clinical sciences | medical physiology | medical physiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>frailty </Res_KW1>
        <Res_KW2>renal transplantation</Res_KW2>
        <Res_KW3>microcirculation</Res_KW3>
        <Res_KW4>metabolomics</Res_KW4>
        <Res_KW5>ageing</Res_KW5>
        <Plain_Description>People with end-stage kidney failure often have low energy and muscle weakness. Clinically, they are “frail”. Since health status improves significantly post-transplant, organ transplantation is a model of reversible frailty. In this study, we’ll measure frailty and biological data in 3 groups: (1) people before and after a kidney transplant (2) people with kidney failure who don’t receive a transplant (3) older people who are frail. This will provide new insights into the causes of frailty.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021082</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephanie Gras</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Defining the features of atypical T cell responses in Human Immunodeficiency Virus (HIV) controllers</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$697,946.10</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>t cells </Res_KW1>
        <Res_KW2>human immunodeficiency virus (hiv)</Res_KW2>
        <Res_KW3>cytotoxic t lymphocyte (ctl) activation</Res_KW3>
        <Res_KW4>human leukocyte antigen (hla)</Res_KW4>
        <Res_KW5>t cell receptor</Res_KW5>
        <Plain_Description>Human immunodeficiency virus (HIV) directly attacks our immune system, impairing our natural defence against infection and disease. HIV has infected ~76 million individuals worldwide, leading to a long-lasting pandemic with no vaccine or cure currently available. However, there are rare individuals able to control HIV infection. Our work focuses on understanding how these individuals’ immune system can control HIV, thereby aiding the design of novel treatments or potential vaccines against HIV.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021085</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David Thorburn</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Modelling of mitochondrial disease in specific cell lineages to understand pathomechanisms and develop effective targeted therapies</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,360,059.40</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell metabolism | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | </Fields_of_Research>
        <Res_KW1>mitochondrial disease </Res_KW1>
        <Res_KW2>inherited metabolic disorders</Res_KW2>
        <Res_KW3>molecular pathogenesis</Res_KW3>
        <Res_KW4>stem cells</Res_KW4>
        <Res_KW5>drug screening</Res_KW5>
        <Plain_Description>Mitochondrial disorders are a group of inherited diseases that can cause severe, life-limiting disease in at least 60 children born in Australia each year. These disorders impact on the brain, heart and other organ systems and we lack effective treatments, partly because we don’t understand the disease mechanisms. We will use human cell model systems, including stem cells differentiated into heart cells, to study disease mechanisms and trial new treatment approaches.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021126</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Garron Dodd</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Reversing Neurofibrosis: A New Way to Treat Type-2 Diabetes</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,594,830.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>hypothalamus </Res_KW1>
        <Res_KW2>neuroendocrinology</Res_KW2>
        <Res_KW3>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW3>
        <Res_KW4>insulin resistance</Res_KW4>
        <Res_KW5>extracellular matrix</Res_KW5>
        <Plain_Description>We aim to discover new treatments for type-2 diabetes (T2D), a national and global health priority. Brain cells that maintain blood glucose levels within a safe range, are encased within a specialised extracellular matrix. We have discovered that this matrix becomes augmented and defective in T2D, a process termed neurofibrosis. Neurofibrosis makes neurons insulin resistant, which results in high blood sugar levels. We will pioneer the very first drugs targeting neurofibrosis to treat T2D.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021130</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Natalie Strobel</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Improving HPV vaccine rates for Aboriginal young people through social media</Grant_Title>
        <Admin_Institution>Edith Cowan University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$974,708.75</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health promotion | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander epidemiology | </Fields_of_Research>
        <Res_KW1>aboriginal health </Res_KW1>
        <Res_KW2>human papillomavirus (hpv)</Res_KW2>
        <Res_KW3>vaccination</Res_KW3>
        <Res_KW4>public health</Res_KW4>
        <Res_KW5>young adults</Res_KW5>
        <Plain_Description>Human papillomavirus (HPV) is a common sexually transmitted infection that can lead to HPV-related cancers. HPV rarely produces symptoms and cannot be cured or treated; therefore, vaccination is essential to protect against HPV and HPV-related diseases. This project aims to improve HPV vaccination rates amongst young Aboriginal people. Our project will combine health messages co-created by young people and implemented by micro-Influencers to improve HPV vaccination.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021155</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Gonzalo del Monte Nieto</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Investigating the morphological and molecular origin of non-compaction cardiomyopathy</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,825,840.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </Fields_of_Research>
        <Res_KW1>congenital heart disease </Res_KW1>
        <Res_KW2>molecular basis of disease</Res_KW2>
        <Res_KW3>heart development</Res_KW3>
        <Res_KW4>systems biology</Res_KW4>
        <Res_KW5>artificial neural networks</Res_KW5>
        <Plain_Description>Every year, 1 in 100 Australian babies are born with heart malformations of a genetic origin stressing the need for further research. In this project, we will investigate one of the most recently classified genetic cardiac condition and therefore, one of the least understood. Our expert team will apply innovative approaches to better understand the condition and provide crucial insights to design customized genetic screening panels and treatments for patients suffering from this disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021163</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicholas Veldhuis</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting Endosomal Receptor Signalling for Superior Pain Relief</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,353,578.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences | biomedical and clinical sciences | medical biotechnology | nanomedicine | </Fields_of_Research>
        <Res_KW1>receptor signalling </Res_KW1>
        <Res_KW2>chronic pain</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>g protein-coupled receptors</Res_KW4>
        <Res_KW5>receptor trafficking</Res_KW5>
        <Plain_Description>G protein-coupled receptors (GPCRs) are important drug targets. A key feature of GPCR function is their ability to internalise when stimulated, and it is now appreciated that this can promote signalling events that are uniquely associated with diseases of global relevance, including chronic pain. This project will define signalling processes mediated from internalised GPCRs, and develop nanomedicines for targeted delivery of drugs to specific sites inside cells for superior pain relief.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021172</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Hardip Patel</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Indigenous telomere-2-telomere human reference genomes to enable discovery, translation and innovations</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$2,549,487.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | biological sciences | bioinformatics and computational biology | sequence analysis | biological sciences | genetics | genome structure and regulation | </Fields_of_Research>
        <Res_KW1>indigenous australians </Res_KW1>
        <Res_KW2>medical genomics</Res_KW2>
        <Res_KW3>human genome project</Res_KW3>
        <Res_KW4>population variation</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>Our project will use the latest DNA sequencing technologies to generate, for the first time, indigenous telomere-2-telomere reference genomes. These genomes will account for ancestral diversity and underpin the implementation of precision medicine, enable discoveries and drive innovations using genomics. Critically, the project will foster existing and create new partnerships with Indigenous communities through mutually agreed benefits of the genomics revolution.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021176</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Alessandra Ferri</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The neuroprotective potential of exercise in individuals with motor neuron disease - a paradigm-changing idea</Grant_Title>
        <Admin_Institution>Victoria University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$648,621.55</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | sports science and exercise | exercise physiology | biomedical and clinical sciences | medical physiology | systems physiology  | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>motor neuron disease (mnd) </Res_KW1>
        <Res_KW2>exercise training</Res_KW2>
        <Res_KW3>neuroprotection</Res_KW3>
        <Res_KW4>muscle</Res_KW4>
        <Res_KW5>brain</Res_KW5>
        <Plain_Description>Every day two Australians die from motor neuron disease (MND) - an incurable neurodegenerative disease. This project aims to discover if exercise can slow neurodegeneration in MND. Thanks to the interdisciplinary expertise of our international consortium, we will investigate the neuroprotective potential of exercise on the brain, spinal cord, and muscle of patients with MND. This research has the potential to change the role of exercise in the treatment of MND.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021181</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Helen Abud</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Unravelling tumour plasticity via parallels with tissue regeneration</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,356,369.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>adult stem cells </Res_KW1>
        <Res_KW2>organogenesis</Res_KW2>
        <Res_KW3>colon</Res_KW3>
        <Res_KW4>colorectal cancer</Res_KW4>
        <Res_KW5>intestine</Res_KW5>
        <Plain_Description>Development of resistance to chemotherapy is a major challenge in the treatment of bowel cancer. We are exploring whether a new cell type that is produced when the lining of the gut is injured, is also produced as bowel cancers acquire drug resistance. We will characterise these cells and examine if approaches directed at targeting these cells are capable of eliminating bowel cancers. This work could provide a rational basis for the design of new combination treatments for bowel cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021182</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Connie Wong</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Unravelling the brain-lung communication pathway as a novel way of improving stroke outcome</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,104,980.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>stroke outcome </Res_KW1>
        <Res_KW2>bacterial infection</Res_KW2>
        <Res_KW3>neutrophils</Res_KW3>
        <Res_KW4>lung</Res_KW4>
        <Res_KW5>vesicle transport</Res_KW5>
        <Plain_Description>Lung infection is highly prevalent and often deadly in patients with stroke, raising the possibility of weakened antibacterial responses in the lung after stroke. The focus of this project is to investigate the mechanisms underlying impaired lung immunity following stroke onset. We will also assess the potential of exosome content as biomarkers to identify high-risk stroke patients who will require antibacterial therapy to limit infection development and improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021183</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Chin-Teng Lin</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Fluent Mobility for the Blind Individual Using Multimodal Auditory Sensory Augmentation</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,604,198.75</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | medical devices | biomedical and clinical sciences | neurosciences | sensory systems | information and computing sciences | graphics, augmented reality and games | virtual and mixed reality | </Fields_of_Research>
        <Res_KW1>blindness </Res_KW1>
        <Res_KW2>sensory aids</Res_KW2>
        <Res_KW3>mobility</Res_KW3>
        <Res_KW4>functional magnetic resonance imaging (fmri)</Res_KW4>
        <Res_KW5>electroencephalography</Res_KW5>
        <Plain_Description>Fluency in blind users' mobility arises from access to an appropriate flow of sensory information, subtle control over the sensory information flow, and natural interaction. Any unimodal sensory augmentation system will fail to provide sufficient fluency, therefore we propose a multimodal sensory augmentation system using smart glasses and gesture control to improve fluency in mobility and orientation for blind individuals.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021186</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Simone Pettigrew</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Developing and applying a world-first alcohol market monitoring system</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$790,147.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>alcohol </Res_KW1>
        <Res_KW2>alcohol and behaviour</Res_KW2>
        <Res_KW3>alcohol consumption</Res_KW3>
        <Res_KW4>harm reduction</Res_KW4>
        <Res_KW5>consumer information</Res_KW5>
        <Plain_Description>The alcohol market is evolving rapidly, with new products being brought to market and creative marketing strategies being implemented, often targeting younger drinkers. This project will deliver a world-first system of monitoring  marketplace changes and providing timely data to policy makers to enable them to implement effective policy responses. A sustainable system of product monitoring and data reporting will be delivered to assist with alcohol harm-reduction strategies long term.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021208</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Stefano Palomba</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>UNIVERSAL NEUROPHOTONIC INTERFACE: A REVOLUTION IN MEDICAL BIONICS</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,474,420.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>physical sciences | atomic, molecular and optical physics | photonics, optoelectronics and optical communications | engineering | biomedical engineering | neural engineering | engineering | biomedical engineering | biomedical engineering not elsewhere classified | </Fields_of_Research>
        <Res_KW1>stem cell biology </Res_KW1>
        <Res_KW2>neurobiology</Res_KW2>
        <Res_KW3>photobiology</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>gene knockout</Res_KW5>
        <Plain_Description>This project aims to deliver the proof-of-concept of a universal nerve interface, which eventually will bidirectionally connect any bionic device to the peripheral nervous system. This would allow the brain to directly control any bionic device and also to receive sensory feedback, i.e. to “feel”. We will achieve this by combining permanently photoactive neurons, located on pre-determined areas on a photonic chip and addressed by light. Their axon will form a nerve-like structure.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021218</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Nicholas West</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A Faster Cure for Tuberculosis: Revealing Adjunctive Antimicrobial Solutions</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,395,113.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>mycobacterium tuberculosis </Res_KW1>
        <Res_KW2>adjunctive therapies</Res_KW2>
        <Res_KW3>antimicrobial resistance</Res_KW3>
        <Res_KW4>antimicrobial therapy</Res_KW4>
        <Res_KW5>bacterial pathogenesis</Res_KW5>
        <Plain_Description>The world urgently needs effective solutions for TB, a bacterial infection that claims more lives than any other. We have identified a "weak link" in the defences of the bacteria responsible and aim to find ALL such vulnerabilities, enabling the development of the next generation of therapy for TB. We will identify ways to weaken these bacterial defences, enhancing potency of existing antibiotics, and rescuing antimicrobial resistance, delaying the need for development of new TB antibiotics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021228</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Cindy Audiger</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Making next-generation dendritic cell vaccines a reality</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$598,229.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>dendritic cell </Res_KW1>
        <Res_KW2>innate immunity</Res_KW2>
        <Res_KW3>anti-tumour vaccine</Res_KW3>
        <Res_KW4>immunotherapy</Res_KW4>
        <Res_KW5>cancer immunotherapy</Res_KW5>
        <Plain_Description>Dendritic cells (DCs) kickstart the immune response to fight infections and cancer. Considering their power, they are also being harnessed for immunotherapy for use as ‘DC vaccines’ for the treatment of solid cancers and other immune disorders. We have found a novel way to make DCs in a petri dish in the large amounts required for such an approach. If we can demonstrate this approach is feasible in mice, it will provide the impetus to seek translational studies for use in humans.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021247</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Patrick Western</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding non-genetic inheritance in health and disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,433,936.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>germ cells </Res_KW1>
        <Res_KW2>epigenetics</Res_KW2>
        <Res_KW3>inheritance</Res_KW3>
        <Res_KW4>fetal origins of disease</Res_KW4>
        <Res_KW5>fetal growth restriction</Res_KW5>
        <Plain_Description>Eggs provide genetic and non-genetic (epigenetic) information that is critical for offspring development. While we understand how genes transmit instructions that regulate offspring development, epigenetic inheritance is poorly understood. This project will determine how an essential epigenetic mechanism acting in eggs controls formation of tissues in offspring and grand-offspring and how dysregulation of this mechanism results in disease. Outcomes will help understand disease inheritance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021260</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Natasha Harvey</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Investigating the application of targeted therapeutics for the treatment of complex lymphatic vascular anomalies</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$694,856.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>lymphatic disease </Res_KW1>
        <Res_KW2>lymphatics</Res_KW2>
        <Res_KW3>transcriptional regulation</Res_KW3>
        <Res_KW4>signal transduction</Res_KW4>
        <Res_KW5>developmental biology</Res_KW5>
        <Plain_Description>Complex lymphatic anomalies arise due to defects in the development of lymphatic vessels during embryogenesis and result in stillbirth or chronic disease. We have identified pathogenic variants in the MDFIC gene underlying a complex lymphatic anomaly termed CCLA. Here, we will investigate the signalling pathways affected by pathogenic MDFIC variants and determine whether small molecule inhibitors of these signalling pathways might provide novel therapeutics able to effectively treat CCLA.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021267</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Phillip Pymm</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Antibody based therapeutic development for coronaviruses</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,103,723.30</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </Fields_of_Research>
        <Res_KW1>structural immunology </Res_KW1>
        <Res_KW2>antibody</Res_KW2>
        <Res_KW3>coronavirus</Res_KW3>
        <Res_KW4>antiviral</Res_KW4>
        <Res_KW5>electron microscopy</Res_KW5>
        <Plain_Description>The first human coronavirus was isolated from individuals suffering from the common cold in the 1960’s. Since then, three highly pathogenic human coronaviruses have arisen in the last two decades; SARS in 2002, MERS in 2012 and the devastating COVID-19 pandemic. It is critical we understand how current and emerging coronaviruses infect humans and more importantly, develop therapeutic agents to tackle current disease, resist future SARS-CoV-2 variants and new coronavirus-origin pandemics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021271</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Daniel Watterson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Structurally informed vaccines and therapies to resist and counter JEV emergence</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,127,596.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical virology  | biological sciences | microbiology | virology  | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>flavivirus </Res_KW1>
        <Res_KW2>structural biology</Res_KW2>
        <Res_KW3>vaccine</Res_KW3>
        <Res_KW4>antibody</Res_KW4>
        <Res_KW5>japanese encephalitis</Res_KW5>
        <Plain_Description>Flaviviruses such as JEV are arthropod-borne human pathogens that infect over 200 million annually. The current JEV vaccines are based on >50 year old strains, raising the question of whether these are still optimal against modern emerging strains including the recent Australian outbreak. In this project we will reveal the molecular differences that define JEV strains. This will provide framework for a new generation of JEV vaccines as well as identify new antivirals to treat JEV infection.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021272</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrii Slonchak</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Dissecting the mechanisms of flavivirus neuro-pathogenesis using the systems biology approach</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$971,941.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>flavivirus </Res_KW1>
        <Res_KW2>flavivirus encephalitis</Res_KW2>
        <Res_KW3>flavivirus infection</Res_KW3>
        <Res_KW4>systems biology</Res_KW4>
        <Res_KW5>viral infection</Res_KW5>
        <Plain_Description>Flaviviruses are important pathogens that Include West Nile, Japanese encephalitis and Zika viruses. They can infect human brain causing severe neurological diseases. This project is aimed to identify the cells in the brain vulnerable to viral infection and elucidate the molecular processes affected by the viruses in the brain. This will explain why flaviviruses cause neurological disease and identify the molecules that can be targeted to prevent or mitigate infection in the brain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021286</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Laura Genovesi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Medulloblastoma plasticity, persistence, relapse and resistance</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$990,845.63</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biological sciences | biochemistry and cell biology | systems biology | </Fields_of_Research>
        <Res_KW1>medulloblastoma </Res_KW1>
        <Res_KW2>plasticity</Res_KW2>
        <Res_KW3>relapse</Res_KW3>
        <Res_KW4>systems biology</Res_KW4>
        <Res_KW5>cdk inhibitor</Res_KW5>
        <Plain_Description>Childhood cancer is devastating. For young children with medulloblastoma the outlook is bleak and if the cancer comes back after treatment it is lethal. We will identify cancer cells that survive treatment with a new drug, Palbociclib, and show how they lead to relapse. We will find out if the presence of these cells predicts relapse in patients, and develop a map of how cells develop tolerance to the drug that will help us to identify ways we might target these cells to prevent relapse.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021290</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Scott Wilson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Functional genetic screen of osteoclasts targeted to risk loci for osteoporosis</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$743,278.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>osteoporosis </Res_KW1>
        <Res_KW2>fragility fracture</Res_KW2>
        <Res_KW3>osteoclast</Res_KW3>
        <Res_KW4>gene regulation</Res_KW4>
        <Res_KW5>functional genomics</Res_KW5>
        <Plain_Description>Numerous genetic risk variants for osteoporosis, which have been identified through genome-wide association studies and are specifically relevant to osteoclast function, have been partially characterised by our group. We will now use targeted Perturb-seq, which involves pooled CRISPR screens that couple targeted genetic perturbations relevant to the risk loci, with single-cell transcriptomics of the osteoclasts to definitively delineate the mechanism of effect of the variants.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021292</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Philip Mosley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Selective Modulation Of Brain Circuits In Obsessive-Compulsive Disorder</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,117,972.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>obsessive-compulsive disorder (ocd) </Res_KW1>
        <Res_KW2>functional magnetic resonance imaging (fmri)</Res_KW2>
        <Res_KW3>neuromodulation</Res_KW3>
        <Res_KW4>neuroscience</Res_KW4>
        <Res_KW5>treatment-resistant</Res_KW5>
        <Plain_Description>Obsessive-compulsive disorder (OCD) is a mental illness that can be very difficult to treat and causes significant disability and suffering. In this research, we plan to understand how focussed electricity delivered through permanent stimulating electrodes (deep brain stimulation) works in the brain to treat OCD and how we can translate this knowledge into new therapies that can be used without the requirement for surgery - thereby increasing acceptability and accessibility for more people.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021305</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Leszek Lisowski</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Bioengineering of next-generation adeno-associated viral vectors for gene therapy clinical applications using whole human liver explant preclinical model</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,163,794.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | medical biotechnology | medical molecular engineering of nucleic acids and proteins | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>gene therapy </Res_KW1>
        <Res_KW2>liver disease</Res_KW2>
        <Res_KW3>adeno-associated virus</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>animal model</Res_KW5>
        <Plain_Description>The recent exciting advancements in gene therapies targeting genetic conditions of the liver, eye and brain rely on viral vectors that enable delivery of the therapeutic cargo to the targeted cells.   Unfortunately, vector utilised for therapeutic delivery to human liver lack in efficacy, which increases therapeutic cost and lowers safety. Most advanced preclinical model of human liver, the human liver itself, will be used to develop the next generation of vectors for clinical implementation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021307</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jesse Goyette</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Modulators of T cell signaling: mechanism of pathogen virulence factors and design of synthetic immunomodulatory constructs</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$834,168.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>membrane signalling </Res_KW1>
        <Res_KW2>t cell activation</Res_KW2>
        <Res_KW3>t cell receptor</Res_KW3>
        <Res_KW4>intracellular signalling</Res_KW4>
        <Res_KW5>signalling pathways</Res_KW5>
        <Plain_Description>T cells are immune cells critical for clearing infections and fighting cancer. They can distinguish healthy from infected or cancerous cells by sensing cues in their environment and encoding this information into networks of biochemical reactions, which are integrated into a functional decision. We will use cutting edge microscopy techniques to decode this information processing mechanism so that we may better intervene when T cells make incorrect decisions and fail to perform their function.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021322</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Peter Crouch</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Improving CNS copper availability to mitigate permanent neurological disability in progressive cases of multiple sclerosis</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$847,286.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - inorganic elements and compounds | </Fields_of_Research>
        <Res_KW1>multiple sclerosis (ms) </Res_KW1>
        <Res_KW2>copper</Res_KW2>
        <Res_KW3>copper deficiency</Res_KW3>
        <Res_KW4>neuroprotection</Res_KW4>
        <Res_KW5>treatment strategies</Res_KW5>
        <Plain_Description>The accumulation of permanent neurological disability in progressive cases of multiple sclerosis represents a major, unmet medical need. New treatment options are required, but their production to date has been limited by incomplete knowledge of the underpinning biological factors and events. This application presents our discovery of a treatable feature of progressive multiple sclerosis and outlines our plan to develop novel compounds that can produce life-changing outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021360</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Marlene Hao</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A gut feeling about new therapies for glioma treatment: lessons from the enteric nervous system</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$985,233.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | peripheral nervous system | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>enteric nervous system </Res_KW1>
        <Res_KW2>glioma</Res_KW2>
        <Res_KW3>glial cells</Res_KW3>
        <Res_KW4>dna repair</Res_KW4>
        <Res_KW5>cancer immunology</Res_KW5>
        <Plain_Description>Gliomas are the most aggressive form of brain cancer. Gliomas come from glial cells, a type of support cell in the nervous system. Glial cells are found in the brain and also in the enteric nervous system, which is located in the gut. However, gliomas are rarely found in the gut and are generally benign. In this study, we aim to identify factors that protect enteric glial cells from forming aggressive cancers in order to develop new treatments for brain cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021380</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Walter Thomas</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Protecting hearts from trastuzumab-induced cardiomyopathy</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$818,191.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacology and pharmaceutical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>erbb receptors </Res_KW1>
        <Res_KW2>cell surface receptor</Res_KW2>
        <Res_KW3>erbb2-mediated cell signalling</Res_KW3>
        <Res_KW4>antibody cancer therapy</Res_KW4>
        <Res_KW5>anti-tumour drugs</Res_KW5>
        <Plain_Description>Heart failure is a serious side-effect of an antibody-based therapy for breast cancer. The antibody targets a growth receptor called HER2, which is also present in hearts cells where it is critical for normal cardiac structure/function. We propose to mutate the HER2 receptor so it is no longer recognised by antibody, but where it retains functionality. In a mouse model of Herceptin-based cardiac toxicity, we will use viruses to deliver the resistant HER2 receptor to heart and rescue function.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021396</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Hamish Scott</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Genomic Autopsy of Pregnancy loss Study (GAPS): genomic investigations to help solve unexplained pregnancy loss at all gestations.</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,489,454.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biomedical and clinical sciences | reproductive medicine | reproduction  | biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>stillbirth </Res_KW1>
        <Res_KW2>miscarriage</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>genetics</Res_KW4>
        <Res_KW5>placenta</Res_KW5>
        <Plain_Description>Despite scientific and medical advances, the rate of miscarriage and stillbirth has not declined in Australia over the past 20 years. Our project aims to better understand the underlying causes of pregnancy loss across all gestations. We will use novel genomic techniques and for the first time study variation in the placenta that may contribute to pregnancy loss. Accurate diagnosis is essential for counselling, and offers families reproductive choices to avoid future recurrence.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021404</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ki Wook Kim</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Pregnancy and early life virome dynamics: contribution to chronic diseases</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,441,627.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health | biological sciences | bioinformatics and computational biology | sequence analysis | biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>type 1 diabetes mellitus (insulin-dependent diabetes mellitus) </Res_KW1>
        <Res_KW2>allergy</Res_KW2>
        <Res_KW3>coeliac disease</Res_KW3>
        <Res_KW4>medical virology</Res_KW4>
        <Res_KW5>prospective cohort study</Res_KW5>
        <Plain_Description>Viral infections during pregnancy and early life can majorly impact on maternal and infant health, and cause lifelong health issues, especially among those at risk of chronic disease. However, little is known about the early life virome of Australians, and whether it is a risk factor for pregnancy complications and chronic diseases. We will use the most comprehensive, sensitive and unbiased methods to assess pregnancy/early exposure to all viruses and their association with chronic diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021463</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Alexander Pinto</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Targeting novel cellular protagonists of cardiac fibrosis</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,492,287.62</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | biological sciences | biochemistry and cell biology | systems biology | biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </Fields_of_Research>
        <Res_KW1>stromal cells </Res_KW1>
        <Res_KW2>cell activation</Res_KW2>
        <Res_KW3>cell differentiation</Res_KW3>
        <Res_KW4>systems biology</Res_KW4>
        <Res_KW5>cardiac fibrosis</Res_KW5>
        <Plain_Description>Heart failure is a leading cause of death. We have recently discovered two new heart cell types that emerge after cardiac stress to drive fibrosis—a key precursor for the development of heart failure. This project aims to determine what genes support the development of these cells and whether targeting these cells prevents the development of fibrosis after cardiac stress. This project may reveal novel approaches to prevent or treat heart failure by targeting these new fibrosis-promoting cells.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021475</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Glen Ulett</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Understanding novel ways that bacteria drive virulence by subverting metal ion intoxication</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$910,641.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | </Fields_of_Research>
        <Res_KW1>bacterial pathogenesis </Res_KW1>
        <Res_KW2>streptococcal infection</Res_KW2>
        <Res_KW3>bacterial pathogenicity</Res_KW3>
        <Res_KW4>bacterial infection</Res_KW4>
        <Res_KW5>microbial pathogenesis</Res_KW5>
        <Plain_Description>The pathogen Group B streptococcus (GBS) is a significant risk to human health, an ageing Australian population and is a major cause of severe infections in babies. This project will define fundamental aspects of streptococcal biology, revealing how bacteria survive in the human body. The outcomes will highlight novel strategies for disease prevention and treatment. Ultimately, this work could reduce the economic and social burdens imposed by GBS infections on our healthcare.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021495</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Zane Andrews</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A neural metabolic memory of diet restriction influences rebound weight gain</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,035,486.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | behavioural neuroscience | biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | medical physiology | medical physiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>neuropeptide y (npy) </Res_KW1>
        <Res_KW2>dopamine</Res_KW2>
        <Res_KW3>diets for weight loss</Res_KW3>
        <Res_KW4>neurobiology</Res_KW4>
        <Res_KW5>obesity</Res_KW5>
        <Plain_Description>The overconsumption of high calorie foods in today’s society is a primary reason for the obesity epidemic. In this proposal we argue that periods of repetitive hunger program a metabolic memory of food shortage, which exacerbates feeding responses, motivation and food reward, especially high energy foods. A strong metabolic memory of food shortage may precipitate compulsive overeating, which is a major cause of obesity in today’s society.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021510</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Kerstin Brinkmann</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Exploring the anti-apoptotic and apoptosis-unrelated functions of MCL-1 during embryonic and blood cell development to advance MCL-1 inhibitors in clinical trials for cancer   </Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$771,528.10</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>apoptosis </Res_KW1>
        <Res_KW2>embryo development</Res_KW2>
        <Res_KW3>cancer chemotherapy</Res_KW3>
        <Res_KW4>bcl-2</Res_KW4>
        <Res_KW5>haematopoiesis</Res_KW5>
        <Plain_Description>In a healthy organism damaged or autoreactive cells kill themselves by a controlled cell death program, called apoptosis. Pro-survival proteins (e.g. MCL-1) block apoptosis, and their enhanced expression causes cancer. Some pro-survival inhibitory drugs (e.g. Venetoclax) are effective and well tolerated, whereas the highly effective MCL-1 inhibitors cause intolerable side effects in clinical trials. This project aims to determine the differences of these proteins to improve cancer therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021525</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kevin Barnham</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Defining the mechanisms that underpin the environmental contribution to Parkinson’s disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,820,255.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | other biomedical and clinical sciences | other biomedical and clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>parkinson disease </Res_KW1>
        <Res_KW2>xenobiotic metabolism</Res_KW2>
        <Res_KW3>glutathione</Res_KW3>
        <Res_KW4>oxidative stress</Res_KW4>
        <Res_KW5>environmental risk factors</Res_KW5>
        <Plain_Description>The number of people with Parkinson’s disease (PD) is doubling every 20 years as a consequence of exposure to environmental stressors from an industrialised world. These stressors increase the risk of developing PD, however, the underlying biology is poorly understood limiting our ability to intervene. We will characterise the link in this pathway and its association with PD. This knowledge will enable us to develop new intervention strategies that can attenuate the rising incidence of disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021560</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Angel Lopez</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Predicting disease progression in patients with myeloid neoplasms to enable early intervention</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,283,269.20</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>risk prediction </Res_KW1>
        <Res_KW2>cytokine receptor</Res_KW2>
        <Res_KW3>transformation</Res_KW3>
        <Res_KW4>stem cell biology</Res_KW4>
        <Res_KW5>haematological malignancy</Res_KW5>
        <Plain_Description>Myelodysplastic and myeloproliferative neoplasms (MDS/MPN) are blood cancers with multiple genetic mistakes that have a risk of progressing to acute myeloid leukaemia (AML), a rapid and fatal disease. There are no reliable approaches to predict who is going to develop AML. Based on the idea that a skewed hormone receptor is the cause of the problem we propose to identify its genetic fingerprint that can predict when MDS and MPN will transform to AML to enable faster and better treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021564</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Alan Rowan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Unveiling the modulators of scarless wound healing</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$994,636.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | biomaterials  | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>wound healing </Res_KW1>
        <Res_KW2>cell biology</Res_KW2>
        <Res_KW3>biomaterials</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>cell differentiation</Res_KW5>
        <Plain_Description>Aberrant wound healing, scarring and fibrosis results in a tremendous burden on public health to treat or have them surgically removed. After injury a fibrin clot forms, this project aims to understand the properties of fibrin clots, that drive scarless, as observed in foetuses, or positive wound healing outcomes. Then engineer these key properties into smart fibrin biomaterials to improve the management of injuries to promote scarless wound healing to improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021586</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Mark Douglas</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Optimising treatment of Hepatitis B with novel predictive biomarkers</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,210,387.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | clinical sciences | infectious diseases | biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>hepatitis b virus </Res_KW1>
        <Res_KW2>hepatitis b infection</Res_KW2>
        <Res_KW3>diagnostic assay</Res_KW3>
        <Res_KW4>diagnostic algorithms</Res_KW4>
        <Res_KW5>antiviral therapy</Res_KW5>
        <Plain_Description>Hepatitis B is treatable but most people have to take medicine for life. Some people can safely stop treatment after a few years but it is difficult to predict for each person whether or not the virus will come back.  We have developed a new test to measure different forms of virus in the liver. This test should identify people who can safely stop treatment and those who need to continue. In this grant we will study how to use our test to improve quality of life for people living with hepatitis B.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021587</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Gerard Kaiko</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Combining multi-omic causal-prediction networks from large patient datasets with a human intestinal organoid pipeline to identify new therapies for IBD </Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$984,565.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>inflammatory bowel disease (ibd) </Res_KW1>
        <Res_KW2>wound repair</Res_KW2>
        <Res_KW3>functional genomics</Res_KW3>
        <Res_KW4>colonic epithelium</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>Inflammatory Bowel Diseases are an increasingly prevalent cause of morbidity worldwide. Therapies that induce mucosal healing are a key unmet clinical need required to improve disease remission. Using a form of artificial intelligence on genomic networks from large patient datasets we have identified novel drug targets in the intestinal epithelium. In this project we will use human 'mini-guts' to investigate the potential of these drug targets to improve healing and reduce disease severity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021595</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Clare Anderson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Sleep Disruption and Alzheimer’s Disease Pathology – Investigating Mechanisms via Acoustic Stimulation of Slow Wave Sleep</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,275,717.60</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | psychophysiology  | psychology | biological psychology  | behavioural neuroscience | </Fields_of_Research>
        <Res_KW1>sleep </Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>brain ageing</Res_KW3>
        <Res_KW4>healthy ageing</Res_KW4>
        <Res_KW5>cognition</Res_KW5>
        <Plain_Description>A change in the sleep-wake system, particularly reduced deep sleep, is associated with impaired memory and cognition, and other aspects of brain health in later life. We will use exciting new technology and never-before-used ways of understanding the brain to reveal the causal role of deep sleep in brain and cognitive health. This will provide critical evidence for the use of sleep therapeutics which increase deep sleep to enhance brain health and promote cognition in older adults.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021623</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ruth Kluck</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Sensitivity to BH3 mimetics identified by BCL2 family interactions</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$596,069.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | chemical sciences | medicinal and biomolecular chemistry | molecular medicine | </Fields_of_Research>
        <Res_KW1>bcl-2 </Res_KW1>
        <Res_KW2>anticancer drug action</Res_KW2>
        <Res_KW3>apoptosis</Res_KW3>
        <Res_KW4>protein complexes</Res_KW4>
        <Res_KW5>monoclonal antibody</Res_KW5>
        <Plain_Description>BH3 mimetics are small molecule therapeutics which have resulted in paradigm shifts in the management of several cancers, although they are not curative and patients inevitably develop resistance. The mimetics bind to prosurvival BCL2 family members and displace proapoptotic members, indicating that sensitivity can be predicted by measuring complexes formed by BCL2 members. This project will develop the first antibodies to those complexes to measure responses of cancer cells to BH3 mimetics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021638</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Sacha Pidot</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>A genomics-powered ultrahigh-throughput pipeline for rapid antibiotic discovery</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$897,480.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>bacteriology </Res_KW1>
        <Res_KW2>antibiotics</Res_KW2>
        <Res_KW3>microbiology</Res_KW3>
        <Res_KW4>organic chemistry</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>Antibiotic resistant bacterial infections are becoming increasingly common in both hospitals and the community. A key strategy to overcome resistant bacteria is to identify new antibiotics. However, we must do this faster and more creatively or we risk rediscovering already known antibiotics. This project will miniaturise and accelerate the antibiotic discovery process, allowing us to investigate previously unseen bacteria and find antibiotics to combat multi-drug resistant infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021644</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ashley Farlow</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Genomic medicine for Indigenous Australians</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$885,257.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | gene mapping | biological sciences | bioinformatics and computational biology | sequence analysis | biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | </Fields_of_Research>
        <Res_KW1>genetic variation </Res_KW1>
        <Res_KW2>genetic association</Res_KW2>
        <Res_KW3>demography</Res_KW3>
        <Res_KW4>renal disease</Res_KW4>
        <Res_KW5>genetic mapping</Res_KW5>
        <Plain_Description>Whole genome sequencing of individuals from four remote Indigenous communities uncovered genomic patterns that suggest why previous studies failed to identify the genetic basis of two important diseases. We will use this information to develop a novel approach to find the causes of chronic kidney disease in people from the Tiwi Islands. These genetic patterns also allow us to recommend guidelines that increase the chance of success for future mapping projects in other Indigenous communities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021675</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Daniel Poole</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing Endogenous Opioids to Treat Gut Motility Disorders and Pain</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,260,809.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | neurosciences | autonomic nervous system  | </Fields_of_Research>
        <Res_KW1>opioid receptors </Res_KW1>
        <Res_KW2>enteric nervous system</Res_KW2>
        <Res_KW3>molecular pharmacology</Res_KW3>
        <Res_KW4>protein structure</Res_KW4>
        <Res_KW5>rational drug design</Res_KW5>
        <Plain_Description>Opioids are highly effective pain killers and anti-diarrheal drugs, but their use can be severely limited by serious side-effects. An alternative therapeutic strategy that largely avoids these side-effects is to harness the actions of opioids produced by the body. This project explores a new approach to enhance the effects of these opioids to provide natural pain relief and a new approach to regulate the movement of contents through the intestine.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021687</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jane Bourke</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Blocking harmful lung damage during acute exacerbations of chronic obstructive pulmonary disease (COPD) caused by infections</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$938,417.91</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>chronic obstructive pulmonary disease (copd) </Res_KW1>
        <Res_KW2>acute exacerbations</Res_KW2>
        <Res_KW3>respiratory infection</Res_KW3>
        <Res_KW4>lung disease</Res_KW4>
        <Res_KW5>drug efficacy</Res_KW5>
        <Plain_Description>Chronic obstructive pulmonary disease (COPD) affects over 2 million Australians and acute attacks, triggered by viruses or bacteria, can be fatal. Standard treatment with steroids is highly damaging to the lungs and safer treatments are urgently needed. Our team of leading clinical and basic science COPD researchers has identified a new drug with the potential to improve patient outcomes. Our pioneering studies will break the connection between COPD attacks, infections, lung damage and death.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021704</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Barbara Fazekas de St Groth</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Mechanisms of regulatory T cell function</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,179,644.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>regulatory t cells </Res_KW1>
        <Res_KW2>bone marrow transplantation</Res_KW2>
        <Res_KW3>graft versus host disease (gvhd)</Res_KW3>
        <Res_KW4>knockout mouse</Res_KW4>
        <Res_KW5>flow cytometry</Res_KW5>
        <Plain_Description>Normal regulation of the immune system is vital to human health, especially after bone marrow transplantation, but we still do yet not know exactly how it is achieved. In this project we will study one of the most important molecules used to regulate immune responses, CTLA-4. We aim to show that secreted CTLA-4, rather than CTLA-4 on the surface of immune cells, is responsible for immune regulation. Secreted CTLA-4 may hold promise as a new therapy for graft-versus host disease after transplant.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021732</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Merlin Thomas</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>The Development of splice-switching oligonucleotides for the management of kidney disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$892,640.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </Fields_of_Research>
        <Res_KW1>alternative splicing </Res_KW1>
        <Res_KW2>antisense oligonucleotides</Res_KW2>
        <Res_KW3>kidney disease</Res_KW3>
        <Res_KW4>diabetic nephropathy</Res_KW4>
        <Res_KW5>nephropathy</Res_KW5>
        <Plain_Description>RNA can now be used to treat human diseases.    It can be used as a template to make a new protein, such as in mRNA vaccines.    But RNA can also be used change how coding elements are spliced together and the protein that results from them.    This strategy has been used to great effect in difficult-to-treat diseases like muscular dystrophy and spinomuscular atrophy.   We will apply this same technology to target pathways critically involved in the development and progression of chronic kidney disease.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021749</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jamie Fletcher</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Pre-emptive targeted therapy to optimise high-risk neuroblastoma treatment</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$524,147.63</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </Fields_of_Research>
        <Res_KW1>neuroblastoma </Res_KW1>
        <Res_KW2>targeted therapy</Res_KW2>
        <Res_KW3>pre-clinical studies</Res_KW3>
        <Res_KW4>drug resistance</Res_KW4>
        <Res_KW5>tumour progression</Res_KW5>
        <Plain_Description>Despite intensive and prolonged treatment, half of all children diagnosed with high-risk neuroblastoma either do not respond, or subsequently relapse. There are no curative therapies for these patients. Current approaches are clearly inadequate for these children, and experimental therapies are being introduced too late. This study aims to change this paradigm through comprehensive pre-clinical evidence supporting earlier intervention with targeted agents.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021763</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Le Souef</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>What codes the development of asthma in children?</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,139,644.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>asthma </Res_KW1>
        <Res_KW2>allergic asthma</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>allergic airways disease</Res_KW5>
        <Plain_Description>Wheezing in children is very common. At present, we cannot predict which young children who wheeze will progress to develop the lung disease asthma. Thus, we cannot prevent asthma and treatment for asthma is broadly the same for everyone. We will analyse skin cells from inside the nose and blood cells from children who wheeze. Changes in these cells will help predict who will go on to develop asthma. Better, more specific treatments can also be developed.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021811</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr David Gonsalvez</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Wnt Signalling in Oligodendroglia: A missing link in MS neuroinflammation</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,220,251.91</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>oligodendrocytes </Res_KW1>
        <Res_KW2>remyelination</Res_KW2>
        <Res_KW3>demyelinating disease</Res_KW3>
        <Res_KW4>neuroinflammation</Res_KW4>
        <Res_KW5>wnt signalling</Res_KW5>
        <Plain_Description>Multiple Sclerosis (MS) is a disease in which a person’s immune system incorrectly attacks a specific group of cells within the central nervous system (CNS) called oligodendroglia. Destruction of these cells causes neurodegeneration that leads to devastating functional deficits. Oligodendrogila have the capacity for regeneration, but it is insufficient. We aim identify new therapeutic targets that boost the ability of oligodendroglia to regenerate and thus limit the neurodegneration in MS.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2021864</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Greg Roach</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2022 Ideas Grants</Sub_Type>
        <Grant_Title>Establishing caffeine as a potential new treatment option for circadian misalignment</Grant_Title>
        <Admin_Institution>Central Queensland University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$666,986.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | biological psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>circadian rhythms </Res_KW1>
        <Res_KW2>sleep/wake patterns</Res_KW2>
        <Res_KW3>caffeine</Res_KW3>
        <Res_KW4>melatonin</Res_KW4>
        <Res_KW5>temperature</Res_KW5>
        <Plain_Description>The aim of this project is to examine the effects of caffeine on the human internal body clock. In particular, we will assess the extent to which a moderate amount of caffeine, equivalent to a double-shot espresso, can shift the timing of the body clock. The results of this project will enable practitioners to use caffeine to treat disorders and behaviours that seriously disrupt the body clocks of 20% of Australian adults (e.g., delayed sleep onset, night work, international flight).</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022034</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jonathan Baell</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Development of bivalent degraders targeting Aurora kinase A for the treatment of polycystic kidney disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$891,093.09</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | </Fields_of_Research>
        <Res_KW1>drug development </Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>medicinal chemistry</Res_KW3>
        <Res_KW4>pharmaceutical treatment</Res_KW4>
        <Res_KW5>pharmacokinetics</Res_KW5>
        <Plain_Description>Autosomal dominant polycystic kidney disease (ADPKD) affects >1:1000 people and is a leading cause of kidney failure. There are no useful treatments.  We have shown this disease is driven by a protein called AURKA. We have discovered a drug candidate that potently degrades this disease-driving protein in cells. This grant will support development of potency and selectivity to give a patented drug candidate for a potential safe and effective treatment for ADPKD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022040</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jonathan Baell</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Development of a New Class of Formyl Peptide Receptor 1 (FPR1) Biased Agonists for the Treatment of Myocardial Infarction</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$944,924.64</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | </Fields_of_Research>
        <Res_KW1>medicinal chemistry </Res_KW1>
        <Res_KW2>g-protein coupled receptors</Res_KW2>
        <Res_KW3>acute myocardial infarction (ami)</Res_KW3>
        <Res_KW4>drug development</Res_KW4>
        <Res_KW5>cardiovascular pharmacology</Res_KW5>
        <Plain_Description>Cardiovascular disease is the leading cause of death, accounting for 30% of all global deaths. We have discovered a highly potent and novel compound that is unique in boosting a particular signalling pathway in heart tissue that can greatly improve recovery from heart attack, but this compound needs further optimization of properties that will enable it to be taken as a pill. This Development Grant will resource optimization of this novel drug candidate for the treatment of heart attack.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022050</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Christopher McDevitt</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Breaking drug resistance in community-acquired bacterial pneumonia (CABP)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,098,502.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | </Fields_of_Research>
        <Res_KW1>streptococcus pneumoniae </Res_KW1>
        <Res_KW2>bacterial respiratory diseases</Res_KW2>
        <Res_KW3>antibiotic resistance</Res_KW3>
        <Res_KW4>antibiotic therapy</Res_KW4>
        <Res_KW5>zinc</Res_KW5>
        <Plain_Description>There is an urgent and critical need to develop new ways to treat infections caused by drug resistant bacterial pathogens (superbugs). Our new therapeutic approach using an antibiotic potentiator is an entirely new strategy to disrupt the antibiotic resistance mechanisms of multidrug-resistant bacteria. Our treatment using the antibiotic potentiator renders drug-resistant superbugs sensitive to existing, frontline antibiotics and will restore the efficiency of existing treatment regimens.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022057</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Kim Delbaere</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>StandingTall: Digital Fall Prevention Solution</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,296,922.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | </Fields_of_Research>
        <Res_KW1>falls prevention </Res_KW1>
        <Res_KW2>exercise</Res_KW2>
        <Res_KW3>healthy ageing</Res_KW3>
        <Res_KW4>aged care</Res_KW4>
        <Res_KW5>allied health</Res_KW5>
        <Plain_Description>Falls in older people worldwide are common, with one in three older people experiencing one or more falls per year. StandingTall is a tailored and progressive digital exercise program designed for older people to do at home by themselves. We will leverage the experience and intellectual resources of leading industry providers and consumers using a co-design partnership approach to ensure the successful commercialisation and implementation of StandingTall into clinical practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022075</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Leann Tilley</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Mechanistically and chemically novel reaction-hijacking pro-inhibitors for malaria</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$514,089.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | enzymes | biological sciences | microbiology | infectious agents | chemical sciences | medicinal and biomolecular chemistry | medicinal and biomolecular chemistry not elsewhere classified | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>drug action</Res_KW2>
        <Res_KW3>mechanism of action</Res_KW3>
        <Res_KW4>antimalarial</Res_KW4>
        <Res_KW5>enzyme inhibitors</Res_KW5>
        <Plain_Description>Diseases caused by drug-resistant infectious agents, such as the malaria parasite, represent an enormous global health threat. New drugs are desperately needed to overcome drug resistance. We have discovered a new "Trojan horse" method to induce malaria parasites to make their own toxic molecules – making them the instruments of their own demise. In this project we will work with a major pharmaceutical company toward developing these new therapeutics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022121</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David Fairlie</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Developing a new type of drug for inflammatory lung disease</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$981,805.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>medicinal chemistry </Res_KW1>
        <Res_KW2>lung inflammation</Res_KW2>
        <Res_KW3>allergic asthma</Res_KW3>
        <Res_KW4>pulmonary fibrosis</Res_KW4>
        <Res_KW5>chronic obstructive pulmonary disease (copd)</Res_KW5>
        <Plain_Description>Millions of Australians have breathing difficulties due to viral/bacterial infections or environmental allergens/pollutants (dust mites, pollen, food, smoke) that trigger inflammation leading to lung disease (e.g. asthma, COPD, fibrosis). We have discovered a new type of drug that blocks inflammation in human cells and damage in mouse models of lung disease. This study can improve drug potency, selectivity and effectiveness and provide proof of concept preclinical data to enable clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022218</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Lynne Bilston</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Development of a novel optical stimulation therapy for Obstructive Sleep Apnoea</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,137,447.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>obstructive sleep apnoea </Res_KW1>
        <Res_KW2>gene therapy</Res_KW2>
        <Res_KW3>sleep apnoea</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>adeno-associated virus</Res_KW5>
        <Plain_Description>Obstructive sleep apnoea is a common sleep disorder where the upper airway collapses repeatedly during sleep, interrupting breathing. It is associated with accidents and elevated risk of cardiovascular disease. Current treatments are poorly adhered to by patients, and there is a substantial market for new therapies that are patient-friendly. This project aims to bring a new minimally invasive light-stimulation therapy, Optosleep, to the stage where it can be tested in human patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022337</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jiawen Li</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Hybrid 3D-printed imaging catheter for more accurate cardiovascular disease detection</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$905,058.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>diagnostic imaging </Res_KW1>
        <Res_KW2>acute myocardial infarction (ami)</Res_KW2>
        <Res_KW3>instrumentation</Res_KW3>
        <Res_KW4>plaque rupture</Res_KW4>
        <Res_KW5>atherosclerosis</Res_KW5>
        <Plain_Description>Most heart attacks are caused by high-risk plaques. A significant unmet need in cardiology is to reliably detect high-risk plaques before they are life-threatening. This project will deliver the first-in-human study and commercialisation of our novel hybrid 3D-printed imaging catheter. This novel device is likely to enable accurate detection of high-risk plaques and prevent (recurrent) heart attacks. This high-tech device is ideal for manufacturing in Australia and has great export potential.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022449</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Rebecca Lim</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Development of nanomedicine for non-alcoholic steatohepatitis</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$890,458.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | nanomedicine | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>liver regeneration </Res_KW1>
        <Res_KW2>fatty liver disease</Res_KW2>
        <Res_KW3>nonalcoholic steatohepatitis</Res_KW3>
        <Res_KW4>end-stage liver disease</Res_KW4>
        <Res_KW5>cell therapy</Res_KW5>
        <Plain_Description>Non-alcoholic steatohepatitis (NASH) is a leading cause for liver cancer. The failure of promising drugs is due to their inability to address all aspects of this complex disease. In this proposal, we provide compelling evidence that nanoparticles shed by amniotic epithelial cells (a perinatal stem-like cell) have multivalent properties in the context of NASH. We propose the development of these ‘amniotic exosomes’ as a regenerative medicine for NASH.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022583</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Colette McKay</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>EarGenie: A diagnostic system to transform the management of infants with hearing loss</Grant_Title>
        <Admin_Institution>Bionics Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,176,999.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | sensory systems | </Fields_of_Research>
        <Res_KW1>deafness </Res_KW1>
        <Res_KW2>hearing aid fitting</Res_KW2>
        <Res_KW3>cochlear implant</Res_KW3>
        <Res_KW4>speech and language development</Res_KW4>
        <Res_KW5>diagnostic algorithms</Res_KW5>
        <Plain_Description>After an infant is diagnosed with a hearing loss via new-born screening, it is critically important that a hearing aid or cochlear implant is provided as soon as possible: otherwise language development is significantly and permanently impacted. In this project we develop a novel hearing assessment system that will reduce the delay between diagnosis and provision of the optimal hearing solution for each infant from 9-24 months down to 2-6 months, thus leading to improved quality of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022585</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jonathan Baell</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Development of novel GPR52 agonists for the treatment of schizophrenia</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$779,955.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | </Fields_of_Research>
        <Res_KW1>medicinal chemistry </Res_KW1>
        <Res_KW2>drug development</Res_KW2>
        <Res_KW3>g-protein coupled receptors</Res_KW3>
        <Res_KW4>schizophrenia and related disorders</Res_KW4>
        <Res_KW5>neuropharmacology</Res_KW5>
        <Plain_Description>We are developing a novel class of drug candidates as better treatments for schizophrenia, a debilitating psychiatric disorder. Current therapeutics address only one component of the disorder and cause significant side-effects, often leading to discontinuation of treatment. There is a well-recognized and significant unmet need for novel, effective treatment options with fewer side effects that also address the negative symptoms and cognitive impairments core to schizophrenia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022625</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Daniel Christ</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Development of a therapeutic monoclonal antibody</Grant_Title>
        <Admin_Institution>Garvan Institute of Medical Research</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$867,242.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Fields_of_Research>
        <Res_KW1>antibody engineering </Res_KW1>
        <Res_KW2>antibody production</Res_KW2>
        <Res_KW3>antibody therapy</Res_KW3>
        <Res_KW4>protein engineering</Res_KW4>
        <Res_KW5>monoclonal antibody</Res_KW5>
        <Plain_Description>This project specifically relates to the development of a product - a humanised monoclonal antibody. The project has now reached an early proof-of-principle-stage of product development and represents a highly promising commercial opportunity for Australia, with annual sales of monoclonals exceeding $100 billion in 2021. To be able to progress our basic discoveries into a commercial product a humanised antibody is required.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022635</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Merlin Thomas</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Splice switching oligonucleotides for the treatment of chronic kidney disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$998,513.10</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | </Fields_of_Research>
        <Res_KW1>antisense oligonucleotides </Res_KW1>
        <Res_KW2>alternative splicing</Res_KW2>
        <Res_KW3>rna processing</Res_KW3>
        <Res_KW4>kidney disease</Res_KW4>
        <Res_KW5>diabetic nephropathy</Res_KW5>
        <Plain_Description>RNA can now be used to safely and selectively treat human diseases.     RNA can be used as a template to make a new protein, such as in mRNA vaccines.     But RNA can also be used change how coding elements are spliced together and the protein that results from them.     This strategy has recently been used to great effect in difficult-to-treat diseases, like muscular dystrophy.    We will now apply this same disruptive RNA technology to develop a novel treatment for chronic kidney disease.    </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022674</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Ivo Mueller</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Development of a Plasmodium vivax multi-analyte lateral flow assay to accelerate malaria elimination</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$945,940.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | biomedical and clinical sciences | clinical sciences | infectious diseases | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>plasmodium </Res_KW1>
        <Res_KW2>serology</Res_KW2>
        <Res_KW3>treatment strategies</Res_KW3>
        <Res_KW4>diagnostic test</Res_KW4>
        <Res_KW5>exposure assessment</Res_KW5>
        <Plain_Description>To efficiently eliminate Plasmodium vivax (Pv), malaria control programs require novel, easy-to-use tools to identify and treat people with hidden dormant Pv liver-stage infections. We have developed the first test to meet this requirement: a novel serological test that recognises specific patterns in a person's immune response to malaria. We are now developing a field-deployable rapid diagnostic test to ensure translation of this public health opportunity to accelerate malaria elimination.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022693</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jason Lee</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>The development of DMX8.1 as a novel treatment for immunotherapy-refractory cancers</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$915,215.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>anticancer drug </Res_KW1>
        <Res_KW2>epigenetics</Res_KW2>
        <Res_KW3>drug resistance</Res_KW3>
        <Res_KW4>drug development</Res_KW4>
        <Res_KW5>cancer immunotherapy</Res_KW5>
        <Plain_Description>Optimal treatment is critical for cancer patient outcome, however, a significant proportion of patients fail to respond and relapse. Using clinically-relevant tumour models, this proposal is aimed at validating the efficacy of a novel drug that can be used either alone or in combination with other therapeutic agents to define the best combination and sequence of treatments to allow immunotherapies to be more effective in more patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022723</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Benjamin Thierry</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2022 Development Grants</Sub_Type>
        <Grant_Title>Preclinical Validation of a Targeted Theranostic Agent for MRI Guided Radiotherapy and Radiosensitisation of Aggressive Brain Tumours</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$837,678.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | </Fields_of_Research>
        <Res_KW1>radiotherapy </Res_KW1>
        <Res_KW2>radiosensitivity</Res_KW2>
        <Res_KW3>magnetic resonance imaging (mri)</Res_KW3>
        <Res_KW4>nanotechnology</Res_KW4>
        <Res_KW5>brain tumours</Res_KW5>
        <Plain_Description>This project aims to validate preclinically FerroTrace-FAPi, a theranostic agent designed to improve and facilitate image guided radiotherapy. Successful outcomes would enable and improve aggressive image-guided treatment of brain tumours with acceptable neurological toxicity, including in the near future with proton beam radiotherapy. It would also pave the way to rapid commercialisation of FerroTrace-FAPi via the FDA orphan-drug designation pathway.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018644</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Genevieve Healy</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-CIHR Healthy Cities Implementation Science Team Grant Scheme</Sub_Type>
        <Grant_Title>Small Steps for Big Changes: Implementing an Evidence-Based Diabetes Prevention Program into Diverse Urban Communities</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,169,612.20</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | preventive medicine | </Fields_of_Research>
        <Res_KW1>community intervention study </Res_KW1>
        <Res_KW2>diabetes prevention </Res_KW2>
        <Res_KW3>physical activity </Res_KW3>
        <Res_KW4>health promotion </Res_KW4>
        <Res_KW5>implementation </Res_KW5>
        <Plain_Description>Small Steps for Big Changes is an evidence-based type 2 diabetes prevention program. Following initial success, we are now scaling up the program to deliver it in community settings across both Canada and Australia. Our trial will investigate how community-, organisation-, provider-, and patient-level factors contribute to implementation outcomes when organisations deliver the same program in different contexts. We will also examine cost-effectiveness and program impacts on diabetes prevention.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018862</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Anne Tiedemann</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-CIHR Healthy Cities Implementation Science Team Grant Scheme</Sub_Type>
        <Grant_Title>Choose To Move Sydney</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,212,853.25</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>physical activity </Res_KW1>
        <Res_KW2>behaviour change </Res_KW2>
        <Res_KW3>implementation </Res_KW3>
        <Res_KW4>healthy ageing </Res_KW4>
        <Res_KW5>older people </Res_KW5>
        <Plain_Description>Physical activity is crucial for health across the lifespan and is key to healthy ageing. Choose To Move (CTM) was developed by researchers in British Columbia, Canada, in collaboration with older adults and community-based organisations and is effective in supporting older people to increase physical activity. This research will adapt CTM to suit the needs of older Arabic speaking people in Sydney, who are particularly inactive and not well supported by existing physical activity programs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2020155</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ben Beck</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-CIHR Healthy Cities Implementation Science Team Grant Scheme</Sub_Type>
        <Grant_Title>Building CapaCITY/É for Sustainable Transportation</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,249,675.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | public health and health services not elsewhere classified | </Fields_of_Research>
        <Res_KW1>implementation </Res_KW1>
        <Res_KW2>transport </Res_KW2>
        <Res_KW3>road safety </Res_KW3>
        <Res_KW4>physical activity </Res_KW4>
        <Res_KW5>health promotion </Res_KW5>
        <Plain_Description>Active and sustainable transport (such as walking and bike riding) are critical to supporting health, mobility and equity outcomes. However, cities globally are struggling to implement infrastructure to enable greater uptake of these modes of transport. Through partnerships with Australian government agencies and Canadian collaborators, we will develop a novel framework that will support governments in successfully implementing interventions to enable active and sustainable transportation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023127</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Gail Garvey</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-CIHR Healthy Cities Implementation Science Team Grant Scheme</Sub_Type>
        <Grant_Title>Supporting Healthy Lifestyle Choices to Promote Mental Health &amp; Wellbeing of Indigenous Youth Aging-Out-of-Care in Urban Settings</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,249,997.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>public health and health services | aboriginal and torres strait islander health | </Fields_of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>wellbeing </Res_KW2>
        <Res_KW3>social and cultural issues </Res_KW3>
        <Res_KW4>youth </Res_KW4>
        <Res_KW5>implementation </Res_KW5>
        <Plain_Description>First Nations children and young people comprise one third of children living in out-of-home care and for many the time spent in care undermines their connection to culture and community. Young people transitioning from care are vulnerable and often have limited capacity to connect with their culture and community. This project will apply a strengths-based approach to co-design culturally-grounded programs to support and improve the wellbeing of First Nations youth (12-17 years)  in care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018589</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jian Li</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 e-Asia Joint Research Program</Sub_Type>
        <Grant_Title>Development of Innovative Antimicrobials for Combatting Multidrug-resistant Gram-negative Bacteria: An integrated multi-disciplinary approach</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$749,920.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmacology and pharmaceutical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>antibiotic resistance </Res_KW1>
        <Res_KW2>drug discovery </Res_KW2>
        <Res_KW3>drug design </Res_KW3>
        <Res_KW4>transporters </Res_KW4>
        <Res_KW5>pharmacokinetics </Res_KW5>
        <Plain_Description>The World Health Organization (WHO) has highlighted antibiotic resistance as a major global health crisis. Gram-negative bacteria top the WHO priority pathogen list due to the lack of therapeutic options, and toxic polymyxins are often the last resort. This project will be the first to integrate cutting-edge computational and experimental approaches to develop novel, safer polymyxins and their inhalation formulations. Our study targets the urgent global medical need for new antibiotics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018677</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Katryn Stacey</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 e-Asia Joint Research Program</Sub_Type>
        <Grant_Title>Gut leak and microbiome contribution to severe dengue disease</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$669,503.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical infection agents (incl. prions) | biomedical and clinical sciences | medical microbiology | medical bacteriology  | biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>dengue fever </Res_KW1>
        <Res_KW2>gastrointestinal symptoms </Res_KW2>
        <Res_KW3>enteric bacteria </Res_KW3>
        <Res_KW4>mucosal inflammation </Res_KW4>
        <Res_KW5>viral disease </Res_KW5>
        <Plain_Description>Mosquito-borne dengue virus is a major health threat in tropical areas. When some patients are recovering from fever, their condition suddenly deteriorates with life-threatening bleeding and shock. We propose that severe disease is the result of virus-induced damage to the gut, allowing entry of bacterial products into the body. Together with collaborators in Thailand and Japan, we will investigate the impact of gut bacteria on dengue disease and possible probiotic treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2018695</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Rhea Longley</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 e-Asia Joint Research Program</Sub_Type>
        <Grant_Title>Applying novel serological exposure markers to quantify residual malaria transmission in the Philippines</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$361,876.50</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | </Fields_of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>serology </Res_KW2>
        <Res_KW3>surveillance </Res_KW3>
        <Res_KW4>plasmodium </Res_KW4>
        <Res_KW5>epidemiology </Res_KW5>
        <Plain_Description>Malaria is an infectious disease that still affects millions of people worldwide, including in the East Asian region. In the Philippines, recent outbreaks of malaria caused by Plasmodium vivax have occurred. Plasmodium vivax is difficult to eliminate due to hidden liver-stage parasites, known as hypnozoites. We will apply our novel surveillance tools to understand how these outbreaks are occurring; to identify the hidden hypnozoite reservoir; and to accelerate malaria elimination.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022885</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrew Brodie</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 NHMRC-EU Joint Programme on Neurodegenerative Disease Research</Sub_Type>
        <Grant_Title>Taking steps against the burden of Parkinson’s disease</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$471,454.80</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>parkinson disease </Res_KW1>
        <Res_KW2>gait disorders</Res_KW2>
        <Res_KW3>brief intervention</Res_KW3>
        <Res_KW4>biomechanics</Res_KW4>
        <Res_KW5>neurophysiology</Res_KW5>
        <Plain_Description>Parkinson’s disease (PD) affects over 10 million people worldwide. Unstable gait and falls affect 70% of PD patients. This EU Joint Project investigates the mechanistic changes underpinning successful treadmill intervention that are enhanced by mechanically or virtual-reality triggered gait adaptations. Four clinical centers (Sydney, Tel Aviv, Bolongna and Kiel) will recruit 168 PD patients randomized 1:1 to intervention or control groups. Outcomes will improve fall prevention in people with PD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022997</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Juergen Goetz</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 NHMRC-EU Joint Programme on Neurodegenerative Disease Research</Sub_Type>
        <Grant_Title>Facilitating focused ultrasound-mediated Tau clearance in Alzheimer's disease and other Tauopathies by understanding the underlying autophagic mechanisms</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$483,493.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>alzheimer disease </Res_KW1>
        <Res_KW2>ultrasound</Res_KW2>
        <Res_KW3>autophagy</Res_KW3>
        <Res_KW4>antibody</Res_KW4>
        <Res_KW5>neuromodulation</Res_KW5>
        <Plain_Description>Ultrasound (US) is routinely used for diagnostic imaging, but applicability of this non-invasive technology extends far beyond bio-imaging. We have shown that US clears toxic Tau typical of Alzheimer’s disease (AD). With a team of experts in AD, US technology and multimodal imaging we aim to understand the underlying Tau clearance mechanisms and monitor the process in relation to blood flow. The proposed work constitutes an important step towards developing an US therapy for AD patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2023333</APP_ID>
        <Date_Announced>2022-12-14T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Bradley Turner</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2022 NHMRC-EU Joint Programme on Neurodegenerative Disease Research</Sub_Type>
        <Grant_Title>The role of microglia in the effects of environmental enrichment in neurodegenerative disorders</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$486,525.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>alzheimer disease </Res_KW1>
        <Res_KW2>amyotrophic lateral sclerosis</Res_KW2>
        <Res_KW3>neurodegeneration</Res_KW3>
        <Res_KW4>environmental intervention</Res_KW4>
        <Res_KW5>amyloid beta-protein</Res_KW5>
        <Plain_Description>Environmental enrichment (EE) is a powerful preclinical manipulation with remarkable therapeutic promise for neurodegenerative diseases, however its molecular mechanisms remain elusive. Here, we will study the role of inflammatory brain cells in mediating clinical and pathological benefits of EE in models of Alzheimer’s disease (AD) and motor neuron disease (MND).  Gene targets in microglia mediating benefits of EE will be identified which could be therapeutically exploited in neurodegeneration.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2022398</APP_ID>
        <Date_Announced>2023-02-24T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Yvonne Clark</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>2022 TCR Improving Indigenous maternal and child health in the early years </Sub_Type>
        <Grant_Title>It’s time to flourish: Co-designed perinatal and early years care, self-determined by Aboriginal and Torres Strait Islander women, Resulting in policy and practice transformation and Exceptional service (ICARE).</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$4,973,482.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander mothers and babies health and wellbeing | </Fields_of_Research>
        <Res_KW1>aboriginal health </Res_KW1>
        <Res_KW2>maternal and child health </Res_KW2>
        <Res_KW3>child development </Res_KW3>
        <Res_KW4>wellbeing </Res_KW4>
        <Res_KW5>decolonization </Res_KW5>
        <Plain_Description>Close the Gap targets and the consistent voices of Aboriginal and Torres Strait Islander people want our babies to be strong and healthy with the best start to life. This begins in pregnancy. This multi-faceted research will provide culturally appropriate and strength-based tools and supports during pregnancy and the early years to empower families. The study will generate new knowledge about empowerment, health system responses and improved data to track and understand the parent’s journey.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
</root>